U.S. patent number RE46,641 [Application Number 13/896,388] was granted by the patent office on 2017-12-19 for dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4.
This patent grant is currently assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services. The grantee listed for this patent is The United States of America, as represented by the Secretary, Department of Health & Human Services, The United States of America, as represented by the Secretary, Department of Health & Human Services. Invention is credited to Joseph E. Blaney, Barry Falgout, Kathryn A. Hanley, Ching-Juh Lai, Lewis Markoff, Brian R. Murphy, Stephen S. Whitehead.
United States Patent |
RE46,641 |
Whitehead , et al. |
December 19, 2017 |
Dengue tetravalent vaccine containing a common 30 nucleotide
deletion in the 3'-UTR of dengue types 1,2,3, and 4, or antigenic
chimeric dengue viruses 1,2,3, and 4
Abstract
The invention relates to a dengue virus tetravalent vaccine
containing a common 30 nucleotide deletion (.DELTA.30) in the
3'-untranslated region of the genome of dengue virus serotypes 1,
2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1,
2, 3, and 4.
Inventors: |
Whitehead; Stephen S.
(Bethesda, MD), Murphy; Brian R. (Bethesda, MD), Markoff;
Lewis (Bethesda, MD), Falgout; Barry (Rockville, MD),
Blaney; Joseph E. (Gettysburg, PA), Hanley; Kathryn A.
(Las Cruces, NM), Lai; Ching-Juh (Bethesda, MD) |
Applicant: |
Name |
City |
State |
Country |
Type |
The United States of America, as represented by the Secretary,
Department of Health & Human Services |
Washington |
DC |
US |
|
|
Assignee: |
The United States of America, as
represented by the Secretary, Department of Health and Human
Services (Washington, DC)
|
Family
ID: |
29406814 |
Appl.
No.: |
13/896,388 |
Filed: |
May 17, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
10970640 |
Apr 14, 2009 |
7517531 |
|
|
|
PCT/US03/13279 |
Apr 25, 2003 |
|
|
|
|
60377860 |
May 3, 2002 |
|
|
|
|
60436500 |
Dec 23, 2002 |
|
|
|
Reissue of: |
12398043 |
Mar 4, 2009 |
8075903 |
Dec 13, 2011 |
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P
37/04 (20180101); C12N 7/00 (20130101); A61P
31/14 (20180101); C12N 7/00 (20130101); A61K
39/12 (20130101); A61K 39/12 (20130101); Y02A
50/30 (20180101); C12N 2770/24161 (20130101); A61K
2039/70 (20130101); A61K 2039/5256 (20130101); C12N
2770/24161 (20130101); A61K 2039/5254 (20130101); C12N
2770/24134 (20130101); A61K 2039/5254 (20130101); A61K
2039/70 (20130101); A61K 2039/5256 (20130101); C12N
2770/24134 (20130101) |
Current International
Class: |
C12N
7/00 (20060101); A61K 39/12 (20060101); A61K
39/00 (20060101) |
Field of
Search: |
;424/202.1
;435/235.1 |
References Cited
[Referenced By]
U.S. Patent Documents
|
|
|
7226602 |
June 2007 |
Whitehead et al. |
7517531 |
April 2009 |
Whitehead et al. |
7560118 |
July 2009 |
Whitehead et al. |
8039003 |
October 2011 |
Whitehead et al. |
|
Foreign Patent Documents
|
|
|
|
|
|
|
01/91790 |
|
Dec 2001 |
|
WO |
|
02/095075 |
|
Nov 2002 |
|
WO |
|
Other References
JM. Troyer et al., "A live attenuated recombinant dengue-4 virus
vaccine candidate with restricted capacity for dissemination in
mosquitoes and lack of transmission from vaccine to mosquitoes",
Am. J. Trop, Med Hyg., vol. 65, pp. 414-419 (2001). cited by
applicant .
S.S. Whitehead et al., "A live, attenuated dengue virus type 1
vaccine candidate with a 30-nucleotide deletion in the 3'
untranslated region is highly attenuated and immunogenic in
monkeys", J. Virol., vol. 77, pp. 1653-1657 (2003). cited by
applicant .
S.S. Whitehead et al., "Substitution of the structural genes of
dengue virus type 4 with those of type 2 results in chimeric
vaccine candidates which are attenuated for mosquitoes, mice, and
rhesus monkeys", Vaccine, vol. 21, pp. 4307-4316 (2003). cited by
applicant .
M. Worobey et al., "Widespread intra-serotype recombination in
natural populations of dengue virus", PNAS USA, vol. 96, pp.
7352-7357 (1999). cited by applicant .
L. Zeng et al., "Identification of specific nucleotide sequences
within the conserved 3'-SL in the dengue type 2 virus genome
required for replication", J. Virol., vol. 72, pp. 7510-7522
(1998). cited by applicant .
N. Bhamarapravati et al., "Live attenuated tetravalent dengue
vaccine", Vaccine, vol. 18, pp. 44-47 (2000). cited by applicant
.
J.E. Blaney, Jr. et al., "Development of a Live Attenuated Dengue
Virus Vaccine Using Reverse Genetics", Viral Immunol., vol. 19, pp.
10-32 (2006). cited by applicant .
A.P. Durbin et al., "The Recombinant Live Attenuated Dengue 4
Candidate Vaccine rDEN4delta30 is Safe, Immunogenic, and Highly
Infectious in Healthy Adults", Am. J. Trop. Med. Hyg., p. 361,
Abstract 379 (2003). cited by applicant .
K.A. Hanley et al., "Paired Charge-to-Alanine Mutagenesis of Dengue
Virus Type 4 NS5 Generates Mutants with Temperature-Sensitive, Host
Range, and Mouse Attenuation Phenotypes", J. Virol., vol. 76, pp.
525-531 (2002). cited by applicant .
N. Kanesa-Thasan et al., "Safety and immunogenicity of attenuated
dengue virus vaccines (Aventis Pasteur) in human volunteers",
Vaccine, vol. 19, pp. 3179-3188 (2001). cited by applicant .
Durbin et al., Attenuation and immunogenicity in humans of a live
dengue virus type-4 vaccine candidate with a 30 nucleotide deletion
in its 3'-untranslated region, American Journal of Tropical
Medicine and Hygeine, vol. 65, pp. 405-413 (2001). cited by
applicant .
Lai et al., Clinical and Diagnostic Virology, vol. 10, pp. 173-179
(1998). cited by applicant .
Olsthoorn et al., RNA, vol. 7, pp. 1370-1377 (2001). cited by
applicant .
Blaney et al., Journal of Virology, vol. 79, pp. 5516-5528 (2005).
cited by applicant .
Proutski et al., Virus Research, vol. 64, pp. 107-123 (1999). cited
by applicant .
J. An et al., "Development of a novel mouse model for dengue virus
infection", Virology, vol. 263, pp. 70-77 (1999). cited by
applicant .
A.D.T. Barrett et al., "Yellow fever vaccines", Biologicals, vol.
25, pp. 17-25 (1997). cited by applicant .
J.L. Blackwell et al., "Translation elongation factor-1 alpha
interacts with the 3' stem-loop region of West Nile virus genomic
RNA", J. Virol., vol. 71, pp. 6433-6444 (1997). cited by applicant
.
J.E. Blaney, Jr., et al., "Chemical mutagenesis of dengue virus
type 4 yields mutant viruses which are temperature sensitive in
vero cells or human liver cells and attenuated in mice", J. Virol.,
vol. 75, pp. 9731-9740 (2001). cited by applicant .
J.E. Blaney, Jr., et al., "Genetic basis of attenuation of dengue
virus type 4 small plaque mutants with restricted replication in
suckling mice and in SCID mice transplanted with human liver
cells", Virology, vol. 300, pp. 125-139 (2002). cited by applicant
.
J.E. Blaney, Jr. et al. "Mutations which enhance the replication of
dengue virus type 4 and an antigenic chimeric dengue virus type 2/4
vaccine candidate in Vero cells", Vaccine, vol. 21, pp. 4317-4327
(2003). cited by applicant .
J.E. Blaney, Jr., et al., "Genetically modified, live attenuated
dengue virus type 3 vaccine candidates", Am. J. Trop. Med. Hyg.,
vol. 71, pp. 811-821 (2004). cited by applicant .
J.E. Blaney, Jr. et al. "Vaccine candidates derived from a novel
infectious cDNA clone of an American genotype dengue virus type 2",
BMC Infect. Dis., 4(39), 10 pages (2004). cited by applicant .
J. Blok et al, "Comparison of a dengue-2 virus and its candidate
vaccine derivative: sequence relationships with the flaviviruses
and other viruses", Virology, vol. 187, pp. 573-590 (1992). cited
by applicant .
M. Bray et al., "Construction of intertypic chimeric dengue viruses
by substitution of structural protein genes", PNAS USA, vol. 88,
pp. 10342-10346 (1991). cited by applicant .
M. Bray et al., "Monkeys immunized with intertypic chimeric dengue
viruses are protected against wild-type virus challenge", J.
Virol., vol. 70, pp. 4162-4166 (1996). cited by applicant .
M. Bray et al., "Genetic determinants responsible for acquisition
of dengue type 2 virus mouse neurovirulence", J. Virol., vol. 72,
pp. 1647-1651 (1998). cited by applicant .
M.A. Brinton et al., "The 3'-nucleotides of flavivirus genomic RNA
form a conserved secondary structure", Virology, vol. 153, pp.
113-121 (1986). cited by applicant .
D.S. Burke et al., "A prospective study of dengue infections in
Bangkok", Am. J. Trop. Med. Hyg., vol. 38, pp. 172-180 (1988).
cited by applicant .
S. Butrapet et al., "Attenuation markers of a candidate dengue type
2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in
the 5' noncoding region and nonstructural proteins 1 and 3", J.
Virol., vol. 74, pp. 3011-3019 (2000). cited by applicant .
T.J. Chambers et al., "Yellow fever virus/dengue-2 virus and yellow
fever virus/dengue-4 virus chimeras: biological characterization,
immunogenicity, and protection against dengue encephalitis in the
mouse model", J. Virol., vol. 77, pp. 3655-3668 (2003). cited by
applicant .
W. Chen et al., "Construction of intertypic chimeric dengue viruses
exhibiting type 3 antigenicity and neurovirulence for mice", J.
Virol., vol. 69, pp. 5186-5190 (1995). cited by applicant .
D.J. Gubler et al., "Impact of dengue/dengue hemorrhagic fever on
the developing world", Adv. Virus Res., vol. 53, pp. 35-70 (1999).
cited by applicant .
S. Guillot et al., "Natural genetic exchanges between vaccine and
wild poliovirus strains in humans", J. Virol., vol. 74, pp.
8434-8443 (2000). cited by applicant .
F. Guirakhoo et al., "Construction, safety and immunogenicity in
nonhuman primates of a chimeric yellow fever-dengue virus
tetravalent vaccine", J. Virol., vol. 75, pp. 7290-7304 (2001).
cited by applicant .
F. Guirakhoo et al., "Viremia and immunogenicity in nonhuman
primates of a tetravalent yellow fever-dengue chimeric vaccine:
genetic reconstructions, dose adjustment, and antibody responses
against wild-type dengue virus isolates", Virology, vol. 298, pp.
146-159 (2002). cited by applicant .
C.S. Hahn et al., "Conserved elements in the 3' untranslated region
of flavivirus RNAs and potential cyclization sequences", J. Mol.
Biol., vol. 198, pp. 33-41 (1987). cited by applicant .
K.A. Hanley et al., "Introduction of mutations into the
non-structural genes or 3' untranslated region of an attenuated
dengue virus type 4 vaccine candidate further decreases replication
in rhesus monkeys while retaining protective immunity", Vaccine,
vol. 22, pp. 3440-3448 (2004). cited by applicant .
C.Y. Huang et al., "Chimeric dengue type 2 (vaccine strain
PDK-53)/dengue type 1 virus as a potential candidate dengue type 1
virus vaccine", J. Virol., vol. 74, pp. 3020-3028 (2000). cited by
applicant .
O. Kew et al., "Outbreak of poliomyelitis in Hispaniola associated
with circulating type 1 vaccine-derived poliovirus", Science, vol.
296, pp. 356-359 (2002). cited by applicant .
A.A. Khromykh et al., "RNA binding properties of core protein of
the flavivirus Kunjin", Arch. Virol., vol. 141, pp. 685-699 (1996).
cited by applicant .
C.J. Lai et al., "Infectious RNA transcribed from stably cloned
full-length cDNA of dengue type 4 virus", PNAS USA, vol. 88, pp.
5139-5143 (1991). cited by applicant .
L. Markoff et al., "A conserved internal hydrophobic domain
mediates the stable membrane integration of the dengue virus capsid
protein", Virology, vol. 233, pp. 105-117 (1997). cited by
applicant .
L. Markoff et al., "Derivation and characterization of a dengue
type 1 host range-restricted mutant virus that is attenuated and
highly immunogenic in monkeys", J. Virol., vol. 76, pp. 3318-3328
(2002). cited by applicant .
A. Mathew et al., "Predominance of HLA-restricted cytotoxic
T-lymphocyte responses to serotype-cross-reactive epitopes on
nonstructural proteins following natural secondary dengue virus
infection", J. Virol., vol. 72, pp. 3999-4004 (1998). cited by
applicant .
R. Men et al., "Dengue type 4 virus mutants containing deletions in
the 3' noncoding region of the RNA genome: analysis of growth
restriction in cell culture and altered viremia pattern and
immunogenicity in rhesus monkeys", J. Virol., vol. 70, pp.
3930-3937 (1996). cited by applicant .
A.G. Pletnev et al., "Construction and characterization of chimeric
tick-borne encephalitis/dengue type 4 viruses", PNAS USA, vol. 89,
pp. 10532-10536 (1992). cited by applicant .
A.G. Platnev et al., "Chimeric tick-borne encephalitis and dengue
type 4 viruses: effects of mutations on neurovirulence in mice", J.
Virol., vol. 67, pp. 4956-4963 (1993). cited by applicant .
A.G. Platnev et al., "Attenuation of the Langat tick-borne
flavivirus by chimerization with mospuito-borne flavivirus dengue
type 4", PNAS USA, vol. 95, pp. 1746-1751 (1998). cited by
applicant .
A.G. Pletnev et al., "West Nile virus/dengue type 4 virus chimeras
that are reduced in neurovirulence and peripheral virulence without
loss of immunogenicity or protective efficacy", PNAS USA, vol. 99,
pp. 3036-3041 (2002). cited by applicant .
S. Polo et al., "Infectious RNA transcripts from full-length dengue
virus type 2 cDNA clones made in yeast", J. Virol., vol. 71, pp.
5366-5374 (1997). cited by applicant .
V. Proutski et al., "Secondary structure of the 3' untranslated
region of flaviviruses: similarities and differences", Nucleic
Acids Res.. vol. 25, pp. 1194-1202 (1997). cited by applicant .
B. Puri et al., "Molecular analysis of dengue virus attenuation
after serial passage in primary dog kidney cells", J. Gen. Virol.,
vol. 78, pp. 2287-2291 (1997). cited by applicant .
B. Puri et al., "Construction of a full length infectious clone for
dengue-1 virus Western Pacific, 74 strain", Virus Genes, vol. 20,
pp. 57-63 (2000). cited by applicant .
S. Rauscher et al., "Secondary structure of the 3'-noncoding region
of flavivirus genomes: comparative analysis of base pairing
probabilities", RNA, vol. 3, pp. 779-791 (1997). cited by applicant
.
C.M. Rice et al., "Nucleotide sequence of yellow fever virus:
implications for flavivirus gene expression and evolution",
Science, vol. 229, pp. 726-733 (1985). cited by applicant .
L. Rosen et al., "Comparative susceptibility of mosquito species
and strains to oral and parenteral infection with dengue and
Japanese encephalitis viruses", Am. J. Trop. Med. Hyg., vol. 34,
pp. 603-615 (1985). cited by applicant .
L. Rosen et al., "Comparative suceptibility of five species of
Toxorhynchites mosquitoes to parenteral infection with dengue and
other flaviviruses", Am. J. Trop. Med. Hyg., vol. 34, pp. 805-809
(1985). cited by applicant .
M. Ta et al., "Mov34 protein from mouse brain interacts with the 3'
noncoding region of Japanese encephalitis virus", J. Virol., vol.
74, pp. 5108-5115 (2000). cited by applicant .
S. Thein et al., "Risk factors in dengue shock syndrome", Am. J.
Trop. Med. Hyg., vol. 56, pp. 566-572 (1997). cited by applicant
.
S.S. Whitehead et al., "Dengue Virus Vaccine Candidates Containing
a Common 30 Nucleotide Deletion in the 3'-UTR of Each Serotype or
Antigenic Chimeric Viruses Representing Each Serotype are
Attenuated and Immunogenic", American Journal of Tropical Medicine
& Hygiene, 69(3), pp. 530-531 (2003). cited by applicant .
A.P. Durbin et al., "rDEN2/4Delta30(ME), A Live Attenuated Chimeric
Dengue Serotype 2 Vaccine is Safe and Highly Immunogenic in Healthy
Dengue-Naive Adults", Human Vaccines, 2(6), pp. 255-260 (2006).
cited by applicant .
European Search Report for EP Appln. No. 10 17 7735, dated May 10,
2011. cited by applicant .
European Search Report for EP Appln. No. 10 17 7740, dated Mar. 25,
2011. cited by applicant.
|
Primary Examiner: Ponnaluri; Shri
Attorney, Agent or Firm: Klarquist Sparkman, LLP
Parent Case Text
RELATED APPLICATIONS
This application is a continuation of U.S. patent application Ser.
No. 10/970,640, filed Oct. 21, 2004, which is a continuation and
claims the benefit of priority of International Application No.
PCT/US03/13279 filed Apr. 25, 2003, designating the United States
of America and published in English on Nov. 13, 2003, as WO
03/092592, which claims the benefit of priority of U.S. Provisional
Application No. 60/377,860 filed May 3, 2002 and U.S. Provisional
Application No. 60/436,500 filed Dec. 23, 2002, all of which are
hereby expressly incorporated by reference in their entireties.
Claims
What is claimed is:
1. A tetravalent immunogenic composition comprising a) a first
attenuated virus that is immunogenic against dengue serotype 1
comprising a nucleic acid that encodes at least one structural
protein from dengue serotype 1 and nonstructural proteins from
dengue serotype 1 or dengue serotype 4; b) a second attenuated
virus that is immunogenic against dengue serotype 2 comprising a
nucleic acid that encodes at least one structural protein from
dengue serotype 2 and nonstructural proteins from dengue serotype
4; c) a third attenuated virus that is immunogenic against dengue
serotype 3 comprising a nucleic acid that encodes at least one
structural protein from dengue serotype 3 and nonstructural
proteins from dengue serotype 3 or dengue serotype 4; and d) a
fourth attenuated virus that is immunogenic against dengue serotype
4 comprising a nucleic acid that encodes at least one structural
protein from dengue serotype 4 and nonstructural proteins from
dengue serotype 4, wherein the first attenuated virus, the second
attenuated virus, the third attenuated virus, and the fourth
attenuated virus each comprise a 3' untranslated region, and
wherein the 3' untranslated region contains a deletion of about 30
nucleotides corresponding to the TL2 stem-loop structure of dengue
serotype 1, dengue serotype 3, or dengue serotype 4; wherein the
tetravalent immunogenic composition is not a combination of
rDEN1/4.DELTA.30, rDEN2/4.DELTA.30, rDEN3/4.DELTA.30, and
rDEN4.DELTA.30.
2. The tetravalent immunogenic composition of claim 1, wherein the
nucleic acid of at least one of a), b), c) or d) further comprises
a mutation that confers a phenotype wherein the phenotype is
host-cell adaptation for improved replication in Vero cells, or
attenuation in mice or monkeys.
3. The composition of claim 1, wherein the 3' untranslated region
of a) comprises a deletion of about 30 nucleotides from the 3'
untranslated region of the dengue type 1 genome corresponding to
the TL2 stem-loop structure between about nucleotides
10562-10591.
4. The composition of claim 1, wherein the 3' untranslated region
of a) comprises a deletion of about 30 nucleotides from the 3'
untranslated region of the dengue type 4 genome corresponding to
the TL2 stem-loop structure between about nucleotides
10478-10507.
5. The composition of claim 1, wherein the 3' untranslated region
of b) comprises a deletion of about 30 nucleotides from the 3'
untranslated region of the dengue type 4 genome corresponding to
the TL2 stem-loop structure between about nucleotides
10478-10507.
6. The composition of claim 1, wherein the 3' untranslated region
of c) comprises a deletion of about 30 nucleotides from the 3'
untranslated region of the dengue type 4 genome corresponding to
the TL2 stem-loop structure between about nucleotides
10478-10507.
7. The composition of claim 1, wherein the 3' untranslated region
of d) comprises a deletion of about 30 nucleotides from the 3'
untranslated region of the dengue type 4 genome corresponding to
the TL2 stem-loop structure between about nucleotides
10478-10507.
8. The composition of claim 1, wherein the nucleic acid that
encodes at least one structural protein from dengue serotype 1
encodes at least two structural proteins from dengue serotype
1.
9. The composition of claim 1, wherein the nucleic acid that
encodes at least one structural protein from dengue serotype 2
encodes at least two structural proteins from dengue serotype
2.
10. The composition of claim 1, wherein the nucleic acid that
encodes at least one structural protein from dengue serotype 3
encodes at least two structural proteins from dengue serotype
3.
11. The composition of claim 1, wherein the nucleic acid that
encodes at least one structural protein from dengue serotype 4
encodes at least two structural proteins from dengue serotype
4.
12. The composition of claim 8, wherein the at least two structural
proteins from dengue serotype 1 are prM and E proteins.
13. The composition of claim 8, wherein the at least two structural
proteins from dengue serotype 1 are C, prM and E proteins.
14. The composition of claim 9, wherein the at least two structural
proteins from dengue serotype 2 are prM and E proteins.
15. The composition of claim 10, wherein the at least two
structural proteins from dengue serotype 3 are C, prM and E
proteins.
16. The composition of claim 11, wherein the at least two
structural proteins from dengue serotype 4 are C, prM and E
proteins.
17. The composition of claim 12, wherein the at least one
structural protein from dengue serotype 2 is prM and E proteins;
wherein the at least one structural protein from dengue serotype 3
is C, prM and E proteins; wherein the at least one structural
protein from dengue serotype 4 is C, prM and E proteins; wherein
the deletion of a) is a deletion of about 30 nucleotides from the
3' untranslated region of the dengue type 4 genome corresponding to
the TL2 stem-loop structure between about nucleotides 10478-10507;
wherein the deletion of b) is a deletion of about 30 nucleotides
from the 3' untranslated region of the dengue type 4 genome
corresponding to the TL2 stem-loop structure between about
nucleotides 10478-10507; wherein the deletion of c) is a deletion
of about 30 nucleotides from the 3' untranslated region of the
dengue type 4 genome corresponding to the TL2 stem-loop structure
between about nucleotides 10478-10507; wherein the deletion of d)
is a deletion of about 30 nucleotides from the 3' untranslated
region of the dengue type 4 genome corresponding to the TL2
stem-loop structure between about nucleotides 10478-10507.
18. The composition of claim 13, wherein the at least one
structural protein from dengue serotype 2 is prM and E proteins,
wherein the at least one structural protein from dengue serotype 3
is C, prM and E proteins; wherein the at least one structural
protein from dengue serotype 4 is C, prM and E proteins; wherein
the deletion of a) is a deletion of about 30 nucleotides from the
3' untranslated region of the dengue type 1 genome corresponding to
the TL2 stem-loop structure between about nucleotides 10562-10591;
wherein the deletion of b) is a deletion of about 30 nucleotides
from the 3' untranslated region of the dengue type 4 genome
corresponding to the TL2 stem-loop structure between about
nucleotides 10478-10507; wherein the deletion of c) is a deletion
of about 30 nucleotides from the 3' untranslated region of the
dengue type 4 genome corresponding to the TL2 stem-loop structure
between about nucleotides 10478-10507; wherein the deletion of d)
is a deletion of about 30 nucleotides from the 3' untranslated
region of the dengue type 4 genome corresponding to the TL2
stem-loop structure between about nucleotides 10478-10507.
19. The composition of claim 1 which is a combination of
rDEN1/4.DELTA.30, rDEN2/4.DELTA.30, rDEN3.DELTA.30, and
rDEN4.DELTA.30.
20. The composition of claim 1 which is a combination of
.[.rDEN1/4.DELTA.30, rDEN2/4.DELTA.30,.]. .Iadd.rDEN1/3.DELTA.30,
rDEN2/3.DELTA.30, .Iaddend.rDEN3.DELTA.30, and rDEN4.DELTA.30.
.[.21. The composition of claim 1 which is a combination of
rDEN1/4.DELTA.30, rDEN2/4.DELTA.30, rDEN3.DELTA.30, and
rDEN4.DELTA.30..].
22. A method of inducing an immune response in a subject comprising
administering an effective amount of the composition of claim 1 to
the subject.
23. The method of claim 22 wherein the subject is a human.
24. A method of inducing an immune response in a subject comprising
administering an effective amount of the composition of claim 17 to
the subject.
25. The method of claim 24 wherein the subject is a human.
26. A method of inducing an immune response in a subject comprising
administering an effective amount of the composition of claim 18 to
the subject.
27. The method of claim 26 wherein the subject is a human.
28. A tetravalent vaccine comprising the composition of claim
1.
29. A tetravalent vaccine comprising the composition of claim
17.
30. A tetravalent vaccine comprising the composition of claim
18.
31. A method of preventing disease caused by dengue virus in a
subject comprising administering an effective amount of the vaccine
of claim 28 to the subject.
32. The method of claim 31 wherein the subject is a human.
33. A method of preventing disease caused by dengue virus in a
subject comprising administering an effective amount of the vaccine
of claim 17 to the subject.
34. The method of claim 33 wherein the subject is a human.
35. A method of preventing disease caused by dengue virus in a
subject comprising administering an effective amount of the vaccine
of claim 18 to the subject.
36. The method of claim 35 wherein the subject is a human.
Description
SEQUENCE LISTING
The present application is being filed along with a Sequence
Listing in electronic format. The Sequence Listing is provided as a
file entitled NIH230-001C1C1_Sequence_Listing.TXT, created Jan. 26,
2008, which is 118 Kb in size. The information in the electronic
format of the Sequence Listing is incorporated herein by reference
in its entirety.
FIELD OF THE INVENTION
The invention relates to a dengue virus tetravalent vaccine
containing a common 30 nucleotide deletion (.DELTA.30) in the
3'-untranslated region of the genome of dengue virus serotypes 1,
2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1,
2, 3, and 4.
BACKGROUND OF THE INVENTION
Dengue virus is a positive-sense RNA virus belonging to the
Flavivirus genus of the family Flaviviridae. Dengue virus is widely
distributed throughout the tropical and semitropical regions of the
world and is transmitted to humans by mosquito vectors. Dengue
virus is a leading cause of hospitalization and death in children
in at least eight tropical Asian countries (WHO 1997 Dengue
Haemorrhagic Fever: Diagnosis, Treatment, Prevention, and Control
2nd Edition, Geneva). There are four serotypes of dengue virus
(DEN1, DEN2, DEN3, and DEN4) that annually cause an estimated
50-100 million cases of dengue fever and 500,000 cases of the more
severe form of dengue virus infection known as dengue hemorrhagic
fever/dengue shock syndrome (DHF/DSS) (Gubler, D. J. and Meltzer,
M. 1999 Adv Virus Res 53:35-70). This latter disease is seen
predominantly in children and adults experiencing a second dengue
virus infection with a serotype different than that of their first
dengue virus infection and in primary infection of infants who
still have circulating dengue-specific maternal antibody (Burke, D.
S. et al. 1988 Am J Trop Med Hyg 38:172-180; Halstead, S. B. et al.
1969 Am J Trop Med Hyg 18:997-1021; Thein, S. et al. 1997 Am J Trop
Med Hyg 56:566-575). A dengue vaccine is needed to lessen disease
burden caused by dengue virus, but none is licensed. Because of the
association of more severe disease with secondary dengue virus
infection, a successful vaccine must simultaneously induce immunity
to all four serotypes. Immunity is primarily mediated by
neutralizing antibody directed against the envelope (E)
glycoprotein, a virion structural protein. Infection with one
serotype induces long-lived homotypic immunity and a short-lived
heterotypic immunity (Sabin, A. 1955 Am J Trop Med Hyg 4:198-207).
Therefore, the goal of immunization is to induce a long-lived
neutralizing antibody response against DEN1, DEN2, DEN3, and DEN4,
which can best be achieved economically using live attenuated virus
vaccines. This is a reasonable goal since a live attenuated vaccine
has already been developed for the related yellow fever virus,
another mosquito-borne flavivirus present in tropical and
semitropical regions of the world (Monath, T. P. and Heinz, F. X.
1996 in: Fields Virology, Fields, D. M et al. eds. Philadelphia:
Lippincott-Raven Publishers, pp. 961-1034).
Several live attenuated dengue vaccine candidates have been
developed and evaluated in humans and non-human primates. The first
live attenuated dengue vaccine candidates were host range mutants
developed by serial passage of wild-type dengue viruses in the
brains of mice and selection of mutants attenuated for humans
(Kimura, R. and Hotta, S. 1944 Jpn J Bacteriol 1:96-99; Sabin, A.
B. and Schlesinger, R. W. 1945 Science 101:640; Wisserman, C. L. et
al. 1963 Am J Trop Med Hyg 12:620-623). Although these candidate
vaccine viruses were immunogenic in humans, their poor growth in
cell culture discouraged further development. Additional live
attenuated DEN1, DEN2, DEN3, and DEN4 vaccine candidates have been
developed by serial passage in non-human tissue culture
(Angsubhakorn, S. et al. 1994 Southeast Asian J Trop Med Public
Health 25:554-559; Bancroft, W. H. et al. 1981 Infect Immun
31:698-703; Bhamarapravati, N. et al. 1987 Bull World Health Organ
65:189-195; Eckels, K. H. et al. 1984 Am J Trop Med Hyg 33:684-698;
Hoke, C. H. Jr. et al. 1990 Am J Trop Med Hyg 43:219-226;
Kanesa-Thasan, N. et al. 2001 Vaccine 19:3179-3188) or by chemical
mutagenesis (McKee, K. T. et al. 1987 Am J Trop Med Hyg
36:435-442). It has proven very difficult to achieve a satisfactory
balance between attenuation and immunogenicity for each of the four
serotypes of dengue virus using these approaches and to formulate a
tetravalent vaccine that is safe and satisfactorily immunogenic
against each of the four dengue viruses (Kanesa-Thasan, N. et al.
2001 Vaccine 19:3179-3188; Bhamarapravati, N. and Sutee, Y 2000
Vaccine 18:44-47).
Two major advances using recombinant DNA technology have recently
made it possible to develop additional promising live attenuated
dengue virus vaccine candidates. First, methods have been developed
to recover infectious dengue virus from cells transfected with RNA
transcripts derived from a full-length cDNA clone of the dengue
virus genome, thus making it possible to derive infectious viruses
bearing attenuating mutations that have been introduced into the
cDNA clone by site-directed mutagenesis (Lai, C. J. et al. 1991
PNAS USA 88:5139-5143). Second, it is possible to produce antigenic
chimeric viruses in which the structural protein coding region of
the full-length cDNA clone of dengue virus is replaced by that of a
different dengue virus serotype or from a more divergent flavivirus
(Bray, M. and Lai, C. J. 1991 PNAS USA 88:10342-10346; Chen, W. et
al. 1995 J Virol 69:5186-5190; Huang, C. Y. et al. 2000 J Virol
74:3020-3028; Pletnev, A. G. and Men, R. 1998 PNAS USA
95:1746-1751). These techniques have been used to construct
intertypic chimeric dengue viruses that have been shown to be
effective in protecting monkeys against homologous dengue virus
challenge (Bray, M. et al. 1996 J Virol 70:4162-4166). A similar
strategy is also being used to develop attenuated antigenic
chimeric dengue virus vaccines based on the attenuation of the
yellow fever vaccine virus or the attenuation of the cell-culture
passaged dengue viruses (Monath, T. P. et al. 1999 Vaccine
17:1869-1882; Huang, C. Y. et al. 2000 J Virol 74:3020-3028).
Another study examined the level of attenuation for humans of a
DEN4 mutant bearing a 30-nucleotide deletion (.DELTA.30) introduced
into its 3'-untranslated region by site-directed mutagenesis and
that was found previously to be attenuated for rhesus monkeys (Men,
R. et al. 1996 J Virol 70:3930-3937). Additional studies were
carried out to examine whether this .DELTA.30 mutation present in
the DEN4 vaccine candidate was the major determinant of its
attenuation for monkeys. It was found that the .DELTA.30 mutation
was indeed the major determinant of attenuation for monkeys, and
that it specified a satisfactory balance between attenuation and
immunogenicity for humans (Durbin, A. P. et al. 2001 Am J Trop Med
Hyg 65:405-13).
SUMMARY OF THE INVENTION
The previously identified .DELTA.30 attenuating mutation, created
in dengue virus type 4 (DEN4) by the removal of 30 nucleotides from
the 3'-UTR, is also capable of attenuating a wild-type strain of
dengue virus type 1 (DEN1). Removal of 30 nucleotides from the DEN1
3'-UTR in a highly conserved region homologous to the DEN4 region
encompassing the .DELTA.30 mutation yielded a recombinant virus
attenuated in rhesus monkeys to a level similar to recombinant
virus DEN4.DELTA.30. This establishes the transportability of the
.DELTA.30 mutation and its attenuation phenotype to a dengue virus
type other than DEN4. The effective transferability of the
.DELTA.30 mutation, described by this work, establishes the
usefulness of the .DELTA.30 mutation to attenuate and improve the
safety of commercializable dengue virus vaccines of any serotype.
We envision a tetravalent dengue virus vaccine containing dengue
virus types 1, 2, 3, and 4 each attenuated by the .DELTA.30
mutation. We also envision a tetravalent dengue virus vaccine
containing recombinant antigenic chimeric viruses in which the
structural genes of dengue virus types 1, 2, and 3 replace those of
DEN4.DELTA.30; 1, 2, and 4 replace those of DEN3.DELTA.30; 1, 3,
and 4 replace those of DEN2.DELTA.30; and 2, 3, and 4 replace those
of DEN1.DELTA.30. In some instances, such chimeric dengue viruses
are attenuated not only by the .DELTA.30 mutation, but also by
their chimeric nature. The presence of the .DELTA.30 attenuating
mutation in each virus component precludes the reversion to a
wild-type virus by intertypic recombination. In addition, because
of the inherent genetic stability of deletion mutations, the
.DELTA.30 mutation represents an excellent alternative for use as a
common mutation shared among each component of a tetravalent
vaccine.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1. The live attenuated tetravalent dengue virus vaccine
contains dengue viruses representing each of the 4 serotypes, with
each serotype containing its full set of unaltered wild-type
structural and non-structural proteins and a shared .DELTA.30
attenuating mutation. The relative location of the .DELTA.30
mutation in the 3' untranslated region (UTR) of each component is
indicated by an arrow.
FIG. 2.A. The .DELTA.30 mutation removes 30 contiguous nucleotides
(shaded) from the 3' UTR of DEN4. Nucleotides are numbered from the
3' terminus. B. Nucleotide sequence alignment of the TL2 region of
DEN1, DEN2, DEN3, and DEN4 and their .DELTA.30 derivatives. Also
shown is the corresponding region for each of the four DEN
serotypes. Upper case letters indicate sequence homology among all
4 serotypes, underlining indicates nucleotide pairing to form the
stem structure. C. Predicted secondary structure of the TL2 region
of each DEN serotype. Nucleotides that are removed by the .DELTA.30
mutation are boxed (DEN1--between nts 10562-10591, DEN2
Tonga/74--between nts 10541-10570, DEN3 Sleman/78--between nts
10535-10565, and DEN4--between nts 10478-10507).
FIG. 3. Viremia levels in rhesus monkeys inoculated with rDEN4
vaccine candidates bearing 5-FU derived mutations. Groups of four
or two (rDEN4 and rDEN4.DELTA.30) monkeys were inoculated with 5.0
log.sub.10PFU virus subcutaneously. Serum was collected daily and
virus titers were determined by plaque assay in Vero cells. The
limit of virus detection was 0.7 log.sub.10PFU/ml. Mean virus
titers are indicated for each group.
FIG. 4. Viremia levels in rhesus monkeys inoculated with rDEN4
vaccine candidates bearing pairs of charge-to-alanine mutations in
NS5. Groups of four or two (rDEN4 and rDEN4.DELTA.30) monkeys were
inoculated with 5.0 log.sub.10PFU virus subcutaneously. Serum was
collected daily and virus titers were determined by plaque assay in
Vero cells. The limit of virus detection was 1.0 log.sub.10PFU/ml.
Mean virus titers are indicated for each group. Viremia was not
detected in any monkey after day 4.
FIG. 5. The .DELTA.30 mutation attenuates both DEN1 and DEN4 for
rhesus monkeys. Groups of 4 monkeys were immunized subcutaneously
with 5.0 log.sub.10 PFU of the indicated virus. Serum was collected
each day following immunization and virus titers were determined
and are shown as mean log.sub.10PFU/ml.
FIG. 6.A. Diagram of the p2 (Tonga/74) full-length cDNA plasmid.
Regions subcloned are indicated above the plasmid. Numbering begins
at the 5' end of the viral sequence. B. The .DELTA.30 mutation
removes the indicated 30 nucleotides from the 3' UTR sequence to
create p2.DELTA.30.
FIG. 7. Viremia levels in rhesus monkeys inoculated with DEN2
(Tonga/74), rDEN2, and rDEN2.DELTA.30 vaccine candidate. Groups of
four monkeys were inoculated with 5.0 log.sub.10PFU virus
subcutaneously. Serum was collected daily and virus titers were
determined by plaque assay in Vero cells. The limit of virus
detection was 0.7 log.sub.10PFU/ml. Mean virus titers are indicated
for each group. Viremia was not detected in any monkey after day
8.
FIG. 8. A. Diagram of the p3 (Sleman/78) full-length cDNA plasmid.
Regions subcloned are indicated above the plasmid. Numbering begins
at the 5' end of the viral sequence. The sequence and insertion
location of the SpeI linker is shown. B. The .DELTA.30 mutation
removes the indicated 31 nucleotides from the 3' UTR sequence to
create p3.DELTA.30.
FIG. 9. A. Recombinant chimeric dengue viruses were constructed by
introducing either the CME or the ME regions of DEN2 (Tonga/74)
into the DEN4 genetic background. The relative location of the
.DELTA.30 mutation in the 3' UTR is indicated by an arrow and
intertypic junctions 1, 2, and 3 are indicated. B. Nucleotide and
amino acid sequence of the intertypic junction regions. Restriction
enzyme recognition sites used in assembly of each chimeric cDNA are
indicated.
FIG. 10. Growth kinetics in Vero cells of chimeric rDEN2/4.DELTA.30
viruses encoding single or combined Vero cell adaptation mutations.
Vero cells were infected with the indicated viruses at an MOI of
0.01. At the indicated time points post-infection, 1 ml samples of
tissue culture medium were removed, clarified by centrifugation,
and frozen at -80.degree. C. The level of virus replication was
assayed by plaque titration in C6/36 cells. Lower limit of
detection was 0.7 log.sub.10PFU/ml. Replication levels on day 4
post-infection are indicated by the dashed line.
FIG. 11. A. Recombinant chimeric dengue viruses were constructed by
introducing either the CME or the ME regions of DEN3 (Sleman/78)
into the DEN4 genetic background. The relative location of the
.DELTA.30 mutation in the 3' UTR is indicated by an arrow and
intertypic junctions 1, 2, and 3 are indicated. Restriction enzyme
recognition sites used in assembly of each chimeric cDNA are
indicated. B. Nucleotide and amino acid sequence of the intertypic
junction regions. Restriction enzyme recognition sites used in
assembly of each chimeric cDNA are indicated.
FIG. 12. A. Recombinant chimeric dengue viruses were constructed by
introducing either the CME or the ME regions of DEN1 (Puerto
Rico/94) into the DEN4 genetic background. The relative location of
the .DELTA.30 mutation in the 3' UTR is indicated by an arrow and
intertypic junctions 1, 2, and 3 are indicated. Restriction enzyme
recognition sites used in assembly of each chimeric cDNA are
indicated. B. Nucleotide and amino acid sequence of the intertypic
junction regions. Restriction enzyme recognition sites used in
assembly of each chimeric cDNA are indicated.
TABLE-US-00001 Brief Description of the Sequences Serotype GenBank
Accession No. or description DEN1 U88535 DEN2 Tonga/74 DEN3
Sleman/78 DEN4 AF326825
TABLE-US-00002 Brief Description of the SEQ ID NOs Figure, Table,
or Identification Appendix SEQ ID NO. TL2 region of DEN1 FIG. 2C 1
TL2 region of DEN2 FIG. 2C 2 TL2 region of DEN3 FIG. 2C 3 TL2
region of DEN4 FIG. 2C 4 TL2 region of DEN1.DELTA.30 FIG. 2B 5 TL2
region of DEN2.DELTA.30 FIG. 2B 6 TL2 region of DEN3.DELTA.30 FIG.
2B 7 TL2 region of DEN4.DELTA.30 FIG. 2B 8 TL2 region of p2 FIG. 6B
9 TL2 region of p2.DELTA.30 FIG. 6B 10 TL2 region of p3 FIG. 8B 11
TL2 region of p3.DELTA.30 FIG. 8B 12 Spel linker in p3 FIG. 8A 13
rDEN2/4 junction 1 FIG. 9B 14-nt, 15-aa rDEN2/4 junction 2 FIG. 9B
16-nt, 17-aa rDEN2/4 junction 3 FIG. 9B 18-nt, 19-aa rDEN3/4
junction 1 FIG. 11B 20-nt, 21-aa rDEN3/4 junction 2 FIG. 11B 22-nt,
23-aa rDEN3/4 junction 3 FIG. 11B 24-nt, 25-aa rDEN1/4 junction 1
FIG. 12B 26-nt, 27-aa rDEN1/4 junction 2 FIG. 12B 28-nt, 29-aa
rDEN1/4 junction 3 FIG. 12B 30-nt, 31-aa D4 selected NS4B region
Table 15 32-nt, 33-aa D1 selected NS4B region Table 15 34-nt, 35-aa
D2 selected NS4B region Table 15 36-nt, 37-aa D3 selected NS4B
region Table 15 38-nt, 39-aa CCACGGGCGCCGT Table 26 40 AAGGCCTGGA
Table 26 41 TATCCCCGGGAC Table 26 42 AGAGCTCTCTC Table 26 43
GAATCTCCACCCGGA Table 26 44 CTGTCGAATC Table 26 45 DEN2 (Tonga/74)
cDNA plasmid p2 Appendix 1 46-nt, 47-aa DEN3 (Sleman/78) cDNA
plasmid p3 Appendix 2 48-nt, 49-aa DEN1 (Puerto Rico/94) CME
Appendix 3 50-nt, 51-aa chimeric region DEN1 (Puerto Rico/94) ME
Appendix 4 52-nt, 53-aa chimeric region
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
Introduction
A molecular approach is herewith used to develop a genetically
stable live attenuated tetravalent dengue virus vaccine. Each
component of the tetravalent vaccine, namely, DEN1, DEN2, DEN3, and
DEN4, must be attenuated, genetically stable, and immunogenic. A
tetravalent vaccine is needed to ensure simultaneous protection
against each of the four dengue viruses, thereby precluding the
possibility of developing the more serious illnesses dengue
hemorrhagic fever/dengue shock syndrome (DHF/DSS), which occur in
humans during secondary infection with a heterotypic wild-type
dengue virus. Since dengue viruses can undergo genetic
recombination in nature (Worobey, M. et al. 1999 PNAS USA
96:7352-7), the tetravalent vaccine should be genetically incapable
of undergoing a recombination event between its four virus
components that could lead to the generation of viruses lacking
attenuating mutations. Previous approaches to develop a tetravalent
dengue virus vaccine have been based on independently deriving each
of the four virus components through separate mutagenic procedures,
such as passage in tissue culture cells derived from a heterologous
host. This strategy has yielded attenuated vaccine candidates
(Bhamarapravati, N. and Sutee, Y. 2000 Vaccine 18:44-7). However,
it is possible that gene exchanges among the four components of
these independently derived tetravalent vaccines could occur in
vaccines, possibly creating a virulent recombinant virus. Virulent
polioviruses derived from recombination have been generated in
vaccines following administration of a trivalent poliovirus vaccine
(Guillot, S. et al. 2000 J Virol 74:8434-43).
The present invention describes: (1) improvements to the previously
described rDEN4.DELTA.30 vaccine candidate, 2) attenuated
rDEN1.DELTA.30, rDEN2.DELTA.30, and rDEN3.DELTA.30 recombinant
viruses containing a 30 nucleotide deletion (.DELTA.30) in a
section of the 3' untranslated region (UTR) that is homologous to
that in the rDEN4.DELTA.30 recombinant virus, (3) a method to
generate a tetravalent dengue virus vaccine composed of
rDEN1.DELTA.30, rDEN2.DELTA.30, rDEN3.DELTA.30, and rDEN4.DELTA.30,
4) attenuated antigenic chimeric viruses, rDEN1/4.DELTA.30,
rDEN2/4.DELTA.30, and rDEN3/4.DELTA.30, for which the CME, ME, or E
gene regions of rDEN4.DELTA.30 have been replaced with those
derived from DEN1, DEN2, or DEN3; alternatively rDEN1/3.DELTA.30,
rDEN2/3.DELTA.30, and rDEN4/3.DELTA.30 for which CME, ME, or E gene
regions of rDEN3.DELTA.30 have been replaced with those derived
from DEN1, 2, or 4; alternatively rDEN1/2.DELTA.30,
rDEN3/2.DELTA.30, and rDEN4/2.DELTA.30 for which CME, ME, or E gene
regions of rDEN2.DELTA.30 have been replaced with those derived
from DEN1, 3, or, 4; and alternatively rDEN2/1.DELTA.30,
rDEN3/1.DELTA.30, and rDEN4/1.DELTA.30 for which CME, ME, or E gene
regions of rDEN1.DELTA.30 have been replaced with those derived
from DEN2, 3, or 4, and 5) a method to generate a tetravalent
dengue virus vaccine composed of rDEN1/4.DELTA.30,
rDEN2/4.DELTA.30, rDEN3/4.DELTA.30, and rDEN4.DELTA.30,
alternatively rDEN1/3.DELTA.30, rDEN2/3.DELTA.30, rDEN4/3.DELTA.30,
and rDEN3.DELTA.30, alternatively rDEN1/2.DELTA.30,
rDEN3/2.DELTA.30, rDEN4/2.DELTA.30, and rDEN2.DELTA.30, and
alternatively rDEN2/1.DELTA.30, rDEN3/1.DELTA.30, rDEN4/1.DELTA.30,
and rDEN1.DELTA.30. These tetravalent vaccines are unique since
they contain a common shared attenuating mutation which eliminates
the possibility of generating a virulent wild-type virus in a
vaccine since each component of the vaccine possesses the same
.DELTA.30 attenuating deletion mutation. In addition, the
rDEN1.DELTA.30, rDEN2.DELTA.30, rDEN3.DELTA.30, rDEN4.DELTA.30
tetravalent vaccine is the first to combine the stability of the
.DELTA.30 mutation with broad antigenicity. Since the .DELTA.30
deletion mutation is in the 3' UTR of each virus, all of the
proteins of the four component viruses are available to induce a
protective immune response. Thus, the method provides a mechanism
of attenuation that maintains each of the proteins of DEN1, DEN2,
DEN3, and DEN4 viruses in a state that preserves the full
capability of each of the proteins of the four viruses to induce
humoral and cellular immune responses against all of the structural
and non-structural proteins present in each dengue virus
serotype.
As previously described, the DEN4 recombinant virus, rDEN4.DELTA.30
(previously referred to as 2A.DELTA.30), was engineered to contain
a 30 nucleotide deletion in the 3' UTR of the viral genome (Durbin,
A. P. et al. 2001 Am J Trop Med Hyg 65:405-13; Men, R. et al. 1996
J Virol 70:3930-7). Evaluation in rhesus monkeys showed the virus
to be significantly attenuated relative to wild-type parental
virus, yet highly immunogenic and completely protective. Also, a
phase I clinical trial with adult human volunteers showed the
rDEN4.DELTA.30 recombinant virus to be safe and satisfactorily
immunogenic (Durbin, A. P. et al. 2001 Am J Trop Med Hyg
65:405-13). To develop a tetravalent vaccine bearing a shared
attenuating mutation in a untranslated region, we selected the
.DELTA.30 mutation to attenuate wild-type dengue viruses of
serotypes 1, 2, and 3 since it attenuated wild-type DEN4 virus for
rhesus monkeys and was safe in humans (FIG. 1).
The .DELTA.30 mutation was first described and characterized in the
DEN4 virus (Men, R. et al. 1996 J Virol 70:3930-7). In DEN4, the
mutation consists of the removal of 30 contiguous nucleotides
comprising nucleotides 10478-10507 of the 3' UTR (FIG. 2A) which
form a putative stem-loop structure referred to as TL2 (Proutski,
V. et al. 1997 Nucleic Acids Res 25:1194-202). Among the
flaviviruses, large portions of the UTR form highly conserved
secondary structures (Hahn, C. S. et al. 1987 J Mol Biol 198:33-41;
Proutski, V. et al. 1997 Nucleic Acids Res 25:1194-202). Although
the individual nucleotides are not necessarily conserved in these
regions, appropriate base pairing preserves the stem-loop structure
in each serotype, a fact that is not readily apparent when only
considering the primary sequence (FIG. 2B, C).
Immunogenic Dengue Chimeras and Methods for their Preparation
Immunogenic dengue chimeras and methods for preparing the dengue
chimeras are provided herein. The immunogenic dengue chimeras are
useful, alone or in combination, in a pharmaceutically acceptable
carrier as immunogenic compositions to minimize, inhibit, or
immunize individuals and animals against infection by dengue
virus.
Chimeras of the present invention comprise nucleotide sequences
encoding the immunogenicity of a dengue virus of one serotype and
further nucleotide sequences selected from the backbone of a dengue
virus of a different serotype. These chimeras can be used to induce
an immunogenic response against dengue virus.
In another embodiment, the preferred chimera is a nucleic acid
chimera comprising a first nucleotide sequence encoding at least
one structural protein from a dengue virus of a first serotype, and
a second nucleotide sequence encoding non-structural proteins from
a dengue virus of a second serotype different from the first. In
another embodiment the dengue virus of the second serotype is DEN4.
In another embodiment, the structural protein can be the C protein
of a dengue virus of the first serotype, the prM protein of a
dengue virus of the first serotype, the E protein of a dengue virus
of the first serotype, or any combination thereof.
The term "residue" is used herein to refer to an amino acid (D or
L) or an amino acid mimetic that is incorporated into a peptide by
an amide bond. As such, the amino acid may be a naturally occurring
amino acid or, unless otherwise limited, may encompass known
analogs of natural amino acids that function in a manner similar to
the naturally occurring amino acids (i.e., amino acid mimetics).
Moreover, an amide bond mimetic includes peptide backbone
modifications well known to those skilled in the art.
Furthermore, one of skill in the art will recognize that individual
substitutions, deletions or additions in the amino acid sequence,
or in the nucleotide sequence encoding for the amino acids, which
alter, add or delete a single amino acid or a small percentage of
amino acids (typically less than 5%, more typically less than 1%)
in an encoded sequence are conservatively modified variations,
wherein the alterations result in the substitution of an amino acid
with a chemically similar amino acid. Conservative substitution
tables providing functionally similar amino acids are well known in
the art. The following six groups each contain amino acids that are
conservative substitutions for one another:
1) Alanine (A), Serine (S), Threonine (T);
2) Aspartic acid (D), Glutamic acid (E);
3) Asparagine (N), Glutamine (Q);
4) Arginine (R), Lysine (K);
5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).
As used herein, the terms "virus chimera," "chimeric virus,"
"dengue chimera" and "chimeric dengue virus" means an infectious
construct of the invention comprising nucleotide sequences encoding
the immunogenicity of a dengue virus of one serotype and further
nucleotide sequences derived from the backbone of a dengue virus of
a different serotype.
As used herein, "infectious construct" indicates a virus, a viral
construct, a viral chimera, a nucleic acid derived from a virus or
any portion thereof, which may be used to infect a cell.
As used herein, "nucleic acid chimera" means a construct of the
invention comprising nucleic acid comprising nucleotide sequences
encoding the immunogenicity of a dengue virus of one serotype and
further nucleotide sequences derived from the backbone of a dengue
virus of a different serotype. Correspondingly, any chimeric virus
or virus chimera of the invention is to be recognized as an example
of a nucleic acid chimera.
The structural and nonstructural proteins of the invention are to
be understood to include any protein comprising or any gene
encoding the sequence of the complete protein, an epitope of the
protein, or any fragment comprising, for example, three or more
amino acid residues thereof.
Dengue Chimeras
Dengue virus is a mosquito-borne flavivirus pathogen. The dengue
virus genome contains a 5' untranslated region (5' UTR), followed
by a capsid protein (C) encoding region, followed by a
premembrane/membrane protein (prM) encoding region, followed by an
envelope protein (E) encoding region, followed by the region
encoding the nonstructural proteins
(NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5) and finally a 3' untranslated
region (3' UTR). The viral structural proteins are C, prM and E,
and the nonstructural proteins are NS1-NS5. The structural and
nonstructural proteins are translated as a single polyprotein and
processed by cellular and viral proteases.
The dengue chimeras of the invention are constructs formed by
fusing structural protein genes from a dengue virus of one
serotype, e.g. DEN1, DEN2, DEN3, or DEN4, with non-structural
protein genes from a dengue virus of a different serotype, e.g.,
DEN1, DEN2, DEN3, or DEN4.
The attenuated, immunogenic dengue chimeras provided herein contain
one or more of the structural protein genes, or antigenic portions
thereof, of the dengue virus of one serotype against which
immunogenicity is to be conferred, and the nonstructural protein
genes of a dengue virus of a different serotype.
The chimera of the invention contains a dengue virus genome of one
serotype as the backbone, in which the structural protein gene(s)
encoding C, prM, or E protein(s) of the dengue genome, or
combinations thereof, are replaced with the corresponding
structural protein gene(s) from a dengue virus of a different
serotype that is to be protected against. The resulting viral
chimera has the properties, by virtue of being chimerized with a
dengue virus of another serotype, of attenuation and is therefore
reduced in virulence, but expresses antigenic epitopes of the
structural gene products and is therefore immunogenic.
The genome of any dengue virus can be used as the backbone in the
attenuated chimeras described herein. The backbone can contain
mutations that contribute to the attenuation phenotype of the
dengue virus or that facilitate replication in the cell substrate
used for manufacture, e.g., Vero cells. The mutations can be in the
nucleotide sequence encoding non-structural proteins, the 5'
untranslated region or the 3' untranslated region. The backbone can
also contain further mutations to maintain the stability of the
attenuation phenotype and to reduce the possibility that the
attenuated virus or chimera might revert back to the virulent
wild-type virus. For example, a first mutation in the 3'
untranslated region and a second mutation in the 5' untranslated
region will provide additional attenuation phenotype stability, if
desired. In particular, a mutation that is a deletion of 30 nts
from the 3' untranslated region of the DEN4 genome between nts
10478-10507 results in attenuation of the DEN4 virus (Men et al.
1996 J Virology 70:3930-3933; Durbin et al. 2001 Am J Trop Med
65:405-413, 2001). Therefore, the genome of any dengue type 4 virus
containing such a mutation at this locus can be used as the
backbone in the attenuated chimeras described herein. Furthermore,
other dengue virus genomes containing an analogous deletion
mutation in the 3' untranslated region of the genomes of other
dengue virus serotypes may also be used as the backbone structure
of this invention.
Such mutations may be achieved by site-directed mutagenesis using
techniques known to those skilled in the art. It will be understood
by those skilled in the art that the virulence screening assays, as
described herein and as are well known in the art, can be used to
distinguish between virulent and attenuated backbone
structures.
Construction of Dengue Chimeras
The dengue virus chimeras described herein can be produced by
substituting at least one of the structural protein genes of the
dengue virus of one serotype against which immunity is desired into
a dengue virus genome backbone of a different serotype, using
recombinant engineering techniques well known to those skilled in
the art, namely, removing a designated dengue virus gene of one
serotype and replacing it with the desired corresponding gene of
dengue virus of a different serotype. Alternatively, using the
sequences provided in GenBank, the nucleic acid molecules encoding
the dengue proteins may be synthesized using known nucleic acid
synthesis techniques and inserted into an appropriate vector.
Attenuated, immunogenic virus is therefore produced using
recombinant engineering techniques known to those skilled in the
art.
As mentioned above, the gene to be inserted into the backbone
encodes a dengue structural protein of one serotype. Preferably the
dengue gene of a different serotype to be inserted is a gene
encoding a C protein, a prM protein and/or an E protein. The
sequence inserted into the dengue virus backbone can encode both
the prM and E structural proteins of the other serotype. The
sequence inserted into the dengue virus backbone can encode the C,
prM and E structural proteins of the other serotype. The dengue
virus backbone is the DEN1, DEN2, DEN3, or DEN4 virus genome, or an
attenuated dengue virus genome of any of these serotypes, and
includes the substituted gene(s) that encode the C, prM and/or E
structural protein(s) of a dengue virus of a different serotype, or
the substituted gene(s) that encode the prM and/or E structural
protein(s) of a dengue virus of a different serotype.
Suitable chimeric viruses or nucleic acid chimeras containing
nucleotide sequences encoding structural proteins of dengue virus
of any of the serotypes can be evaluated for usefulness as vaccines
by screening them for phenotypic markers of attenuation that
indicate reduction in virulence with retention of immunogenicity.
Antigenicity and immunogenicity can be evaluated using in vitro or
in vivo reactivity with dengue antibodies or immunoreactive serum
using routine screening procedures known to those skilled in the
art.
Dengue Vaccines
The preferred chimeric viruses and nucleic acid chimeras provide
live, attenuated viruses useful as immunogens or vaccines. In a
preferred embodiment, the chimeras exhibit high immunogenicity
while at the same time not producing dangerous pathogenic or lethal
effects.
The chimeric viruses or nucleic acid chimeras of this invention can
comprise the structural genes of a dengue virus of one serotype in
a wild-type or an attenuated dengue virus backbone of a different
serotype. For example, the chimera may express the structural
protein genes of a dengue virus of one serotype in either of a
dengue virus or an attenuated dengue virus background of a
different serotype.
The strategy described herein of using a genetic background that
contains nonstructural regions of a dengue virus genome of one
serotype, and, by chimerization, the properties of attenuation, to
express the structural protein genes of a dengue virus of a
different serotype has lead to the development of live, attenuated
dengue vaccine candidates that express structural protein genes of
desired immunogenicity. Thus, vaccine candidates for control of
dengue pathogens can be designed.
Viruses used in the chimeras described herein are typically grown
using techniques known in the art. Virus plaque or focus forming
unit (FFU) titrations are then performed and plaques or FFU are
counted in order to assess the viability, titer and phenotypic
characteristics of the virus grown in cell culture. Wild type
viruses are mutagenized to derive attenuated candidate starting
materials.
Chimeric infectious clones are constructed from various dengue
serotypes. The cloning of virus-specific cDNA fragments can also be
accomplished, if desired. The cDNA fragments containing the
structural protein or nonstructural protein genes are amplified by
reverse transcriptase-polymerase chain reaction (RT-PCR) from
dengue RNA with various primers. Amplified fragments are cloned
into the cleavage sites of other intermediate clones. Intermediate,
chimeric dengue clones are then sequenced to verify the sequence of
the inserted dengue-specific cDNA.
Full genome-length chimeric plasmids constructed by inserting the
structural or nonstructural protein gene region of dengue viruses
into vectors are obtainable using recombinant techniques well known
to those skilled in the art.
Methods of Administration
The viral chimeras described herein are individually or jointly
combined with a pharmaceutically acceptable carrier or vehicle for
administration as an immunogen or vaccine to humans or animals. The
terms "pharmaceutically acceptable carrier" or "pharmaceutically
acceptable vehicle" are used herein to mean any composition or
compound including, but not limited to, water or saline, a gel,
salve, solvent, diluent, fluid ointment base, liposome, micelle,
giant micelle, and the like, which is suitable for use in contact
with living animal or human tissue without causing adverse
physiological responses, and which does not interact with the other
components of the composition in a deleterious manner.
The immunogenic or vaccine formulations may be conveniently
presented in viral plaque forming unit (PFU) unit or focus forming
unit (FFU) dosage form and prepared by using conventional
pharmaceutical techniques. Such techniques include the step of
bringing into association the active ingredient and the
pharmaceutical carrier(s) or excipient(s). In general, the
formulations are prepared by uniformly and intimately bringing into
association the active ingredient with liquid carriers.
Formulations suitable for parenteral administration include aqueous
and non-aqueous sterile injection solutions which may contain
anti-oxidants, buffers, bacteriostats and solutes which render the
formulation isotonic with the blood of the intended recipient, and
aqueous and non-aqueous sterile suspensions which may include
suspending agents and thickening agents. The formulations may be
presented in unit-dose or multi-dose containers, for example,
sealed ampoules and vials, and may be stored in a freeze-dried
(lyophilized) condition requiring only the addition of the sterile
liquid carrier, for example, water for injections, immediately
prior to use. Extemporaneous injection solutions and suspensions
may be prepared from sterile powders, granules and tablets commonly
used by one of ordinary skill in the art.
Preferred unit dosage formulations are those containing a dose or
unit, or an appropriate fraction thereof, of the administered
ingredient. It should be understood that in addition to the
ingredients particularly mentioned above, the formulations of the
present invention may include other agents commonly used by one of
ordinary skill in the art.
The immunogenic or vaccine composition may be administered through
different routes, such as oral or parenteral, including, but not
limited to, buccal and sublingual, rectal, aerosol, nasal,
intramuscular, subcutaneous, intradermal, and topical. The
composition may be administered in different forms, including, but
not limited to, solutions, emulsions and suspensions, microspheres,
particles, microparticles, nanoparticles and liposomes. It is
expected that from about 1 to about 5 doses may be required per
immunization schedule. Initial doses may range from about 100 to
about 100,000 PFU or FFU, with a preferred dosage range of about
500 to about 20,000 PFU or FFU, a more preferred dosage range of
from about 1000 to about 12,000 PFU or FFU and a most preferred
dosage range of about 1000 to about 4000 PFU or FFU. Booster
injections may range in dosage from about 100 to about 20,000 PFU
or FFU, with a preferred dosage range of about 500 to about 15,000,
a more preferred dosage range of about 500 to about 10,000 PFU or
FFU, and a most preferred dosage range of about 1000 to about 5000
PFU or FFU. For example, the volume of administration will vary
depending on the route of administration. Intramuscular injections
may range in volume from about 0.1 ml to 1.0 ml.
The composition may be stored at temperatures of from about
-100.degree. C. to about 4.degree. C. The composition may also be
stored in a lyophilized state at different temperatures including
room temperature. The composition may be sterilized through
conventional means known to one of ordinary skill in the art. Such
means include, but are not limited to, filtration. The composition
may also be combined with bacteriostatic agents to inhibit
bacterial growth.
Administration Schedule
The immunogenic or vaccine composition described herein may be
administered to humans, especially individuals travelling to
regions where dengue virus infection is present, and also to
inhabitants of those regions. The optimal time for administration
of the composition is about one to three months before the initial
exposure to the dengue virus. However, the composition may also be
administered after initial infection to ameliorate disease
progression, or after initial infection to treat the disease.
Adjuvants
A variety of adjuvants known to one of ordinary skill in the art
may be administered in conjunction with the chimeric virus in the
immunogen or vaccine composition of this invention. Such adjuvants
include, but are not limited to, the following: polymers,
co-polymers such as polyoxyethylene-polyoxypropylene copolymers,
including block co-polymers, polymer p 1005, Freund's complete
adjuvant (for animals), Freund's incomplete adjuvant; sorbitan
monooleate, squalene, CRL-8300 adjuvant, alum, QS 21, muramyl
dipeptide, CpG oligonucleotide motifs and combinations of CpG
oligonucleotide motifs, trehalose, bacterial extracts, including
mycobacterial extracts, detoxified endotoxins, membrane lipids, or
combinations thereof.
Nucleic Acid Sequences
Nucleic acid sequences of dengue virus of one serotype and dengue
virus of a different serotype are useful for designing nucleic acid
probes and primers for the detection of dengue virus chimeras in a
sample or specimen with high sensitivity and specificity. Probes or
primers corresponding to dengue virus can be used to detect the
presence of a vaccine virus. The nucleic acid and corresponding
amino acid sequences are useful as laboratory tools to study the
organisms and diseases and to develop therapies and treatments for
the diseases.
Nucleic acid probes and primers selectively hybridize with nucleic
acid molecules encoding dengue virus or complementary sequences
thereof. By "selective" or "selectively" is meant a sequence which
does not hybridize with other nucleic acids to prevent adequate
detection of the dengue virus sequence. Therefore, in the design of
hybridizing nucleic acids, selectivity will depend upon the other
components present in the sample. The hybridizing nucleic acid
should have at least 70% complementarity with the segment of the
nucleic acid to which it hybridizes. As used herein to describe
nucleic acids, the term "selectively hybridizes" excludes the
occasional randomly hybridizing nucleic acids, and thus has the
same meaning as "specifically hybridizing." The selectively
hybridizing nucleic acid probes and primers of this invention can
have at least 70%, 80%, 85%, 90%, 95%, 97%, 98% and 99%
complementarity with the segment of the sequence to which it
hybridizes, preferably 85% or more.
The present invention also contemplates sequences, probes and
primers that selectively hybridize to the encoding nucleic acid or
the complementary, or opposite, strand of the nucleic acid.
Specific hybridization with nucleic acid can occur with minor
modifications or substitutions in the nucleic acid, so long as
functional species-species hybridization capability is maintained.
By "probe" or "primer" is meant nucleic acid sequences that can be
used as probes or primers for selective hybridization with
complementary nucleic acid sequences for their detection or
amplification, which probes or primers can vary in length from
about 5 to 100 nucleotides, or preferably from about 10 to 50
nucleotides, or most preferably about 18-24 nucleotides. Isolated
nucleic acids are provided herein that selectively hybridize with
the species-specific nucleic acids under stringent conditions and
should have at least five nucleotides complementary to the sequence
of interest as described in Molecular Cloning: A Laboratory Manual,
2nd ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor
Laboratory, Cold Spring Harbor, N.Y., 1989.
If used as primers, the composition preferably includes at least
two nucleic acid molecules which hybridize to different regions of
the target molecule so as to amplify a desired region. Depending on
the length of the probe or primer, the target region can range
between 70% complementary bases and full complementarity and still
hybridize under stringent conditions. For example, for the purpose
of detecting the presence of dengue virus, the degree of
complementarity between the hybridizing nucleic acid (probe or
primer) and the sequence to which it hybridizes is at least enough
to distinguish hybridization with a nucleic acid from other
organisms.
The nucleic acid sequences encoding dengue virus can be inserted
into a vector, such as a plasmid, and recombinantly expressed in a
living organism to produce recombinant dengue virus peptide and/or
polypeptides.
The nucleic acid sequences of the invention include a diagnostic
probe that serves to report the detection of a cDNA amplicon
amplified from the viral genomic RNA template by using a
reverse-transcription/polymerase chain reaction (RT/PCR), as well
as forward and reverse amplimers that are designed to amplify the
cDNA amplicon. In certain instances, one of the amplimers is
designed to contain a vaccine virus-specific mutation at the
3'-terminal end of the amplimer, which effectively makes the test
even more specific for the vaccine strain because extension of the
primer at the target site, and consequently amplification, will
occur only if the viral RNA template contains that specific
mutation.
Automated PCR-based nucleic acid sequence detection systems have
been recently developed. TaqMan assay (Applied Biosystems) is
widely used. A more recently developed strategy for diagnostic
genetic testing makes use of molecular beacons (Tyagi and Kramer,
1996 Nature Biotechnology 14:303-308). Molecular beacon assays
employ quencher and reporter dyes that differ from those used in
the TaqMan assay. These and other detection systems may used by one
skilled in the art.
EXAMPLE 1
Improvement of Dengue Virus Vaccine Candidate rDEN4.DELTA.30
The safety of recombinant live-attenuated dengue-4 vaccine
candidate rDEN4.DELTA.30 was evaluated in twenty human volunteers
who received a dose of 5.0 log.sub.10 plaque forming units (PFU)
(Durbin A. P. et al. 2001 Am J Trop Med Hyg 65:405-413). The
vaccine candidate was found to be safe, well-tolerated and
immunogenic in all of the vaccines. However, five of the vaccines
experienced a transient elevation in alanine aminotransferase
levels, three experienced neutropenia and ten vaccines developed an
asymptomatic macular rash, suggesting that it may be necessary to
further attenuate this vaccine candidate.
Currently, a randomized, double-blind, placebo-controlled, dose
de-escalation study is being conducted to determine the human
infectious dose 50 (HID.sub.50) of rDEN4.DELTA.30. Each dose cohort
consists of approximately twenty vaccines and four placebo
recipients. To date, complete data for doses of 3.0 log.sub.10 PFU
and 2.0 log.sub.10 PFU has been collected. rDEN4.DELTA.30 infected
100% of vaccines when 3.0 log.sub.10 PFU was administered and 95%
of vaccines when 2.0 log.sub.10 PFU was administered (Table 1). The
vaccine candidate caused no symptomatic illness at either dose
(Table 1). One vaccine who received 3.0 log.sub.10 PFU experienced
a transient elevation in alanine aminotransferase levels and
approximately one fourth of the vaccines experienced neutropenia at
both doses (Table 1). Neutropenia was transient and mild. More than
half of the vaccines developed a macular rash at both doses; the
occurrence of rash was not correlated with vaccination dose or with
viremia (Table 1 and Table 2). Neither peak titer nor onset of
viremia differed between the 3.0 log.sub.10 PFU and 2.0 log.sub.10
PFU doses, though both measures of viremia were significantly lower
for these doses than for a dose of 5.0 log.sub.10 PFU (Table 3).
The vaccine candidate was immunogenic in 95% of vaccines at both
doses and neutralizing antibody did not decline between days 28 and
42 post-vaccination (Table 4). Although the HID.sub.50 has not been
determined yet, it is clearly less than 2.0 log.sub.10 PFU.
Interestingly, decreases in the dose of vaccine have had no
consistent effect on immunogenicity, viremia, benign neutropenia or
the occurrence of rash. Thus it will not necessarily be possible to
further attenuate rDEN4.DELTA.30 by decreasing the dose of virus
administered, and other approaches must be developed.
TABLE-US-00003 TABLE 1 rDEN4.DELTA.30 clinical summary No. No. Mean
No. volunteers with: No. of in- with peak Neutro- subjects
Dose.sup.a fected viremia titer.sup.b Fever Rash penia.sup.c .upa-
rw.ALT 20 5.0 20 14 1.2 (0.2) 1.sup.d 10 3 5 20 3.0 20 7 0.4 (0.0)
0 11 5 1.sup.e 20 2.0 19 11 0.6 (0.1) 1.sup.d 16 4 0 8 0 0 0 0 0 0
0 0 .sup.aLog.sub.10 pfu .sup.bLog.sub.10 pfu/mL .sup.cNeutropenia
defined as ANC <1500/dl .sup.dT Max in volunteer = 100.4.degree.
F. .sup.eALT day 0 = 78, ALT max = 91 (day 14)
TABLE-US-00004 TABLE 2 Pattern of rash in vaccinees No. No. Viremia
Viremia Mean with with & no Mean day of duration Dose.sup.a
viremia rash rash rash onset .+-. SD (days .+-. SD) 5 14/20 10/20
9/20 5/20 .sub. 8.1 .+-. 1.3 [A].sup.a 3.6 .+-. 2.0 [A] 3 7/20
11/20 6/20 1/20 12.2 .+-. 1.4 [B] 5.0 .+-. 2.1 [A] 2 11/20 16/20
9/20 2/20 11.2 .+-. 1.4 [B] 6.9 .+-. 1.7 [B] .sup.alog.sub.10 pfu
.sup.bMeans in each column with different letters are significantly
different (.alpha. = 0.05)
TABLE-US-00005 TABLE 3 rDEN4.DELTA.30 viremia summary Mean onset of
Mean duration # with Mean peak titer viremia of viremia Dose.sup.a
viremia (log.sub.10 pfu/mL) (day .+-. SD) (day .+-. SD) 5 14 1.2
.+-. 0.2 [A] .sub. 5.8 .+-. 2.4 [A].sup.b 4.4 .+-. 2.4 [A] 3 7 0.4
.+-. 0.0 [B] 9.1 .+-. 2.5 [B] 1.6 .+-. 1.0 [B] 2 11 0.6 .+-. 0.1
[B] 8.7 .+-. 2.4 [B] 2.6 .+-. 2.0 [A] .sup.alog.sub.10 pfu
.sup.bMeans in each column with different letters are significantly
different (.alpha. = 0.05)
TABLE-US-00006 TABLE 4 Immunogenicity of rDEN4.DELTA.30 Geometric
mean serum neutralizing No. of Dose No. antibody titer (range) %
sero- subjects (log.sub.10) infected Day 28 Day 42 conversion 20
5.0 20 567 (72-2455) 399 (45-1230) 100 20 3.0 20 156 (5-2365) 158
(25-1222) 95 20 2.0 19 163 (5-943) 165 (5-764) 95 8 0 0 0 0 0
Two approaches have been taken to further attenuate rDEN4.DELTA.30.
This first is the generation and characterization of attenuating
point mutations in rDEN4 using 5' fluorouracil mutagenesis (Blaney,
J. E. Jr. et al. 2002 Virology 300: 125-139; Blaney, J. E. Jr. et
al. 2001 J. Virol. 75: 9731-9740). This approach has identified a
panel of point mutations that confer a range of temperature
sensitivity (ts) and small plaque (sp) phenotypes in Vero and HuH-7
cells and attenuation (att) phenotypes in suckling mouse brain and
SCID mice engrafted with HuH-7 cells (SCID-HuH-7 mice). In this
example, a subset of these mutations has been introduced to
rDEN4.DELTA.30 and the phenotypes of the resulting viruses
evaluated.
A second approach was to create a series of paired
charge-to-alanine mutations in contiguous pairs of charged amino
acid residues in the rDEN4 NS5 gene. As demonstrated previously,
mutation of 32 individual contiguous pairs of charged amino acid
residues in rDEN4 NS5 conferred a range of ts phenotypes in Vero
and HuH-7 cells and a range of att phenotypes in suckling mouse
brain (Hanley, K. H. et al. 2002 J. Virol. 76 525-531). As
demonstrated below, these mutations also confer an att phenotype in
SCID-HuH-7 mice. These mutations have been introduced, either as
single pairs or sets of two pairs, into rDEN4.DELTA.30 to determine
whether they are compatible with the .DELTA.30 mutation and whether
they enhance the att phenotypes of rDEN4.DELTA.30.
A panel of rDEN4 viruses bearing individual point mutations have
been characterized which possess temperature sensitive and/or small
plaque phenotypes in tissue culture and varying levels of
attenuated replication in suckling mouse brain when compared to
wild type rDEN4 virus (Blaney, J. E. et al. 2002 Virology
300:125-139; Blaney, J. E. et al. 2001 J. Virol. 75:9731-9740).
Three mutations have been selected to combine with the .DELTA.30
deletion mutation to evaluate their ability to further restrict
replication of rDEN4.DELTA.30 in rhesus monkeys. First, the
missense mutation in NS3 at nucleotide 4995 (Ser>Pro) which
confers temperature sensitivity in Vero and HuH-7 cells and
restricted replication in suckling mouse brain was previously
combined with the .DELTA.30 mutation (Blaney, J. E. et al. 2001 J
Virol. 75:9731-9740). The resulting virus, rDEN4.DELTA.30-4995, was
found to be more restricted (1,000-fold) in mouse brain replication
than rDEN4.DELTA.30 virus (<5-fold) when compared to wild type
rDEN4 virus. Second, a missense mutation at nucleotide 8092
(Glu>Gly) which also confers temperature sensitivity in Vero and
HuH-7 cells and 10,000-fold restricted replication in suckling
mouse brain was combined with the .DELTA.30 mutation here. Third, a
substitution in the 3' UTR at nucleotide 10634 which confers
temperature sensitivity in Vero and HuH-7 cells, small plaque size
in HuH-7 cells, and approximately 1,000-fold restricted replication
in suckling mouse brain and SCID mice transplanted with HuH-7 cells
was combined with the .DELTA.30 mutation here (Blaney, J. E. et al.
2002 Virology 300:125-139).
For the present investigation, subcloned fragments of p4 (Durbin,
A. P. et al. 2001 Am J Trop Med Hyg 65:405-13) containing the above
mutations were introduced into the p4.DELTA.30 cDNA clone. For
transcription and recovery of virus, cDNA was linearized with
Acc65I (isoschizomer of KpnI which cleaves leaving only a single 3'
nucleotide) and used as template for transcription by SP6 RNA
polymerase as previously described (Blaney, J. E. et al. 2002
Virology 300:125-139). C6/36 mosquito cells were transfected using
liposome-mediated transfection and cell culture supernatants were
harvested between days five and seven. Recovered virus was
terminally diluted twice in Vero cells and passaged two
(rDEN4.DELTA.30-4995) or three (rDEN4.DELTA.30-8092 and
rDEN4.DELTA.30-10634) times in Vero cells.
The complete genomic sequences of rDEN4.DELTA.30-4995,
rDEN4.DELTA.30-8092, and rDEN4.DELTA.30-10634 viruses were
determined as previously described (Durbin et al. 2001 Am. J. Trop.
Med. Hyg. 65:405-413). As expected, each rDEN4.DELTA.30 virus
derivative contained the .DELTA.30 mutation. Unexpectedly, in
rDEN4.DELTA.30-4995 virus, the nucleotide changes in the codon
containing nucleotide 4995, resulted in a Ser>Leu amino acid
change rather than a Ser>Pro change since the p4.DELTA.30-4995
cDNA was designed to introduce the Ser>Pro change (Table 5). The
p4.DELTA.30-4995 cDNA clone was indeed found to encode a Ser>Pro
change at nucleotide 4995, so it is unclear how the virus
population acquired the Ser>Leu mutation. Nevertheless, this
virus was evaluated to assess the phenotype specified by this
missense mutation. rDEN4.DELTA.30-4995 virus was also found to
contain an incidental mutation at nucleotides 4725-6 which resulted
in a single amino acid change (Ser>Asp). The rDEN4.DELTA.30-8092
and rDEN4.DELTA.30-10634 viruses contained the appropriate
nucleotide substitutions as well as additional incidental mutations
in E, NS4B and NS4B, respectively (Table 5).
TABLE-US-00007 TABLE 5 Missense and UTR mutations present in
rDEN4.DELTA.30 virus derivatives bearing introduced point
mutations. Amino Amino Nucleotide Nucleotide acid acid Virus Gene
position substitution position.sup.a change rDEN4.DELTA.30- NS3
4725 U > G 1542 Ser > Asp 4995 NS3 4726 C >A 1542 Ser >
Asp NS3 4995.sup.b U > C 1632 Ser > Leu rDEN4.DELTA.30- E
1612 A > C 504 Asp > Ala 8092 NS4B 7131 A > G 2344 Thr
> Ala NS5 8092.sup.b A > G 2664 Glu > Gly rDEN4.DELTA.30-
NS4B 6969 A > U 2290 Met > Leu 10634 NS4B 7182 G > C 2361
Gly > Arg 3' UTR 10634.sup.b U > C none none .sup.aAmino acid
position in DEN4 polyprotein beginning with the methionine residue
of the C protein (nucleotides 102-104) as position 1.
.sup.bMutations restricts replication in mouse models of DEN4
infection which were introduced by Kunkel mutagenesis.
Replication of the three modified rDEN4.DELTA.30 viruses were
compared to rDEN4.DELTA.30 and wild type rDEN4 virus in the
suckling mouse brain model and SCID mice transplanted with HuH-7
cells (SCID-HuH-7 mice). Experiments were conducted as previously
described (Blaney, J. E. et al. 2002 Virology 300:125-139; Blaney,
J. E. et al. 2001 J Virol. 75:9731-9740). Briefly, for infection of
suckling mouse brain, groups of six seven-day-old mice were
inoculated intracerebrally with 4.0 log.sub.10 PFU of virus and the
brain of each mouse was removed five days later. Clarified
supernatants of 10% brain suspensions were then frozen at
-70.degree. C., and the virus titer was determined by plaque assay
in Vero cells. For analysis of DEN4 virus replication in SCID-HuH-7
mice, four to six week-old SCID mice were injected
intraperitoneally with 10.sup.7 HuH-7 cells. Five to six weeks
after transplantation, mice were infected by direct inoculation
into the tumor with 4.0 log.sub.10 PFU of virus, and serum for
virus titration was obtained by tail-nicking on day 7. The virus
titer was determined by plaque assay in Vero cells.
Wild type rDEN4 virus replicated to 6.0 log.sub.10PFU/g in suckling
mouse brain, and rDEN4.DELTA.30 was restricted in replication by
0.7 log.sub.10PFU/g, which is similar to previous observations
(Table 6) (Blaney, J. E. et al. 2001 J Virol. 75:9731-9740).
rDEN4.DELTA.30-4995, rDEN4.DELTA.30-8092, and rDEN4.DELTA.30-10634
viruses were found to have restricted replication in suckling mouse
brain when compared to rDEN4 virus of 3.3, 2.8, and 2.4
log.sub.10PFU/g, respectively. These results indicate that the
additional attenuating mutations serve to further restrict
replication of the rDEN4.DELTA.30 virus in mouse brain ranging from
50-fold (rDEN4.DELTA.30-10634) to 400-fold (rDEN4.DELTA.30-4995).
In SCID-HuH-7 mice, virus titer of rDEN4.DELTA.30 virus was 0.4
log.sub.10PFU/ml lower than rDEN4 virus, which is also similar to
previous studies (Blaney, J. E. et al. 2002 Virology 300:125-139).
Each modified rDEN4.DELTA.30 virus was found to be further
restricted in replication in SCID-HuH-7 mice (Table 6).
rDEN4.DELTA.30-4995, rDEN4.DELTA.30-8092, and rDEN4.DELTA.30-10634
viruses had restricted replication in SCID-HuH-7 mice when compared
to rDEN4 virus of 2.9, 1.1, and 2.3 log.sub.10PFU/g below the level
of wild type rDEN4 virus, respectively. Two important observations
were made: (1) The 4995, 8092 and 10634 mutations were compatible
for viability with the .DELTA.30 mutation, and (2) These three
modified rDEN4.DELTA.30 viruses had between a 10 and 1,000-fold
reduction in replication in comparison to rDEN4 wild-type virus,
which allows viruses with a wide range of attenuation in this model
to be further evaluated in monkeys or humans.
TABLE-US-00008 TABLE 6 Addition of point mutations in NS3, NS5, or
the 3' UTR to rDEN4.DELTA.30 virus further attenuates the virus for
suckling mouse brain and SCID-HuH-7 mice. Replication in suckling
Replication in SCID- mouse brain.sup.a HuH-7 mice.sup.c Mean
log.sub.10- Mean No. Virus titer .+-. SE unit No. Virus titer .+-.
SE log.sub.10-unit of log.sub.10 PFU/g reduction of log.sub.10
PFU/ml reduction Virus mice brain from wt.sup.b mice serum from
wt.sup.b rDEN4 12 6.0 .+-. 0.1 -- 13 6.4 .+-. 0.2 -- rDEN4.DELTA.30
12 5.3 .+-. 0.1 0.7 20 6.0 .+-. 0.2 0.4 rDEN4.DELTA.30-4995 6 2.7
.+-. 0.4 3.3 5 3.5 .+-. 0.3 2.9 rDEN4.DELTA.30-8092 6 3.2 .+-. 0.2
2.8 7 5.0 .+-. 0.4 1.1 rDEN4.DELTA.30-10634 12 3.6 .+-. 0.1 2.4 5
4.4 .+-. 0.3 2.3 .sup.aGroups of 6 suckling mice were inoculated
i.e. with 10.sup.4 PFU of virus. Brains were removed 5 days later,
homogenized, and titered in Vero cells. .sup.bComparison of mean
virus titers of mice inoculated with mutant virus and concurrent
rDEN4 wt control. .sup.cGroups of HuH-7-SCID mice were inoculated
directly into the tumor with 10.sup.4 PFU virus. Serum was
collected on day 6 and 7 and titered in Vero cells.
Based on the findings in the two mouse models of DEN4 virus
infection, each of the rDEN4.DELTA.30-4995, rDEN4.DELTA.30-8092,
and rDEN4.DELTA.30-10634 viruses was evaluated in the rhesus
macaque model of DEN4 infection which has been previously described
(Durbin et al. 2001 Am. J. Trop. Med. Hyg. 65:405-413). Briefly,
groups of four (rDEN4.DELTA.30-4995, rDEN4.DELTA.30-8092, and
rDEN4.DELTA.30-10634) or two (rDEN4, rDEN4.DELTA.30, mock) monkeys
were inoculated with 5.0 log.sub.10PFU virus subcutaneously.
Monkeys were observed daily and serum was collected on days 0 to 6,
8, 10, and 12, and virus titers were determined by plaque assay in
Vero cells for measurement of viremia. On day 28, serum was drawn
and the level of neutralizing antibodies was tested by plaque
reduction assay in Vero cells as previously described (Durbin et
al. 2001 Am. J. Trop. Med. Hyg. 65:405-413).
Viremia was detected beginning on day 1 post-infection and ended by
day 4 in all monkeys (Table 7, FIG. 3). Viremia was present in each
monkey infected with rDEN4, rDEN4.DELTA.30, or rDEN4.DELTA.30-10634
virus, but only 2 out of 4 monkeys infected with
rDEN4.DELTA.30-4995 or rDEN4.DELTA.30-8092 virus had detectable
viremia. As expected, infection with rDEN4 virus resulted in the
highest mean number of viremic days per monkey (3.0 days) as well
as mean peak virus titer (2.2 log.sub.10PFU/ml). Monkeys infected
with rDEN4.DELTA.30 virus had both a lower mean number of viremic
days per monkey (2.0 days) and mean peak virus titer (1.1
log.sub.10PFU/ml) compared to rDEN4 virus. Groups of monkeys
infected with each of the modified rDEN4.DELTA.30 viruses had a
further restricted mean number of viremic days with those
inoculated with rDEN4.DELTA.30-8092 virus having the lowest value,
0.5 days, a 4-fold reduction compared to rDEN4.DELTA.30 virus. The
mean peak virus titer of monkeys infected with rDEN4.DELTA.30-4995
(0.9 log.sub.10PFU/ml) or rDEN4.DELTA.30-8092 (0.7
log.sub.10PFU/ml) was also lower than those infected with
rDEN4.DELTA.30 virus. However, the mean peak virus titer of monkeys
infected with rDEN4.DELTA.30-10634 (1.3 log.sub.10PFU/ml) was
slightly higher than those infected with rDEN4.DELTA.30
particularly on day 2 (FIG. 3).
TABLE-US-00009 TABLE 7 Addition of point mutations to
rDEN4.DELTA.30 further attenuates the virus for rhesus monkeys.
Mean peak Geometric mean No. of Mean no. virus titer serum
neutralizing monkeys of viremic (log.sub.10 antibody titer No. of
with days per PFU/ml .+-. (reciprocal dilution) Virus.sup.a monkeys
viremia monkey.sup.b SE) Day 0 Day 28 mock 2 0 0 <0.7 <10
<10 rDEN4 2 2 3.0 2.2 .+-. 0.6 <10 398 rDEN4.DELTA.30 2 2 2.0
1.1 .+-. 0.4 <10 181 rDEN4.DELTA.30-4995 4 2 0.8 0.9 .+-. 0.2
<10 78 rDEN4.DELTA.30-8092 4 2 0.5 0.7 .+-. 0.1 <10 61
rDEN4.DELTA.30-10634 4 4 1.3 1.3 .+-. 0.2 <10 107 .sup.aGroups
of rhesus monkeys were inoculated subcutaneously with 10.sup.5 PFU
of the indicated virus in a 1 ml dose. Serum was collected on days
0 to 6, 8, 10, 12, and 28. Virus titer was determined by plaque
assay in Vero cells. .sup.bViremia was not detected in any monkey
after day 4.
Serum collected on day 0 and 28 was tested for the level of
neutralizing antibodies against rDEN4. No detectable neutralizing
antibodies were found against DEN4 on day 0, as expected, since the
monkeys were pre-screened to be negative for neutralizing
antibodies against flaviviruses (Table 7). On day 28, monkeys
infected with rDEN4 had a mean serum neutralizing antibody titer
(reciprocal dilution) of 398 which was approximately two-fold
higher than monkeys infected with rDEN4.DELTA.30 virus (1:181).
This result and the two-fold higher level of viremia in rDEN4
virus-infected monkeys are similar to results obtained previously
(Durbin et al. 2001 Am. J. Trop. Med. Hyg. 65:405-413). Monkeys
infected with rDEN4.DELTA.30-4995 (1:78), rDEN4.DELTA.30-8092
(1:61), and rDEN4.DELTA.30-10634 (1:107) viruses each had a reduced
mean serum neutralizing antibody titer compared to monkeys infected
with rDEN4.DELTA.30 virus. The four monkeys which had no detectable
viremia did have serum neutralizing antibody titers indicating that
they were indeed infected. Despite the slight increase in mean peak
virus titer of rDEN4.DELTA.30-10634 virus compared with
rDEN4.DELTA.30 virus, rDEN4.DELTA.30-10634 virus had a lower mean
serum neutralizing antibody titer compared to monkeys infected with
rDEN4.DELTA.30 virus. This and the lower mean number of viremic
days per monkey suggests that the 10634 mutation can attenuate the
replication of rDEN4.DELTA.30 virus in monkeys.
On day 28 after inoculation, all monkeys were challenged with 5.0
log.sub.10PFU wild type rDEN4 virus subcutaneously. Monkeys were
observed daily and serum was collected on days 28 to 34, 36, and
38, and virus titers were determined by plaque assay in Vero cells
for measurement of viremia after challenge. Twenty eight days after
rDEN4 virus challenge, serum was drawn and the level of
neutralizing antibodies was tested by plaque reduction assay in
Vero cells. Mock-inoculated monkeys had a mean peak virus titer of
2.3 log.sub.10PFU/ml after challenge with a mean number of viremic
days of 3.5 (Table 8). However, monkeys inoculated with rDEN4,
rDEN4.DELTA.30, or each of the modified rDEN4.DELTA.30 viruses had
no detectable viremia, indicating that despite the decreased
replication and immunogenicity of rDEN4.DELTA.30-4995,
rDEN4.DELTA.30-8092, and rDEN4.DELTA.30-10634 viruses, each was
sufficiently immunogenic to induce protection against wild type
rDEN4. Increases in mean neutralizing antibody titer were minimal
(<3-fold) following challenge in all inoculation groups except
mock-infected providing further evidence that the monkeys were
protected from the challenge.
TABLE-US-00010 TABLE 8 rDEN4.DELTA.30 containing additional point
mutations protects rhesus monkeys from wt DEN4 virus challenge Mean
no. of Mean peak Geometric mean viremic days virus titer serum
neutralizing No. of per monkey (log.sub.10 antibody titer (re- mon-
after rDEN4 PFU/ml .+-. ciprocal dilution) Virus.sup.a keys
challenge SE) Day 28 Day 56 Mock 2 3.5 2.3 .+-. 0.1 <10 358
rDEN4 2 0.0 <0.7 398 753 rDEN4.DELTA.30 2 0.0 <0.7 181 202
rDEN4.DELTA.30-4995 4 0.0 <0.7 78 170 rDEN4.DELTA.30-8092 4 0.0
<0.7 61 131 rDEN4.DELTA.30- 4 0.0 <0.7 107 177 10634 .sup.a28
days after primary inoculation with the indicated viruses, rhesus
monkeys were challenged subcutaneously with 10.sup.5 PFU rDEN4
virus in a 1 ml dose. Serum was collected on days 28 to 34, 36, 38,
and 56. Virus titer was determined by plaque assay in Vero
cells.
Taken together, these results indicate that the three point
mutations, 4995, 8092, and 10634) described above do further
attenuate the rDEN4.DELTA.30 vaccine candidate in suckling mouse
brain, SCID-HuH-7 mice, and rhesus monkeys. Because of additional
incidental mutations (Table 4) present in each modified
rDEN4.DELTA.30 virus, the phenotypes cannot be directly attributed
to the individual 4995, 8092, and 10634 point mutations. However,
the presence of similar mouse-attenuation phenotypes in other rDEN4
viruses bearing one of these three mutations supports the
contention that the 4995, 8092, and 10634 point mutations are
responsible for the att phenotypes of the modified rDEN4.DELTA.30
viruses. Since rDEN4.DELTA.30-4995, rDEN4.DELTA.30-8092, and
rDEN4.DELTA.30-10634 virus demonstrated decreased replication in
rhesus monkeys while retaining sufficient immunogenicity to confer
protective immunity, these viruses are contemplated as dengue
vaccines for humans.
DEN4 viruses carrying both .DELTA.30 and charge-to-alanine
mutations were next generated. A subset of seven groups of
charge-to-alanine mutations described above were identified that
conferred between a 10-fold and 1,000-fold decrease in replication
in SCID-HuH-7 mice and whose unmutated sequence was well-conserved
across the four dengue serotypes. These mutations were introduced
as single pairs and as two sets of pairs to rDEN4.DELTA.30 using
conventional cloning techniques. Transcription and recovery of
virus and terminal dilution of viruses were conducted as described
above. Assay of the level of temperature sensitivity of the
charge-cluster-to-alanine mutant viruses in Vero and HuH-7 cells,
level of replication in the brain of suckling mice and level of
replication in SCID-HuH-7 mice was conducted as described
above.
Introduction of one pair of charge-to-alanine mutations to rDEN4
produced recoverable virus in all cases (Table 9). Introduction of
two pairs of charge-to-alanine mutations produced recoverable virus
in two out of three cases (rDEN4.DELTA.30-436-437-808-809 was not
recoverable).
rDEN4.DELTA.30 is not ts in Vero or HuH-7 cells. In contrast, seven
of the seven sets of charge-to-alanine mutations used in this
example conferred a ts phenotype in HuH-7 cells and five also
conferred a ts phenotype in Vero cells. All six viruses carrying
both .DELTA.30 and charge-to-alanine mutations showed a ts
phenotype in both Vero and HuH-7 cells (Table 9). rDEN4.DELTA.30 is
not attenuated in suckling mouse brain, whereas five of the seven
sets of charge-to-alanine mutations conferred an att phenotype in
suckling mouse brain (Table 10). Four of the viruses carrying both
.DELTA.30 and charge-to-alanine mutations were attenuated in
suckling mouse brain (Table 10). In one case
(rDEN4.DELTA.30-23-24-396-397) combination of two mutations that
did not attenuate alone resulted in an attenuated virus. Generally,
viruses carrying both .DELTA.30 and charge-to-alanine mutations
showed levels of replication in the suckling mouse brain more
similar to their charge-to-alanine mutant parent virus than to
rDEN4.DELTA.30.
rDEN4.DELTA.30 is attenuated in SCID-HuH-7 mice, as are six of the
seven charge-to-alanine mutant viruses used in this example.
Viruses carrying both .DELTA.30 and charge-to-alanine mutations
tended to show similar or slightly lower levels of replication in
SCID-HuH-7 mice compared to their charge-to-alanine mutant parent
virus (Table 10). In three cases, viruses carrying both .DELTA.30
and charge-to-alanine mutations showed at least a fivefold greater
reduction in SCID-HuH-7 mice than rDEN4.DELTA.30.
The complete genomic sequence of five viruses (rDEN4-200-201,
rDEN4.DELTA.30-200-201, rDEN4-436-437 [clone 1],
rDEN4.DELTA.30-436-437, and rDEN4-23-24-200-201) that replicated to
>10.sup.5 PFU/ml in Vero cells at 35.degree. C. and that showed
a hundredfold or greater reduction in replication in SCID-HuH-7
mice was determined (Table 11). Each of the five contained one or
more incidental mutations. In one virus, rDEN4.DELTA.30-436-437,
the one additional mutation has been previously associated with
Vero cell adaptation (Blaney, J. E. Jr. et al. 2002 Virology
300:125-139). Each of the remaining viruses contained at least one
incidental mutation whose phenotypic effect is unknown.
Consequently, the phenotypes described cannot be directly
attributed to the charge-to-alanine mutations. However, the fact
that rDEN4 and rDEN4.DELTA.30 viruses carrying the same
charge-to-alanine mutations shared similar phenotypes provides
strong support for the ability of charge-to-alanine mutations to
enhance the attenuation of rDEN4.DELTA.30. Because rDEN4-436-[clone
1] contained 4 incidental mutations, a second clone of this virus
was prepared. rDEN4-436-437 [clone 2] contained only one incidental
mutation (Table 11), and showed the same phenotypes as
rDEN4-436-437 in cell culture and SCID-HuH-7 mice. rDEN4-436-437
[clone 2] was used in the rhesus monkey study described below.
TABLE-US-00011 TABLE 9 Addition of charge-to-alanine mutations to
rDEN4.DELTA.30 confers a ts phenotype in both Vero and HuH-7 cells.
Mean virus titer (log.sub.10 PFU/ml) at indicated temperature
(.degree. C.).sup.a AA No. nt Vero HuH-7 Virus changed.sup.b
changed 35 37 38 39 .DELTA..sup.c 35 37 38 39 .DELTA. rDEN4 none 0
7.4 7.1 7.7 7.2 0.2 7.7 7.5 7.5 7.4 0.3 rDEN4.DELTA.30 none 30 6.6
6.6 6.5 6.5 0.1 7.4 6.9 7.0 6.4 1.0 rDEN4-23-24 KE 3 6.7 6.6 6.0
6.5 0.2 7.1 7.3 5.6 <1.7 >5.4 rDEN4.DELTA.30-23-24 6.1 5.5
4.9 <1.7 4.4 6.5 5.9 4.7 <1.7 >4.2- rDEN4-200-201 KH 4 5.3
4.8 4.8 4.3 1.0 5.7 5.4 2.7 <1.7 >4.0 rDEN4.DELTA.30-200-201
6.0 5.3 5.6 <1.7 >4.3 5.8 5.0 5.9 <1.7 &- gt;4.1
rDEN4-436-437 DK 4 5.2 4.2 3.4 1.9 3.3 5.9 4.9 3.2 <1.7 >4.2
rDEN4.DELTA.30-436-437 6.3 5.7 5.5 <1.7 >4.6 6.5 5.7 5.1
<1.7 &- gt;4.8 [clone 1] rDEN4-808-809 ED 3 4.6 4.1 <1.7
<1.7 >2.9 5.2 <1.7 <1.7 <- ;1.7 >3.5
rDEN4.DELTA.30-808-809 5.6 4.9 4.9 <1.7 >3.9 5.9 4.8 5.1
<1.7 &- gt;4.2 rDEN4-23-24-200-201 KE, KH 7 6.0 5.2 4.2
<1.7 >4.3 6.9 6.3 <1.7 <1.7 >5.2
rDEN4.DELTA.30-23-24-200-201 4.5 4.2 4.8 <1.7 >2.8 4.9 4.5
2.9 <- ;1.7 >3.2 rDEN4-23-24-396-397 KE, RE 7 6.5 5.8 5.5
<1.7 >4.8 7.1 5.9 5.4 <1.7 >5.4
rDEN4.DELTA.30-23-24-396-397 6.1 5.2 4.8 <1.7 >4.4 6.9 5.4
4.9 <- ;1.7 >5.2 rDEN-436-437-808-809 DK, ED 7 4.9 4.9 5.1
<1.7 >3.2 5.5 3.2 <1.7 <1.7 >3.8 .sup.aUnderlined
values indicate a 2.5 or 3.5 log.sub.10 PFU/ml reduction in titer
in Vero or HuH-7 cells, respectively, at the indicated temperature
when compared to the permissive temperature (35.degree. C.).
.sup.bAmino acid pair(s) changed to pair of Ala residues.
.sup.cReduction in titer (log.sub.10 pfu/ml) compared to the
permissive temperature (35.degree. C.).
TABLE-US-00012 TABLE 10 Addition of charge-to-alanine mutations
attenuates rDEN4.DELTA.30 in suckling mouse brain and enhances
attenuation in SCID-HuH-7 mice. Replication in suckling mice.sup.a
Replication inSCID-HuH-7 mice.sup.c Mean virus Mean log Mean virus
Mean log titer .+-. SE (log.sub.10 reduction titer .+-. SE
(log.sub.10 reduction Virus n PFU/g brain) from wt.sup.b n PFU/ml
serum) from wt.sup.d rDEN4 18 6.2 .+-. 0.4 -- 33 5.4 .+-. 0.3 --
rDEN4.DELTA.30 12 5.9 .+-. 0.8 0.2 8 3.4 .+-. 0.3 2.3 rDEN4-23-24
18 4.7 .+-. 0.1 1.6 19 4.7 .+-. 0.5 1.3 rDEN4.DELTA.30-23-24 6 5.6
.+-. 0.3 0.7 7 4.6 .+-. 0.4 1.5 rDEN4-200-201 12 5.5 .+-. 0.5 0.6
12 3.7 .+-. 0.2 2.6 rDEN4.DELTA.30-200-201 6 5.5 .+-. 0.6 0.1 4 3.3
.+-. 0.6 1.8 rDEN4-436-437 18 2.7 .+-. 0.4 3.5 10 2.9 .+-. 0.7 2.5
rDEN4.DELTA.30-436-437 [clone 1] 6 2.9 .+-. 0.3 3.4 4 2.3 .+-. 0.4
2.8 rDEN4-808-809 6 1.8 .+-. 0.1 3.1 8 3.2 .+-. 0.4 3.0
rDEN4.DELTA.30-808-809 12 3.9 .+-. 0.7 2.1 4 3.7 .+-. 0.6 2.4
rDEN4-23-24-200-201 12 5.3 .+-. 0.5 0.7 13 3.4 .+-. 0.1 2.9
rDEN4.DELTA.30-23-24-200-201 6 3.0 .+-. 0.2 2.6 5 1.8 .+-. 0.1 3.3
rDEN4-23-24-396-397 12 4.6 .+-. 0.9 1.5 8 3.6 .+-. 0.3 2.3
rDEN4.DELTA.30-23-24-396-397 6 3.0 .+-. 0.2 2.6 5 2.2 .+-. 0.3 2.9
rDEN-436-437-808-809 6 <1.7 .+-. 0.0 3.6 8 2.1 .+-. 0.3 2.4
.sup.aGroups of six suckling mice were inoculated i.e. with
10.sup.4 PFU virus in a 30 .mu.l inoculum. The brain was removed 5
days later, homogenized, and virus was quantitated by titration in
Vero cells. .sup.bDetermined by comparing the mean viral titers in
mice inoculated with sample virus and concurrent wt controls (n =
6). The attenuation (att) phenotype is defined as a reduction of
.gtoreq.1.5 log.sub.10 PFU/g compared to wt virus; reductions of
.gtoreq.1.5 are listed in boldface. .sup.cGroups of SCID-HuH-7 mice
were inoculated directly into the tumor with 10.sup.4 PFU virus.
.sup.dDetermined by comparing mean viral titers in mice inoculated
with sample virus and concurrent wt controls. The attenuation
phenotype is defined as a reduction of .gtoreq.1.5 log.sub.10 PFU/g
compared to wt virus; reductions of .gtoreq.1.5 are listed in
boldface.
TABLE-US-00013 TABLE 11 Missense and UTR mutations present in rDEN4
virus derivatives bearing charge-to-alanine and the .DELTA.30
mutation. Nucleotide Nucleotide Amino acid Virus Gene.sup.a,b
position substitution position.sup.c Amino acid change.sup.b
rDEN4-200-201 prM 626 A > T 61 Glu > Asp NS4A 6659 C > T
93 Len > Phe NS5 8160-8165 AAACA > GCAGC 200-201 LysHis >
AlaAla rDEN4.DELTA.30-200-201 NS3 4830 G > A 102 Gly > Arg
NS5 8106 G > A 181 Val > Ile NS5 8160-8165 AAACA > GCAGC
200-201 LysHis > AlaAla 3' UTR 10478-10507 .DELTA.30 deletion
None None rDEN4-436-437 [clone 1] E 2331 T > G 464 Trp > Gly
NS1 2845 C > T 140 Ser > Phe NS3* 4891 T > C 122 Ile >
Thr NS5 8869-8873 GACAA > GCAGC 436-437 AspLys > AlaAla NS5
9659 A > G 699 Lys > Arg rDEN4-436-437 [clone 2] NS4B 7153 T
> C 108 Val > Ala NS5 8869-8873 GACAA > GCAGC 436-437
AspLys > AlaAla rDEN4.DELTA.30-436-437 NS4B* 7163 A > C 111
Leu > Phe NS5 8869-73 GACAA > GCAGC 436-437 AspLys >
AlaAla 3' UTR 10478-10507 .DELTA.30 deletion None None
rDBN4-23-24-200-20 1 NS3 6751 A > C 124 Lys > Thr NS5
7629-7633 AAAGA > GCAGC 23-24 LysGlu > AlaAla NS5 8160-8165
AAACA > GCAGC 200-201 LysHis > AlaAla .sup.aAsterisk
indicates previously identified Vero cell adaptation mutation.
.sup.bBold values indicate mutations designed to occur in the
designated virus. .sup.cAmino acid position in the protein product
of the designated DEN4 gene; numbering starts with the amino
terminus of the protein.
Based on the attenuation in the SCID-HuH7 mouse model, four of the
charge-to-alanine mutant viruses (rDEN4-200-201,
rDEN4.DELTA.30-200-201, rDEN4-436-437 [clone 2],
rDEN4.DELTA.30-436-437) were evaluated in rhesus macaques as
described above. As with the study of viruses carrying attenuating
point mutations, viremia was detected on day 1 post-infection and
ended by day 4 in all monkeys (FIG. 4, Table 12). Viremia was
detected in most of the monkeys infected; only one of the four
monkeys infected with rDEN4.DELTA.30-200-201 and one of the four
monkeys infected with rDEN4.DELTA.30-436-437 showed no detectable
viremia. Monkeys infected with rDEN4 showed the highest mean peak
virus titer; and in each case viruses carrying the .DELTA.30
mutation showed an approximately 0.5 log decrease in mean peak
virus titer relative to their parental viruses and a 0.5 to 2 day
decrease in mean number of viremic days per monkey. Monkeys
infected with viruses carrying both the .DELTA.30 and
charge-to-alanine mutations showed a two-fold reduction in mean
peak viremia relative to those infected with rDEN4.DELTA.30. This
suggests that addition of the charge-to -alanine mutations further
attenuates rDEN4.DELTA.30 for rhesus macaques.
As expected, none of the monkeys in this study showed detectable
levels of neutralizing antibody on day 0. On day 28, every monkey
infected with a virus showed a detectable levels of neutralizing
antibody, indicating that all of the monkeys, even those that
showed no detectable viremia, had indeed been infected. As in the
study of attenuating point mutations, monkeys infected with rDEN4
had a mean serum neutralizing antibody titer (reciprocal dilution)
which was approximately twice that of monkeys that had been
infected with rDEN4.DELTA.30. Monkeys infected with rDEN4-200-201
and rDEN4-436-437 [clone 2] had similar mean neutralizing antibody
titers to rDEN4, and those infected with rDEN4.DELTA.30-200-201 and
rDEN4.DELTA.30-436-437 had similar mean neutralizing antibody
titers to rDEN4. In each case the addition of the .DELTA.30
mutation to a virus resulted in a two-fold decrease in neutralizing
antibody. Thus, although the addition of charge-to-alanine
mutations to rDEN4.DELTA.30 decreased mean peak viremia below that
of rDEN4.DELTA.30 alone, it did not affect levels of neutralizing
antibody.
TABLE-US-00014 TABLE 12 Addition of paired charge-to-alanine
mutations to rDEN4.DELTA.30 further attenuates the virus for rhesus
monkeys. Geometric mean No. of Mean no. Mean peak serum
neutralizing monkeys of viremic virus titer antibody titer No. of
with days per (log.sub.10 (reciprocal dilution) Virus.sup.a monkeys
viremia monkey.sup.b PFU/ml .+-. SE) Day 0 Day 28 mock 2 0 0
<0.7 <5 <5 rDEN4 2 2 2.5 2.6 .+-. 0.3 <5 276
rDEN4.DELTA.30 2 2 2.0 2.1 .+-. 0.1 <5 131 rDEN4-200, 201 4 4
2.3 1.8 .+-. 0.3 <5 212 rDEN4.DELTA.30-200, 201 4 3 1.5 1.3 .+-.
0.2 <5 139 rDEN4-436, 437 [cl 2) 4 4 3.3 1.8 .+-. 0.2 <5 273
rDEN4.DELTA.30-436, 437 4 3 1.3 1.0 .+-. 0.0 <5 143 .sup.aGroups
of rhesus monkeys were inoculated subcutaneously with 10.sup.5 PFU
of the indicated virus in a 1 ml dose. Serum was collected on days
0 to 6, 8, 10 and 28. Virus titer was determined by plaque assay in
Vero cells. .sup.bViremia was not detected in any monkey after day
4.
After challenge with rDEN4 on day 28, mock-infected monkeys had a
mean peak virus titer of 1.5 log.sub.10PFU/ml and a mean number of
viremic days of 3.0 (Table 13). However, none of the monkeys
previously inoculated with rDEN4, rDEN4.DELTA.30 or the
charge-to-alanine mutant viruses showed detectable viremia.
Additionally, none of the monkeys showed a greater than four-fold
increase in serum neutralizing antibody titer. Together these data
indicate that infection with any of the viruses, including those
carrying both .DELTA.30 and the charge-to-alanine mutations,
protected rhesus macaques from challenge with rDEN4.
TABLE-US-00015 TABLE 13 rDEN4.DELTA.30 containing charge-to-alanine
mutations protects rhesus monkeys from wt DEN4 virus challenge Mean
no. of Geometric mean viremic days Mean peak serum neutralizing per
monkey virus titer antibody titer No. of after rDEN4 (log.sub.10
(reciprocal dilution) Virus.sup.a monkeys challenge PFU/ml .+-. SE)
Day 28 Day 56 mock 2 3.0 1.5 .+-. 0.7 <5 284 rDEN4 2 0.0 <0.7
276 316 rDEN4.DELTA.30 2 0.0 <0.7 131 96 rDEN4-200, 201 4 0.0
<0.7 212 356 rDEN4.DELTA.30-200, 201 4 0.0 <0.7 139 132
rDEN4-436, 437 [cl 2] 4 0.0 <0.7 273 401 rDEN4.DELTA.30-436, 437
4 0.0 <0.7 143 182 .sup.a28 days after primary inoculation with
the indicated viruses, rhesus monkeys were challenged
subcutaneously with 10.sup.5 PFU rDEN4 virus in a 1 ml dose. Serum
was collected on days 28 to 34, 36, 10, and 56. Virus titer was
determined by plaque assay in Vero cells.
Addition of charge-to-alanine mutations to rDEN4.DELTA.30 can
confer a range of ts phenotypes in both Vero and HuH-7 cells and
att phenotypes in suckling mouse brain and can either enhance or
leave unchanged attenuation in SCID-HuH-7 mice. Most importantly,
addition of these mutations can decrease the viremia produced by
rDEN4.DELTA.30 in rhesus macaques without decreasing neutralizing
antibody titer or protective efficacy. Thus addition of such
mutations to rDEN4.DELTA.30 is contemplated as enhancing
attenuation in humans. Also, mutations are contemplated as being
added that do not change the overall level of attenuation, but
stabilize the attenuation phenotype because they themselves are
independently attenuating even in the absence of the .DELTA.30
mutation. Charge-to-alanine mutations are particularly useful
because they occur outside of the structural gene regions, and so
can be used to attenuate structural gene chimeric viruses.
Moreover, they involve at least three nucleotide changes, making
them unlikely to revert to wild type sequence.
A series of point mutations that enhance the replication of rDEN4
in Vero cells tissue culture have been identified; these are
primarily located in the NS4B gene (Blaney, J. E. et. al. 2002
Virology 300:125-139; Blaney, J. E. et al. 2001 J Virol
75:9731-9740). Vero cell adaptation mutations confer two desirable
features upon a vaccine candidate. First, they enhance virus yield
in Vero cells, the intended substrate for vaccine production, and
thus render vaccine production more cost-effective. Second,
although each of these Vero adaptation mutations are point
mutations, they are likely to be extremely stable during vaccine
manufacture, because they give a selective advantage in Vero cells.
At least one Vero cell adaptation mutation, at position 7129, was
also shown to decrease mosquito infectivity of rDEN4; poor mosquito
infectivity is another desirable characteristic of a dengue vaccine
candidate. To investigate the generality of this finding, we tested
the effect of the remaining Vero cell adaptation mutations on the
ability of rDEN4 to infect Aedes aegypti mosquitoes fed on an
infectious bloodmeal. Table 14 shows the infectivity of each virus
carrying a single Vero cell adaptation mutation at high titer. Of
these, only one mutation, at position 7182, was associated with a
large decrease in mosquito infectivity. Thus 7182 may be a
particularly valuable mutation to include in an rDEN4 vaccine
candidate, as it has opposite effects on replication in Vero cells
and in mosquitoes.
TABLE-US-00016 TABLE 14 Effect of Vero cell adaptation mutations on
rDEN4 mosquito infectivity Aedes aegypti (oral infection)
Dose.sup.a % infected.sup.b Virus (log.sub.10 pfu) No. tested
Midgut Head rDEN4 4.3 27 70 25 rDEN4-4891 4.4 23 74 13 rDEN4-4995
4.8 20 80 50 rDEN4-7153 4.8 20 80 30 rDEN4-7546 4.6 20 55 10
rDEN4-7162 5.0 20 55 25 rDEN4-7163 4.9 15 73 72 rDEN4-7182 5.0 20
20 0 rDEN4-7630 4.3 10 70 10 .sup.aVirus titer ingested, assuming a
2 .mu.l bloodmeal. .sup.bPercentage of mosquitoes with IFA
detectable antigen in midgut or head tissue prepared 21 days after
oral infection.
EXAMPLE 2
Generation and Characterization of a Recombinant DEN1 Virus
Containing the .DELTA.30 Mutation
We first sought to determine if the .DELTA.30 mutation was able to
satisfactorily attenuate a wild-type DEN virus other than the DEN4
serotype. To do this, the .DELTA.30 mutation was introduced into
the cDNA for DEN1 (Western Pacific). The pRS424DEN1WP cDNA clone
(Puri, B. et al. 2000 Virus Genes 20:57-63) was digested with BamHI
and used as template in a PCR using Pfu polymerase with forward
primer 30 (DEN1 nt 10515-10561 and 10592-10607) and the M13 reverse
sequencing primer (101 nt beyond the 3' end of DEN1 genome
sequence). The resulting PCR product was 292 bp and contained the
.DELTA.30 mutation. The pRS424DEN1WP cDNA was partially digested
with Apa I, then digested to completion with Sac II and the vector
was gel isolated, mixed with PCR product, and used to transform
yeast strain YPH857 to yield growth on plates lacking tryptophan
(Polo, S. et al. 1997 J Virol 71:5366-74). Positive yeast colonies
were confirmed by PCR and restriction enzyme analysis. DNA isolated
from two independent yeast colonies was used to transform E. coli
strain STBL2. Plasmid DNA suitable for generating RNA transcripts
was prepared and the presence of the .DELTA.30 mutation was
verified by sequence analysis.
For transcription and generation of virus, cDNA (designated
pRS424DEN1.DELTA.30) that was linearized with Sac II was used as
template in a transcription reaction using SP6 RNA polymerase as
described (Polo, S. et al. 1997 J Virol 71:5366-74). Transcription
reactions were electroporated into LLC-MK2 cells and infection was
confirmed by observation of CPE and immunofluorescence and
harvested on day 14. Virus stocks were amplified on C6/36 mosquito
cells and titered on LLC-MK2 cells. The genome of the resulting
virus, rDEN1.DELTA.30, was sequenced to confirm the presence of the
.DELTA.30 mutation. The .DELTA.30 mutation removes nucleotides
10562-10591of DEN1 (FIG. 2B, C), which corresponds to the TL2 of
DEN1. The virus replicates efficiently in Vero cell culture to
titers of 6.5 log.sub.10 PFU/ml, indicating that the .DELTA.30
mutation is compatible with efficient growth of DEN1 in cell
culture, a property essential for manufacture of the vaccine. Using
similar techniques, parent virus rDEN1 was generated. Incidental
mutations arising from virus passage in tissue culture were
identified in both rDEN1 and rDEN1.DELTA.30 using sequence analysis
and are listed in Table 15. An additional rDEN1.DELTA.30 virus was
derived by transfection and amplification in Vero cells. Although
this virus was not evaluated in the studies described below, its
sequence analysis is included in Table 15. The properties of
rDEN1.DELTA.30 as a vaccine in vivo were next examined.
TABLE-US-00017 TABLE 15 Missense mutations present among the
recombinant DEN1 viruses and correlation of NS4B region mutations
with those found in DEN4 Nucleo- Nucleo- Amino Amino Transfection
tide tide acid acid Virus cell type Gene position change position
change wt rDEN1 LLC-MK2 prM 816 C > U 241 Ala > Val NS4B
7165.sup.a U > G 2357 Phe > Leu NS4B 7173.sup.b U > C 2360
Val > Ala rDEN1.DELTA.30 LLC-MK2 E 1748 A > U 552 Thr >
Ser rDEN1.DELTA.30 Vero E 1545 A > G 484 Lys > Arg .sup.aSame
nucleotide as 7154 in rDEN4. .sup.bSame nucleotide as 7162 in
rDEN4
Nucleotide and amino acid comparison of selected NS4B region:
TABLE-US-00018 7 7 7 7 7 7 DEN4 1 1 1 1 1 1 base 3 4 5 6 7 8
Number:
890123456789012345678901234567890123456789012345678901234567 ++ ++
+ ++++ + + + + ++ + ++++++++ ++ ++ ++ D47128-
CCAACAACCUUGACAGCAUCCUUAGUCAUGCUUUUAGUCCAUUAUGCAAUAAUAGGCCCA P T T
L T A S L V M L L V H T A I I G P D17139-
CCGCUGACGCUGACAGCGGCGGUAUUUAUGCUAGUGGCUCAUUAUGCCAUAAUUGGACCC P L T
L T A A V P M L V A H T A I I G P D27135-
CCUAUAACCCUCACAGCGGCUCUUCUUUUAUUGGUAGCACAUUAUGCCAUCAUAGGACCG P I T
L T A A L L L L V A H T A I I G P D37130-
CCACUAACUCUCACAGCGGCAGUUCUCCUGCUAGUCACGCAUUAUGCUAUUAUAGGUCCA P L T
L T A A V L L L V T H T A I I G P + + + + + + + + + + + + + D4 =
rDEN4 D1 = rDEN1(WP) D2 = rDEN2(Tonga/74) D3 = rDEN3(Sleman/78) +
Homology among all four serotypes Nucleotides are underlined in
even multiples of 10.
Evaluation of the replication, immunogenicity, and protective
efficacy of rDEN1.DELTA.30 and wild-type parental rDEN1 virus
(derived from the pRS424DEN1WP cDNA) in juvenile rhesus monkeys was
performed as follows. Dengue virus-seronegative monkeys were
injected subcutaneously with 5.0 log.sub.10 PFU of virus in a 1 ml
dose divided between two injections in each side of the upper
shoulder area. Monkeys were observed daily and blood was collected
on days 0-10 and 28 and serum was stored at -70.degree. C. Titer of
virus in serum samples was determined by plaque assay in Vero cells
as described previously (Durbin, A. P. et al. 2001 Am J Trop Med
Hyg 65:405-13). Plaque reduction neutralization titers were
determined for the day 28 serum samples as previously described
(Durbin, A. P. et al. 2001 Am J Trop Med Hyg 65:405-13). All
monkeys were challenged on day 28 with a single dose of 5.0
log.sub.10 PFU of wild-type rDEN1 and blood was collected for 10
days. Virus titer in post-challenge sera was determined by plaque
assay in Vero cells. Monkeys inoculated with full-length wild-type
rDEN1 were viremic for 2-3 days with a mean peak titer of 2.1
log.sub.10 PFU/ml (Table 16), and monkeys inoculated with
rDEN1.DELTA.30 were viremic for less than 1 day with a mean peak
titer of 0.8 log.sub.10 PFU/ml, indicating that the .DELTA.30
mutation is capable of attenuating DEN1. As expected for an
attenuated virus, the immune response, as measured by neutralizing
antibody titer, was lower following inoculation with rDEN1.DELTA.30
compared to inoculation with wild-type rDEN1 (Table 16), yet
sufficiently high to protect the animals against wild-type DEN1
virus challenge. Wild-type rDEN1 virus was not detected in any
serum sample collected following virus challenge, indicating that
monkeys were completely protected following immunization with
either full-length wild-type rDEN1 or recombinant virus
rDEN1.DELTA.30. The level of attenuation specified by the .DELTA.30
mutation was comparable in both the DEN1 and DEN4 genetic
backgrounds (FIG. 5).
TABLE-US-00019 TABLE 16 The .DELTA.30 mutation attenuates rDEN1 for
rhesus monkeys Mean no. Mean peak Mean Mean peak days with titer
neutralization titer of Virus* n viremia (log.sub.10 pfu/ml) titer
challenge virus rDEN1 4 2.8 2.1 1230 <0.7 rDEN1.DELTA.30 4 0.5
0.8 780 <0.7 *Rhesus monkeys were inoculated subcuateously with
5.0 log.sub.10 PFU of virus. Serum samples were collected daily for
10 days. Serum for neutralization assay was collected on day 28.
All monkeys were challenged on day 28 with 5.0 log.sub.10 PFU of
rDEN1.
As previously reported, rDEN4 virus replicated to greater than 6.0
log.sub.10PFU/ml serum in SCID-HuH-7 mice, while the replication of
rDEN4 virus bearing the .DELTA.30 mutation was reduced by about
10-fold (Blaney, J. E. Jr. et al. 2002 Virology 300:125-139). The
replication of rDEN1.DELTA.30 was compared to that of wt rDEN1 in
SCID-HuH-7 mice (Table 17). rDEN1.DELTA.30 replicated to a level
approximately 100-fold less than its wt rDEN1 parent. This result
further validates the use of the SCID-HuH-7 mouse model for the
evaluation of attenuated strains of DEN virus, with results
correlating closely with those observed in rhesus monkeys.
TABLE-US-00020 TABLE 17 The .DELTA.30 mutation attenuates rDEN1 for
HuH-7-SCID mice No. of Mean peak virus titer.sup.6 Virus Mice.sup.5
(log.sub.10 pfu/ml .+-. SE) wt rDEN1 9 7.3 .+-. 0.2 rDEN1.DELTA.30
8 5.0 .+-. 0.3 .sup.5Groups of HuH-7-SCID mice were inoculated
directly into the tumor with 4.0 log.sub.10 pfu virus. Serum was
collected on day 6 and 7, and virus titer was determined by plaque
assay in Vero cells. .sup.6Significant difference was found between
rDEN1 and rDEN1.DELTA.30 viruses, Tukey-Kramer test (P <
0.005).
Finally, the infectivity of rDEN1 and rDEN1.DELTA.30 for mosquitoes
was assessed, using the methods described in detail in Example 5.
Previously, the .DELTA.30 mutation was shown to decrease the
ability of rDEN4 to cross the mosquito midgut barrier and establish
a salivary gland infection (Troyer, J. M. et al. 2001 Am J Trop Med
Hyg 65:414-419). However neither rDEN1 nor rDEN1.DELTA.30 was able
to infect the midgut of Aedes aegypti mosquitoes efficiently via an
artificial bloodmeal (Table 18), so it was not possible to
determine whether .DELTA.30 might further block salivary gland
infection. A previous study also showed that the .DELTA.30 had no
effect on the infectivity of rDEN4 for Toxorhynchites splendens
mosquitoes infected via intrathoracic inoculation (Troyer, J. M. et
al. 2001 Am J Trop Med Hyg 65:414-419), and a similar pattern was
seen for rDEN1 and rDEN1.DELTA.30 (Table 18). The genetic basis for
the inability of rDEN1 to infect the mosquito midgut has not been
defined at this time. However, this important property of
restricted infectivity for the mosquito midgut is highly desirable
in a vaccine candidate since it would serve to greatly restrict
transmission of the vaccine virus from a vaccine to a mosquito
vector.
TABLE-US-00021 TABLE 18 DEN1 and DEN1.DELTA.30 viruses are both
highly infectious for Toxorhynchites splendens, but do not infect
Aedes aegypti efficiently. Toxorhynchites splendens (intrathoracic
inoculation) Aedes aegypti (oral infection) Dose.sup.a Dose.sup.c %
infected.sup.d Virus (log.sub.10 pfu) No. tested % infected.sup.b
(log.sub.10 pfu) No. tested Midgut Head rDEN1 3.5 7 100 4.0 26 11 0
2.5 8 75 1.5 7 71 0.5 5 60 MID.sub.50 < 0.5 MID.sub.50 .gtoreq.
4.4 rDEN1.DELTA.30 2.7 8 100 3.2 20 10 0 1.7 7 100 0.7 6 83
MID.sub.50 < 0.7 MID.sub.50 .gtoreq. 3.6 .sup.aAmount of virus
present in 0.22 .mu.l inoculum. .sup.bPercentage of mosquitoes with
IFA detectable antigen in head tissue prepared 14 days after
inoculation. .sup.cVirus titer ingested, assuming a 2 .mu.l
bloodmeal. .sup.dPercentage of mosquitoes with IFA detectable
antigen in midgut or head tissue prepared 21 days after oral
infection. When virus infection was detected, but did not exceed a
frequency of 50% at the highest dose of virus ingested, the
MID.sub.50 was estimated by assuming that a 10-fold more
concentrated virus dose would infect 100% of the mosquitoes.
Thus, the .DELTA.30 mutation, first described in DEN4, was
successfully transferred to rDEN1. The resulting virus,
rDEN1.DELTA.30, was shown to be attenuated in monkeys and
SCID-HuH-7 mice to levels similar to recombinant virus
rDEN4.DELTA.30, thereby establishing the conservation of the
attenuation phenotype specified by the .DELTA.30 mutation in a
different DEN virus background. Based on the favorable results of
rDEN4.DELTA.30 in recent clinical trials (Durbin, A. P. et al. 2001
Am J Trop Med Hyg 65:405-13), it is predicted that rDEN1.DELTA.30
will be suitably attenuated in humans. To complete the tetravalent
vaccine, attenuated rDEN2 and rDEN3 recombinant viruses bearing the
.DELTA.30 mutation are contemplated as being prepared (See Examples
3 and 4 below). The demonstration that the .DELTA.30 mutation
specifies a phenotype that is transportable to another DEN serotype
has important implications for development of the tetravalent
vaccine. This indicates that the .DELTA.30 mutation is expected to
have a corresponding effect on DEN2 and DEN3 wild-type viruses.
EXAMPLE 3
Generation and Characterization of a Recombinant DEN2 Virus
Containing the .DELTA.30 Mutation
Evaluation of rDEN1.DELTA.30 showed that it was satisfactorily
attenuated. Based on this result, we sought to extend our
technology to the creation of a DEN2 vaccine candidate. To do this,
the .DELTA.30 mutation was introduced into the cDNA of DEN2. A DEN2
virus isolate from a 1974 dengue epidemic in the Kingdom of Tonga
(Tonga/74) (Gubler, D. J. et al. 1978 Am J Trop Med Hyg 27:581-589)
was chosen to represent wt DEN2. The genome of DEN2 (Tonga/74) was
sequenced in its entirety and served as consensus sequence for the
construction of a full-length cDNA clone (Appendix 1). cDNA
fragments of DEN2 (Tonga/74) were generated by
reverse-transcription of the genome as indicated in FIG. 6A. Each
fragment was subcloned into a plasmid vector and sequenced to
verify that it matched the consensus sequence as determined for the
virus. This yielded seven cloned cDNA fragments spanning the
genome. Cloned fragments were modified as follows: Fragment X,
representing the 5' end of the genome was abutted to the SP6
promoter; Fragment L was modified to contain a
translationally-silent SpeI restriction site at genomic nucleotide
2353; Fragment R was modified to contain a translationally-silent
SpeI restriction site also at genomic nucleotide 2353, and to
stabilize the eventual full-length clone, two additional
translationally-silent mutations at nucleotides 2362-2364 and 2397
were created to ensure that translation stop codons were present in
all reading frames other than that used to synthesize the virus
polyprotein; Fragment A was modified at nucleotide 3582 to ablate a
naturally occurring SpeI restriction site and at nucleotide 4497 to
ablate a naturally occurring KpnI restriction site; Fragment C was
modified at nucleotide 9374 to ablate a naturally occurring KpnI
restriction site; and Fragment Y, representing the 3' end of the
genome was abutted to a KpnI restriction site. Each fragment was
added incrementally between the AscI and KpnI restriction sites of
DEN4 cDNA clone p4 (Durbin, A. P. et al. 2001 Am J Trop Med Hyg
65:405-13) to generate a full-length DEN2 cDNA clone (p2) with the
same vector background successfully used to generate rDEN4 and
rDEN4.DELTA.30. cDNA clone p2 was sequenced to confirm that the
virus genome region matched the DEN2 (Tonga/74) consensus sequence,
with the exception of the translationally-silent modifications
noted above. The .DELTA.30 mutation was introduced into Fragment Y
to generate Fragment Y.DELTA.30. To create p2.DELTA.30, the
Fragment Y region of p2 was replaced with Fragment Y.DELTA.30 (FIG.
6A, B).
For transcription and generation of infectious virus, cDNA (p2 and
p2.DELTA.30) was linearized with Acc65I (isoschizomer of KpnI which
cleaves leaving only a single 3' nucleotide) and used as template
in a transcription reaction using SP6 RNA polymerase as previously
described (Blaney, J. E. et. al. 2002 Virology 300:125-139).
Transcripts were introduced into Vero cells or C6/36 mosquito cells
using liposome-mediated transfection and cell culture supernatants
were harvested on day 7.
rDEN2 virus was recovered from the p2 cDNA in both Vero and C6/36
cells, while rDEN2.DELTA.30 was recovered from the p2.DELTA.30 cDNA
clone in only C6/36 cells (Table 19). The level of infectious virus
recovered in C6/36 cells was comparable for the p2 and p2.DELTA.30
cDNA clones when assayed by plaque titration and immunostaining in
Vero or C6/36 cells. As previously observed, the efficiency of
transfection in C6/36 cells was higher than that in Vero cells. Two
rDEN2.DELTA.30 viruses were recovered from independent cDNA clones,
#2 and #10.
TABLE-US-00022 TABLE 19 rDEN2 virus is recovered in Vero and C6/36
cells, but rDEN2.DELTA.30 virus is recovered only in C6/36 cells.
Virus titer of transfection harvest (day 7) determined in the
indicated Transfection cDNA cell type (log.sub.10 PFU/ml) cell type
construct Clone Virus Vero cells C6/36 cells Vero cells p2 #8A
rDEN2 3.1 4.3 p2.DELTA.30 #2 rDEN2.DELTA.30 <0.7 <0.7
p2.DELTA.30 #10 rDEN2.DELTA.30 <0.7 <0.7 C6/36 cells p2 #8A
rDEN2 5.5 7.5 p2.DELTA.30 #2 rDEN2.DELTA.30 4.8 7.6 p2.DELTA.30 #10
rDEN2.DELTA.30 4.6 7.5
To produce working stocks of rDEN2 and rDEN2.DELTA.30 viruses,
transfection harvests were passaged and terminally diluted in Vero
cells, and genomic sequences of the viruses were determined. The
Vero cell transfection harvest of rDEN2 virus was terminally
diluted once in Vero cells, and individual virus clones were
passaged once in Vero cells. To assess whether any homologous Vero
cell adaptation mutations identified in the rDEN4 NS4B 7100-7200
region were present in these virus clones, seven independent
terminally diluted clones were sequenced over this region. Each of
the seven rDEN2 viruses contained a single nucleotide substitution
in this region at nucleotide 7169 (U>C) resulting in a
Val>Ala amino acid change. This nucleotide corresponds to the
7162 mutation identified in rDEN4 (Blaney, J. E. et. al. 2002
Virology 300:125-139), which has a known Vero cell adaptation
phenotype suggesting that this mutation may confer a replication
enhancement phenotype in rDEN2 virus. One rDEN2 virus clone was
completely sequenced and in addition to the 7169 mutation, a
missense mutation (Glu>Ala) was found in NS5 at residue 3051
(Table 20).
TABLE-US-00023 TABLE 20 Missense mutations which accumulate in
rDEN2 and rDEN2.DELTA.30 viruses after transfection or passage in
Vero cells. Nucleotide Nucleotide Amino acid Amino acid Virus Gene
position substitution position.sup.a change rDEN2.sup.b NS4B .sup.
7169.sup.c U > C 2358 Val > Ala (Vero) NS5 9248 A > C 3051
Glu > Ala rDEN2.DELTA.30.sup.d NS3 4946 A > G 1617 Lys >
Arg (Vero) NS4B .sup. 7169.sup.c U > C 2358 Val > Ala
.sup.aAmino acid position in DEN2 polyprotein beginning with the
methionine residue of the C protein (nucleotides 97-99) as position
1. .sup.bVirus was recovered in Vero cells and terminally-diluted
once in Vero cells. Virus stock was prepared in Vero cells. cSame
nucleotide position as 7162 in rDEN4. .sup.dVirus was recovered in
C6/36 cells and passaged three times in Vero cells. Virus was then
terminally diluted and a stock was prepared in Vero cells.
Because both rDEN2 and rDEN2.DELTA.30 viruses grown in Vero cells
acquired the same mutation at nucleotide 7169, which corresponds to
the Vero cell adaptation mutation previously identified in rDEN4 at
nucleotide 7162, it was reasoned that this mutation is associated
with growth adaptation of rDEN2 and rDEN2.DELTA.30 in Vero cells.
In anticipation that the 7169 mutation may allow rDEN2.DELTA.30 to
be recovered directly in Vero cells, the mutation was introduced
into the rDEN2.DELTA.30 cDNA plasmid to create p2.DELTA.30-7169.
Transcripts synthesized from p2.DELTA.30-7169, as well as p2 and
p2.DELTA.30 were introduced into Vero cells or C6/36 mosquito cells
using liposome-mediated transfection as described above. Virus
rDEN2.DELTA.30-7169 was recovered from the p2.DELTA.30-7169 cDNA in
both Vero and C6/36 cells, while rDEN2.DELTA.30 was recovered from
the p2.DELTA.30 cDNA clone in only C6/36 cells (Table 21). The 7169
mutation is both necessary and sufficient for the recovery of
rDEN2.DELTA.30 in Vero cells.
TABLE-US-00024 TABLE 21 rDEN2.DELTA.30-7169 virus containing the
7169 Vero cell adaptation mutation is recovered in both Vero and
C6/36 cells Virus titer of transfection harvest (day 14) determined
in Transfection cDNA C6/36 cells cell type construct Clone Virus
(log.sub.10 PFU/ml) Vero cells p2 #8A rDEN2 6.8 p2.DELTA.30 #2
rDEN2.DELTA.30 <0.7 p2.DELTA.30-7169.sup.a #37
rDEN2.DELTA.30-7169 5.1 C6/36 cells p2 #8A rDEN2 6.9 p2.DELTA.30 #2
rDEN2.DELTA.30 7.1 p2.DELTA.30-7169 #37 rDEN2.DELTA.30-7169 7.2
.sup.aNucleotide 7169 in rDEN2 corresponds to nucleotide 7162 in
rDEN4 which has been shown to be associated with growth adaptation
in Vero cells.
To initially assess the ability of the .DELTA.30 mutation to
attenuate rDEN2 virus in an animal model, the replication of DEN2
(Tonga/74), rDEN2, and rDEN2.DELTA.30 viruses was evaluated in
SCID-HuH-7 mice. Previously, attenuation of vaccine candidates in
SCID-HuH-7 mice has been demonstrated to be predictive of
attenuation in the rhesus monkey model of infection (Examples 1 and
2). The recombinant viruses tested in this experiment were
recovered in C6/36 cells. The DEN2 Tonga/74 virus isolate, rDEN2,
and two independent rDEN2.DELTA.30 viruses, (clones 20A and 21A)
which were derived from two independent p2.DELTA.30 cDNA clones,
were terminally diluted twice in C6/36 cells prior to production of
a working stock in C6/36 cells. These viruses should not contain
any Vero cell adaptation mutations. DEN2 Tonga/74 virus replicated
to a mean virus titer of 6.2 log.sub.10PFU/ml in the serum of
SCID-HuH-7 mice, and rDEN2 virus replicated to a similar level, 5.6
log.sub.10PFU/ml (Table 22). Both rDEN2.DELTA.30 viruses were
greater than 100-fold restricted in replication compared to rDEN2
virus. These results indicate that the .DELTA.30 mutation has an
attenuating effect on replication of rDEN2 virus similar to that
observed for rDEN4 and rDEN1 viruses.
TABLE-US-00025 TABLE 22 The .DELTA.30 mutation restricts rDEN2
virus replication in SCID-HuH-7 mice. Mean virus Mean
log.sub.10-unit No. of titer .+-. SE (log.sub.10 reduction from
Virus mice PFU/ml serum).sup.a value for wt.sup.b DEN2 (Tonga/74) 8
6.2 .+-. 0.3 -- rDEN2 9 5.6 .+-. 0.2 -- rDEN2.DELTA.30 (clone 20A)
9 3.1 .+-. 0.2 2.5 rDEN2.DELTA.30 (clone 21A) 9 2.9 .+-. 0.3 2.7
.sup.aGroups of SCID-HuH-7 mice were inoculated directly into the
tumor with 10.sup.4 PFU virus grown in C6/36 cells. Serum was
collected on day 7 and titered in C6/36 cells. .sup.bComparison of
mean virus titers of mice inoculated with mutant virus and
concurrent rDEN2 control.
DEN2 virus replication in SCID-HuH-7 mice was also determined using
DEN2 (Tonga/74), rDEN2, and rDEN2.DELTA.30 which were passaged in
Vero cells (see Table 20, footnotes b and d). Both rDEN2 and
rDEN2.DELTA.30 had acquired a mutation in NS4B, nucleotide 7169,
corresponding to the 7162 mutation identified in rDEN4 as Vero cell
adaptation mutation. In the presence of the 7169 mutation, the
.DELTA.30 mutation reduced replication of rDEN2.DELTA.30 by 1.0
log.sub.10PFU/ml (Table 23). Previously, using virus grown in C6/36
cells and lacking the 7169 mutation, the .DELTA.30 mutation reduced
replication of rDEN2.DELTA.30 by about 2.5 log.sub.10PFU/ml (Table
22). These results indicate that Vero cell growth adaptation in
DEN2 may also confer a slight growth advantage in HuH-7 liver
cells. Nevertheless, the attenuation conferred by the .DELTA.30
mutation is still discernible in these Vero cell growth adapted
viruses.
TABLE-US-00026 TABLE 23 The .DELTA.30 mutation restricts Vero cell
adapted rDEN2 virus replication in SCID-HuH-7 mice. Mean
log.sub.10-unit No. Mean virus titer .+-. SE reduction from Virus
of mice (log.sub.10 PFU/ml serum).sup.a value for wt.sup.b DEN2
(Tonga/74) 6 5.9 .+-. 0.3 -- rDEN2 7 5.9 .+-. 0.2 -- rDEN2.DELTA.30
9 4.9 .+-. 0.3 1.0 .sup.aGroups of SCID-HuH-7 mice were inoculated
directly into the tumor with 10.sup.4 PFU virus. Serum was
collected on day 7 and titered in C6/36 cells. .sup.bComparison of
mean virus titers of mice inoculated with rDEN2.DELTA.30 and rDEN2
control.
Evaluation of the replication, immunogenicity, and protective
efficacy of rDEN2.DELTA.30 and wild-type parental rDEN2 virus in
juvenile rhesus monkeys was performed as follows. Dengue
virus-seronegative monkeys were injected subcutaneously with 5.0
log.sub.10 PFU of virus in a 1 ml dose divided between two
injections in each side of the upper shoulder area. Monkeys were
observed daily and blood was collected on days 0-10 and 28 and
serum was stored at -70.degree. C. Viruses used in this experiment
were passaged in Vero cells, and recombinant viruses contained the
mutations shown in Table 20 (See footnotes b and d). Titer of virus
in serum samples was determined by plaque assay in Vero cells as
described previously (Durbin, A. P. et al. 2001 Am J Trop Med Hyg
65:405-13). Plaque reduction neutralization titers were determined
for the day 28 serum samples as previously described (Durbin, A. P.
et al. 2001 Am J Trop Med Hyg 65:405-13). All monkeys were
challenged on day 28 with a single dose of 5.0 log.sub.10 PFU of wt
DEN2 (Tonga/74) and blood was collected for 10 days. Virus titer in
post-challenge sera was determined by plaque assay in Vero cells.
Monkeys inoculated with wt DEN2 (Tonga/74) or rDEN2 were viremic
for 4-5 days with a mean peak titer of 2.1 or 1.9 log.sub.10
PFU/ml, respectively.
Monkeys inoculated with rDEN2.DELTA.30 were viremic for 2-3 days
with a mean peak titer of 1.7 log.sub.10 PFU/ml (Table 24, FIG. 7),
indicating that the .DELTA.30 mutation is capable of attenuating
DEN2, although not to the same low level observed in rDEN1.DELTA.30
(Table 16). As expected for an attenuated virus, the immune
response, as measured by neutralizing antibody titer, was lower
following inoculation with rDEN2.DELTA.30 compared to inoculation
with wt DEN2 (Tonga/74) or rDEN2 (Table 24), yet sufficiently high
to protect the animals against wt DEN2 virus challenge (Table 25).
Thus, the decreased number of days of viremia for rDEN2.DELTA.30,
the decreased mean peak titer, and the decreased serum antibody
response indicate that the .DELTA.30 mutation attenuates rDEN2 for
rhesus monkeys.
TABLE-US-00027 TABLE 24 rDEN2.DELTA.30 is slightly more attenuated
for rhesus monkeys than rDEN2 Geometric mean No. of Mean no. serum
neutralizing monkeys of viremic Mean peak antibody titer No. of
with days per virus titer (log.sub.10 (reciprocal dilution)
Virus.sup.a monkeys viremia monkey.sup.b PFU/ml .+-. SE) Day 0 Day
28 mock 2 0 0 <0.7 <10 <10 DEN2 (Tonga/74) 4 4 4.5 2.1
.+-. 0.3 <10 311 rDEN2 (Vero) 4 4 4.0 1.9 .+-. 0.1 <10 173
rDEN2.DELTA.30 (Vero) 4 4 2.8 1.7 .+-. 0.2 <10 91 .sup.aGroups
of rhesus monkeys were inoculated subcutaneously with 10.sup.5 PFU
of the indicated virus in a 1 ml dose. Serum was collected on days
0 to 6, 8, 10, 12, and 28. Virus titer was determined by plaque
assay in Vero cells. .sup.bViremia was not detected in any monkey
after day 8.
TABLE-US-00028 TABLE 25 rDEN2.DELTA.30 protects rhesus monkeys from
wt DEN2 virus challenge Geometric mean Mean no. of serum
neutralizing viremic days per Mean peak antibody titer No. of
monkey after virus titer (reciprocal dilution) Virus.sup.a monkeys
DEN2 challenge (log.sub.10 PFU/ml .+-. SE) Day 28 Day 56 Mock 2 4.0
2.1 .+-. 0.1 <10 338 DEN2 (Tonga/74) 4 0 <0.7 311 334 rDEN2
(Vero) 4 0 <0.7 173 318 rDEN2.DELTA.30 (Vero) 4 0 <0.7 91 267
.sup.a28 days after inoculation with the indicated viruses, monkeys
were challenged subcutaneously with 10.sup.5 PFU DEN2 (Tonga/74) in
a 1 ml dose. Serum was collected on days 28 to 34, 36, 38, and 56.
Virus titer was determined by plaque assay in Vero cells.
The infectivity of DEN2 (Tonga/74), rDEN2 and rDEN2.DELTA.30 for
Aedes aegypti mosquitoes via an artificial bloodmeal was evaluated
using the methods described in detail in Example 5. However at
doses of 3.3 to 3.5 log.sub.10 pfu ingested, none of these three
viruses infected any mosquitoes, indicating that DEN2 (Tonga/74) is
poorly infectious for Aedes aegypti. As with rDEN1, the genetic
basis for this lack of infectivity remains to be defined. The
important property of restricted infectivity for the mosquito
midgut is highly desirable in a vaccine candidate because it would
serve to greatly restrict transmission of the virus from a vaccine
to a mosquito vector.
Several missense mutation identified in rDEN4 have been
demonstrated to confer attenuated replication in suckling mouse
brain and/or SCID-HuH-7 mice (Blaney, J. E. et al. 2002 Virology
300:125-139; Blaney, J. E. et al. 2001 J Virol 75:9731-9740). In
addition, missense mutations that enhance replication of rDEN4
virus in Vero cells have been characterized. The significant
sequence conservation among the DEN virus serotypes provides a
strategy by which the mutations identified in rDEN4 viruses are
contemplated as being used to confer similar phenotypes upon rDEN2
virus. Six mutations identified in rDEN4 virus that are at a site
conserved in rDEN2 virus are being introduced into the p2 and
p2.DELTA.30 cDNA clones (Table 26). Specifically, two rDEN4
mutations, NS3 4891 and 4995, which confer Vero cell adaptation
phenotypes and decreased replication in mouse brain, one mutation,
NS4B 7182, which confers a Vero cell adaptation phenotype, and
three mutations, NS12650, NS3 5097, and 3' UTR 10634 which confer
decreased replication in mouse brain and SCID-HuH-7 mice are being
evaluated. These mutations have been introduced into sub-cloned
fragments of the p2 and p2.DELTA.30 cDNA clones, and have been used
to generate mutant full-length cDNA clones (Table 26), from which
virus has been recovered in C6/36 cells (Table 27). The evaluation
of these mutant rDEN2 viruses is contemplated as determining that
such point mutations can be transported into a different DEN virus
serotype and confer a similar useful phenotype, as has been
demonstrated for the .DELTA.30 deletion mutation.
TABLE-US-00029 TABLE 26 Introduction of conserved point mutations
characterized in rDEN4 viruses into rDEN2 Tonga/74 virus. Phenotype
in rDEN4 virus Mutation in rDEN4 virus Mutation introduced into
DEN2 virus Vero Mouse SCID- Nucleo- Amino Amino Nucleo- Amino Amino
Adap- brain HuH-7 tide acid acid tide acid acid RE site/mutagenic
tation.sup.a att.sup.b att.sup.c Gene/region position
position.sup.d chang- e position position.sup.d change region.sup.e
+ + - NS3 4891 1597 Ile > Thr 4889 1598 Ile > Thr Nar I
CCAcgGGcGCCGT + + - NS3 4995 1632 Ser > Pro 4993 1633 Ser >
Pro Stu I AAGGccTGGA + - - NS4b 7182 2361 Gly > Ser 7189 2365
Gly > Ser Xma I TAtccCCGGGAC - + + NS1 2650 850 Asn > Ser
2648 851 Asn > Ser Sac I AGAgcTctcTC - + + NS3 5097 1666 Asp
> Asn 5095 1667 Asp > Asn Xma I GaATCTCCACCCgGA - + + 3' UTR
10634 n/a.sup.f n/a 10698 n/a n/a none CTGTcGAATC .sup.aPresence of
the indicated mutation increases plaque size in Vero cells two-fold
or greater than rDEN4 virus. .sup.bPresence of the indicated
mutation restricts replication in 7-day-old mouse brain greater
than 100-fold compared to rDEN4 virus. .sup.cPresence of the
indicated mutation restricts replication in SCID-HuH-7 mice greater
than 100-fold compared to rDEN4 virus. .sup.dAmino acid position in
DEN4 or DEN2 polyprotein beginning with the methionine residue of
the C protein (nucleotides 102-104 or 97-99, respectively) as
position 1. .sup.ePrimers were engineered which introduced
(underline) translationally-silent restriction enzyme (RE) sites.
Lowercase letters indicate nt changes and bold letters indicate the
site of the 5-FU mutation, which in some oligonucleotides differs
from the original nucleotide substitution change in order to create
a unique RE site. The change preserves the codon for the amino acid
substitution. .sup.fNucleotide substitution in the 3' UTR is U >
C in DEN4 and DEN2 virus.
TABLE-US-00030 TABLE 27 rDEN2 viruses containing conserved 5-FU
mutations are recovered in C6/36 cells. Virus Nucleotide Virus
titer of transfection (nucleotide position in harvest (day 7)
determined in position in rDEN2) rDEN4 C6/36 cells (log.sub.10
PFU/ml) rDEN2-4889 4891 7.6 rDEN2-4993 4995 7.2 rDEN2-7189 7182 3.5
rDEN2-2648 2650 --.sup.a rDEN2-5095 5097 --.sup.a rDEN2-10698 10634
7.7 .sup.aTransfection has not yet been attempted.
EXAMPLE 4
Generation and Characterization of a Recombinant DEN3 Virus
Containing the .DELTA.30 Mutation
Because rDEN1.DELTA.30 was satisfactorily attenuated, we sought to
extend our technology to the creation of a DEN3 vaccine candidate.
To do this, the .DELTA.30 mutation was introduced into the cDNA of
DEN3, similar to the method used to create rDEN2.DELTA.30. A DEN3
virus isolate from a 1978 dengue epidemic in rural Sleman, Central
Indonesia (Sleman/78) (Gubler, D. J. et al. 1981 Am J Trop Med Hyg
30:1094-1099) was chosen to represent wt DEN3. The genome of DEN3
(Sleman/78) was sequenced in its entirety and served as consensus
sequence for the construction of a full-length cDNA clone (Appendix
2). cDNA fragments of DEN3 (Sleman/78) were generated by
reverse-transcription of the genome as indicated in FIG. 8A. Each
fragment was subcloned into a plasmid vector and sequenced to
verify that it matched the consensus sequence as determined for the
virus. This yielded six cloned cDNA fragments spanning the genome.
Cloned fragments were modified as follows: Fragment 5, representing
the 5' end of the genome was abutted to the SP6 promoter preceded
by an AscI restriction site; Fragment 1L was modified to contain a
translationally-silent SpeI restriction site at genomic nucleotide
2345; Fragment 1R was modified to contain a translationally-silent
SpeI restriction site also at genomic nucleotide 2345, and to
stabilize the eventual full-length clone, three additional
translationally-silent mutations at nucleotides 2354-2356,
2360-2362, and 2399 were created to ensure that translation stop
codons were present in all reading frames other than that used to
synthesize the virus polyprotein; Fragment 3 was modified at
nucleotide 9007 to ablate a naturally occurring KpnI restriction
site; and Fragment 4, representing the 3' end of the genome was
abutted to a KpnI restriction site. Each fragment was added
incrementally between the AscI and KpnI restriction sites of DEN4
cDNA clone p4 (Durbin, A. P. et al. 2001 Am J Trop Med Hyg
65:405-13) to generate a full-length DEN3 cDNA clone with the same
vector background successfully used to generate rDEN4 and rDEN2.
However, a stable, full-length clone could not be recovered in E.
coli when fragments 1L and 1R were combined into the same cDNA
molecule. To overcome this instability, a synthetic DNA linker
(FIG. 8A) containing redundant termination codons in each of the
forward and reverse open reading frames was introduced into the
SpeI restriction site at the same time that fragment 1L was added
to complete the full-length cDNA construct. The resulting p3 clone
containing the linker sequence was stable in E. coli, indicating
that the linker sequence was sufficient to interrupt whatever
deleterious element exists in this region. cDNA clone p3 was
sequenced and the virus genome was found to match the DEN3
(Sleman/78) consensus sequence, with the exception of the linker
sequence and translationally-silent modifications noted above
(Appendix 2--shown with the linker sequence removed). The .DELTA.30
mutation was introduced into Fragment 4 to generate Fragment
4.DELTA.30. To create p3.DELTA.30, the Fragment 4 region of p3 was
replaced with Fragment 4.DELTA.30 (FIG. 8A, B).
For transcription and generation of infectious virus, cDNA plasmids
p3 and p3.DELTA.30 were digested with SpeI and religated to remove
the linker sequence, linearized with Acc65I (isoschizomer of KpnI
which cleaves leaving only a single 3' nucleotide), and used as
templates in a transcription reaction using SP6 RNA polymerase as
previously described (Blaney, J. E. et. al 2002 Virology
300:125-139). Transcripts were introduced into Vero cells or C6/36
mosquito cells using liposome-mediated transfection and cell
culture supernatants were harvested on day 14.
rDEN3 virus was recovered from the p3 cDNA in both Vero and C6/36
cells, while rDEN3.DELTA.30 was recovered from the p3.DELTA.30 cDNA
clone in only C6/36 cells (Table 28). The level of infectious virus
recovered in C6/36 cells was comparable for the p3 and p3.DELTA.30
cDNA clones when assayed by plaque titration in Vero or C6/36
cells. As previously observed, the efficiency of transfection in
C6/36 cells was higher than that in Vero cells. Two rDEN3.DELTA.30
viruses were recovered from independent cDNA clones, #22 and
#41.
TABLE-US-00031 TABLE 28 rDEN3 virus is recovered in Vero and C6/36
cells, but rDEN3.DELTA.30 virus is recovered only in C6/36 cells.
Virus titer of transfection harvest (day 14) determined in the
indicated cell type Transfection cDNA (log.sub.10 PFU/ml) cell type
construct Clone Virus Vero cells C6/36 cells Vero cells p3 #50
rDEN3 5.2 6.3 p3.DELTA.30 #22 rDEN3.DELTA.30 <0.7 <0.7
p3.DELTA.30 #41 rDEN3.DELTA.30 <0.7 <0.7 C6/36 cells p3 #50
rDEN3 5.2 6.0 p3.DELTA.30 #22 rDEN3.DELTA.30 5.9 6.9 p3.DELTA.30
#41 rDEN3.DELTA.30 5.1 7.2
To produce working stocks of viruses, transfection harvests will be
passaged and terminally diluted in Vero cells, and genomic
sequences of the viruses will be determined. To improve virus yield
in Vero cells, the Vero cell adaptation mutation previously
identified in rDEN4 at nucleotide 7162 was introduced into the
homologous NS4B region of p3 and p3.DELTA.30 to create p3-7164 and
p3.DELTA.30-7164. This mutation creates a Val to Ala substitution
at amino acid position 2357. As demonstrated for rDEN2.DELTA.30,
this mutation allowed for the direct recovery of virus in Vero
cells (Table 27) and is anticipated to have the same effect for
rDEN3.DELTA.30.
To initially assess the ability of the .DELTA.30 mutation to
attenuate rDEN3 virus in an animal model, the replication of DEN3
(Sleman/78), rDEN3, and rDEN3.DELTA.30 viruses will be evaluated in
SCID-HuH-7 mice and rhesus monkeys. Previously, attenuation of
vaccine candidates in SCID-HuH-7 mice has been demonstrated to be
predictive of attenuation in the rhesus monkey model of infection
(Examples 1 and 2). The evaluation of these mutant rDEN3 viruses is
contemplated as determining that the .DELTA.30 deletion mutations
can be transported into the DEN3 virus serotype and confer a
similar useful phenotype, as has been demonstrated for DEN1, DEN2,
and DEN4.
In summary, the strategy of introducing the .DELTA.30 mutation into
wild-type DEN viruses of each serotype to generate a suitably
attenuated tetravalent vaccine formulation is a unique and
attractive approach for several reasons. First, the mutation
responsible for attenuation is a 30-nucleotide deletion in the 3'
UTR, thus assuring that all of the structural and non-structural
proteins expressed by each of the four components of the
tetravalent vaccine are authentic wild-type proteins. Such
wild-type proteins should elicit an antibody response that is broad
based, rather than based solely on the M and E proteins that are
present in chimeric dengue virus vaccine candidates (Guirakhoo, F.
et al. 2001 J Virol 75:7290-304; Huang, C. Y. et al. 2000 J Virol
74:3020-8). The uniqueness of this approach derives from the fact
that other live attenuated dengue virus vaccines have mutations in
their structural or non-structural proteins (Butrapet, S. et al.
2000 J Virol 74:3011-9; Puri, B. et al. 1997 J Gen Virol
78:2287-91), therefore the immune response induced by these viruses
will be to a mutant protein, rather than a wild-type protein.
Second, deletion mutations are genetically more stable than point
mutations, and reversion of the attenuation phenotype is unlikely.
In humans, DEN4.DELTA.30 present in serum of vaccines retained its
.DELTA.30 mutation, confirming its genetic stability in vivo
(Durbin, A. P. et al. 2001 Am J Trop Med Hyg 65:405-13). The
attenuating mutations in other existing dengue live attenuated
vaccine candidates are based on less stable point mutations
(Butrapet, S. et al. 2000 J Virol 74:3011-9: Puri, B. et al. 1997 J
Gen Virol 78:2287-91). Third, since the .DELTA.30 mutation is
common to each of the four viruses of the tetravalent vaccine,
recombination between any of the four vaccine serotypes would not
lead to loss of the attenuating mutation or reversion to a
wild-type phenotype. Recombination between components of the
trivalent polio vaccine has been observed (Guillot, S. et al. 2000
J Virol 74:8434-43), and naturally occurring recombinant dengue
viruses have been described (Worobey, M. et al. 1999 PNAS USA
96:7352-7) indicating the ability of this flavivirus to exchange
genetic elements between two different viruses. Clearly, gene
exchange is readily achieved between different DEN virus serotypes
using recombinant cDNA techniques (Bray, M. and Lai, C. J. 1991
PNAS USA 88:10342-6). Fourth, viruses with wild-type structural
proteins appear more infectious than viruses with altered
structural proteins (Huang, C. Y. et al. 2000 J Virol 74:3020-80).
This permits the use of a low quantity of each of the four virus
components in the final vaccine, contributing to the low cost of
manufacture. Low-cost manufacture is an essential element in
defining the ultimate utility of a dengue virus vaccine.
EXAMPLE 5
Generation and Characterization of Intertypic Chimeric DEN2 Viruses
Containing the .DELTA.30 Mutation
The four serotypes of dengue virus are defined by antibody
responses induced by the structural proteins of the virus,
primarily by a neutralizing antibody response to the envelope (E)
protein. These structural proteins include the E glycoprotein, a
membrane protein (M), and a capsid (C) protein. The mature virus
particle consists of a well-organized outer protein shell
surrounding a lipid bilayer membrane and a less-well-defined inner
nucleocapsid core (Kuhn, R. J. et al. 2002 Cell 108:717-25). The E
glycoprotein is the major protective antigen and readily induces
virus neutralizing antibodies that confer protection against dengue
virus infection. An effective dengue vaccine must therefore
minimally contain the E protein of all four serotypes, namely DEN1,
DEN2, DEN3, and DEN4, thereby inducing broad immunity and
precluding the possibility of developing the more serious illnesses
DHF/DSS, which occur in humans during secondary infection with a
heterotypic wild-type dengue virus. Based on a previously reported
strategy (Bray, M. and Lai, C. J. 1991 PNAS USA 88:10342-6), a
recombinant cDNA technology is being used to develop a live
attenuated tetravalent dengue virus vaccine composed of a set of
intertypic chimeric dengue viruses bearing the structural proteins
of each serotype.
Following the identification of a suitably attenuated and
immunogenic DEN4 recombinant virus, namely DEN4.DELTA.30 (Durbin,
A. P et al. 2001 Am J Trop Med Hyg 65:405-13), chimeric viruses
based on the DEN4 cDNA have been generated in which the C-M-E (CME)
or M-E (ME) genes have been replaced with the corresponding genes
derived from the prototypic DEN2 New Guinea C(NGC) strain (FIG.
9A). To create the CME chimeric viruses, the BglII/YhoI region of
the cDNA for either rDEN4 or rDEN4.DELTA.30 was replaced with a
similar region derived from DEN2. Likewise, to create the ME
chimeric viruses, the PstI/XhoI region of the cDNA for either rDEN4
or rDEN4.DELTA.30 was replaced with a homologous region derived
from DEN2. The nucleotide and amino acid sequences of the resulting
junctions are shown in FIG. 9B. The GenBank accession number for
the nucleotide sequence of rDEN4.DELTA.30 is AF326837. The GenBank
accession number for DEN2 NGC is M29095, which represents the mouse
neurovirulent strain of DEN2 NGC and differs from the prototypic
strain used here as previously documented (Bray, M. et al. 1998 J
Virol 72:1647-51).
For transcription and generation of virus, chimeric cDNA clones
were linearized and used as template in a transcription reaction
using SP6 RNA polymerase as described (Durbin, A. P et al. 2001 Am
J Trop Med Hyg 65:405-13). Transcripts were introduced into Vero
cells using liposome-mediated transfection and recombinant dengue
virus was harvested on day 7. The genomes of the resulting viruses
were confirmed by sequence analysis of viral RNA isolated from
recovered virus as previously described (Durbin, A. P et al. 2001
Am J Trop Med Hyg 65:405-13). Incidental mutations arising from
virus passage in tissue culture were identified in all viruses and
are listed in Table 29. Notably, each virus contained a missense
mutation in NS4B corresponding to a previously identified mutation
from rDEN4 and associated with adaptation to replication in Vero
cells (See Table 30 for correlation of nucleotide positions between
rDEN4 and chimeric viruses). All viruses replicated in Vero cells
to titers in excess of 6.0 log.sub.10 PFU/ml, indicating that the
chimeric viruses, even those containing the .DELTA.30 mutation,
replicate efficiently in cell culture, a property essential for
manufacture of the vaccine.
TABLE-US-00032 TABLE 29 Missense mutations observed among the Vero
cell-grown chimeric DEN2/4 viruses Amino Amino Nucleotide
Nucleotide acid acid Virus Gene position change position change
rDEN2/4 (CME) NS4B 7161.sup.a A > U 2355 Leu > Phe
rDEN2/4.DELTA.30 M 743 G > A 216 Gly > Glu (CME) E 1493 C
> U 466 Ser > Phe NS4B 7544.sup.b C > T 2483 Ala > Val
rDEN2/4 (ME) E 1065 U > C 322 Phe > Leu NS4B 7163.sup.a A
> U 2354 Leu > Phe rDEN2/4.DELTA.30 NS4B 7163.sup.a A > C
2354 Leu > Phe (ME) .sup.aSame nucleotide position as 7163 in
rDEN4. .sup.bSame nucleotide position as 7546 in rDEN4.
TABLE-US-00033 TABLE 30 Nucleotide (nt) length differences for DEN
chimeric viruses compared to rDEN4. rDEN nt difference chimeric
from rDEN4 ORF start Amino acid length virus (following CME region)
(nt position) C M E 1/4 ME 0 102 113 166 495 1/4 CME +3 102 114 166
495 2/4 ME 0 102 113 166 495 2/4 CME -2 97 114 166 495 3/4 ME -6
102 113 166 493 3/4 CME -3 102 114 166 493 rDEN4 -- 102 113 166
495
Results of a safety, immunogenicity, and efficacy study in monkeys
are presented in Table 31. Monkeys inoculated with wild-type DEN2
were viremic for approximately 5 days with a mean peak titer of 2.1
log.sub.10 PFU/ml, while monkeys inoculated with any of the
chimeric DEN2 viruses were viremic for 1.2 days or less and had a
mean peak titer of less than 1.0 log.sub.10 PFU/ml. This reduction
in the magnitude and duration of viremia clearly indicates that the
chimeric viruses containing either the CME or ME proteins of DEN2
were more attenuated than the parental DEN2 NGC virus. Neither the
animals receiving the wild-type DEN2 nor the DEN2/4 chimeric
viruses were ill. The decreased replication of the attenuated
viruses in monkeys is accompanied by a reduction in the immune
response of inoculated monkeys. This is indicated in Table 31 by
approximately a 5-fold reduction in the level of neutralizing
antibody following inoculation with the chimeric viruses in
comparison to titers achieved in animals inoculated with wild-type
virus. Addition of the .DELTA.30 mutation to the CME chimeric virus
further attenuated the virus, such that rDEN2/4.DELTA.30(CME) did
not replicate in monkeys to a detectable level and did not induce a
detectable immune response. This virus appeared over-attenuated,
and if similar results were seen in humans, this virus would not be
suitable for use as a vaccine. However, addition of the .DELTA.30
mutation to the ME chimeric virus did not further attenuate this
chimeric virus and the resulting rDEN2/4.DELTA.30(ME) virus appears
satisfactorily attenuated and immunogenic for use as a vaccine.
TABLE-US-00034 TABLE 31 Chimerization between dengue virus types 2
and 4 results in recombinant viruses which are attenuated for
rhesus monkeys. Geometric mean Mean no. Mean peak neutralizing days
with virus titer antibody titer Group* Virus n viremia (log.sub.10
pfu/ml) (reciprocal) 1 rDEN2/4 (CME) 6 1.2 0.9 50 2
rDEN2/4.DELTA.30 8 0 <0.7 <5 (CME) 3 rDEN2/4 (ME) 4 1.0 0.8
76 4 rDEN2/4.DELTA.30 4 0.3 0.7 62 (ME) 5 DEN2 NGC 6 5.5 2.1 312
*Rhesus monkeys were inoculated subcutaneously with 5.0 log.sub.10
PFU of virus. Serum samples were collected daily for 10 days. Serum
for neutralization assay was collected on day 28. Serum samples
obtained before virus inoculation had a neutralizing antibody titer
of <5.
As described in the previous examples, SCID mice transplanted with
the cells are a sensitive model for the evaluation of dengue virus
attenuation. Each chimeric DEN2/4 virus was inoculated into groups
of SCID-HuH-7 mice and levels of virus in the serum were determined
(Table 32). Chimeric viruses replicated to levels between 20- and
150-fold lower than either of the parental viruses (rDEN4 and
DEN2-NGC). CME chimeric viruses were slightly more attenuated than
the comparable ME chimeric viruses, with the .DELTA.30 mutation
providing a 0.5 log.sub.10 reduction in replication. This level of
attenuation exerted by the .DELTA.30 mutation was similar to that
observed previously for rDEN4.DELTA.30.
TABLE-US-00035 TABLE 32 Chimerization between dengue virus types 2
and 4 results in recombinant viruses which are attenuated for
HuH-7-SCID mice. No. of Mean peak virus titer Statistical
Virus.sup.a mice (log.sub.10 pfu/m1 .+-. SE) group.sup.b rDEN4 32
6.3 .+-. 0.2 A DEN2-NGC 9 6.1 .+-. 0.2 A rDEN2/4 (CME) 7 4.4 .+-.
0.3 B rDEN2/4.DELTA.30 (CME) 7 3.9 .+-. 0.3 B rDEN2/4 (ME) 6 4.8
.+-. 0.5 B rDEN2/4.DELTA.30 (ME) 9 4.3 .+-. 0.2 B .sup.aGroups of
HuH-7-SCID mice were inoculated into the tumor with 4.0 log.sub.10
PFU of the indicated virus. Serum was collected on day 7 and virus
titer was determined in Vero cells. .sup.bMean peak titers were
assigned to statistical groups using the Tukey post-hoc test (P
< 0.05). Groups with the same letter designation are not
significantly different.
To evaluate the replication levels of each DEN2/4 chimeric virus in
mosquitoes, two different genera of mosquitoes were experimentally
infected. Aedes aegypti were infected by ingesting a
virus-containing blood meal. By evaluating the presence of virus
antigen in both the midgut and head tissue, infectivity could be
determined for the local tissues (midgut), and the ability of virus
to disseminate and replicate in tissues beyond the midgut barrier
(head) could also be measured. The presence of virus in the head is
limited by the ability of the ingested virus to replicate in the
midgut and then disseminate to the salivary glands in the head, as
well as the innate ability of the virus to replicate in the
salivary glands. Intrathoracic inoculation of virus into
Toxorhynchites splendens bypasses the mosquito midgut barrier.
Parental viruses rDEN4 and DEN2-NGC readily infect Ae. aegypti and
T splendens (Table 33), with DEN2-NGC appearing to be much more
infectious in T. splendens. Each of the rDEN2/4 chimeric viruses
was also tested in both mosquito types. In many cases it was not
possible to inoculate Ae. aegypti with an undiluted virus stock of
sufficient titer to achieve a detectable infection due to the very
low infectivity of several of the viruses. Nevertheless, it is
clear that the rDEN2/4 chimeric viruses are less infectious for the
midgut and head. Parental viruses rDEN4 and DEN2-NGC, administered
at a maximum dose of approximately 4.0 log.sub.10PFU, were
detectable in 74% and 94% of midgut preparations, and 32% and 71%
of head preparations, respectively. Among the chimeric viruses, the
highest level of infectivity, as observed for rDEN2/4.DELTA.30
(CME), resulted in only 26% infected midgut samples and 6% head
samples. In the more permissive T. splendens, the rDEN2/4 chimeric
viruses were generally less infectious than either parental virus,
with CME chimeric viruses being less infectious than ME viruses. It
has previously been reported for DEN4 that the .DELTA.30 mutation
does not have a discernable effect on virus infectivity in T.
splendens similar to that observed here for the rDEN2/4 chimeric
viruses (Troyer, J. M. et al. 2001 Am J Trop Med Hyg
65:414-419).
TABLE-US-00036 TABLE 33 Dengue 2/4 chimeric viruses are less
infectious compared to either parental virus strain in mosquitoes
Toxorhynchites splendens Aedes aegypti (intrathoracic inoculation)
(oral infection) Dose.sup.a No. % Dose.sup.c No. % infected.sup.d
Virus log.sub.10 pfu tested infected.sup.b log.sub.10 pfu tested
Midgut Head rDEN4 3.3 6 83 3.8 38 74 32 2.3 7 57 2.8 15 26 6 1.3 6
0 1.8 20 10 5 MID.sub.50 = 2.2 MID.sub.50 = 3.4 MID.sub.50 .gtoreq.
4.1 DEN2-NGC 2.5 5 100 4.0 17 94 71 1.2 15 93 3.0 25 36 16 0.2 4 75
2.0 30 0 0 0.02 8 38 MID.sub.50 = 3.2 MID.sub.50 = 3.6 MID.sub.50 =
0.5 rDEN2/4 (CME) 3.9 9 11 4.4 11 9 0 2.9 5 0 3.4 10 0 0 MID.sub.50
.gtoreq. 4.3 MID.sub.50 .gtoreq. 4.9 Nc.sup.e rDEN2/4.DELTA.30 3.5
6 17 4.0 15 26 6 (CME) 2.5 6 17 3.0 10 0 0 MID.sub.50 .gtoreq. 3.9
MID.sub.50 .gtoreq. 4.3 MID.sub.50 .gtoreq. 4.5 rDEN2/4 (ME) 3.4 6
100 3.9 23 4 0 2.4 5 20 MID.sub.50 .gtoreq. 4.4 Nc 1.4 5 0
MID.sub.50 = 2.8 rDEN2/4.DELTA.30 2.6 11 9 3.1 30 0 0 (ME)
MID.sub.50 .gtoreq. 3.0 nc Nc .sup.aAmount of virus present in 0.22
.mu.l inoculum. .sup.bPercentage of mosquitoes with IFA detectable
antigen in head tissue prepared 14 days after inoculation.
.sup.cVirus titer ingested, assuming a 2 .mu.l bloodmeal.
.sup.dPercentage of mosquitoes with IFA detectable antigen in
midgut or head tissue prepared 21 days after oral infection. When
virus infection was detected, but did not exceed a frequency of 50%
at the highest dose of virus ingested, the MID.sub.50 was estimated
by assuming that a 10-fold more concentrated virus dose would
infect 100% of the mosquitoes. .sup.enc = not calculated, since
virus antigen was not detected.
Chimerization of the DEN2 structural genes with rDEN4.DELTA.30
virus resulted in a virus, rDEN2/4.DELTA.30(CME), that had
decreased replication in Vero cells compared to either parent
virus. To evaluate Vero cell adaptation mutations (Blaney, J. E. et
al. 2002 Virology 300:125-139) as a means of increasing the virus
yield of a DEN vaccine candidate in Vero cells, selected mutations
were introduced into this chimeric virus. Accordingly,
rDEN2/4.DELTA.30(CME) viruses bearing adaptation mutations were
recovered, terminally diluted, and propagated in C6/36 cells to
determine if the virus yield in Vero cells could be increased.
rDEN2/4.DELTA.30(CME) viruses bearing Vero cell adaptation
mutations were generated as follows. DNA fragments were excised
from rDEN4 cDNA constructs encompassing single or double DEN4 Vero
cell adaptation mutations and introduced into the cDNA clone of
rDEN2/4.DELTA.30(CME). The presence of the Vero cell adaptation
mutation was confirmed by sequence analysis, and RNA transcripts
derived from the mutant cDNA clones were transfected, terminally
diluted, and propagated in C6/36 cells.
For evaluation of growth kinetics, Vero cells were infected with
the indicated viruses at a multiplicity of infection (MOI) of 0.01.
Confluent cell monolayers in duplicate 25-cm.sup.2 tissue culture
flasks were washed and overlaid with a 1 ml inoculum containing the
indicated virus. After a two hour incubation at 37.degree. C.,
cells were washed three times in MEM and 5 ml of MEM supplemented
with 2% FBS was added. A 1 ml aliquot of tissue culture medium was
removed, replaced with fresh medium, and designated the day 0
time-point. At the indicated time points post-infection, 1 ml
samples of tissue culture medium were removed, clarified by
centrifugation, and frozen at -80.degree. C. The level of virus
replication was assayed by plaque titration in C6/36 cells and
visualized by immunoperoxidase staining. The limit of detection was
<0.7 log.sub.10PFU/ml.
The growth properties of rDEN2/4.DELTA.30(CME) viruses bearing
single Vero cell adaptation mutations at NS4B -7153, -7162, -7163,
-7182, NS5-7630 or three combinations of mutations were compared in
Vero cells with rDEN2/4.DELTA.30 (CME) virus (FIG. 10). Without an
introduced Vero cell adaptation mutation, rDEN2/4.DELTA.30(CME)
virus yield peaked at 4.4 log.sub.10PFU/ml. Each individual
adaptation mutation and the combined mutations conferred a
substantial increase in replication. Specifically,
rDEN2/4.DELTA.30(CME)-7182 grew to the highest titer of 7.1
log.sub.10PFU/ml, which was a 500-fold increase in yield.
rDEN2/4.DELTA.30(CME)-7162 had the lowest yield but still was
increased 125-fold over the level of replication by
rDEN2/4.DELTA.30(CME) virus. Introduction of two adaptation
mutations into rDEN2/4.DELTA.30(CME) virus did not significantly
increase virus yield over that of viruses bearing single Vero cell
adaptation mutations. The observed increase of up to 500-fold in
virus yield by the introduction of a Vero cell adaptation mutation
into this chimeric vaccine candidate demonstrates the value of
identifying and characterizing specific replication-promoting
sequences in DEN viruses.
These results have particular significance for the development of a
live attenuated dengue virus vaccine. First, it is clear that
chimerization leads to attenuation of the resulting virus, as
indicated by studies in rhesus monkeys, HuH7-SCID mice and
mosquitoes. Although this conclusion was not made in the previous
study with DEN2/DEN4 or DEN1/DEN4 chimeric viruses (Bray, M. et al.
1996 J Virol 70:4162-6), careful examination of the data would
suggest that the chimeric viruses are more attenuated in monkeys
compared to the wild-type parent viruses. Second, the .DELTA.30
mutation can further augment this attenuation in a
chimeric-dependent manner. Specifically, in this example, chimeric
viruses bearing the CME region of DEN2 were over-attenuated by the
addition of .DELTA.30, whereas the attenuation phenotype of
chimeric viruses bearing just the ME region of DEN2 was unaltered
by the addition of the .DELTA.30 mutation. This unexpected finding
indicates that in a tetravalent vaccine comprised of individual
component viruses bearing a shared attenuating mutation, such as
the .DELTA.30 mutation, only ME chimeric viruses can be utilized
since CME chimeric viruses bearing the .DELTA.30 mutation can be
over-attenuated in rhesus monkeys and might provide only limited
immunogenicity in humans.
EXAMPLE 6
Generation and Characterization of Intertypic Chimeric DEN3 Viruses
Containing the .DELTA.30 Mutation
Chimeric viruses based on the DEN4 cDNA have been generated in
which the CME or ME genes have been replaced with the corresponding
genes derived from DEN3 (Sleman/78), a virus isolate from the 1978
dengue outbreak in the Sleman region of Indonesia (Gubler, D. J. et
al. 1981 Am J Trop Med Hyg 30:1094-1099) (Appendix 2). As described
in Example 5 for the DEN2 chimeric viruses, CME chimeric viruses
for DEN3 were generated by replacing the BglII/XhoI region of the
cDNA for either rDEN4 or rDEN4.DELTA.30 with a similar region
derived from DEN3 (Sleman/78) (FIG. 11A). Likewise, to create the
ME chimeric viruses, the PstI/XhoI region of the cDNA for either
rDEN4 or rDEN4.DELTA.30 was replaced with a similar region derived
from DEN3 (Sleman/78). The nucleotide and amino acid sequences of
the resulting junctions are shown in FIG. 1B. The genomes of the
resulting viruses were confirmed by sequence analysis of viral RNA
isolated from recovered virus as previously described (Durbin, A. P
et al. 2001 Am J Trop Med Hyg 65:405-13). Incidental mutations
arising from virus passage in tissue culture were identified in all
viruses and are listed in Table 34. Notably, each virus contained a
missense mutation in NS4B corresponding to a previously identified
mutation from rDEN4 and associated with adaptation to growth in
Vero cells (See Table 30 for correlation of nucleotide positions
between rDEN4 and chimeric viruses). All viruses replicated in Vero
cells to titers in excess of 5.7 log.sub.10 PFU/ml, indicating that
the chimeric viruses, even those containing the .DELTA.30 mutation,
replicate efficiently in cell culture, a property essential for
manufacture of the vaccine.
TABLE-US-00037 TABLE 34 Missense mutations observed among Vero
cell-grown chimeric DEN3/4 viruses Amino Nucleotide Nucleotide
Amino acid acid Virus Gene position change position change
rDEN3/4.DELTA.30 M 825 T > C 242 Phe > Leu (CME) E 1641 C
> T 514 Leu > Phe E 2113 A > G 671 Lys > Arg NS4B
7159.sup.a T > C 2353 Leu > Ser rDEN3/4 M 460 A > G 120
Asp > Gly (ME) NS4B 7177.sup.b G > U 2359 Gly > Val NS5
7702 C > U 2534 Ser > Phe rDEN3/4.DELTA.30 E 1432 A > U
444 Gln > Leu (ME) NS4B 7156.sup.a U > C 2352 Leu > Ser
NS5 8692 A > C 2864 Asn > His .sup.aSame nucleotide position
as 7162 in rDEN4. .sup.bSame nucleotide position as 7183 in
rDEN4.
As described in the previous examples, SCID mice transplanted with
HuH-7 cells are a sensitive model for the evaluation of dengue
virus attenuation. Each chimeric DEN3/4 virus was inoculated into
groups of SCID-HuH-7 mice and levels of virus in the serum were
determined (Table 35). While chimeric virus rDEN3/4 (CME) was not
attenuated, the remaining chimeric viruses replicated to levels
between 40- and 400-fold lower than either of the parental viruses
(rDEN4 and DEN3-Sleman/78). In the CME chimeric virus, the
.DELTA.30 mutation providing a remarkable 2.7 log.sub.10 reduction
in replication. This level of attenuation conferred by the
.DELTA.30 mutation in the CME chimeric virus was much greater than
that observed previously for rDEN4.DELTA.30. The rDEN3/4 (ME) virus
was 100-fold reduced in replication compared to either parent virus
indicating that the ME chimerization was attenuating per se.
Addition of the .DELTA.30 mutation to rDEN3/4 (ME) did not result
in additional attenuation.
TABLE-US-00038 TABLE 35 Chimerization between dengue virus types 3
and 4 results in recombinant viruses which are attenuated for
HuH-7-SCID mice. No. of Mean peak virus titer Statistical
Virus.sup.a mice (log.sub.10 pfu/ml .+-. SE) group.sup.b rDEN4 32
6.3 .+-. 0.2 A DEN3-Sleman/78 23 6.4 .+-. 0.2 A rDEN3/4 (CME) 7 6.4
.+-. 0.6 A rDEN3/4.DELTA.30 (CME) 5 3.7 .+-. 0.4 B rDEN3/4 (ME) 6
4.2 .+-. 0.7 B rDEN3/4.DELTA.30 (ME) 7 4.7 .+-. 0.4 A, B
.sup.aGroups of HuH-7-SCID mice were inoculated into the tumor with
4.0 log.sub.10 PFU of the indicated virus. Serum was collected on
day 7 and virus titer was determined in Vero cells. .sup.bMean peak
titers were assigned to statistical groups using the Tukey post-hoc
test (P < 0.05). Groups with the same letter designation are not
significantly different.
Evaluation of the replication and immunogenicity of the DEN3
chimeric recombinant viruses and wild-type DEN3 virus in monkeys
was performed as described in Example 5. Results of this safety and
immunogenicity study in monkeys are presented in Table 36. Monkeys
inoculated with rDEN3/4(CME) and wild-type DEN (Sleman/78) were
viremic for approximately 2 days with a mean peak titer of between
1.6 and 1.8 log.sub.10 PFU/ml, respectively, indicating that
chimerization of the CME structural genes of DEN3 did not lead to
attenuation of virus replication, a different pattern than that
observed for DEN2 chimerization (Table 31). However, chimerization
of the ME structural genes resulted in attenuated viruses with
undetectable viremia in monkeys, although all monkeys seroconverted
with a greater than 10-fold increase in serum antibody levels. As
expected for an attenuated virus, the immune response, as measured
by neutralizing antibody titer, was lower following inoculation
with any of the chimeric viruses compared to inoculation with wt
(Sleman/78), yet sufficiently high to protect the animals against
wt DEN3 virus challenge (Table 37). It is clear that addition of
the .DELTA.30 mutation to rDEN3/4(CME) was capable of further
attenuating the resulting virus rDEN3/4.DELTA.30(CME).
TABLE-US-00039 TABLE 36 The .DELTA.30 mutation further attenuates
rDEN3/4 (CME) for rhesus monkeys Geometric mean Mean no. Mean peak
serum neutralizing of viremic virus titer antibody titer No. of
days per (log.sub.10 (reciprocal dilution) Virus monkeys
monkey.sup.b PFU/ml .+-. SE) Day 0 Day 28 DEN3 4 2.3 1.8 <5 707
(Sleman/78) rDEN3/4 4 2.0 1.6 <5 211 (CME) rDEN3/4.DELTA.30 4 0
<1.0 <5 53 (CME) rDEN3/4 4 0 <1.0 <5 70 (ME)
rDEN3/4.DELTA.30 4 0 <1.0 <5 58 (ME) .sup.aGroups of rhesus
monkeys were inoculated subcutaneously with 10.sup.5 PFU of the
indicated virus in a 1 ml dose. Serum was collected on days 0 to 6,
8, 10, 12, and 28. Virus titer was determined by plaque assay in
Vero cells. .sup.bViremia was not detected in any monkey after day
4.
TABLE-US-00040 TABLE 37 rDEN3/4 chimeric viruses protect rhesus
monkeys from wt DEN3 virus challenge Mean no. of Geometric mean
viremic days per Mean peak serum neutralizing monkey after virus
titer antibody titer No. of rDEN3 (log.sub.10 (reciprocal dilution)
Virus.sup.a monkeys challenge PFU/ml .+-. SE) Day 28 Day 56 Mock 2
5.0 2.5 .+-. 0.4 <5 372 DEN3 (Sleman/78) 4 0 <1.0 707 779
rDEN3/4 (CME) 4 0 <1.0 211 695 rDEN3/4.DELTA.30 (CME) 4 0.8 1.1
.+-. 0.2 53 364 rDEN3/4 (ME) 4 0 <1.0 70 678 rDEN3/4.DELTA.30
(ME) 4 0 <1.0 58 694 .sup.a2.8 days after primary inoculation
with the indicated viruses, rhesus monkeys were challenged
subcutaneously with 10.sup.5 PFU DEN3 (Sleman/78) virus in a 1 ml
dose. Serum was collected on days 28 to 34, 36, 38, and 56. Virus
titer was determined by plaque assay in Vero cells.
To evaluate the replication levels of each DEN3/4 chimeric virus in
mosquitoes, Aedes aegypti were infected by ingesting a
virus-containing blood meal (Table 38). Parental viruses rDEN4 and
DEN3 (Sleman/78) readily infect Ae. aegypti. Each of the rDEN3/4
chimeric viruses was also tested. In many cases it was not possible
to infect Ae. aegypti with an undiluted virus stock of sufficient
titer to achieve a detectable infection due to the very low
infectivity of several of the viruses. At a dose of approximately
2.8-2.9 log.sub.10PFU, rDEN4, DEN3 (Sleman/78), and rDEN3/4(CME)
were equally infectious and disseminated to the head with equal
efficiency. For the remaining chimeric viruses, infection was not
detectable even at a dose of 3.4 log.sub.10PFU, indicating that
replication of rDEN3/4(ME) and rDEN3/4.DELTA.30(CME) is restricted
in Ae. aegypti. By comparing infectivity of rDEN3/4(CME) and
rDEN3/4.DELTA.30(CME), it is clear that the .DELTA.30 mutation is
capable of further attenuating the chimeric virus for
mosquitoes.
TABLE-US-00041 TABLE 38 Ability of DEN3/4 chimeric viruses to
infect Aedes aegypti fed an infectious bloodmeal. Dose No. No. (%)
No. (%) Ingested Mosquitoes Midgut Disseminated Virus Tested
(log.sub.10 pfu).sup.a Tested Infections.sup.b,c,d Infections.sup.e
rDEN4 3.8 18 14 (77%) 2 (14%) 2.8 20 7 (34%) 2 (10%) 1.8 18 0 0
MID.sub.50 = 3.4 MID.sub.50 .gtoreq. 4.4 DEN3 2.9 16 3 (18%) 2
(12%) (Sleman) 1.9 10 1 (10%) 0 MID.sub.50 .gtoreq. 3.5 MID.sub.50
.gtoreq. 3.5 rDEN3/4 3.9 20 6 (30%) 2 (10%) (CME) 2.9 18 4 (22%) 0
1.9 13 1 (7%) 0 MID.sub.50 .gtoreq. 4.2 MID.sub.50 .gtoreq. 4.5
DEN3/4.DELTA.30 3.3 20 0 0 (CME) MID.sub.50 .gtoreq. 4.3 MID.sub.50
.gtoreq. 4.3 DEN3/4 3.4 15 0 0 (ME) MID.sub.50 .gtoreq. 4.4
MID.sub.50 .gtoreq. 4.4 .sup.aAmount of virus ingested, assuming a
2.mu. bloodmeal. .sup.bNumber (percentage) of mosquitoes with
detectable dengue virus in midgut tissue; mosquitoes were assayed
21 days post feed, and dengue virus antigen was identified by IFA.
.sup.cWhen infection was detected, but did not exceed a frequency
of 50% at the highest dose of virus ingested, the MID.sub.50 was
estimated by assuming that a 10-fold more concentrated virus dose
would infect 100% of the mosquitoes. .sup.dWhen no infection was
detected, the MID.sub.50 was assumed to be greater than a 10-fold
higher dose of virus than the one used. .sup.eNumber (percentage)
of mosquitoes with detectable dengue virus antigen in both midgut
and head tissue.
EXAMPLE 7
Generation and Characterization of Intertypic Chimeric DEN1 Viruses
Containing the .DELTA.30 Mutation
Chimeric viruses based on the DEN4 cDNA have been generated in
which the CME or ME genes have been replaced with the corresponding
genes derived from DEN1 (Puerto Rico/94), a virus isolate from a
1994 dengue outbreak in Puerto Rico (Appendices 3 and 4). As
described in Example 4 for the DEN2 chimeric viruses, CME chimeric
viruses for DEN1 were generated by replacing the BglII/XhoI region
of the cDNA for either rDEN4 or rDEN4.DELTA.30 with a similar
region derived from DEN1 (Puerto Rico/94) (FIG. 12A). Likewise, to
create the ME chimeric viruses, the PstI/XhoI region of the cDNA
for either rDEN4 or rDEN4.DELTA.30 was replaced with a similar
region derived from DEN1 (Puerto Rico/94). The nucleotide and amino
acid sequences of the resulting junctions are shown in FIG.
12B.
For transcription and generation of virus, chimeric cDNA clones
were linearized and used as template in a transcription reaction
using SP6 RNA polymerase as described. Transcripts were introduced
into C6/36 mosquito cells using liposome-mediated transfection and
recombinant dengue virus was harvested between day 7 and 14.
Viruses were subsequently grown in Vero cells and biologically
cloned by terminal dilution in Vero cells. All viruses replicated
in Vero cells to titers in excess of 6.0 log.sub.10 PFU/ml,
indicating that the chimeric viruses, even those containing the
.DELTA.30 mutation, replicate efficiently in cell culture. Genomic
sequence analysis is currently underway to identify incidental
mutations arising from virus passage in tissue culture.
To evaluate the replication levels of DEN1/4 (CME) and
rDEN1/4.DELTA.30(CME) chimeric virus in mosquitoes, Aedes aegypti
were infected by ingesting a virus-containing blood meal (Table
39). Parental virus rDEN4 infects Ae. aegypti with an MID50 of 4.0
log.sub.10PFU. However, parental virus DEN1 (Puerto Rico/94), is
unable to infect Ae. aegypti at a dose of up to 3.4 log.sub.10PFU.
Thus CME chimeric viruses DEN1/4 and rDEN1/4.DELTA.30 share this
inability to infect Ae. aegypti. Therefore, it is unnecessary in
Ae. aegypti to evaluate the effect of the .DELTA.30 mutation on the
infectivity of the DEN1/4 chimeric viruses, in a manner similar to
that used for the DEN2/4 and DEN3/4 chimeric viruses.
TABLE-US-00042 TABLE 39 Inability of DEN1/4 chimeric viruses to
infect Aedes aegypti fed an infectious bloodmeal. Dose No. No. (%)
No. (%) Virus ingested Mosquitoes Midgut Disseminated tested
(log.sub.10 pfu).sup.a Tested Infections.sup.b,c,d Infections.sup.e
rDEN4 4.3 21 18 (85%) 8 (44%) 3.3 15 3 (20%) 0 2.3 20 0 0
MID.sub.50 = 4.0 MID.sub.50 .gtoreq. 4.3 DEN1 3.4 21 0 0 (Puerto
MID.sub.50 .gtoreq. 4.4 MID.sub.50 .gtoreq. 4.4 Rico/94) rDEN 1/4
3.8 20 0 0 (CME) MID.sub.50 .gtoreq. 4.8 MID.sub.50 .gtoreq. 4.8
rDEN1/4.DELTA.30 2.8 20 0 0 (CME) MID.sub.50 .gtoreq. 3.8
MID.sub.50 .gtoreq. 3.8 .sup.aAmount of virus ingested, assuming a
2 .mu.l bloodmeal. .sup.bNumber (percentage) of mosquitoes with
detectable dengue virus in midgut tissue; mosquitoes were assayed
21 days post feed, and dengue virus antigen was identified by IFA.
.sup.cWhen infection was detected, but did not exceed a frequency
of 50% at the highest dose of virus ingested, the MID.sub.50 was
estimated by assuming that a 10-fold more concentrated virus dose
would infect 100% of the mosquitoes. .sup.dWhen no infection was
detected, the MID.sub.50 was assumed to be greater than a 10-fold
higher dose of virus than the one used. .sup.eNumber (percentage)
of mosquitoes with detectable dengue virus antigen in both midgut
and head tissue.
As described in the previous examples, SCID mice transplanted with
the cells are a sensitive model for the evaluation of dengue virus
attenuation. Each chimeric DEN1/4 virus was inoculated into groups
of SCID-HuH-7 mice and levels of virus in the serum were determined
(Table 40). Chimeric viruses replicated to levels between 15- and
250-fold lower than either of the parental viruses, rDEN4 and DEN1
(Puerto Rico/94). CME chimeric viruses were more attenuated than
the comparable ME chimeric viruses, with the .DELTA.30 mutation
providing a 0.8 log.sub.10 reduction in replication. This level of
attenuation exerted by the .DELTA.30 mutation in the CME chimeric
viruses was similar to that observed previously for rDEN4.DELTA.30.
However, the attenuating effect of the .DELTA.30 mutation in the ME
chimeric viruses is indiscernible.
TABLE-US-00043 TABLE 40 Chimerization between dengue virus types 1
and 4 results in recombinant viruses which are attenuated for
HuH-7-SCID mice. No. of Mean peak virus titer Statistical
Virus.sup.a mice (log.sub.10 pfu/ml .+-. SE) group.sup.b rDEN4 32
6.3 .+-. 0.2 A DEN1 (Puerto Rico/94) 4 6.4 .+-. 0.2 A rDEN1/4 (CME)
8 4.7 .+-. 0.2 B, C rDEN1/4.DELTA.30 (CME) 6 3.9 .+-. 0.4 C rDEN1/4
(ME) 6 5.0 .+-. 0.2 B rDEN1/4.DELTA.30 (ME) 6 5.1 .+-. 0.3 B
.sup.aGroups of HuH-7-SCID mice were inoculated into the tumor with
4.0 log.sub.10 PFU of the indicated virus. Serum was collected on
day 7 and virus titer was determined in Vero cells. .sup.bMean peak
titers were assigned to statistical groups using the Tukey post-hoc
test (P < 0.05). Groups with the same letter designation are not
significantly different.
TABLE-US-00044 APPENDIX 1 Nucleotide and amino acid sequence of
DEN2 (Tonga/74) cDNA plasmid p2 10 20 30 40 50 60 70 80 90 100
AGTTGTTAGTCTACGTGGACCGACAAAGACAGATTCTTTGAGGGAGCTAAGCTCAACGTAGTTCTAACTGTTTT-
TTGATTAGAGAGCAGATCTCTGATGA Met> 110 120 130 140 150 160 170 180
190 200
ATAACCAACGGAAAAAGGCGAGAAACACGCCTTTCAATATGCTGAAACGCGAGAGAAACCGCGTGTCAACTGTA-
CAACAGTTGACAAAGAGATTCTCACT
AsnAsnGlnArgLysLysAlaArgAsnThrProPheAsnMetLeuLysArgGluArgAsnArgValSerThrVa-
lGlnGlnLeuThrLysArgPheSerLeu> 210 220 230 240 250 260 270 280
290 300
TGGAATGCTGCAGGGACGAGGACCACTAAAATTGTTCATGGCCCTGGTGGCATTCCTTCGTTTCCTAACAATCC-
CACCAACAGCAGGGATATTAAAAAGA
GlyMetLeuGlnGlyArgGlyProLeuLysLeuPheMetAlaLeuValAlaPheLeuArgPheLeuThrIlePr-
oProThrAlaGlyIleLeuLysArg> 310 320 330 340 350 360 370 380 390
400
TGGGGAACAATTAAAAAATCAAAGGCTATTAATGTTCTGAGAGGCTTCAGGAAAGAGATTGGAAGGATGCTGAA-
TATCTTAAACAGGAGACGTAGAACTG
TrpGlyThrIleLysLysSerLysAlaIleAsnValLeuArgGlyPheArgLysGluIleGlyArgMetLeuAs-
nIleLeuAsnArgArgArgArgThr> 410 420 430 440 450 460 470 480 490
500
TAGGCATGATCATCATGCTGACTCCAACAGTGATGGCGTTTCATCTGACCACACGCAACGGAGAACCACACATG-
ATTGTCAGTAGACAAGAAAAAGGGAA
ValGlyMetIleIleMetLeuThrProThrValMetAlaPheHisLeuThrThrArgAsnGlyGluProHisMe-
tIleValSerArgGlnGluLysGlyLys> 510 520 530 540 550 560 570 580
590 600
AAGCCTTCTGTTCAAGACAAAGGATGGCACGAACATGTGTACCCTCATGGCCATGGACCTTGGTGAGTTGTGTG-
AAGACACAATCACGTATAAATGTCCT
SerLeuLeuPheLysThrLysAspGlyThrAsnMetCysThrLeuMetAlaMetAspLeuGlyGluLeuCysGl-
uAspThrIleThrTyrLysCysPro> 610 620 630 640 650 660 670 680 690
700
TTTCTCAAGCAGAACGAACCAGAAGACATAGATTGTTGGTGCAACTCCACGTCCACATGGGTAACTTATGGGAC-
ATGTACCACCACAGGAGAGCACAGAA
PheLeuLysGlnAsnGluProGluAspIleAspCysTrpCysAsnSerThrSerThrTrpValThrTyrGlyTh-
rCysThrThrThrGlyGluHisArg> 710 720 730 740 750 760 770 780 790
800
GAGAAAAAAGATCAGTGGCGCTTGTTCCACACGTGGGAATGGGATTGGAGACACGAACTGAAACATGGATGTCA-
TCAGAAGGGGCCTGGAAACATGCCCA
ArgGluLysArgSerValAlaLeuValProHisValGlyMetGlyLeuGluThrArgThrGluThrTrpMetSe-
rSerGluGlyAlaTrpLysHisAlaGln> 810 820 830 840 850 860 870 880
890 900
GAGAATTGAAACTTGGATTCTGAGACATCCAGGCTTTACCATAATGGCCGCAATCCTGGCATACACCATAGGGA-
CGACGCATTTCCAAAGAGTCCTGATA
ArgIleGluThrTrpIleLeuArgHisProGlyPheThrIleMetAlaAlaIleLeuAlaTyrThrIleGlyTh-
rThrHisPheGlnArgValLeuIle> 910 920 930 940 950 960 970 980 990
1000
TTCATCCTACTGACAGCCATCGCTCCTTCAATGACAATGCGCTGCATAGGAATATCAAATAGGGACTTTGTGGA-
AGGAGTGTCAGGAGGGAGTTGGGTTG
PheIleLeuLeuThrAlaIleAlaProSerMetThrMetArgCysIleGlyIleSerAsnArgAspPheValGl-
uGlyValSerGlyGlySerTrpVal> 1010 1020 1030 1040 1050 1060 1070
1080 1090 1100
ACATAGTTTTAGAACATGGAAGTTGTGTGACGACGATGGCAAAAAACAAACCAACACTGGACTTTGAACTGATA-
AAAACAGAAGCCAAACAACCTGCCAC
AspIleValLeuGluHisGlySerCysValThrThrMetAlaLysAsnLysProThrLeuAspPheGluLeuIl-
eLysThrGluAlaLysGlnProAlaThr> 1110 1120 1130 1140 1150 1160 1170
1180 1190 1200
CTTAAGGAAGTACTGTATAGAGGCCAAACTGACCAACACGACAACAGACTCGCGCTGCCCAACACAAGGGGAAC-
CCACCCTGAATGAAGAGCAGGACAAA
LeuArgLysTyrCysIleGluAlaLysLeuThrAsnThrThrThrAspSerArgCysProThrGlnGlyGluPr-
oThrLeuAsnGluGluGlnAspLys> 1210 1220 1230 1240 1250 1260 1270
1280 1290 1300
AGGTTTGTCTGCAAACATTCCATGGTAGACAGAGGATGGGGAAATGGATGTGGATTGTTTGGAAAAGGAGGCAT-
CGTGACCTGTGCTATGTTCACATGCA
ArgPheValCysLysHisSerMetValAspArgGlyTrpGlyAsnGlyCysGlyLeuPheGlyLysGlyGlyIl-
eValThrCysAlaMetPheThrCys> 1310 1320 1330 1340 1350 1360 1370
1380 1390 1400
AAAAGAACATGGAAGGAAAAATTGTGCAGCCAGAAAACCTGGAATACACTGTCGTGATAACACCTCATTCAGGG-
GAAGAACATGCAGTGGGAAATGACAC
LysLysAsnMetGluGlyLysIleValGlnProGluAsnLeuGluTyrThrValValIleThrProHisSerGl-
yGluGluHisAlaValGlyAsnAspThr> 1410 1420 1430 1440 1450 1460 1470
1480 1490 1500
AGGAAAACATGGTAAAGAAGTCAAGATAACACCACAGAGCTCCATCACAGAGGCGGAACTGACAGGCTATGGCA-
CTGTTACGATGGAGTGCTCTCCAAGA
GlyLysHisGlyLysGluValLysIleThrProGlnSerSerIleThrGluAlaGluLeuThrGlyTyrGlyTh-
rValThrMetGluCysSerProArg> 1510 1520 1530 1540 1550 1560 1570
1580 1590 1600
ACGGGCCTCGACTTCAATGAGATGGTGTTGCTGCAAATGGAAGACAAAGCCTGGCTGGTGCACAGACAATGGTT-
CCTAGACCTACCGTTGCCATGGCTGC
ThrGlyLeuAspPheAsnGluMetValLeuLeuGlnMetGluAspLysAlaTrpLeuValHisArgGlnTrpPh-
eLeuAspLeuProLeuProTrpLeu> 1610 1620 1630 1640 1650 1660 1670
1680 1690 1700
CCGGAGCAGACACACAAGGATCAAATTGGATACAGAAAGAAACACTGGTCACCTTCAAAAATCCCCATGCGAAA-
AAACAGGATGTTGTTGTCTTAGGATC
ProGlyAlaAspThrGlnGlySerAsnTrpIleGlnLysGluThrLeuValThrPheLysAsnProHisAlaLy-
sLysGlnAspValValValLeuGlySer> 1710 1720 1730 1740 1750 1760 1770
1780 1790 1800
CCAAGAGGGGGCCATGCATACAGCACTCACAGGGGCTACGGAAATCCAGATGTCATCAGGAAACCTGCTGTTCA-
CAGGACATCTCAAGTGCAGGCTGAGA
GlnGluGlyAlaMetHisThrAlaLeuThrGlyAlaThrGluIleGlnMetSerSerGlyAsnLeuLeuPheTh-
rGlyHisLeuLysCysArgLeuArg> 1810 1820 1830 1840 1850 1860 1870
1880 1890 1900
ATGGACAAATTACAACTTAAAGGGATGTCATACTCCATGTGCACAGGAAAGTTTAAAATTGTGAAGGAAATAGC-
AGAAACACAACATGGAACAATAGTCA
MetAspLysLeuGlnLeuLysGlyMetSerTyrSerMetCysThrGlyLysPheLysIleValLysGluIleAl-
aGluThrGlnHisGlyThrIleVal> 1910 1920 1930 1940 1950 1960 1970
1980 1990 2000
TTAGAGTACAATATGAAGGAGACGGCTCTCCATGCAAGATCCCCTTTGAGATAATGGATCTGGAAAAAAGACAT-
GTTTTGGGCCGCCTGATCACAGTCAA
IleArgValGlnTyrGluGlyAspGlySerProCysLysIleProPheGluIleMetAspLeuGluLysArgHi-
sValLeuGlyArgLeuIleThrValAsn> 2010 2020 2030 2040 2050 2060 2070
2080 2090 2100
CCCAATTGTAACAGAAAAGGACAGTCCAGTCAACATAGAAGCAGAACCTCCATTCGGAGACAGCTACATCATCA-
TAGGAGTGGAACCAGGACAATTGAAG
ProIleValThrGluLysAspSerProValAsnIleGluAlaGluProProPheGlyAspSerTyrIleIleIl-
eGlyValGluProGlyGlnLeuLys> 2110 2120 2130 2140 2150 2160 2170
2180 2190 2200
CTGGACTGGTTCAAGAAAGGAAGTTCCATCGGCCAAATGTTTGAGACAACAATGAGGGGAGCGAAAAGAATGGC-
CATTTTGGGTGACACAGCCTGGGATT
LeuAspTrpPheLysLysGlySerSerIleGlyGlnMetPheGluThrThrMetArgGlyAlaLysArgMetAl-
aIleLeuGlyAspThrAlaTrpAsp> 2210 2220 2230 2240 2250 2260 2270
2280 2290 2300
TTGGATCTCTGGGAGGAGTGTTCACATCAATAGGAAAGGCTCTCCACCAGGTTTTTGGAGCAATCTACGGGGCT-
GCTTTCAGTGGGGTCTCATGGACTAT
PheGlySerLeuGlyGlyValPheThrSerIleGlyLysAlaLeuHisGlnValPheGlyAlaIleTyrGlyAl-
aAlaPheSerGlyValSerTrpThrMet> 2310 2320 2330 2340 2350 2360 2370
2380 2390 2400
GAAGATCCTCATAGGAGTTATCATCACATGGATAGGAATGAACTCACGTAGCACTAGTCTGAGCGTGTCACTGG-
TGTTAGTGGGAATCGTGACACTTTAC
LysIleLeuIleGlyValIleIleThrTrpIleGlyMetAsnSerArgSerThrSerLeuSerValSerLeuVa-
lLeuValGlyIleValThrLeuTyr> 2410 2420 2430 2440 2450 2460 2470
2480 2490 2500
TTGGGAGTTATGGTGCAGGCCGATAGTGGTTGCGTTGTGAGCTGGAAGAACAAAGAACTAAAATGTGGCAGTGG-
AATATTCGTCACAGATAACGTGCATA
LeuGlyValMetValGlnAlaAspSerGlyCysValValSerTrpLysAsnLysGluLeuLysCysGlySerGl-
yIlePheValThrAspAsnValHis> 2510 2520 2530 2540 2550 2560 2570
2580 2590 2600
CATGGACAGAACAATACAAGTTCCAACCAGAATCCCCTTCAAAACTGGCCTCAGCCATCCAGAAAGCGCATGAA-
GAGGGCATCTGTGGAATCCGCTCAGT
ThrTrpThrGluGlnTyrLysPheGlnProGluSerProSerLysLeuAlaSerAlaIleGlnLysAlaHisGl-
uGluGlyIleCysGlyIleArgSerVal> 2610 2620 2630 2640 2650 2660 2670
2680 2690 2700
AACAAGACTGGAAAATCTTATGTGGAAACAGATAACATCAGAATTGAATCATATTCTATCAGAAAATGAAGTGA-
AACTGACCATCATGACAGGAGACATC
ThrArgLeuGluAsnLeuMetTrpLysGlnIleThrSerGluLeuAsnHisIleLeuSerGluAsnGluValLy-
sLeuThrIleMetThrGlyAspIle> 2710 2720 2730 2740 2750 2760 2770
2780 2790 2800
AAAGGAATCATGCAGGTAGGAAAACGATCTTTGCGGCCTCAACCCACTGAGTTGAGGTATTCATGGAAAACATG-
GGGTAAAGCGAAAATGCTCTCCACAG
LysGlyIleMetGlnValGlyLysArgSerLeuArgProGlnProThrGluLeuArgTyrSerTrpLysThrTr-
pGlyLysAlaLysMetLeuSerThr> 2810 2820 2830 2840 2850 2860 2870
2880 2890 2900
AACTCCACAATCAGACCTTCCTCATTGATGGTCCCGAAACAGCAGAATGCCCCAACACAAACAGAGCTTGGAAT-
TCACTGGAAGTTGAGGACTACGGCTT
GluLeuHisAsnGlnThrPheLeuIleAspGlyProGluThrAlaGluCysProAsnThrAsnArgAlaTrpAs-
nSerLeuGluValGluAspTyrGlyPhe> 2910 2920 2930 2940 2950 2960 2970
2980 2990 3000
TGGAGTATTCACTACCAATATATGGCTAAGATTGAGAGAAAAGCAGGATGTATTTTGTGACTCAAAACTCATGT-
CAGCGGCCATAAAGGACAACAGAGCC
GlyValPheThrThrAsnIleTrpLeuArgLeuArgGluLysGlnAspValPheCysAspSerLysLeuMetSe-
rAlaAlaIleLysAspAsnArgAla> 3010 3020 3030 3040 3050 3060 3070
3080 3090 3100
GTCCATGCTGATATGGGTTATTGGATAGAAAGCGCACTCAATGATACATGGAAGATAGAGAAAGCTTCTTTCAT-
TGAAGTCAAAAGTTGCCACTGGCCAA
ValHisAlaAspMetGlyTyrTrpIleGluSerAlaLeuAsnAspThrTrpLysIleGluLysAlaSerPheIl-
eGluValLysSerCysHisTrpPro> 3110 3120 3130 3140 3150 3160 3170
3180 3190 3200
AGTCACACACCCTATGGAGTAATGGAGTGCTAGAAAGCGAGATGGTCATTCCAAAGAATTTCGCTGGACCAGTG-
TCACAACATAATAACAGACCAGGCTA
LysSerHisThrLeuTrpSerAsnGlyValLeuGluSerGluMetValIleProLysAsnPheAlaGlyProVa-
lSerGlnHisAsnAsnArgProGlyTyr> 3210 3220 3230 3240 3250 3260 3270
3280 3290 3300
TTACACACAAACAGCAGGACCTTGGCATCTAGGCAAGCTTGAGATGGACTTTGATTTCTGCGAAGGGACTACAG-
TGGTGGTAACCGAGAACTGTGGAAAC
TyrThrGlnThrAlaGlyProTrpHisLeuGlyLysLeuGluMetAspPheAspPheCysGluGlyThrThrVa-
lValValThrGluAsnCysGlyAsn> 3310 3320 3330 3340 3350 3360 3370
3380 3390 3400
AGAGGGCCCTCTTTAAGAACAACCACTGCCTCAGGAAAACTCATAACGGAATGGTGTTGTCGATCTTGCACACT-
ACCACCACTAAGATACAGAGGTGAGG
ArgGlyProSerLeuArgThrThrThrAlaSerGlyLysLeuIleThrGluTrpCysCysArgSerCysThrLe-
uProProLeuArgTyrArgGlyGlu> 3410 3420 3430 3440 3450 3460 3470
3480 3490 3500
ATGGATGTTGGTACGGGATGGAAATCAGACCATTGAAAGAGAAAGAAGAAAATCTGGTCAGTTCTCTGGTTACA-
GCCGGACATGGGCAGATTGACAATTT
AspGlyCysTrpTyrGlyMetGluIleArgProLeuLysGluLysGluGluAsnLeuValSerSerLeuValTh-
rAlaGlyHisGlyGlnIleAspAsnPhe> 3510 3520 3530 3540 3550 3560
3570
3580 3590 3600
CTCATTAGGAATCTTGGGAATGGCACTGTTCCTTGAAGAAATGCTCAGGACTCGAGTAGGAACAAAACATGCAA-
TATTACTCGTCGCAGTTTCTTTCGTG
SerLeuGlyIleLeuGlyMetAlaLeuPheLeuGluGluMetLeuArgThrArgValGlyThrLysHisAlaIl-
eLeuLeuValAlaValSerPheVal> 3610 3620 3630 3640 3650 3660 3670
3680 3690 3700
ACGCTAATCACAGGGAACATGTCTTTTAGAGACCTGGGAAGAGTGATGGTTATGGTGGGTGCCACCATGACAGA-
TGACATAGGCATGGGTGTGACTTATC
ThrLeuIleThrGlyAsnMetSerPheArgAspLeuGlyArgValMetValMetValGlyAlaThrMetThrAs-
pAspIleGlyMetGlyValThrTyr> 3710 3720 3730 3740 3750 3760 3770
3780 3790 3800
TCGCTCTACTAGCAGCTTTTAGAGTCAGACCAACCTTTGCAGCTGGACTGCTCTTGAGAAAACTGACCTCCAAG-
GAATTAATGATGACTACCATAGGAAT
LeuAlaLeuLeuAlaAlaPheArgValArgProThrPheAlaAlaGlyLeuLeuLeuArgLysLeuThrSerLy-
sGluLeuMetMetThrThrIleGlyIle> 3810 3820 3830 3840 3850 3860 3870
3880 3890 3900
CGTTCTTCTCTCCCAGAGTAGCATACCAGAGACCATTCTTGAACTGACCGACGCGTTAGCTCTAGGCATGATGG-
TCCTCAAGATGGTGAGAAACATGGAA
ValLeuLeuSerGlnSerSerIleProGluThrIleLeuGluLeuThrAspAlaLeuAlaLeuGlyMetMetVa-
lLeuLysMetValArgAsnMetGlu> 3910 3920 3930 3940 3950 3960 3970
3980 3990 4000
AAATATCAGCTGGCAGTGACCATCATGGCTATTTTGTGCGTCCCAAATGCTGTGATATTACAGAACGCATGGAA-
AGTGAGTTGCACAATATTGGCAGTGG
LysTyrGlnLeuAlaValThrIleMetAlaIleLeuCysValProAsnAlaValIleLeuGlnAsnAlaTrpLy-
sValSerCysThrIleLeuAlaVal> 4010 4020 4030 4040 4050 4060 4070
4080 4090 4100
TGTCTGTTTCCCCCCTGCTCTTAACATCCTCACAACAGAAAGCGGACTGGATACCATTAGCGTTGACGATCAAA-
GGTCTTAATCCAACAGCCATTTTTCT
ValSerValSerProLeuLeuLeuThrSerSerGlnGlnLysAlaAspTrpIleProLeuAlaLeuThrIleLy-
sGlyLeuAsnProThrAlaIlePheLeu> 4110 4120 4130 4140 4150 4160 4170
4180 4190 4200
AACAACCCTCTCAAGAACCAACAAGAAAAGGAGCTGGCCTTTAAATGAGGCCATCATGGCGGTTGGGATGGTGA-
GTATCTTGGCCAGCTCTCTCTTAAAG
ThrThrLeuSerArgThrAsnLysLysArgSerTrpProLeuAsnGluAlaIleMetAlaValGlyMetValSe-
rIleLeuAlaSerSerLeuLeuLys> 4210 4220 4230 4240 4250 4260 4270
4280 4290 4300
AATGACATCCCCATGACAGGACCATTAGTGGCTGGAGGGCTCCTTACTGTGTGCTACGTGCTAACTGGGCGGTC-
AGCCGATCTGGAATTAGAGAGAGCTA
AsnAspIleProMetThrGlyProLeuValAlaGlyGlyLeuLeuThrValCysTyrValLeuThrGlyArgSe-
rAlaAspLeuGluLeuGluArgAla> 4310 4320 4330 4340 4350 4360 4370
4380 4390 4400
CCGATGTCAAATGGGATGACCAGGCAGAGATATCAGGTAGCAGTCCAATCCTGTCAATAACAATATCAGAAGAT-
GGCAGCATGTCAATAAAGAATGAAGA
ThrAspValLysTrpAspAspGlnAlaGluIleSerGlySerSerProIleLeuSerIleThrIleSerGluAs-
pGlySerMetSerIleLysAsnGluGlu> 4410 4420 4430 4440 4450 4460 4470
4480 4490 4500
GGAAGAGCAAACACTGACTATACTCATTAGAACAGGATTGCTTGTGATCTCAGGACTCTTTCCGGTATCAATAC-
CAATTACAGCAGCAGCATGGTATCTG
GluGluGlnThrLeuThrIleLeuIleArgThrGlyLeuLeuValIleSerGlyLeuPheProValSerIlePr-
oIleThrAlaAlaAlaTrpTyrLeu> 4510 4520 4530 4540 4550 4560 4570
4580 4590 4600
TGGGAAGTAAAGAAACAACGGGCTGGAGTGCTGTGGGATGTCCCCTCACCACCACCCGTGGGAAAAGCTGAATT-
GGAAGATGGAGCCTACAGAATCAAGC
TrpGluValLysLysGlnArgAlaGlyValLeuTrpAspValProSerProProProValGlyLysAlaGluLe-
uGluAspGlyAlaTyrArgIleLys> 4610 4620 4630 4640 4650 4660 4670
4680 4690 4700
AAAAAGGAATCCTTGGATATTCCCAGATCGGAGCTGGAGTTTACAAAGAAGGAACATTTCACACAATGTGGCAC-
GTCACACGTGGCGCTGTCCTAATGCA
GlnLysGlyIleLeuGlyTyrSerGlnIleGlyAlaGlyValTyrLysGluGlyThrPheHisThrMetTrpHi-
sValThrArgGlyAlaValLeuMetHis> 4710 4720 4730 4740 4750 4760 4770
4780 4790 4800
TAAGGGGAAGAGGATTGAACCATCATGGGCGGACGTCAAGAAAGACTTAATATCATATGGAGGAGGTTGGAAGC-
TAGAAGGAGAATGGAAAGAAGGAGAA
LysGlyLysArgIleGluProSerTrpAlaAspValLysLysAspLeuIleSerTyrGlyGlyGlyTrpLysLe-
uGluGlyGluTrpLysGluGlyGlu> 4810 4820 4830 4840 4850 4860 4870
4880 4890 4900
GAAGTCCAGGTCTTGGCATTGGAGCCAGGGAAAAATCCAAGAGCCGTCCAAACAAAGCCTGGCCTTTTTAGAAC-
CAACACTGGAACCATAGGTGCCGTAT
GluValGlnValLeuAlaLeuGluProGlyLysAsnProArgAlaValGlnThrLysProGlyLeuPheArgTh-
rAsnThrGlyThrIleGlyAlaVal> 4910 4920 4930 4940 4950 4960 4970
4980 4990 5000
CTCTGGACTTTTCCCCTGGGACGTCAGGATCTCCAATCGTCGACAAAAAAGGAAAAGTTGTAGGTCTCTATGGC-
AATGGTGTCGTTACAAGGAGTGGAGC
SerLeuAspPheSerProGlyThrSerGlySerProIleValAspLysLysGlyLysValValGlyLeuTyrGl-
yAsnGlyValValThrArgSerGlyAla> 5010 5020 5030 5040 5050 5060 5070
5080 5090 5100
ATATGTGAGTGCCATAGCTCAGACTGAAAAAAGCATTGAAGACAATCCAGAGATTGAAGATGACATCTTTCGAA-
AGAGAAGATTGACTATCATGGATCTC
TyrValSerAlaIleAlaGlnThrGluLysSerIleGluAspAsnProGluIleGluAspAspIlePheArgLy-
sArgArgLeuThrIleMetAspLeu> 5110 5120 5130 5140 5150 5160 5170
5180 5190 5200
CACCCAGGAGCAGGAAAGACAAAGAGATACCTCCCGGCCATAGTCAGAGAGGCCATAAAAAGAGGCTTGAGAAC-
ACTAATCCTAGCCCCCACTAGAGTCG
HisProGlyAlaGlyLysThrLysArgTyrLeuProAlaIleValArgGluAlaIleLysArgGlyLeuArgTh-
rLeuIleLeuAlaProThrArgVal> 5210 5220 5230 5240 5250 5260 5270
5280 5290 5300
TGGCAGCTGAAATGGAGGAAGCCCTTAGAGGACTTCCAATAAGATACCAAACTCCAGCTATCAGGGCTGAGCAC-
ACCGGGCGGGAGATTGTAGACTTAAT
ValAlaAlaGluMetGluGluAlaLeuArgGlyLeuProIleArgTyrGlnThrProAlaIleArgAlaGluHi-
sThrGlyArgGluIleValAspLeuMet> 5310 5320 5330 5340 5350 5360 5370
5380 5390 5400
GTGTCATGCCACATTTACCATGAGGCTGCTATCACCAATCAGGGTGCCAAATTACAACCTGATCATCATGGACG-
AAGCCCATTTTACAGATCCAGCAAGC
CysHisAlaThrPheThrMetArgLeuLeuSerProIleArgValProAsnTyrAsnLeuIleIleMetAspGl-
uAlaHisPheThrAspProAlaSer> 5410 5420 5430 5440 5450 5460 5470
5480 5490 5500
ATAGCAGCTAGGGGATACATCTCAACTCGAGTGGAGATGGGGGAGGCAGCTGGAATTTTTATGACAGCCACTCC-
TCCGGGTAGTAGAGATCCATTTCCTC
IleAlaAlaArgGlyTyrIleSerThrArgValGluMetGlyGluAlaAlaGlyIlePheMetThrAlaThrPr-
oProGlySerArgAspProPhePro> 5510 5520 5530 5540 5550 5560 5570
5580 5590 5600
AGAGCAATGCACCAATTATGGACGAAGAAAGAGAAATTCCGGAACGTTCATGGAACTCTGGGCACGAGTGGGTC-
ACGGATTTTAAAGGAAAGACTGTCTG
GlnSerAsnAlaProIleMetAspGluGluArgGluIleProGluArgSerTrpAsnSerGlyHisGluTrpVa-
lThrAspPheLysGlyLysThrValTrp> 5610 5620 5630 5640 5650 5660 5670
5680 5690 5700
GTTTGTTCCAAGCATAAAAACCGGAAATGACATAGCAGCCTGCCTGAGAAAGAATGGAAAGAGGGTGATACAAC-
TCAGTAGGAAGACCTTTGATTCTGAA
PheValProSerIleLysThrGlyAsnAspIleAlaAlaCysLeuArgLysAsnGlyLysArgValIleGlnLe-
uSerArgLysThrPheAspSerGlu> 5710 5720 5730 5740 5750 5760 5770
5780 5790 5800
TATGTCAAGACTAGAACCAATGACTGGGATTTCGTGGTTACAACTGACATCTCGGAAATGGGCGCCAACTTTAA-
AGCTGAGAGGGTCATAGACCCCAGAC
TyrValLysThrArgThrAsnAspTrpAspPheValValThrThrAspIleSerGluMetGlyAlaAsnPheLy-
sAlaGluArgValIleAspProArg> 5810 5820 5830 5840 5850 5860 5870
5880 5890 5900
GCTGCATGAAACCAGTTATATTGACAGACGGCGAAGAGCGGGTGATTCTGGCAGGACCCATGCCAGTGACCCAC-
TCTAGTGCAGCACAAAGAAGAGGGAG
ArgCysMetLysProValIleLeuThrAspGlyGluGluArgValIleLeuAlaGlyProMetProValThrHi-
sSerSerAlaAlaGlnArgArgGlyArg> 5910 5920 5930 5940 5950 5960 5970
5980 5990 6000
AATAGGAAGGAATCCAAGGAATGAAAATGATCAATATATATATATGGGGGAACCACTGGAAAATGATGAAGACT-
GTGCGCACTGGAAGGAAGCTAAGATG
IleGlyArgAsnProArgAsnGluAsnAspGlnTyrIleTyrMetGlyGluProLeuGluAsnAspGluAspCy-
sAlaHisTrpLysGluAlaLysMet> 6010 6020 6030 6040 6050 6060 6070
6080 6090 6100
CTCCTAGATAATATCAACACACCTGAAGGAATCATTCCCAGCTTGTTCGAGCCAGAGCGTGAAAAGGTGGATGC-
CATTGACGGTGAATATCGCTTGAGAG
LeuLeuAspAsnIleAsnThrProGluGlyIleIleProSerLeuPheGluProGluArgGluLysValAspAl-
aIleAspGlyGluTyrArgLeuArg> 6110 6120 6130 6140 6150 6160 6170
6180 6190 6200
GAGAAGCACGGAAAACTTTTGTGGACCTAATGAGAAGAGGAGACCTACCAGTCTGGTTGGCTTATAAAGTGGCA-
GCTGAAGGTATCAACTACGCAGACAG
GlyGluAlaArgLysThrPheValAspLeuMetArgArgGlyAspLeuProValTrpLeuAlaTyrLysValAl-
aAlaGluGlyIleAsnTyrAlaAspArg> 6210 6220 6230 6240 6250 6260 6270
6280 6290 6300
AAGATGGTGTTTTGACGGAACCAGAAACAATCAAATCTTGGAAGAAAATGTGGAAGTGGAAATCTGGACAAAGG-
AAGGGGAAAGGAAAAAATTGAAACCT
ArgTrpCysPheAspGlyThrArgAsnAsnGlnIleLeuGluGluAsnValGluValGluIleTrpThrLysGl-
uGlyGluArgLysLysLeuLysPro> 6310 6320 6330 6340 6350 6360 6370
6380 6390 6400
AGATGGTTAGATGCTAGGATCTACTCCGACCCACTGGCGCTAAAAGAGTTCAAGGAATTTGCAGCCGGAAGAAA-
GTCCCTAACCCTGAACCTAATTACAG
ArgTrpLeuAspAlaArgIleTyrSerAspProLeuAlaLeuLysGluPheLysGluPheAlaAlaGlyArgLy-
sSerLeuThrLeuAsnLeuIleThr> 6410 6420 6430 6440 6450 6460 6470
6480 6490 6500
AGATGGGCAGACTCCCAACTTTTATGACTCAGAAGGCCAGAGATGCACTAGACAACTTGGCGGTGCTGCACACG-
GCTGAAGCGGGTGGAAAGGCATACAA
GluMetGlyArgLeuProThrPheMetThrGlnLysAlaArgAspAlaLeuAspAsnLeuAlaValLeuHisTh-
rAlaGluAlaGlyGlyLysAlaTyrAsn> 6510 6520 6530 6540 6550 6560 6570
6580 6590 6600
TCATGCTCTCAGTGAATTACCGGAGACCCTGGAGACATTGCTTTTGCTGACACTGTTGGCCACAGTCACGGGAG-
GAATCTTCCTATTCCTGATGAGCGGA
HisAlaLeuSerGluLeuProGluThrLeuGluThrLeuLeuLeuLeuThrLeuLeuAlaThrValThrGlyGl-
yIlePheLeuPheLeuMetSerGly> 6610 6620 6630 6640 6650 6660 6670
6680 6690 6700
AGGGGTATGGGGAAGATGACCCTGGGAATGTGCTGCATAATCACGGCCAGCATCCTCTTATGGTATGCACAAAT-
ACAGCCACATTGGATAGCAGCCTCAA
ArgGlyMetGlyLysMetThrLeuGlyMetCysCysIleIleThrAlaSerIleLeuLeuTrpTyrAlaGlnIl-
eGlnProHisTrpIleAlaAlaSer> 6710 6720 6730 6740 6750 6760 6770
6780 6790 6800
TAATATTGGAGTTCTTTCTCATAGTCTTGCTCATTCCAGAACCAGAAAAGCAGAGGACACCTCAGGATAATCAA-
TTGACTTATGTCATCATAGCCATCCT
IleIleLeuGluPhePheLeuIleValLeuLeuIleProGluProGluLysGlnArgThrProGlnAspAsnGl-
nLeuThrTyrValIleIleAlaIleLeu> 6810 6820 6830 6840 6850 6860 6870
6880 6890 6900
CACAGTGGTGGCCGCAACCATGGCAAACGAAATGGGTTTTCTGGAAAAAACAAAGAAAGACCTCGGACTGGGAA-
ACATTGCAACTCAGCAACCTGAGAGC
ThrValValAlaAlaThrMetAlaAsnGluMetGlyPheLeuGluLysThrLysLysAspLeuGlyLeuGlyAs-
nIleAlaThrGlnGlnProGluSer> 6910 6920 6930 6940 6950 6960 6970
6980 6990 7000
AACATTCTGGACATAGATCTACGTCCTGCATCAGCATGGACGTTGTATGCCGTGGCTACAACATTTATCACACC-
AATGTTGAGACATAGCATTGAAAATT
AsnIleLeuAspIleAspLeuArgProAlaSerAlaTrpThrLeuTyrAlaValAlaThrThrPheIleThrPr-
oMetLeuArgHisSerIleGluAsn> 7010 7020 7030 7040 7050 7060 7070
7080 7090 7100
CCTCAGTAAATGTGTCCCTAACAGCCATAGCTAACCAAGCCACAGTGCTAATGGGTCTCGGAAAAGGATGGCCA-
TTGTCAAAGATGGACATTGGAGTTCC
SerSerValAsnValSerLeuThrAlaIleAlaAsnGlnAlaThrValLeuMetGlyLeuGlyLysGlyTrpPr-
oLeuSerLysMetAspIleGlyValPro>
7110 7120 7130 7140 7150 7160 7170 7180 7190 7200
CCTCCTTGCTATTGGGTGTTACTCACAAGTCAACCCTATAACCCTCACAGCGGCTCTTCTTTTATTGGTAGCAC-
ATTATGCCATCATAGGACCGGGACTT
LeuLeuAlaIleGlyCysTyrSerGlnValAsnProIleThrLeuThrAlaAlaLeuLeuLeuLeuValAlaHi-
sTyrAlaIleIleGlyProGlyLeu> 7210 7220 7230 7240 7250 7260 7270
7280 7290 7300
CAAGCCAAAGCAACTAGAGAAGCTCAGAAAAGAGCAGCAGCGGGCATCATGAAAAACCCAACTGTGGATGGAAT-
AACAGTGATAGATCTAGATCCAATAC
GlnAlaLysAlaThrArgGluAlaGlnLysArgAlaAlaAlaGlyIleMetLysAsnProThrValAspGlyIl-
eThrValIleAspLeuAspProIle> 7310 7320 7330 7340 7350 7360 7370
7380 7390 7400
CCTATGATCCAAAGTTTGAAAAGCAGTTGGGACAAGTAATGCTCCTAGTCCTCTGCGTGACCCAAGTGCTGATG-
ATGAGGACTACGTGGGCTTTGTGTGA
ProTyrAspProLysPheGluLysGlnLeuGlyGlnValMetLeuLeuValLeuCysValThrGlnValLeuMe-
tMetArgThrThrTrpAlaLeuCysGlu> 7410 7420 7430 7440 7450 7460 7470
7480 7490 7500
AGCCTTAACTCTAGCAACTGGACCCGTGTCCACATTGTGGGAAGGAAATCCAGGGAGATTCTGGAACACAACCA-
TTGCAGTGTCAATGGCAAACATCTTT
AlaLeuThrLeuAlaThrGlyProValSerThrLeuTrpGluGlyAsnProGlyArgPheTrpAsnThrThrIl-
eAlaValSerMetAlaAsnIlePhe> 7510 7520 7530 7540 7550 7560 7570
7580 7590 7600
AGAGGGAGTTACCTGGCTGGAGCTGGACTTCTCTTTTCTATCATGAAGAACACAACCAGCACGAGAAGAGGAAC-
TGGCAATATAGGAGAAACGTTAGGAG
ArgGlySerTyrLeuAlaGlyAlaGlyLeuLeuPheSerIleMetLysAsnThrThrSerThrArgArgGlyTh-
rGlyAsnIleGlyGluThrLeuGly> 7610 7620 7630 7640 7650 7660 7670
7680 7690 7700
AGAAATGGAAAAGCAGACTGAACGCATTGGGGAAAAGTGAATTCCAGATCTACAAAAAAAGTGGAATTCAAGAA-
GTGGACAGAACCTTAGCAAAAGAAGG
GluLysTrpLysSerArgLeuAsnAlaLeuGlyLysSerGluPheGlnIleTyrLysLysSerGlyIleGlnGl-
uValAspArgThrLeuAlaLysGluGly> 7710 7720 7730 7740 7750 7760 7770
7780 7790 7800
CATTAAAAGAGGAGAAACGGATCATCACGCTGTGTCGCGAGGCTCAGCAAAACTGAGATGGTTCGTTGAAAGGA-
ATTTGGTCACACCAGAAGGGAAAGTA
IleLysArgGlyGluThrAspHisHisAlaValSerArgGlySerAlaLysLeuArgTrpPheValGluArgAs-
nLeuValThrProGluGlyLysVal> 7810 7820 7830 7840 7850 7860 7870
7880 7890 7900
GTGGACCTTGGTTGTGGCAGAGGGGGCTGGTCATACTATTGTGGAGGATTAAAGAATGTAAGAGAAGTTAAAGG-
CTTAACAAAAGGAGGACCAGGACACG
ValAspLeuGlyCysGlyArgGlyGlyTrpSerTyrTyrCysGlyGlyLeuLysAsnValArgGluValLysGl-
yLeuThrLysGlyGlyProGlyHis> 7910 7920 7930 7940 7950 7960 7970
7980 7990 8000
AAGAACCTATCCCTATGTCAACATATGGGTGGAATCTAGTACGCTTACAGAGCGGAGTTGATGTTTTTTTTGTT-
CCACCAGAGAAGTGTGACACATTGTT
GluGluProIleProMetSerThrTyrGlyTrpAsnLeuValArgLeuGlnSerGlyValAspValPhePheVa-
lProProGluLysCysAspThrLeuLeu> 8010 8020 8030 8040 8050 8060 8070
8080 8090 8100
GTGTGACATAGGGGAATCATCACCAAATCCCACGGTAGAAGCGGGACGAACACTCAGAGTCCTCAACCTAGTGG-
AAAATTGGCTGAACAATAACACCCAA
CysAspIleGlyGluSerSerProAsnProThrValGluAlaGlyArgThrLeuArgValLeuAsnLeuValGl-
uAsnTrpLeuAsnAsnAsnThrGln> 8110 8120 8130 8140 8150 8160 8170
8180 8190 8200
TTTTGCGTAAAGGTTCTTAACCCGTACATGCCCTCAGTCATTGAAAGAATGGAAACCTTACAACGGAAATACGG-
AGGAGCCTTGGTGAGAAATCCACTCT
PheCysValLysValLeuAsnProTyrMetProSerValIleGluArgMetGluThrLeuGlnArgLysTyrGl-
yGlyAlaLeuValArgAsnProLeu> 8210 8220 8230 8240 8250 8260 8270
8280 8290 8300
CACGGAATTCCACACATGAGATGTACTGGGTGTCCAATGCTTCCGGGAACATAGTGTCATCAGTGAACATGATT-
TCAAGAATGCTGATCAACAGATTCAC
SerArgAsnSerThrHisGluMetTyrTrpValSerAsnAlaSerGlyAsnIleValSerSerValAsnMetIl-
eSerArgMetLeuIleAsnArgPheThr> 8310 8320 8330 8340 8350 8360 8370
8380 8390 8400
TATGAGACACAAGAAGGCCACCTATGAGCCAGATGTCGACCTCGGAAGCGGAACCCGCAATATTGGAATTGAAA-
GTGAGACACCGAACCTAGACATAATT
MetArgHisLysLysAlaThrTyrGluProAspValAspLeuGlySerGlyThrArgAsnIleGlyIleGluSe-
rGluThrProAsnLeuAspIleIle> 8410 8420 8430 8440 8450 8460 8470
8480 8490 8500
GGGAAAAGAATAGAAAAAATAAAACAAGAGCATGAAACGTCATGGCACTATGATCAAGACCACCCATACAAAAC-
ATGGGCTTACCATGGCAGCTATGAAA
GlyLysArgIleGluLysIleLysGlnGluHisGluThrSerTrpHisTyrAspGlnAspHisProTyrLysTh-
rTrpAlaTyrHisGlySerTyrGlu> 8510 8520 8530 8540 8550 8560 8570
8580 8590 8600
CAAAACAGACTGGATCAGCATCATCCATGGTGAACGGAGTAGTCAGATTGCTGACAAAACCCTGGGACGTTGTT-
CCAATGGTGACACAGATGGCAATGAC
ThrLysGlnThrGlySerAlaSerSerMetValAsnGlyValValArgLeuLeuThrLysProTrpAspValVa-
lProMetValThrGlnMetAlaMetThr> 8610 8620 8630 8640 8650 8660 8670
8680 8690 8700
AGACACAACTCCTTTTGGACAACAGCGCGTCTTCAAAGAGAAGGTGGATACGAGAACCCAAGAACCAAAAGAAG-
GCACAAAAAAACTAATGAAAATCACG
AspThrThrProPheGlyGlnGlnArgValPheLysGluLysValAspThrArgThrGlnGluProLysGluGl-
yThrLysLysLeuMetLysIleThr> 8710 8720 8730 8740 8750 8760 8770
8780 8790 8800
GCAGAGTGGCTCTGGAAAGAACTAGGAAAGAAAAAGACACCTAGAATGTGTACCAGAGAAGAATTCACAAAAAA-
GGTGAGAAGCAATGCAGCCTTGGGGG
AlaGluTrpLeuTrpLysGluLeuGlyLysLysLysThrProArgMetCysThrArgGluGluPheThrLysLy-
sValArgSerAsnAlaAlaLeuGly> 8810 8820 8830 8840 8850 8860 8870
8880 8890 8900
CCATATTCACCGATGAGAACAAGTGGAAATCGGCGCGTGAAGCCGTTGAAGATAGTAGGTTTTGGGAGCTGGTT-
GACAAGGAAAGGAACCTCCATCTTGA
AlaIlePheThrAspGluAsnLysTrpLysSerAlaArgGluAlaValGluAspSerArgPheTrpGluLeuVa-
lAspLysGluArgAsnLeuHisLeuGlu> 8910 8920 8930 8940 8950 8960 8970
8980 8990 9000
AGGGAAATGTGAAACATGTGTATACAACATGATGGGGAAAAGAGAGAAAAAACTAGGAGAGTTTGGTAAAGCAA-
AAGGCAGCAGAGCCATATGGTACATG
GlyLysCysGluThrCysValTyrAsnMetMetGlyLysArgGluLysLysLeuGlyGluPheGlyLysAlaLy-
sGlySerArgAlaIleTrpTyrMet> 9010 9020 9030 9040 9050 9060 9070
9080 9090 9100
TGGCTCGGAGCACGCTTCTTAGAGTTTGAAGCCCTAGGATTTTTGAATGAAGACCATTGGTTCTCCAGAGAGAA-
CTCCCTGAGTGGAGTGGAAGGAGAAG
TrpLeuGlyAlaArgPheLeuGluPheGluAlaLeuGlyPheLeuAsnGluAspHisTrpPheSerArgGluAs-
nSerLeuSerGlyValGluGlyGlu> 9110 9120 9130 9140 9150 9160 9170
9180 9190 9200
GGCTGCATAAGCTAGGTTACATCTTAAGAGAGGTGAGCAAGAAAGAAGGAGGAGCAATGTATGCCGATGACACC-
GCAGGCTGGGACACAAGAATCACAAT
GlyLeuHisLysLeuGlyTyrIleLeuArgGluValSerLysLysGluGlyGlyAlaMetTyrAlaAspAspTh-
rAlaGlyTrpAspThrArgIleThrIle> 9210 9220 9230 9240 9250 9260 9270
9280 9290 9300
AGAGGATTTGAAAAATGAAGAAATGATAACGAACCACATGGCAGGAGAACACAAGAAACTTGCCGAGGCCATTT-
TTAAATTGACGTACCAAAACAAGGTG
GluAspLeuLysAsnGluGluMetIleThrAsnHisMetAlaGlyGluHisLysLysLeuAlaGluAlaIlePh-
eLysLeuThrTyrGlnAsnLysVal> 9310 9320 9330 9340 9350 9360 9370
9380 9390 9400
GTGCGTGTGCAAAGACCAACACCAAGAGGCACAGTAATGGACATCATATCGAGAAGAGACCAAAGGGGTAGTGG-
ACAAGTTGGCACCTATGGCCTCAACA
ValArgValGlnArgProThrProArgGlyThrValMetAspIleIleSerArgArgAspGlnArgGlySerGl-
yGlnValGlyThrTyrGlyLeuAsn> 9410 9420 9430 9440 9450 9460 9470
9480 9490 9500
CTTTCACCAACATGGAAGCACAACTAATTAGGCAAATGGAGGGGGAAGGAATCTTCAAAAGCATCCAGCACTTG-
ACAGCCTCAGAAGAAATCGCTGTGCA
ThrPheThrAsnMetGluAlaGlnLeuIleArgGlnMetGluGlyGluGlyIlePheLysSerIleGlnHisLe-
uThrAlaSerGluGluIleAlaValGln> 9510 9520 9530 9540 9550 9560 9570
9580 9590 9600
AGATTGGCTAGTAAGAGTAGGGCGTGAAAGGTTGTCAAGAATGGCCATCAGTGGAGATGATTGTGTTGTGAAAC-
CTTTAGATGATAGATTTGCAAGAGCT
AspTrpLeuValArgValGlyArgGluArgLeuSerArgMetAlaIleSerGlyAspAspCysValValLysPr-
oLeuAspAspArgPheAlaArgAla> 9610 9620 9630 9640 9650 9660 9670
9680 9690 9700
CTAACAGCTCTAAATGACATGGGAAAGGTTAGGAAGGACATACAGCAATGGGAGCCCTCAAGAGGATGGAACGA-
CTGGACGCAGGTGCCCTTCTGTTCAC
LeuThrAlaLeuAsnAspMetGlyLysValArgLysAspIleGlnGlnTrpGluProSerArgGlyTrpAsnAs-
pTrpThrGlnValProPheCysSer> 9710 9720 9730 9740 9750 9760 9770
9780 9790 9800
ACCATTTTCACGAGTTAATTATGAAAGATGGTCGCACACTCGTAGTTCCATGCAGAAACCAAGATGAATTGATC-
GGCAGAGCCCGAATTTCCCAGGGAGC
HisHisPheHisGluLeuIleMetLysAspGlyArgThrLeuValValProCysArgAsnGlnAspGluLeuIl-
eGlyArgAlaArgIleSerGlnGlyAla> 9810 9820 9830 9840 9850 9860 9870
9880 9890 9900
TGGGTGGTCTTTACGGGAGACGGCCTGTTTGGGGAAGTCTTACGCCCAAATGTGGAGCTTGATGTACTTCCACA-
GACGTGATCTCAGGCTAGCGGCAAAT
GlyTrpSerLeuArgGluThrAlaCysLeuGlyLysSerTyrAlaGlnMetTrpSerLeuMetTyrPheHisAr-
gArgAspLeuArgLeuAlaAlaAsn> 9910 9920 9930 9940 9950 9960 9970
9980 9990 10000
GCCATCTGCTCGGCAGTCCCATCACACTGGATTCCAACAAGCCGGACAACCTGGTCCATACACGCCAGCCATGA-
ATGGATGACGACGGAAGACATGTTGA
AlaIleCysSerAlaValProSerHisTrpIleProThrSerArgThrThrTrpSerIleHisAlaSerHisGl-
uTrpMetThrThrGluAspMetLeu> 10010 10020 10030 10040 10050 10060
10070 10080 10090 10100
CAGTTTGGAACAGAGTGTGGATCCTAGAAAATCCATGGATGGAAGACAAAACTCCAGTGGAATCATGGGAGGAA-
ATCCCATACCTGGGAAAAAGAGAAGA
ThrValTrpAsnArgValTrpIleLeuGluAsnProTrpMetGluAspLysThrProValGluSerTrpGluGl-
uIleProTyrLeuGlyLysArgGluAsp> 10110 10120 10130 10140 10150
10160 10170 10180 10190 10200
CCAATGGTGCGGCTCGCTGATTGGGCTGACAAGCAGAGCCACCTGGGCGAAGAATATCCAGACAGCAATAAACC-
AAGTCAGATCCCTCATTGGCAATGAG
GlnTrpCysGlySerLeuIleGlyLeuThrSerArgAlaThrTrpAlaLysAsnIleGlnThrAlaIleAsnGl-
nValArgSerLeuIleGlyAsnGlu> 10210 10220 10230 10240 10250 10260
10270 10280 10290 10300
GAATACACAGATTACATGCCATCCATGAAAAGATTCAGAAGAGAAGAGGAAGAGGCAGGAGTTTTGTGGTAGAA-
AAACATGAAACAAAACAGAAGTCAGG
GluTyrThrAspTyrMetProSerMetLysArgPheArgArgGluGluGluGluAlaGlyValLeuTrp***&-
gt; 10310 10320 10330 10340 10350 10360 10370 10380 10390 10400
TCGGATTAAGCCATAGTACGGGAAAAACTATGCTACCTGTGAGCCCCGTCCAAGGACGTTAAAAGAAGTCAGGC-
CATTTTGATGCCATAGCTTGAGCAAA 10410 10420 10430 10440 10450 10460
10470 10480 10490 10500
CTGTGCAGCCTGTAGCTCCACCTGAGAAGGTGTAAAAAATCCGGGAGGCCACAAACCATGGAAGCTGTACGCAT-
GGCGTAGTGGACTAGCGGTTAGAGGA 10510 10520 10530 10540 10550 10560
10570 10580 10590 10600
GACCCCTCCCTTACAGATCGCAGCAACAATGGGGGCCCAAGGTGAGATGAAGCTGTAGTCTCACTGGAAGGACT-
AGAGGTTAGAGGAGACCCCCCCAAAA 10610 10620 10630 10640 10650 10660
10670 10680 10690 10700
CAAAAAACAGCATATTGACGCTGGGAAAGACCAGAGATCCTGCTGTCTCCTCAGCATCATTCCAGGCACAGGAC-
GCCAGAAAATGGAATGGTGCTGTTGA 10710 10720 10730 10740 10750 10760
10770 10780 10790 10800
ATCAACAGGTTCTGGTACCGGTAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGT-
TCCCAACGATCAAGGCGAGTTACATG 10810 10820 10830 10840 10850 10860
10870
10880 10890 10900
ATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAG-
TGTTATCACTCATGGTTATGGCAGCA 10910 10920 10930 10940 10950 10960
10970 10980 10990 11000
CTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATT-
CTGAGAATAGTGTATGCGGCGACCGA 11010 11020 11030 11040 11050 11060
11070 11080 11090 11100
GTTGCTCTTGCCCGGCGTCAACACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGA-
AAACGTTCTTCGGGGCGAAAACTCTC 11110 11120 11130 11140 11150 11160
11170 11180 11190 11200
AAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTA-
CTTTCACCAGCGTTTCTGGGTGAGCA 11210 11220 11230 11240 11250 11260
11270 11280 11290 11300
AAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCT-
TTTTCAATATTATTGAAGCATTTATC 11310 11320 11330 11340 11350 11360
11370 11380 11390 11400
AGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACA-
TTTCCCCGAAAAGTGCCACCTGACGT 11410 11420 11430 11440 11450 11460
11470 11480 11490 11500
CTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAAGAAT-
TCTCATGTTTGACAGCTTATCATCGA 11510 11520 11530 11540 11550 11560
11570 11580 11590 11600
TAAGCTTTAATGCGGTAGTTTATCACAGTTAAATTGCTAACGCAGTCAGGCACCGTGTATGAAATCTAACAATG-
CGCTCATCGTCATCCTCGGCACCGTC 11610 11620 11630 11640 11650 11660
11670 11680 11690 11700
ACCCTGGATGCTGTAGGCATAGGCTTGGTTATGCCGGTACTGCCGGGCCTCTTGCGGGATATCGTCCATTCCGA-
CAGCATCGCCAGTCACTATGGCGTGC 11710 11720 11730 11740 11750 11760
11770 11780 11790 11800
TGCTGGCGCTATATGCGTTGATGCAATTTCTATGCGCACCCGTTCTCGGAGCACTGTCCGACCGCTTTGGCCGC-
CGCCCAGTCCTGCTCGCTTCGCTACT 11810 11820 11830 11840 11850 11860
11870 11880 11890 11900
TGGAGCCACTATCGACTACGCGATCATGGCGACCACACCCGTCCTGTGGATCCTCTACGCCGGACGCATCGTGG-
CCGGCATCACCGGCGCCACAGGTGCG 11910 11920 11930 11940 11950 11960
11970 11980 11990 12000
GTTGCTGGCGCCTATATCGCCGACATCACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTG-
TTTCGGCGTGGGTATGGTGGCAGGCC 12010 12020 12030 12040 12050 12060
12070 12080 12090 12100
CCGTGGCCGGGGGACTGTTGGGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTC-
AACCTACTACTGGGCTGCTTCCTAAT 12110 12120 12130 12140 12150 12160
12170 12180 12190 12200
GCAGGAGTCGCATAAGGGAGAGCGTCGACCGATGCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGG-
CGCGGGGCATGACTATCGTCGCCGCA 12210 12220 12230 12240 12250 12260
12270 12280 12290 12300
CTTATGACTGTCTTCTTTATCATGCAACTCGTAGGACAGGTGCCGGCAGCGCTCTGGGTCATTTTCGGCGAGGA-
CCGCTTTCGCTGGAGCGCGACGATGA 12310 12320 12330 12340 12350 12360
12370 12380 12390 12400
TCGGCCTGTCGCTTGCGGTATTCGGAATCTTGCACGCCCTCGCTCAAGCCTTCGTCACTGGTCCCGCCACCAAA-
CGTTTCGGCGAGAAGCAGGCCATTAT 12410 12420 12430 12440 12450 12460
12470 12480 12490 12500
CGCCGGCATGGCGGCCGACGCGCTGGGCTACGTCTTGCTGGCGTTCGCGACGCGAGGCTGGATGGCCTTCCCCA-
TTATGATTCTTCTCGCTTCCGGCGGC 12510 12520 12530 12540 12550 12560
12570 12580 12590 12600
ATCGGGATGCCCGCGTTGCAGGCCATGCTGTCCAGGCAGGTAGATGACGACCATCAGGGACAGCTTCAAGGATC-
GCTCGCGGCTCTTACCAGCCTAACTT 12610 12620 12630 12640 12650 12660
12670 12680 12690 12700
CGATCACTGGACCGCTGATCGTCACGGCGATTTATGCCGCCTCGGCGAGCACATGGAACGGGTTGGCATGGATT-
GTAGGCGCCGCCCTATACCTTGTCTG 12710 12720 12730 12740 12750 12760
12770 12780 12790 12800
CCTCCCCGCGTTGCGTCGCGGTGCATGGAGCCGGGCCACCTCGACCTGAATGGAAGCCGGCGGCACCTCGCTAA-
CGGATTCACCACTCCAAGAATTGGAG 12810 12820 12830 12840 12850 12860
12870 12880 12890 12900
CCAATCAATTCTTGCGGAGAACTGTGAATGCGCAAACCAACCCTTGGCAGAACATATCCATCGCGTCCGCCATC-
TCCAGCAGCCGCACGCGGCGCATCTC 12910 12920 12930 12940 12950 12960
12970 12980 12990 13000
GGGCAGCGTTGGGTCCTGGCCACGGGTGCGCATGATCGTGCTCCTGTCGTTGAGGACCCGGCTAGGCTGGCGGG-
GTTGCCTTACTGGTTAGCAGAATGAA 13010 13020 13030 13040 13050 13060
13070 13080 13090 13100
TCACCGATACGCGAGCGAACGTGAAGCGACTGCTGCTGCAAAACGTCTGCGACCTGAGCAACAACATGAATGGT-
CTTCGGTTTCCGTGTTTCGTAAAGTC 13110 13120 13130 13140 13150 13160
13170 13180 13190 13200
TGGAAACGCGGAAGTCAGCGCCCTGCACCATTATGTTCCGGATCTGCATCGCAGGATGCTGCTGGCTACCCTGT-
GGAACACCTACATCTGTATTAACGAA 13210 13220 13230 13240 13250 13260
13270 13280 13290 13300
GCGCTGGCATTGACCCTGAGTGATTTTTCTCTGGTCCCGCCGCATCCATACCGCCAGTTGTTTACCCTCACAAC-
GTTCCAGTAACCGGGCATGTTCATCA 13310 13320 13330 13340 13350 13360
13370 13380 13390 13400
TCAGTAACCCGTATCGTGAGCATCCTCTCTCGTTTCATCGGTATCATTACCCCCATGAACAGAAATCCCCCTTA-
CACGGAGGCATCAGTGACCAAACAGG 13410 13420 13430 13440 13450 13460
13470 13480 13490 13500
AAAAAACCGCCCTTAACATGGCCCGCTTTATCAGAAGCCAGACATTAACGCTTCTGGAGAAACTCAACGAGCTG-
GACGCGGATGAACAGGCAGACATCTG 13510 13520 13530 13540 13550 13560
13570 13580 13590 13600
TGAATCGCTTCACGACCACGCTGATGAGCTTTACCGCAGCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACC-
TCTGACACATGCAGCTCCCGGAGACG 13610 13620 13630 13640 13650 13660
13670 13680 13690 13700
GTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTG-
TCGGGGCGCAGCCATGACCCAGTCAC 13710 13720 13730 13740 13750 13760
13770 13780 13790 13800
GTAGCGATAGCGGAGTGTATACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGC-
GGTGTGAAATACCGCACAGATGCGTA 13810 13820 13830 13840 13850 13860
13870 13880 13890 13900
AGGAGAAAATACCGCATCAGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCG-
GCGAGCGGTATCAGCTCACTCAAAGG 13910 13920 13930 13940 13950 13960
13970 13980 13990 14000
CGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCC-
AGGAACCGTAAAAAGGCCGCGTTGCT 14010 14020 14030 14040 14050 14060
14070 14080 14090 14100
GGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACC-
CGACAGGACTATAAAGATACCAGGCG 14110 14120 14130 14140 14150 14160
14170 14180 14190 14200
TTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCT-
CCCTTCGGGAAGCGTGGCGCTTTCTC 14210 14220 14230 14240 14250 14260
14270 14280 14290 14300
ATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCC-
GTTCAGCCCGACCGCTGCGCCTTATC 14310 14320 14330 14340 14350 14360
14370 14380 14390 14400
CGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGA-
TTAGCAGAGCGAGGTATGTAGGCGGT 14410 14420 14430 14440 14450 14460
14470 14480 14490 14500
GCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCT-
GAAGCCAGTTACCTTCGGAAAAAGAG 14510 14520 14530 14540 14550 14560
14570 14580 14590 14600
TTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACG-
CGCAGAAAAAAAGGATCTCAAGAAGA 14610 14620 14630 14640 14650 14660
14670 14680 14690 14700
TCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGAT-
TATCAAAAAGGATCTTCACCTAGATC 14710 14720 14730 14740 14750 14760
14770 14780 14790 14800
CTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATG-
CTTAATCAGTGAGGCACCTATCTCAG 14810 14820 14830 14840 14850 14860
14870 14880 14890 14900
CGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTA-
CCATCTGGCCCCAGTGCTGCAATGAT 14910 14920 14930 14940 14950 14960
14970 14980 14990 15000
ACCGCGAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAA-
GTGGTCCTGCAACTTTATCCGCCTCC 15010 15020 15030 15040 15050 15060
15070 15080 15090 15100
ATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGC-
CATTGCTGCAAGATCTGGCTAGCGAT 15110 15120 15130 15140 15150
GACCCTGCTGATTGGTTCGCTGACCATTTCCGGGCGCGCCGATTTAGGTGACACTATAG Bases 1
to 10713: DEN2 virus genome cDNA Bases 97 to 10269: DEN2
polyproteIn ORF Bases 97 to 438: C protein ORF Bases 439 to 936:
prM protein ORF Bases 937 to 2421: E protein ORF Bases 2422 to
3477: NS1 protein ORF Bases 3478 to 4131: NS2A protein ORF Bases
4132 to 4521: NS2B protein ORF Bases 4522 to 6375: NS3 protein ORF
Bases 6376 to 6756: NS4A protein ORF Bases 6757 to 6825: 2K protein
ORF Bases 6826 to 7569: NS4B protein ORF Bases 7570 to 10269: NS5
protein ORF
TABLE-US-00045 APPENDIX 2 Nucleotide and amino acid sequence of
DEN3 (S1eman/78) cDNA plasmid p3 10 20 30 40 50 60 70 80 90 100
AGTTGTTAGTCTACGTGGACCGACAAGAACAGTTTCGACTCGGAAGCTTGCTTAACGTAGTACTGACAGTTTTT-
TATTAGAGAGCAGATCTCTGATGAAC MetAsn> 110 120 130 140 150 160 170
180 190 200
AACCAACGGAAAAAGACGGGAAAACCGTCTATCAATATGCTGAAACGCGTGAGAAACCGTGTGTCAACTGGATC-
ACAGTTGGCGAAGAGATTCTCAAGAG
AsnGlnArgLysLysThrGlyLysProSerIleAsnMetLeuLysArgValArgAsnArgValSerThrGlySe-
rGlnLeuAlaLysArgPheSerArg> 210 220 230 240 250 260 270 280 290
300
GACTGCTGAACGGCCAAGGACCAATGAAATTGGTTATGGCGTTCATAGCTTTCCTCAGATTTCTAGCCATTCCA-
CCGACAGCAGGAGTCTTGGCTAGATG
GlyLeuLeuAsnGlyGlnGlyProMetLysLeuValMetAlaPheIleAlaPheLeuArgPheLeuAlaIlePr-
oProThrAlaGlyValLeuAlaArgTrp> 310 320 330 340 350 360 370 380
390 400
GGGAACCTTTAAGAAGTCGGGGGCTATTAAGGTCCTGAGAGGCTTCAAGAAGGAGATCTCAAACATGCTGAGCA-
TTATCAACAGACGGAAAAAGACATCG
GlyThrPheLysLysSerGlyAlaIleLysValLeuArgGlyPheLysLysGluIleSerAsnMetLeuSerIl-
eIleAsnArgArgLysLysThrSer> 410 420 430 440 450 460 470 480 490
500
CTCTGTCTCATGATGATGTTACCAGCAACACTTGCTTTCCACTTGACTTCACGAGATGGAGAGCCGCGCATGAT-
TGTGGGGAAGAATGAAAGAGGAAAAT
LeuCysLeuMetMetMetLeuProAlaThrLeuAlaPheHisLeuThrSerArgAspGlyGluProArgMetIl-
eValGlyLysAsnGluArgGlyLys> 510 520 530 540 550 560 570 580 590
600
CCCTACTTTTTAAGACAGCCTCTGGAATCAACATGTGCACACTCATAGCCATGGATTTGGGAGAGATGTGTGAT-
GACACGGTCACCTACAAATGCCCCCT
SerLeuLeuPheLysThrAlaSerGlyIleAsnMetCysThrLeuIleAlaMetAspLeuGlyGluMetCysAs-
pAspThrValThrTyrLysCysProLeu> 610 620 630 640 650 660 670 680
690 700
CATTACTGAAGTGGAGCCTGAAGACATTGACTGCTGGTGCAACCTTACATCGACATGGGTGACCTACGGAACGT-
GCAATCAAGCTGGAGAGCACAGACGC
IleThrGluValGluProGluAspIleAspCysTrpCysAsnLeuThrSerThrTrpValThrTyrGlyThrCy-
sAsnGlnAlaGlyGluHisArgArg> 710 720 730 740 750 760 770 780 790
800
GACAAAAGATCGGTGGCGTTAGCTCCCCATGTCGGCATGGGACTGGACACACGCACCCAAACCTGGATGTCGGC-
TGAAGGAGCTTGGAGACAGGTCGAGA
AspLysArgSerValAlaLeuAlaProHisValGlyMetGlyLeuAspThrArgThrGlnThrTrpMetSerAl-
aGluGlyAlaTrpArgGlnValGlu> 810 820 830 840 850 860 870 880 890
900
AGGTAGAGACATGGGCCTTTAGGCACCCAGGGTTCACAATACTAGCCCTATTTCTTGCCCATTACATAGGCACT-
TCCTTGACCCAGAAAGTGGTTATTTT
LysValGluThrTrpAlaPheArgHisProGlyPheThrIleLeuAlaLeuPheLeuAlaHisTyrIleGlyTh-
rSerLeuThrGlnLysValValIlePhe> 910 920 930 940 950 960 970 980
990 1000
CATACTACTAATGCTGGTCACCCCATCCATGACAATGAGATGCGTGGGAGTAGGAAACAGAGATTTTGTGGAAG-
GCCTATCAGGAGCTACGTGGGTTGAC
IleLeuLeuMetLeuValThrProSerMetThrMetArgCysValGlyValGlyAsnArgAspPheValGluGl-
yLeuSerGlyAlaThrTrpValAsp> 1010 1020 1030 1040 1050 1060 1070
1080 1090 1100
GTGGTGCTCGAGCACGGTGGGTGTGTGACTACCATGGCTAAGAACAAGCCCACGCTGGATATAGAGCTCCAGAA-
GACCGAGGCCACCCAACTGGCGACCC
ValValLeuGluHisGlyGlyCysValThrThrMetAlaLysAsnLysProThrLeuAspIleGluLeuGlnLy-
sThrGluAlaThrGlnLeuAlaThr> 1110 1120 1130 1140 1150 1160 1170
1180 1190 1200
TAAGGAAACTATGTATTGAGGGAAAAATTACCAACGTAACAACCGACTCAAGGTGCCCCACCCAAGGGGAAGCG-
ATTTTACCTGAGGAGCAGGACCAGAA
LeuArgLysLeuCysIleGluGlyLysIleThrAsnValThrThrAspSerArgCysProThrGlnGlyGluAl-
aIleLeuProGluGluGlnAspGlnAsn> 1210 1220 1230 1240 1250 1260 1270
1280 1290 1300
CCACGTGTGCAAGCACACATACGTGGACAGAGGCTGGGGAAACGGTTGTGGTTTGTTTGGCAAGGGAAGCCTGG-
TAACATGCGCGAAATTTCAATGTTTG
HisValCysLysHisThrTyrValAspArgGlyTrpGlyAsnGlyCysGlyLeuPheGlyLysGlySerLeuVa-
lThrCysAlaLysPheGlnCysLeu> 1310 1320 1330 1340 1350 1360 1370
1380 1390 1400
GAATCAATAGAGGGAAAAGTGGTGCAGCATGAGAACCTCAAATACACCGTCATCATCACAGTGCACACAGGAGA-
TCAACACCAGGTGGGAAATGAAACGC
GluSerIleGluGlyLysValValGlnHisGluAsnLeuLysTyrThrValIleIleThrValHisThrGlyAs-
pGlnHisGlnValGlyAsnGluThr> 1410 1420 1430 1440 1450 1460 1470
1480 1490 1500
AGGGAGTCACGGCTGAGATAACACCCCAGGCATCAACCGTTGAAGCCATCTTACCTGAATATGGAACCCTTGGG-
CTAGAATGCTCACCACGGACAGGTTT
GlnGlyValThrAlaGluIleThrProGlnAlaSerThrValGluAlaIleLeuProGluTyrGlyThrLeuGl-
yLeuGluCysSerProArgThrGlyLeu> 1510 1520 1530 1540 1550 1560 1570
1580 1590 1600
AGATTTCAATGAAATGATTTTGTTGACAATGAAGAACAAAGCATGGATGGTACATAGACAATGGTTTTTTGACC-
TACCTTTACCATGGACATCAGGAGCT
AspPheAsnGluMetIleLeuLeuThrMetLysAsnLysAlaTrpMetValHisArgGlnTrpPhePheAspLe-
uProLeuProTrpThrSerGlyAla> 1610 1620 1630 1640 1650 1660 1670
1680 1690 1700
ACAACAGAAACACCAACCTGGAATAAGAAAGAGCTTCTTGTGACATTCAAAAACGCACATGCAAAAAAGCAAGA-
AGTAGTAGTCCTTGGATCGCAAGAGG
ThrThrGluThrProThrTrpAsnLysLysGluLeuLeuValThrPheLysAsnAlaHisAlaLysLysGlnGl-
uValValValLeuGlySerGlnGlu> 1710 1720 1730 1740 1750 1760 1770
1780 1790 1800
GAGCAATGCACACAGCACTGACAGGAGCTACAGAGATCCAAACCTCAGGAGGCACAAGTATTTTTGCGGGGCAC-
TTAAAATGTAGACTCAAGATGGACAA
GlyAlaMetHisThrAlaLeuThrGlyAlaThrGluIleGlnThrSerGlyGlyThrSerIlePheAlaGlyHi-
sLeuLysCysArgLeuLysMetAspLys> 1810 1820 1830 1840 1850 1860 1870
1880 1890 1900
ATTGGAACTCAAGGGGATGAGCTATGCAATGTGCTTGAATGCCTTTGTGTTGAAGAAAGAAGTCTCCGAAACGC-
AACATGGGACAATACTCATCAAGGTT
LeuGluLeuLysGlyMetSerTyrAlaMetCysLeuAsnAlaPheValLeuLysLysGluValSerGluThrGl-
nHisGlyThrIleLeuIleLysVal> 1910 1920 1930 1940 1950 1960 1970
1980 1990 2000
GAGTACAAAGGGGAAGATGCACCTTGCAAGATTCCTTTCTCCACGGAGGATGGACAAGGGAAAGCCCACAATGG-
CAGACTGATCACAGCTAACCCAGTGG
GluTyrLysGlyGluAspAlaProCysLysIleProPheSerThrGluAspGlyGlnGlyLysAlaHisAsnGl-
yArgLeuIleThrAlaAsnProVal> 2010 2020 2030 2040 2050 2060 2070
2080 2090 2100
TGACCAAGAAGGAGGAGCCTGTCAATATTGAGGCAGAACCTCCTTTTGGGGAAAGCAATATAGTAATTGGAATT-
GGAGACAAAGCCTTGAAAATCAACTG
ValThrLysLysGluGluProValAsnIleGluAlaGluProProPheGlyGluSerAsnIleValIleGlyIl-
eGlyAspLysAlaLeuLysIleAsnTrp> 2110 2120 2130 2140 2150 2160 2170
2180 2190 2200
GTACAAGAAGGGAAGCTCGATTGGGAAGATGTTCGAGGCCACTGCCAGAGGTGCAAGGCGCATGGCCATCTTGG-
GAGACACAGCCTGGGACTTTGGATCA
TyrLysLysGlySerSerIleGlyLysMetPheGluAlaThrAlaArgGlyAlaArgArgMetAlaIleLeuGl-
yAspThrAlaTrpAspPheGlySer> 2210 2220 2230 2240 2250 2260 2270
2280 2290 2300
GTAGGTGGTGTTTTAAATTCATTAGGAAAAATGGTGCACCAAATATTTGGAAGTGCTTACACAGCCCTATTTAG-
TGGAGTCTCCTGGATAATGAAAATTG
ValGlyGlyValLeuAsnSerLeuGlyLysMetValHisGlnIlePheGlySerAlaTyrThrAlaLeuPheSe-
rGlyValSerTrpIleMetLysIle> 2310 2320 2330 2340 2350 2360 2370
2380 2390 2400
GAATAGGTGTCCTTTTAACCTGGATAGGGTTGAATTCAAAAAACACTAGTATGAGCTTTAGCTGCATTGTGATA-
GGAATCATTACACTCTATCTGGGAGC
GlyIleGlyValLeuLeuThrTrpIleGlyLeuAsnSerLysAsnThrSerMetSerPheSerCysIleValIl-
eGlyIleIleThrLeuTyrLeuGlyAla> 2410 2420 2430 2440 2450 2460 2470
2480 2490 2500
CGTGGTGCAAGCTGACATGGGGTGTGTCATAAACTGGAAAGGCAAAGAACTCAAATGTGGAAGTGGAATTTTCG-
TCACTAATGAGGTCCACACCTGGACA
ValValGlnAlaAspMetGlyCysValIleAsnTrpLysGlyLysGluLeuLysCysGlySerGlyIlePheVa-
lThrAsnGluValHisThrTrpThr> 2510 2520 2530 2540 2550 2560 2570
2580 2590 2600
GAGCAATACAAATTTCAAGCAGACTCCCCCAAAAGACTGGCGACAGCCATTGCAGGCGCTTGGGAGAATGGAGT-
GTGCGGAATCAGGTCGACAACCAGAA
GluGlnTyrLysPheGlnAlaAspSerProLysArgLeuAlaThrAlaIleAlaGlyAlaTrpGluAsnGlyVa-
lCysGlyIleArgSerThrThrArg> 2610 2620 2630 2640 2650 2660 2670
2680 2690 2700
TGGAGAACCTCTTGTGGAAGCAAATAGCCAATGAACTGAACTACATATTATGGGAAAACAACATCAAATTAACG-
GTAGTTGTGGGTGATATAATTGGGGT
MetGluAsnLeuLeuTrpLysGlnIleAlaAsnGluLeuAsnTyrIleLeuTrpGluAsnAsnIleLysLeuTh-
rValValValGlyAspIleIleGlyVal> 2710 2720 2730 2740 2750 2760 2770
2780 2790 2800
CTTAGAGCAAGGGAAAAGAACACTAACACCACAACCCATGGAACTAAAATATTCATGGAAAACATGGGGAAAGG-
CGAAGATAGTGACAGCTGAAACACAA
LeuGluGlnGlyLysArgThrLeuThrProGlnProMetGluLeuLysTyrSerTrpLysThrTrpGlyLysAl-
aLysIleValThrAlaGluThrGln> 2810 2820 2830 2840 2850 2860 2870
2880 2890 2900
AATTCCTCTTTCATAATAGATGGGCCAAACACACCAGAGTGTCCAAGTGCCTCAAGAGCATGGAATGTGTGGGA-
GGTGGAAGATTACGGGTTCGGAGTCT
AsnSerSerPheIleIleAspGlyProAsnThrProGluCysProSerAlaSerArgAlaTrpAsnValTrpGl-
uValGluAspTyrGlyPheGlyVal> 2910 2920 2930 2940 2950 2960 2970
2980 2990 3000
TCACAACTAACATATGGCTGAAACTCCGAGAGATGTACACCCAACTATGTGACCACAGGCTAATGTCGGCAGCC-
GTTAAGGATGAGAGGGCCGTACACGC
PheThrThrAsnIleTrpLeuLysLeuArgGluMetTyrThrGlnLeuCysAspHisArgLeuMetSerAlaAl-
aValLysAspGluArgAlaValHisAla> 3010 3020 3030 3040 3050 3060 3070
3080 3090 3100
CGACATGGGCTATTGGATAGAAAGCCAAAAGAATGGAAGTTGGAAGCTAGAAAAGGCATCCCTCATAGAGGTAA-
AAACCTGCACATGGCCAAAATCACAC
AspMetGlyTyrTrpIleGluSerGlnLysAsnGlySerTrpLysLeuGluLysAlaSerLeuIleGluValLy-
sThrCysThrTrpProLysSerHis> 3110 3120 3130 3140 3150 3160 3170
3180 3190 3200
ACTCTTTGGAGCAATGGTGTGCTAGAGAGTGACATGATCATCCCAAAGAGTCTGGCTGGTCCCATTTCGCAACA-
CAACTACAGGCCCGGATACCACACCC
ThrLeuTrpSerAsnGlyValLeuGluSerAspMetIleIleProLysSerLeuAlaGlyProIleSerGlnHi-
sAsnTyrArgProGlyTyrHisThr> 3210 3220 3230 3240 3250 3260 3270
3280 3290 3300
AAACGGCAGGACCCTGGCACTTAGGAAAATTGGAGCTGGACTTCAACTATTGTGAAGGAACAACAGTTGTCATC-
ACAGAAAATTGTGGGACAAGAGGCCC
GlnThrAlaGlyProTrpHisLeuGlyLysLeuGluLeuAspPheAsnTyrCysGluGlyThrThrValValIl-
eThrGluAsnCysGlyThrArgGlyPro> 3310 3320 3330 3340 3350 3360 3370
3380 3390 3400
ATCACTGAGAACAACAACAGTGTCAGGGAAGTTGATACACGAATGGTGTTGCCGCTCGTGTACACTTCCTCCCC-
TGCGATACATGGGAGAAGACGGCTGC
SerLeuArgThrThrThrValSerGlyLysLeuIleHisGluTrpCysCysArgSerCysThrLeuProProLe-
uArgTyrMetGlyGluAspGlyCys> 3410 3420 3430 3440 3450 3460 3470
3480 3490 3500
TGGTATGGCATGGAAATTAGACCCATTAATGAGAAAGAAGAGAACATGGTAAAGTCTTTAGTCTCAGCAGGGAG-
TGGAAAGGTGGATAACTTCACAATGG
TrpTyrGlyMetGluIleArgProIleAsnGluLysGluGluAsnMetValLysSerLeuValSerAlaGlySe-
rGlyLysValAspAsnPheThrMet> 3510 3520 3530 3540 3550 3560
3570
3580 3590 3600
GTGTCTTGTGTTTGGCAATCCTTTTTGAAGAGGTGATGAGAGGAAAATTTGGGAAAAAGCACATGATTGCAGGG-
GTTCTCTTCACGTTTGTACTCCTTCT
GlyValLeuCysLeuAlaIleLeuPheGluGluValMetArgGlyLysPheGlyLysLysHisMetIleAlaGl-
yValLeuPheThrPheValLeuLeuLeu> 3610 3620 3630 3640 3650 3660 3670
3680 3690 3700
CTCAGGGCAAATAACATGGAGAGACATGGCGCACACACTCATAATGATTGGGTCCAACGCCTCTGACAGAATGG-
GAATGGGCGTCACTTACCTAGCATTG
SerGlyGlnIleThrTrpArgAspMetAlaHisThrLeuIleMetIleGlySerAsnAlaSerAspArgMetGl-
yMetGlyValThrTyrLeuAlaLeu> 3710 3720 3730 3740 3750 3760 3770
3780 3790 3800
ATTGCAACATTTAAAATTCAGCCATTTTTGGCTTTGGGATTCTTCCTGAGGAAACTGACATCTAGAGAAAATTT-
ATTGTTGGGAGTTGGGTTGGCCATGG
IleAlaThrPheLysIleGlnProPheLeuAlaLeuGlyPhePheLeuArgLysLeuThrSerArgGluAsnLe-
uLeuLeuGlyValGlyLeuAlaMet> 3810 3820 3830 3840 3850 3860 3870
3880 3890 3900
CAACAACGTTACAACTGCCAGAGGACATTGAACAAATGGCGAATGGAATAGCTTTAGGGCTCATGGCTCTTAAA-
TTAATAACACAATTTGAAACATACCA
AlaThrThrLeuGlnLeuProGluAspIleGluGlnMetAlaAsnGlyIleAlaLeuGlyLeuMetAlaLeuLy-
sLeuIleThrGlnPheGluThrTyrGln> 3910 3920 3930 3940 3950 3960 3970
3980 3990 4000
ACTATGGACGGCATTAGTCTCCCTAATGTGTTCAAATACAATTTTCACGTTGACTGTTGCCTGGAGAACAGCCA-
CCCTGATTTTGGCCGGAATTTCTCTT
LeuTrpThrAlaLeuValSerLeuMetCysSerAsnThrIlePheThrLeuThrValAlaTrpArgThrAlaTh-
rLeuIleLeuAlaGlyIleSerLeu> 4010 4020 4030 4040 4050 4060 4070
4080 4090 4100
TTGCCAGTGTGCCAGTCTTCGAGCATGAGGAAAACAGATTGGCTCCCAATGGCTGTGGCAGCTATGGGAGTTCC-
ACCCCTACCACTTTTTATTTTCAGTT
LeuProValCysGlnSerSerSerMetArgLysThrAspTrpLeuProMetAlaValAlaAlaMetGlyValPr-
oProLeuProLeuPheIlePheSer> 4110 4120 4130 4140 4150 4160 4170
4180 4190 4200
TGAAAGATACGCTCAAAAGGAGAAGCTGGCCACTGAATGAGGGGGTGATGGCTGTTGGACTTGTGAGTATTCTA-
GCTAGTTCTCTCCTTAGGAATGACGT
LeuLysAspThrLeuLysArgArgSerTrpProLeuAsnGluGlyValMetAlaValGlyLeuValSerIleLe-
uAlaSerSerLeuLeuArgAsnAspVal> 4210 4220 4230 4240 4250 4260 4270
4280 4290 4300
GCCCATGGCTGGACCATTAGTGGCTGGGGGCTTGCTGATAGCGTGCTACGTCATAACTGGCACGTCAGCAGACC-
TCACTGTAGAAAAAGCAGCAGATGTG
ProMetAlaGlyProLeuValAlaGlyGlyLeuLeuIleAlaCysTyrValIleThrGlyThrSerAlaAspLe-
uThrValGluLysAlaAlaAspVal> 4310 4320 4330 4340 4350 4360 4370
4380 4390 4400
ACATGGGAGGAAGAGGCTGAGCAAACAGGAGTGTCCCACAATTTAATGATCACAGTTGATGACGATGGAACAAT-
GAGAATAAAAGATGATGAGACTGAGA
ThrTrpGluGluGluAlaGluGlnThrGlyValSerHisAsnLeuMetIleThrValAspAspAspGlyThrMe-
tArgIleLysAspAspGluThrGlu> 4410 4420 4430 4440 4450 4460 4470
4480 4490 4500
ACATCTTAACAGTGCTTTTGAAAACAGCATTACTAATAGTGTCAGGCATTTTTCCATACTCCATACCCGCAACA-
CTGTTGGTCTGGCACACTTGGCAAAA
AsnIleLeuThrValLeuLeuLysThrAlaLeuLeuIleValSerGlyIlePheProTyrSerIleProAlaTh-
rLeuLeuValTrpHisThrTrpGlnLys> 4510 4520 4530 4540 4550 4560 4570
4580 4590 4600
GCAAACCCAAAGATCCGGTGTCCTATGGGACGTTCCCAGCCCCCCAGAGACACAGAAAGCAGAACTGGAAGAAG-
GGGTTTATAGGATCAAGCAGCAAGGA
GlnThrGlnArgSerGlyValLeuTrpAspValProSerProProGluThrGlnLysAlaGluLeuGluGluGl-
yValTyrArgIleLysGlnGlnGly> 4610 4620 4630 4640 4650 4660 4670
4680 4690 4700
ATTTTTGGGAAAACCCAAGTGGGGGTTGGAGTACAAAAAGAAGGAGTTTTCCACACCATGTGGCACGTCACAAG-
AGGAGCAGTGTTGACACACAATGGGA
IlePheGlyLysThrGlnValGlyValGlyValGlnLysGluGlyValPheHisThrMetTrpHisValThrAr-
gGlyAlaValLeuThrHisAsnGly> 4710 4720 4730 4740 4750 4760 4770
4780 4790 4800
AAAGACTGGAACCAAACTGGGCTAGCGTGAAAAAAGATCTGATTTCATACGGAGGAGGATGGAAATTGAGTGCA-
CAATGGCAAAAAGGAGAGGAGGTGCA
LysArgLeuGluProAsnTrpAlaSerValLysLysAspLeuIleSerTyrGlyGlyGlyTrpLysLeuSerAl-
aGlnTrpGlnLysGlyGluGluValGln> 4810 4820 4830 4840 4850 4860 4870
4880 4890 4900
GGTTATTGCCGTAGAGCCTGGGAAGAACCCAAAGAACTTTCAAACCATGCCAGGCATTTTCCAGACAACAACAG-
GGGAGATAGGAGCGATTGCACTGGAC
ValIleAlaValGluProGlyLysAsnProLysAsnPheGlnThrMetProGlyIlePheGlnThrThrThrGl-
yGluIleGlyAlaIleAlaLeuAsp> 4910 4920 4930 4940 4950 4960 4970
4980 4990 5000
TTCAAGCCTGGAACTTCAGGATCTCCCATCATAAACAGAGAGGGAAAGGTACTGGGATTGTATGGCAATGGAGT-
GGTCACAAAGAATGGTGGCTATGTCA
PheLysProGlyThrSerGlySerProIleIleAsnArgGluGlyLysValLeuGlyLeuTyrGlyAsnGlyVa-
lValThrLysAsnGlyGlyTyrVal> 5010 5020 5030 5040 5050 5060 5070
5080 5090 5100
GTGGAATAGCACAAACAAATGCAGAACCAGACGGACCGACACCAGAGTTGGAAGAAGAGATGTTCAAAAAGCGA-
AATCTAACCATAATGGATCTCCATCC
SerGlyIleAlaGlnThrAsnAlaGluProAspGlyProThrProGluLeuGluGluGluMetPheLysLysAr-
gAsnLeuThrIleMetAspLeuHisPro> 5110 5120 5130 5140 5150 5160 5170
5180 5190 5200
CGGGTCAGGAAAGACGCGGAAATATCTTCCAGCTATTGTTAGAGAGGCAATCAAGAGACGCTTAAGGACTCTAA-
TTTTGGCACCAACAAGGGTAGTTGCA
GlySerGlyLysThrArgLysTyrLeuProAlaIleValArgGluAlaIleLysArgArgLeuArgThrLeuIl-
eLeuAlaProThrArgValValAla> 5210 5220 5230 5240 5250 5260 5270
5280 5290 5300
GCTGAGATGGAAGAAGCATTGAAAGGGCTCCCAATAAGGTATCAAACAACTGCAACAAAATCTGAACACACAGG-
GAGAGAGATTGTTGATCTAATGTGCC
AlaGluMetGluGluAlaLeuLysGlyLeuProIleArgTyrGlnThrThrAlaThrLysSerGluHisThrGl-
yArgGluIleValAspLeuMetCys> 5310 5320 5330 5340 5350 5360 5370
5380 5390 5400
ACGCAACGTTCACAATGCGTTTGCTGTCACCAGTCAGGGTTCCAAACTACAACTTGATAATAATGGATGAGGCT-
CATTTCACAGACCCAGCCAGTATAGC
HisAlaThrPheThrMetArgLeuLeuSerProValArgValProAsnTyrAsnLeuIleIleMetAspGluAl-
aHisPheThrAspProAlaSerIleAla> 5410 5420 5430 5440 5450 5460 5470
5480 5490 5500
GGCTAGAGGGTACATATCAACTCGTGTAGGAATGGGAGAGGCAGCCGCAATTTTCATGACAGCCACACCCCCTG-
GAACAGCTGATGCCTTTCCTCAGAGC
AlaArgGlyTyrIleSerThrArgValGlyMetGlyGluAlaAlaAlaIlePheMetThrAlaThrProProGl-
yThrAlaAspAlaPheProGlnSer> 5510 5520 5530 5540 5550 5560 5570
5580 5590 5600
AACGCTCCAATTCAAGATGAAGAAAGAGACATACCAGAACGCTCATGGAATTCAGGCAATGAATGGATTACCGA-
CTTTGCCGGGAAGACGGTGTGGTTTG
AsnAlaProIleGlnAspGluGluArgAspIleProGluArgSerTrpAsnSerGlyAsnGluTrpIleThrAs-
pPheAlaGlyLysThrValTrpPhe> 5610 5620 5630 5640 5650 5660 5670
5680 5690 5700
TCCCTAGCATCAAAGCTGGAAATGACATAGCAAACTGCTTGCGGAAAAATGGAAAAAAGGTCATTCAACTTAGT-
AGGAAGACTTTTGACACAGAATATCA
ValProSerIleLysAlaGlyAsnAspIleAlaAsnCysLeuArgLysAsnGlyLysLysValIleGlnLeuSe-
rArgLysThrPheAspThrGluTyrGln> 5710 5720 5730 5740 5750 5760 5770
5780 5790 5800
AAAGACTAAACTAAATGATTGGGACTTTGTGGTGACAACAGACATTTCAGAAATGGGAGCCAATTTCAAAGCAG-
ACAGAGTGATCGACCCAAGAAGATGT
LysThrLysLeuAsnAspTrpAspPheValValThrThrAspIleSerGluMetGlyAlaAsnPheLysAlaAs-
pArgValIleAspProArgArgCys> 5810 5820 5830 5840 5850 5860 5870
5880 5890 5900
CTCAAGCCAGTGATTTTGACAGACGGACCCGAGCGCGTGATCCTGGCGGGACCAATGCCAGTCACCGTAGCGAG-
CGCTGCGCAAAGGAGAGGGAGAGTTG
LeuLysProValIleLeuThrAspGlyProGluArgValIleLeuAlaGlyProMetProValThrValAlaSe-
rAlaAlaGlnArgArgGlyArgVal> 5910 5920 5930 5940 5950 5960 5970
5980 5990 6000
GCAGGAACCCACAAAAAGAAAATGACCAATACATATTCATGGGCCAGCCCCTCAATAATGATGAAGACCATGCT-
CACTGGACAGAAGCAAAAATGCTGCT
GlyArgAsnProGlnLysGluAsnAspGlnTyrIlePheMetGlyGlnProLeuAsnAsnAspGluAspHisAl-
aHisTrpThrGluAlaLysMetLeuLeu> 6010 6020 6030 6040 6050 6060 6070
6080 6090 6100
AGACAACATCAACACACCAGAAGGGATCATACCAGCTCTCTTTGAACCAGAAAGGGAGAAGTCAGCCGCCATAG-
ACGGCGAATACCGCCTGAAGGGTGAG
AspAsnIleAsnThrProGluGlyIleIleProAlaLeuPheGluProGluArgGluLysSerAlaAlaIleAs-
pGlyGluTyrArgLeuLysGlyGlu> 6110 6120 6130 6140 6150 6160 6170
6180 6190 6200
TCCAGGAAGACCTTCGTGGAACTCATGAGGAGGGGTGACCTCCCAGTTTGGCTAGCCCATAAAGTAGCATCAGA-
AGGGATCAAATATACAGATAGAAAGT
SerArgLysThrPheValGluLeuMetArgArgGlyAspLeuProValTrpLeuAlaHisLysValAlaSerGl-
uGlyIleLysTyrThrAspArgLys> 6210 6220 6230 6240 6250 6260 6270
6280 6290 6300
GGTGTTTTGATGGAGAACGCAACAATCAAATTTTAGAGGAGAATATGGATGTGGAAATCTGGACAAAGGAAGGA-
GAAAAGAAAAAATTGAGACCTAGGTG
TrpCysPheAspGlyGluArgAsnAsnGlnIleLeuGluGluAsnMetAspValGluIleTrpThrLysGluGl-
yGluLysLysLysLeuArgProArgTrp> 6310 6320 6330 6340 6350 6360 6370
6380 6390 6400
GCTTGATGCCCGCACTTATTCAGATCCCTTAGCGCTCAAGGAATTCAAGGACTTTGCGGCTGGTAGAAAGTCAA-
TTGCCCTTGATCTTGTGACAGAAATA
LeuAspAlaArgThrTyrSerAspProLeuAlaLeuLysGluPheLysAspPheAlaAlaGlyArgLysSerIl-
eAlaLeuAspLeuValThrGluIle> 6410 6420 6430 6440 6450 6460 6470
6480 6490 6500
GGAAGAGTGCCTTCACACTTAGCTCACAGAACGAGAAACGCCCTGGACAATCTGGTGATGTTGCACACGTCAGA-
ACATGGCGGGAGGGCCTACAGGCATG
GlyArgValProSerHisLeuAlaHisArgThrArgAsnAlaLeuAspAsnLeuValMetLeuHisThrSerGl-
uHisGlyGlyArgAlaTyrArgHis> 6510 6520 6530 6540 6550 6560 6570
6580 6590 6600
CAGTGGAGGAACTACCAGAAACAATGGAAACACTCTTACTCCTGGGACTCATGATCCTGTTAACAGGTGGAGCA-
ATGCTTTTCTTGATATCAGGTAAAGG
AlaValGluGluLeuProGluThrMetGluThrLeuLeuLeuLeuGlyLeuMetIleLeuLeuThrGlyGlyAl-
aMetLeuPheLeuIleSerGlyLysGly> 6610 6620 6630 6640 6650 6660 6670
6680 6690 6700
GATTGGAAAGACTTCAATAGGACTCATTTGTGTAGCTGCTTCCAGCGGTATGTTATGGATGGCTGATGTCCCAC-
TCCAATGGATCGCGTCTGCCATAGTC
IleGlyLysThrSerIleGlyLeuIleCysValAlaAlaSerSerGlyMetLeuTrpMetAlaAspValProLe-
uGlnTrpIleAlaSerAlaIleVal> 6710 6720 6730 6740 6750 6760 6770
6780 6790 6800
CTGGAGTTTTTTATGATGGTGTTACTTATACCAGAACCAGAAAAGCAGAGAACTCCCCAAGACAATCAACTCGC-
ATATGTCGTGATAGGCATACTCACAC
LeuGluPhePheMetMetValLeuLeuIleProGluProGluLysGlnArgThrProGlnAspAsnGlnLeuAl-
aTyrValValIleGlyIleLeuThr> 6810 6820 6830 6840 6850 6860 6870
6880 6890 6900
TGGCTGCAATAGTAGCAGCCAATGAAATGGGACTGTTGGAAACCACAAAGAGAGATTTAGGAATGTCCAAAGAA-
CCAGGTGTTGTTTCTCCAACCAGCTA
LeuAlaAlaIleValAlaAlaAsnGluMetGlyLeuLeuGluThrThrLysArgAspLeuGlyMetSerLysGl-
uProGlyValValSerProThrSerTyr> 6910 6920 6930 6940 6950 6960 6970
6980 6990 7000
TTTGGATGTGGACTTGCACCCAGCATCAGCCTGGACATTGTACGCTGTGGCCACAACAGTAATAACACCAATGT-
TGAGACATACCATAGAGAATTCCACA
LeuAspValAspLeuHisProAlaSerAlaTrpThrLeuTyrAlaValAlaThrThrValIleThrProMetLe-
uArgHisThrIleGluAsnSerThr> 7010 7020 7030 7040 7050 7060 7070
7080 7090 7100
GCAAATGTGTCCCTGGCAGCTATAGCCAACCAGGCAGTGGTCCTGATGGGTTTAGACAAAGGATGGCCGATATC-
GAAAATGGACTTAGGCGTGCCACTAT
AlaAsnValSerLeuAlaAlaIleAlaAsnGlnAlaValValLeuMetGlyLeuAspLysGlyTrpProIleSe-
rLysMetAspLeuGlyValProLeu>
7110 7120 7130 7140 7150 7160 7170 7180 7190 7200
TGGCACTGGGTTGTTATTCACAAGTGAACCCACTAACTCTCACAGCGGCAGTTCTCCTGCTAGTCACGCATTAT-
GCTATTATAGGTCCAGGATTGCAGGC
LeuAlaLeuGlyCysTyrSerGlnValAsnProLeuThrLeuThrAlaAlaValLeuLeuLeuValThrHisTy-
rAlaIleIleGlyProGlyLeuGlnAla> 7210 7220 7230 7240 7250 7260 7270
7280 7290 7300
AAAAGCCACTCGTGAAGCTCAAAAAAGGACAGCTGCTGGAATAATGAAGAATCCAACGGTGGATGGGATAATGA-
CAATAGACCTAGATCCTGTAATATAC
LysAlaThrArgGluAlaGlnLysArgThrAlaAlaGlyIleMetLysAsnProThrValAspGlyIleMetTh-
rIleAspLeuAspProValIleTyr> 7310 7320 7330 7340 7350 7360 7370
7380 7390 7400
GATTCAAAATTTGAAAAGCAACTAGGACAGGTTATGCTCCTGGTTCTGTGTGCAGTTCAACTTTTGTTAATGAG-
AACATCATGGGCTTTTTGTGAAGCTC
AspSerLysPheGluLysGlnLeuGlyGlnValMetLeuLeuValLeuCysAlaValGlnLeuLeuLeuMetAr-
gThrSerTrpAlaPheCysGluAla> 7410 7420 7430 7440 7450 7460 7470
7480 7490 7500
TAACCCTAGCCACAGGACCAATAACAACACTCTGGGAAGGATCACCTGGGAAGTTCTGGAACACCACGATAGCT-
GTTTCCATGGCGAACATCTTTAGAGG
LeuThrLeuAlaThrGlyProIleThrThrLeuTrpGluGlySerProGlyLysPheTrpAsnThrThrIleAl-
aValSerMetAlaAsnIlePheArgGly> 7510 7520 7530 7540 7550 7560 7570
7580 7590 7600
GAGCTATTTAGCAGGAGCTGGGCTTGCTTTTTCTATCATGAAATCAGTTGGAACAGGAAAGAGAGGGACAGGGT-
CACAGGGTGAAACCTTGGGAGAAAAG
SerTyrLeuAlaGlyAlaGlyLeuAlaPheSerIleMetLysSerValGlyThrGlyLysArgGlyThrGlySe-
rGlnGlyGluThrLeuGlyGluLys> 7610 7620 7630 7640 7650 7660 7670
7680 7690 7700
TGGAAAAAGAAATTGAATCAATTACCCCGGAAAGAGTTTGACCTTTACAAGAAATCCGGAATCACTGAAGTGGA-
TAGAACAGAAGCCAAAGAAGGGTTGA
TrpLysLysLysLeuAsnGlnLeuProArgLysGluPheAspLeuTyrLysLysSerGlyIleThrGluValAs-
pArgThrGluAlaLysGluGlyLeu> 7710 7720 7730 7740 7750 7760 7770
7780 7790 7800
AAAGAGGAGAAATAACACACCATGCCGTGTCCAGAGGCAGCGCAAAACTTCAATGGTTCGTGGAGAGAAACATG-
GTCATCCCCGAAGGAAGAGTCATAGA
LysArgGlyGluIleThrHisHisAlaValSerArgGlySerAlaLysLeuGlnTrpPheValGluArgAsnMe-
tValIleProGluGlyArgValIleAsp> 7810 7820 7830 7840 7850 7860 7870
7880 7890 7900
CTTAGGCTGTGGAAGAGGAGGCTGGTCATATTATTGTGCAGGACTGAAAAAAGTTACAGAAGTGCGAGGATACA-
CAAAAGGCGGCCCAGGACATGAAGAA
LeuGlyCysGlyArgGlyGlyTrpSerTyrTyrCysAlaGlyLeuLysLysValThrGluValArgGlyTyrTh-
rLysGlyGlyProGlyHisGluGlu> 7910 7920 7930 7940 7950 7960 7970
7980 7990 8000
CCAGTACCTATGTCTACATACGGATGGAACATAGTCAAGTTAATGAGTGGAAAGGATGTGTTTTATCTTCCACC-
TGAAAAGTGTGATACTCTATTGTGTG
ProValProMetSerThrTyrGlyTrpAsnIleValLysLeuMetSerGlyLysAspValPheTyrLeuProPr-
oGluLysCysAspThrLeuLeuCys> 8010 8020 8030 8040 8050 8060 8070
8080 8090 8100
ACATTGGAGAATCTTCACCAAGCCCAACAGTGGAAGAAAGCAGAACCATAAGAGTCTTGAAGATGGTTGAACCA-
TGGCTAAAAAATAACCAGTTTTGCAT
AspIleGlyGluSerSerProSerProThrValGluGluSerArgThrIleArgValLeuLysMetValGluPr-
oTrpLeuLysAsnAsnGlnPheCysIle> 8110 8120 8130 8140 8150 8160 8170
8180 8190 8200
TAAAGTATTGAACCCTTACATGCCAACTGTGATTGAGCACCTAGAAAGACTACAAAGGAAACATGGAGGAATGC-
TTGTGAGAAATCCACTCTCACGAAAC
LysValLeuAsnProTyrMetProThrValIleGluHisLeuGluArgLeuGlnArgLysHisGlyGlyMetLe-
uValArgAsnProLeuSerArgAsn> 8210 8220 8230 8240 8250 8260 8270
8280 8290 8300
TCCACGCACGAAATGTACTGGATATCTAATGGCACAGGCAATATCGTTTCTTCAGTCAACATGGTATCCAGATT-
GCTACTTAACAGATTCACAATGACAC
SerThrHisGluMetTyrTrpIleSerAsnGlyThrGlyAsnIleValSerSerValAsnMetValSerArgLe-
uLeuLeuAsnArgPheThrMetThr> 8310 8320 8330 8340 8350 8360 8370
8380 8390 8400
ATAGGAGACCCACCATAGAGAAAGATGTGGATTTAGGAGCGGGGACCCGACATGTCAATGCGGAACCAGAAACA-
CCCAACATGGATGTCATTGGGGAAAG
HisArgArgProThrIleGluLysAspValAspLeuGlyAlaGlyThrArgHisValAsnAlaGluProGluTh-
rProAsnMetAspValIleGlyGluArg> 8410 8420 8430 8440 8450 8460 8470
8480 8490 8500
AATAAGAAGGATCAAGGAGGAGCATAGTTCAACATGGCACTATGATGATGAAAATCCTTATAAAACGTGGGCTT-
ACCATGGATCCTATGAAGTTAAGGCC
IleArgArgIleLysGluGluHisSerSerThrTrpHisTyrAspAspGluAsnProTyrLysThrTrpAlaTy-
rHisGlySerTyrGluValLysAla> 8510 8520 8530 8540 8550 8560 8570
8580 8590 8600
ACAGGCTCAGCCTCCTCCATGATAAATGGAGTCGTGAAACTCCTCACGAAACCATGGGATGTGGTGCCCATGGT-
GACACAGATGGCAATGACGGATACAA
ThrGlySerAlaSerSerMetIleAsnGlyValValLysLeuLeuThrLysProTrpAspValValProMetVa-
lThrGlnMetAlaMetThrAspThr> 8610 8620 8630 8640 8650 8660 8670
8680 8690 8700
CCCCATTCGGCCAGCAAAGGGTTTTTAAAGAGAAAGTGGACACCAGGACACCCAGACCTATGCCAGGAACAAGA-
AAGGTTATGGAGATCACAGCGGAATG
ThrProPheGlyGlnGlnArgValPheLysGluLysValAspThrArgThrProArgProMetProGlyThrAr-
gLysValMetGluIleThrAlaGluTrp> 8710 8720 8730 8740 8750 8760 8770
870 8790 8800
GCTTTGGAGAACCCTGGGAAGGAACAAAAGACCCAGATTATGTACGAGAGAGGAGTTCACAAAAAAGGTCAGAA-
CCAACGCAGCTATGGGCGCCGTTTTT
LeuTrpArgThrLeuGlyArgAsnLysArgProArgLeuCysThrArgGluGluPheThrLysLysValArgTh-
rAsnAlaAlaMetGlyAlaValPhe> 8810 8820 8830 8840 8850 8860 8870
8880 8890 8900
ACAGAGGAGAACCAATGGGACAGTGCTAGAGCTGCTGTTGAGGATGAAGAATTCTGGAAACTCGTGGACAGAGA-
ACGTGAACTCCACAAATTGGGCAAGT
ThrGluGluAsnGlnTrpAspSerAlaArgAlaAlaValGluAspGluGluPheTrpLysLeuValAspArgGl-
uArgGluLeuHisLysLeuGlyLys> 8910 8920 8930 8940 8950 8960 8970
8980 8990 9000
GTGGAAGCTGCGTTTACAACATGATGGGCAAGAGAGAGAAGAAACTTGGAGAGTTTGGCAAAGCAAAAGGCAGT-
AGAGCCATATGGTACATGTGGTTGGG
CysGlySerCysValTyrAsnMetMetGlyLysArgGluLysLysLeuGlyGluPheGlyLysAlaLysGlySe-
rArgAlaIleTrpTyrMetTrpLeuGly> 9010 9020 9030 9040 9050 9060 9070
9080 9090 9100
AGCCAGATACCTTGAGTTCGAAGCACTCGGATTCTTAAATGAAGACCATTGGTTCTCGCGTGAAAACTCTTACA-
GTGGAGTAGAAGGAGAAGGACTGCAC
AlaArgTyrLeuGluPheGluAlaLeuGlyPheLeuAsnGluAspHisTrpPheSerArgGluAsnSerTyrSe-
rGlyValGluGlyGluGlyLeuHis> 9110 9120 9130 9140 9150 9160 9170
9180 9190 9200
AAGCTGGGATACATCTTAAGAGACATTTCCAAGATACCCGGAGGAGCTATGTATGCTGATGACACAGCTGGTTG-
GGACACAAGAATAACAGAAGATGACC
LysLeuGlyTyrIleLeuArgAspIleSerLysIleProGlyGlyAlaMetTyrAlaAspAspThrAlaGlyTr-
pAspThrArgIleThrGluAspAsp> 9210 9220 9230 9240 9250 9260 9270
9280 9290 9300
TGCACAATGAGGAAAAAATCACACAGCAAATGGACCCTGAACACAGGCAGTTAGCAAACGCTATATTCAAGCTC-
ACATACCAAAACAAAGTGGTCAAAGT
LeuHisAsnGluGluLysIleThrGlnGlnMetAspProGluHisArgGlnLeuAlaAsnAlaIlePheLysLe-
uThrTyrGlnAsnLysValValLysVal> 9310 9320 9330 9340 9350 9360 9370
9380 9390 9400
TCAACGACCAACTCCAAAGGGCACGGTAATGGACATCATATCTAGGAAAGACCAAAGAGGCAGTGGACAGGTGG-
GAACTTATGGTCTGAATACATTCACC
GlnArgProThrProLysGlyThrValMetAspIleIleSerArgLysAspGlnArgGlySerGlyGlnValGl-
yThrTyrGlyLeuAsnThrPheThr> 9410 9420 9430 9440 9450 9460 9470
9480 9490 9500
AACATGGAAGCCCAGTTAATCAGACAAATGGAAGGAGAAGGTGTGTTGTCGAAGGCAGACCTCGAGAACCCTCA-
TCTGCTAGAGAAGAAAGTTACACAAT
AsnMetGluAlaGlnLeuIleArgGlnMetGluGlyGluGlyValLeuSerLysAlaAspLeuGluAsnProHi-
sLeuLeuGluLysLysValThrGln> 9510 9520 9530 9540 9550 9560 9570
9580 9590 9600
GGTTGGAAACAAAAGGAGTGGAGAGGTTAAAAAGAATGGCCATCAGCGGGGATGATTGCGTGGTGAAACCAATT-
GATGACAGGTTCGCCAATGCCCTGCT
TrpLeuGluThrLysGlyValGluArgLeuLysArgMetAlaIleSerGlyAspAspCysValValLysProIl-
eAspAspArgPheAlaAsnAlaLeuLeu> 9610 9620 9630 9640 9650 9660 9670
9680 9690 9700
TGCCCTGAATGACATGGGAAAAGTTAGGAAGGACATACCTCAATGGCAGCCATCAAAGGGATGGCATGATTGGC-
AACAGGTCCCTTTCTGCTCCCACCAC
AlaLeuAsnAspMetGlyLysValArgLysAspIleProGlnTrpGlnProSerLysGlyTrpHisAspTrpGl-
nGlnValProPheCysSerHisHis> 9710 9720 9730 9740 9750 9760 9770
9780 9790 9800
TTTCATGAATTGATCATGAAAGATGGAAGAAAGTTGGTAGTTCCCTGCAGACCTCAGGATGAATTAATCGGGAG-
AGCGAGAATCTCTCAAGGAGCAGGAT
PheHisGluLeuIleMetLysAspGlyArgLysLeuValValProCysArgProGlnAspGluLeuIleGlyAr-
gAlaArgIleSerGlnGlyAlaGly> 9810 9820 9830 9840 9850 9860 9870
9880 9890 9900
GGAGCCTTAGAGAAACTGCATGCCTAGGGAAAGCCTACGCCCAAATGTGGACTCTCATGTACTTTCACAGAAGA-
GATCTTAGACTAGCATCCAACGCCAT
TrpSerLeuArgGluThrAlaCysLeuGlyLysAlaTyrAlaGlnMetTrpThrLeuMetTyrPheHisArgAr-
gAspLeuArgLeuAlaSerAsnAlaIle> 9910 9920 9930 9940 9950 9960 9970
9980 9990 10000
ATGTTCAGCAGTACCAGTCCATTGGGTCCCCACAAGCAGAACGACGTGGTCTATTCATGCTCACCATCAGTGGA-
TGACTACAGAAGACATGCTTACTGTT
CysSerAlaValProValHisTrpValProThrSerArgThrThrTrpSerIleHisAlaHisHisGlnTrpMe-
tThrThrGluAspMetLeuThrVal> 10010 10020 10030 10040 10050 10060
10070 10080 10090 10100
TGGAACAGGGTGTGGATAGAGGATAATCCATGGATGGAAGACAAAACTCCAGTCAAAACCTGGGAAGATGTTCC-
ATATCTAGGGAAGAGAGAAGACCAAT
TrpAsnArgValTrpIleGluAspAsnProTrpMetGluAspLysThrProValLysThrTrpGluAspValPr-
oTyrLeuGlyLysArgGluAspGln> 10110 10120 10130 10140 10150 10160
10170 10180 10190 10200
GGTGCGGATCACTCATTGGTCTCACTTCCAGAGCAACCTGGGCCCAGAACATACTTACGGCAATCCAACAGGTG-
AGAAGCCTTATAGGCAATGAAGAGTT
TrpCysGlySerLeuIleGlyLeuThrSerArgAlaThrTrpAlaGlnAsnIleLeuThrAlaIleGlnGlnVa-
lArgSerLeuIleGlyAsnGluGluPhe> 10210 10220 10230 10240 10250
10260 10270 10280 10290 10300
TCTGGACTACATGCCTTCGATGAAGAGATTCAGGAAGGAGGAGGAGTCAGAGGGAGCCATTTGGTAAACGTAGG-
AAGTGAAAAAGAGGCAAACTGTCAGG
LeuAspTyrMetProSerMetLysArgPheArgLysGluGluGluSerGluGlyAlaIleTrp***>
10310 10320 10330 10340 10350 10360 10370 10380 10390 10400
CCACCTTAAGCCACAGTACGGAAGAAGCTGTGCAGCCTGTGAGCCCCGTCCAAGGACGTTAAAAGAAGAAGTCA-
GGCCCAAAAGCCACGGTTTGAGCAAA 10410 10420 10430 10440 10450 10460
10470 10480 10490 10500
CCGTGCTGCCTGTGGCTCCGTCGTGGGGACGTAAAACCTGGGAGGCTGCAAACTGTGGAAGCTGTACGCACGGT-
GTAGCAGACTAGCGGTTAGAGGAGAC 10510 10520 10530 10540 10550 10560
10570 10580 10590 10600
CCCTCCCATGACACAACGCAGCAGCGGGGCCCGAGCTCTGAGGGAAGCTGTACCTCCTTGCAAAGGACTAGAGG-
TTAGAGGAGACCCCCCGCAAATAAAA 10610 10620 10630 10640 10650 10660
10670 10680 10690 10700
ACAGCATATTGACGCTGGGAGAGACCAGAGATCCTGCTGTCTCCTCAGCATCATTCCAGGCACAGAACGCCAGA-
AAATGGAATGGTGCTGTTGAATCAAC 10710 10720 10730 10740 10750 10760
10770 10780 10790 10800
AGGTTCTGGTACCGGTAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAA-
CGATCAAGGCGAGTTACATGATCCCC 10810 10820 10830 10840 10850 10860
10870 10880 10890 10900
CATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTAT-
CACTCATGGTTATGGCAGCACTGCAT 10910 10920 10930 10940 10950 10960
10970 10980 10990 11000
AATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGA-
ATAGTGTATGCGGCGACCGAGTTGCT 11010 11020 11030 11040 11050 11060
11070 11080 11090 11100
CTTGCCCGGCGTCAACACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGT-
TCTTCGGGGCGAAAACTCTCAAGGAT 11110 11120 11130 11140 11150 11160
11170 11180 11190 11200
CTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCA-
CCAGCGTTTCTGGGTGAGCAAAAACA 11210 11220 11230 11240 11250 11260
11270 11280 11290 11300
GGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCA-
ATATTATTGAAGCATTTATCAGGGTT 11310 11320 11330 11340 11350 11360
11370 11380 11390 11400
ATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCC-
CGAAAAGTGCCACCTGACGTCTAAGA 11410 11420 11430 11440 11450 11460
11470 11480 11490 11500
AACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCACGAGGCCCTTTCGTCTTCAAGAATTCTCAT-
GTTTGACAGCTTATCATCGATAAGCT 11510 11520 11530 11540 11550 11560
11570 11580 11590 11600
TTAATGCGGTAGTTTATCACAGTTAAATTGCTAACGCAGTCAGGCACCGTGTATGAAATCTAACAATGCGCTCA-
TCGTCATCCTCGGCACCGTCACCCTG 11610 11620 11630 11640 11650 11660
11670 11680 11690 11700
GATGCTGTAGGCATAGGCTTGGTTATGCCGGTACTGCCGGGCCTCTTGCGGGATATCGTCCATTCCGACAGCAT-
CGCCAGTCACTATGGCGTGCTGCTGG 11710 11720 11730 11740 11750 11760
11770 11780 11790 11800
CGCTATATGCGTTGATGCAATTTCTATGCGCACCCGTTCTCGGAGCACTGTCCGACCGCTTTGGCCGCCGCCCA-
GTCCTGCTCGCTTCGCTACTTGGAGC 11810 11820 11830 11840 11850 11860
11870 11880 11890 11900
CACTATCGACTACGCGATCATGGCGACCACACCCGTCCTGTGGATCCTCTACGCCGGACGCATCGTGGCCGGCA-
TCACCGGCGCCACAGGTGCGGTTGCT 11910 11920 11930 11940 11950 11960
11970 11980 11990 12000
GGCGCCTATATCGCCGACATCACCGATGGGGAAGATCGGGCTCGCCACTTCGGGCTCATGAGCGCTTGTTTCGG-
CGTGGGTATGGTGGCAGGCCCCGTGG 12010 12020 12030 12040 12050 12060
12070 12080 12090 12100
CCGGGGGACTGTTGGGCGCCATCTCCTTGCATGCACCATTCCTTGCGGCGGCGGTGCTCAACGGCCTCAACCTA-
CTACTGGGCTGCTTCCTAATGCAGGA 12110 12120 12130 12140 12150 12160
12170 12180 12190 12200
GTCGCATAAGGGAGAGCGTCGACCGATGCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTCCGGTGGGCGCGGG-
GCATGACTATCGTCGCCGCACTTATG 12210 12220 12230 12240 12250 12260
12270 12280 12290 12300
ACTGTCTTCTTTATCATGCAACTCGTAGGACAGGTGCCGGCAGCGCTCTGGGTCATTTTCGGCGAGGACCGCTT-
TCGCTGGAGCGCGACGATGATCGGCC 12310 12320 12330 12340 12350 12360
12370 12380 12390 12400
TGTCGCTTGCGGTATTCGGAATCTTGCACGCCCTCGCTCAAGCCTTCGTCACTGGTCCCGCCACCAAACGTTTC-
GGCGAGAAGCAGGCCATTATCGCCGG 12410 12420 12430 12440 12450 12460
12470 12480 12490 12500
CATGGCGGCCGACGCGCTGGGCTACGTCTTGCTGGCGTTCGCGACGCGAGGCTGGATGGCCTTCCCCATTATGA-
TTCTTCTCGCTTCCGGCGGCATCGGG 12510 12520 12530 12540 12550 12560
12570 12580 12590 12600
ATGCCCGCGTTGCAGGCCATGCTGTCCAGGCAGGTAGATGACGACCATCAGGGACAGCTTCAAGGATCGCTCGC-
GGCTCTTACCAGCCTAACTTCGATCA 12610 12620 12630 12640 12650 12660
12670 12680 12690 12700
CTGGACCGCTGATCGTCACGGCGATTTATGCCGCCTCGGCGAGCACATGGAACGGGTTGGCATGGATTGTAGGC-
GCCGCCCTATACCTTGTCTGCCTCCC 12710 12720 12730 12740 12750 12760
12770 12780 12790 12800
CGCGTTGCGTCGCGGTGCATGGAGCCGGGCCACCTCGACCTGAATGGAAGCCGGCGGCACCTCGCTAACGGATT-
CACCACTCCAAGAATTGGAGCCAATC 12810 12820 12830 12840 12850 12860
12870 12880 12890 12900
AATTCTTGCGGAGAACTGTGAATGCGCAAACCAACCCTTGGCAGAACATATCCATCGCGTCCGCCATCTCCAGC-
AGCCGCACGCGGCGCATCTCGGGCAG 12910 12920 12930 12940 12950 12960
12970 12980 12990 13000
CGTTGGGTCCTGGCCACGGGTGCGCATGATCGTGCTCCTGTCGTTGAGGACCCGGCTAGGCTGGCGGGGTTGCC-
TTACTGGTTAGCAGAATGAATCACCG 13010 13020 13030 13040 13050 13060
13070 13080 13090 13100
ATACGCGAGCGAACGTGAAGCGACTGCTGCTGCAAAACGTCTGCGACCTGAGCAACAACATGAATGGTCTTCGG-
TTTCCGTGTTTCGTAAAGTCTGGAAA 13110 13120 13130 13140 13150 13160
13170 13180 13190 13200
CGCGGAAGTCAGCGCCCTGCACCATTATGTTCCGGATCTGCATCGCAGGATGCTGCTGGCTACCCTGTGGAACA-
CCTACATCTGTATTAACGAAGCGCTG 13210 13220 13230 13240 13250 13260
13270 13280 13290 13300
GCATTGACCCTGAGTGATTTTTCTCTGGTCCCGCCGCATCCATACCGCCAGTTGTTTACCCTCACAACGTTCCA-
GTAACCGGGCATGTTCATCATCAGTA 13310 13320 13330 13340 13350 13360
13370 13380 13390 13400
ACCCGTATCGTGAGCATCCTCTCTCGTTTCATCGGTATCATTACCCCCATGAACAGAAATCCCCCTTACACGGA-
GGCATCAGTGACCAAACAGGAAAAAA 13410 13420 13430 13440 13450 13460
13470 13480 13490 13500
CCGCCCTTAACATGGCCCGCTTTATCAGAAGCCAGACATTAACGCTTCTGGAGAAACTCAACGAGCTGGACGCG-
GATGAACAGGCAGACATCTGTGAATC 13510 13520 13530 13540 13550 13560
13570 13580 13590 13600
GCTTCACGACCACGCTGATGAGCTTTACCGCAGCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGAC-
ACATGCAGCTCCCGGAGACGGTCACA 13610 13620 13630 13640 13650 13660
13670 13680 13690 13700
GCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGG-
CGCAGCCATGACCCAGTCACGTAGCG 13710 13720 13730 13740 13750 13760
13770 13780 13790 13800
ATAGCGGAGTGTATACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTG-
AAATACCGCACAGATGCGTAAGGAGA 13810 13820 13830 13840 13850 13860
13870 13880 13890 13900
AAATACCGCATCAGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGC-
GGTATCAGCTCACTCAAAGGCGGTAA 13910 13920 13930 13940 13950 13960
13970 13980 13990 14000
TACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAAC-
CGTAAAAAGGCCGCGTTGCTGGCGTT 14010 14020 14030 14040 14050 14060
14070 14080 14090 14100
TTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAG-
GACTATAAAGATACCAGGCGTTTCCC 14110 14120 14130 14140 14150 14160
14170 14180 14190 14200
CCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTC-
GGGAAGCGTGGCGCTTTCTCATAGCT 14210 14220 14230 14240 14250 14260
14270 14280 14290 14300
CACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAG-
CCCGACCGCTGCGCCTTATCCGGTAA 14310 14320 14330 14340 14350 14360
14370 14380 14390 14400
CTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCA-
GAGCGAGGTATGTAGGCGGTGCTACA 14410 14420 14430 14440 14450 14460
14470 14480 14490 14500
GAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCC-
AGTTACCTTCGGAAAAAGAGTTGGTA 14510 14520 14530 14540 14550 14560
14570 14580 14590 14600
GCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGA-
AAAAAAGGATCTCAAGAAGATCCTTT 14610 14620 14630 14640 14650 14660
14670 14680 14690 14700
GATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAA-
AAAGGATCTTCACCTAGATCCTTTTA 14710 14720 14730 14740 14750 14760
14770 14780 14790 14800
AATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAAT-
CAGTGAGGCACCTATCTCAGCGATCT 14810 14820 14830 14840 14850 14860
14870 14880 14890 14900
GTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCT-
GGCCCCAGTGCTGCAATGATACCGCG 14910 14920 14930 14940 14950 14960
14970 14980 14990 15000
AGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTC-
CTGCAACTTTATCCGCCTCCATCCAG 15010 15020 15030 15040 15050 15060
15070 15080 15090 15100
TCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGC-
TGCAAGATCTGGCTAGCGATGACCCT 15110 15120 15130 15140 15150
GCTGATTGGTTCGCTGACCATTTCCGGGCGCGCCGATTTAGGTGACACTATAG Bases 1 to
10707: DEN3 virus genome cDNA Bases 95 to 10264: DEN3 polyprotern
ORF Bases 95 to 436: C protein ORF Bases 437 to 934: prM protein
ORF Bases 935 to 2413: E protein ORF Bases 2414 to 3469: NS1
protein ORF Bases 3470 to 4123: NS2A protein ORF Bases 4124 to
4513: NS2B protein ORF Bases 4514 to 6370: NS3 protein ORF Bases
6371 to 6751: NS4A protein ORF Bases 6752 to 6820: 2K protein ORF
Bases 6821 to 7564: NS4B protein ORF Bases 7575 to 10264: NS5
protein ORF
TABLE-US-00046 APPENDIX 3 Nucleotide and amino acid sequence of
DENt (Puerto Rico/94) CME chimeric region 10 20 30 40 50 60 70 80
90 100
AGTTGTTAGTCTGTGTGGACCGACAAGGACAGTTCCAAATCGGAAGCTTGCTTAACACAGTTCTAACAGTTTGT-
TTGAATAGAGAGCAGATCTCTGGAAA 110 120 130 140 150 160 170 180 190 200
AATGAACAACCAACGGAAAAAGACGGGTCGACCGTCTTTCAATATGCTGAAACGCGCGAGAAACCGCGTGTCAA-
CTGGTTCACAGTTGGCGAAGAGATTC
MetAsnAsnGlnArgLysLysThrGlyArgProSerPheAsnMetLeuLysArgAlaArgAsnArgValSerTh-
rGlySerGlnLeuAlaLysArgPhe> 210 220 230 240 250 260 270 280 290
300
TCAAAAGGATTGCTTTCAGGCCAAGGACCCATGAAATTGGTGATGGCTTTCATAGCATTTCTAAGATTTCTAGC-
CATACCCCCAACAGCAGGAATTTTGG
SerLysGlyLeuLeuSerGlyGlnGlyProMetLysLeuValMetAlaPheIleAlaPheLeuArgPheLeuAl-
aIleProProThrAlaGlyIleLeu> 310 320 330 340 350 360 370 380 390
400
CTAGATGGAGCTCATTCAAGAAGAATGGAGCGATCAAAGTGTTACGGGGTTTCAAAAAAGAGATCTCAAGCATG-
TTGAACATTATGAACAGGAGGAAAAA
AlaArgTrpSerSerPheLysLysAsnGlyAlaIleLysValLeuArgGlyPheLysLysGluIleSerSerMe-
tLeuAsnIleMetAsnArgArgLysLys> 410 420 430 440 450 460 470 480
490 500
ATCTGTGACCATGCTCCTCATGCTGCTGCCCACAGCCCTGGCGTTCCATTTGACCACACGAGGGGGAGAGCCAC-
ACATGATAGTTAGTAAGCAGGAAAGA
SerValThrMetLeuLeuMetLeuLeuProThrAlaLeuAlaPheHisLeuThrThrArgGlyGlyGluProHi-
sMetIleValSerLysGlnGluArg> 510 520 530 540 550 560 570 580 590
600
GGAAAGTCACTGTTGTTTAAGACCTCTGCAGGCATCAATATGTGCACTCTCATTGCGATGGATTTGGGAGAGTT-
ATGCGAGGACACAATGACCTACAAAT
GlyLysSerLeuLeuPheLysThrSerAlaGlyIleAsnMetCysThrLeuIleAlaMetAspLeuGlyGluLe-
uCysGluAspThrMetThrTyrLys> 610 620 630 640 650 660 670 680 690
700
GCCCCCGGATCACTGAGGCGGAACCAGATGACGTTGACTGCTGGTGCAATGCCACAGACACATGGGTGACCTAT-
GGGACGTGTTCTCAAACCGGCGAACA
CysProArgIleThrGluAlaGluProAspAspValAspCysTrpCysAsnAlaThrAspThrTrpValThrTy-
rGlyThrCysSerGlnThrGlyGluHis> 710 720 730 740 750 760 770 780
790 800
CCGACGAGACAAACGTTCCGTGGCACTGGCCCCACACGTGGGACTTGGTCTAGAAACAAGAACCGAAACATGGA-
TGTCCTCTGAAGGTGCCTGGAAACAA
ArgArgAspLysArgSerValAlaLeuAlaProHisValGlyLeuGlyLeuGluThrArgThrGluThrTrpMe-
tSerSerGluGlyAlaTrpLysGln> 810 820 830 840 850 860 870 880 890
900
GTACAAAAAGTGGAGACTTGGGCTTTGAGACACCCAGGATTCACGGTGACAGCCCTTTTTTTAGCACATGCCAT-
AGCAACATCCATTACTCAGAAAGGGA
ValGlnLysValGluThrTrpAlaLeuArgHisProGlyPheThrValThrAlaLeuPheLeuAlaHisAlaIl-
eGlyThrSerIleThrGlnGlyGly> 910 920 930 940 950 960 970 980 990
1000
TCATTTTCATTCTGCTGATGCTAGTAACACCATCAATGGCCATGCGATGTGTGGGAATAGGCAACAGAGACTTC-
GTTGAAGGACTGTCAGGAGCAACGTG
IleIlePheIleLeuLeuMetLeuValThrProSerMetAlaMetArgCysValGlyIleGlyAsnArgAspPh-
eValGluGlyLeuSerGlyAlaThrTrp> 1010 1020 1030 1040 1050 1060 1070
1080 1090 1100
GGTGGACGTGGTATTGGAGCATGGAAGCTGCGTCACCACCATGGCAAAAGATAAACCAACATTGGACATTGAAC-
TCTTGAAGACGGAGGTCACAAACCCT
ValAspValValLeuGluHisGlySerCysValThrThrMetAlaLysAspLysProThrLeuAspIleGluLe-
uLeuLysThrGluValThrAsnPro> 1110 1120 1130 1140 1150 1160 1170
1180 1190 1200
GCCGTCTTGCGCAAACTGTGCATTGAAGCTAAAATATCAAACACCACCACCGATTCAAGGTGTCCAACACAAGG-
AGAGGCTACACTGGTGGAAGAACAGG
AlaValLeuArgLysLeuCysIleGluAlaLysIleSerAsnThrThrThrAspSerArgCysProThrGlnGl-
yGluAlaThrLeuValGluGluGln> 1210 1220 1230 1240 1250 1260 1270
1280 1290 1300
ACTCGAACTTTGTGTGTCGACGAACGTTTGTGGACAGAGGCTGGGGTAATGGCTGCGGACTATTTGGAAAAGGA-
AGCCTACTGACGTGTGCTAAGTTCAA
AspSerAsnPheValCysArgArgThrPheValAspArgGlyTrpGlyAsnGlyCysGlyLeuPheGlyLysGl-
ySerLeuLeuThrCydAlaLysPheLys> 1310 1320 1330 1340 1350 1360 1370
1380 1390 1400
GTGTGTGACAAAACTAGAAGGAAAGATAGTTCAATATGAAAACTTAAAATATTCAGTGATAGTCACTGTCCACA-
CTGGGGACCAGCACCAGGTGGGAAAC
CysValThrLysLeuGluGlyLysIleValGlnTyrGluAsnLeuLysTyrSerValIleValThrValHisTh-
rGlyAspGlnHisGlnValGlyAsn> 1410 1420 1430 1440 1450 1460 1470
1480 1490 1500
GAGACTACAGAACATGGAACAATTGCAACCATAACACCTCAAGCTCCTACGTCGGAAATACAGCTGACTGACTA-
CGGAGCCCTCACATTGGACTGCTCGC
GluThrThrGluHisGLyThrIleAlaThrIleThrProGlnAlaProThrSerGluIleGlnLeuThrAspTy-
rGlyAlaLeuThrLeuAspCysSer> 1510 1520 1530 1540 1550 1560 1570
1580 1590 1600
CTAGAACAGGGCTGGACTTTAATGAGATGGTTCTATTGACAATGAAAGAAAAATCATGGCTTGTCCACAAACAA-
TGGTTTCTAGACTTACCACTGCCTTG
ProArgThrGlyLeuAspPheAsnGluMetValLeuLeuThrMetLysGluLysSerTrpLeuValHisLysGl-
nTrpPheLeuAspLeuProLeuProTrp> 1610 1620 1630 1640 1650 1660 1670
1680 1690 1700
GACTTCAGGAGCTTCAACATCTCAAGAGACTTGGAACAGACAAGATTTGCTGGTCACATTCAAGACAGCTCATG-
CAAAGAAACAGGAAGTAGTCGTACTG
ThrSerGlyAlaSerThrSerGlnGluThrTrpAsnArgGlnAspLeuLeuValThrPheLysThrAlaHisAl-
aLysLysGlnGluValValValLeu> 1710 1720 1730 1740 1750 1760 1770
1780 1790 1800
GGATCACAGGAAGGAGCAATGCACACTGCGTTGACTGGGGCGACAGAAATCCAGACGTCAGGAACGACAACAAT-
CTTTGCAGGACACCTGAAATGCAGAC
GlySerGlnGluGLyAlaMetHisThrAlaLeuThrGlyAlaThrGluIleGlnThrSerGlyThrThrThrIl-
ePheAlaGlyHisLeuLyscysArg> 1810 1820 1830 1840 1850 1860 1870
1880 1890 1900
TAAAAATGGATAAACTGACTTTAAAAGGGATGTCATATGTAATGTGCACAGGCTCATTTAAGCTAGAGAAGGAA-
GTGGCTGAGACCCAGCATGGAACTGT
LeuLysMetAspLysLeuThrLeuLysGlyMetSerTyrValMetCysThrGlySerPheLysLeuGluLysGl-
uValAlaGluThrGlnHisGlyThrVal> 1910 1920 1930 1940 1950 1960 1970
1980 1990 2000
TTTAGTGCAGGTTAAATACGAAGGAACAGATGCGCCATGCAAGATCCCTTTTTCGGCCCAAGATGAGAAAGGAG-
TGACCCAGAATGGGAGATTGATAACA
LeuValGlnValLysTyrGluGLyThrAspAlaProCysLysIleProPheSerAlaGlnAspGluLysGlyVa-
lThrGlnAsnGlyArgLeuIleThr> 2010 2020 2030 2040 2050 2060 2070
2080 2090 2100
GCCAACCCCATAGTCACTGACAAAGAAAAACCAGTCAACATTGAGACAGAACCACCTTTTGGTGAGAGCTACAT-
CGTGGTAGGGGCAGGTGAAAAAGCTT
AlaAsnProIleValThrAspLysGluLysProValAsnIleGluThrGluProProPheGlyGLuSerTyrIl-
eValValGlyAlaGlyGluLysAla> 2110 2120 2130 2140 2150 2160 2170
2180 2190 2200
TGAAACTGAGCTGGTTCAAGAAAGGGAGCAGCATAGGGAAAATGTTCGAAGCAACTGCCCGAGGAGCGCGAAGG-
ATGGCTATCCTGGGAGACACCGCATG
LeuLysLeuSerTrpPheLysLysGlySerSerIleGlyLysMetPheGluAlaThrAlaArgGlyAlaArgAr-
gMetAlaIleLeuGlyAspThrAlaTrp> 2210 2220 2230 2240 2250 2260 2270
2280 2290 2300
GGACTTTGGCTCTATAGGAGGAGTGTTCACATCAGTGGGAAAATTGGTACACCAGGTTTTTGGAGCCGCATATG-
GGGTTCTGTTCAGCGGTGTTTCTTGG
AspPheGlySerIleGlyGLyValPheThrSerValGlyLysLeuValHisGlnValPheGlyAlaAlatyrGl-
yValLeuPheSerGlyValSerTrp> 2310 2320 2330 2340 2350 2360 2370
2380 2390 2400
ACCATGAAAATAGGAATAGGGATTCTGCTGACATGGCTAGGATTAAACTCGAGGAACACTTCAATGGCTATGAC-
GTGCATAGCTGTTGGAGGAATCACTC
ThrMetLysIleGLyIleGlyIleLeuLeuThrTrpLeuGlyLeuAsnSerArgAsnThrSerMetAlaMetTh-
rCysIleAlaValGlyGlyIleThr> 2410 2420 TGTTTCTGGGCTTCACAGTTCAAGCA
LeuPheLeuGlyPheThrValGlnAla> Bases 1 to 88 (BglII): DEN4 Bases
89 (BglII) to 2348 (XhoI): DEN1 Bases 2349 (XhoI) to 2426: DEN4
Bases 102 to 443: C protein ORF Bases 444 to 941: prM protein ORF
Bases 942 to 2426: B protein ORF
TABLE-US-00047 APPENDIX 4 Nucleotide and amino acid sequence of
DEN1 (Puerto Rico/94) ME chimeric region 10 20 30 40 50 60 70 80 90
100
AGTTGTTAGTCTGTGTGGACCGACAAGGACAGTTCCAAATCGGAAGCTTGCTTAACACAGTTCTAACAGTTTGT-
TTGAATAGAGAGCAGATCTCTGGAAA 110 120 130 140 150 160 170 180 190 200
AATGAACCAACGAAAAAAGGTGGTTAGACCACCTTCAATATGCTGAAACGCGAGAGAAACCGCGTATCAACCCC-
TCAAGGGTTGGTGAAGAGGATTCTCA
MetAsnGlnArgLysLysValValArgProProPheAsnMetLeuLysArgGluArgAsnArgValSerThrPr-
oGlnGlyLeuValLysArgPheSer> 210 220 230 240 250 260 270 280 290
300
ACCGGACTTTTTTCTGGGAAAGGACCCTTACGGATGGTGCTAGCATTCATCACGTTTTTGCGAGTCCTTTCCAT-
CCCACCAACAGCAGGGATTCTGAAGA
ThrGlyLeuPheSerGlyLysGlyProLeuArgMetValLeuAlaPheIleThrPheLeuArgValLeuSerIl-
eProProThrALaGlyIleLeuLys> 310 320 330 340 350 360 370 380 390
400
GATGGGGACAGTTGAAGAAAAATAAGGCCATCAAGATACTGATTGGATTCAGGAAGGAGATAGGCCGCATGCTG-
AACATCTTGAACGGGAGAAAAAGGTC
ArgTrpGlyGlnLeuLysLysAsnLysAlaIleLysIleLeuIleGlyPheArgLysGluIleGlyArgMetLe-
uAsnIleLeuAsnGlyArgLysArgSer> 410 420 430 440 450 460 470 480
490 500
TGCAGCCATGCTCCTCATGCTGCTGCCCACAGCCCTGGCGTTCCATTTGACCACACGAGGGGGAGAGCCACACA-
TGATAGTTAGTAAGCAGGAAAGAGGA
AlaAlaMetLeuLeuMetLeuLeuProThrALaLeuAlaPheHisLeuThrThrArgGlyGlyGluProHisMe-
tIleValSerLysGlnGluArgGly> 510 520 530 540 550 560 570 580 590
600
AAGTCACTGTTGTTTAAGACCTCTGCAGGCATCAATATGTGCACTCTCATTGCGATGGATTTGGGAGAGTTATG-
CGAGGACACAATGACCTACAAATGCC
LysSerLeuLeuPheLysThrSerAlaGlyIleAsnMetCysThrLeuIleAlaMetAspLeuGlyGluLeuCy-
sGluAspThrMetThrTyrLysCys> 610 620 630 640 650 660 670 680 690
700
CCCGGATCACTGAGGCGGAACCAGATGACGTTGACTGCTGGTGCAATGCCACAGACACATGGGTGACCTATGGG-
ACGTGTTCTCAAACCGGCGAACACCG
ProArgIleThrGluAlaGluProAspAspValAspCysTrpCysAsnAlaThrAspThrTrpValThrTyrGl-
yThrCysSerGlnThrGlyGluHisArg> 710 720 730 740 750 760 770 780
790 800
ACGAGACAAACGTTCCGTGGCACTGGCCCCACACGTGGGACTTGGTCTAGAAACAAGAACCGAAACATGGATGT-
CCTCTGAAGGTGCCTGGAAACAAGTA
ArgAspLysArgSerValAlaLeuAlaProHisValGlyLeuGlyLeuGluThrArgThrGluThrTrpMetSe-
rSerGluGlyAlaTrpLysGlnVal> 810 820 830 840 850 860 870 880 890
900
CAAAAAGTGGAGACTTGGGCTTTGAGACACCCAGGATTCACGGTGACAGCCCTTTTTTTAGCACATGCCATAGG-
AACATCCATTACTCAGAAAGGGATCA
GlyLysValGluThrTrpAlaLeuArgHisProGlyPheThrValThrAlaLeuPheLeuAlaHisAlaIleGl-
yThrSerIleThrGlnLysGlyIle> 910 920 930 940 950 960 970 980 990
1000
TTTTCATTCTGCTGATGCTAGTAACACCATCAATGGCCATGCGATGTGTGGGAATAGGCAACAGAGACTTCGTT-
GAAGGACTGTCAGGAGCAACGTGGGT
IlePheIleLeuLeuMetLeuValThrProSerMetALaMetArgCysValGlyIleGlyAsnArgAspPheVa-
lGluGlyLeuSerGlyAlaThrTrpVal> 1010 1020 1030 1040 1050 1060 1070
1080 1090 1100
GGACGTGGTATTGGAGCATGGAAGCTGCGTCACCACCATGGCAAAAGATAAACCAACATTGGACATTGAACTCT-
TGAAGACGGAGGTCACAAACCCTGCC
AspValValLeuGluHisGlySerCysValThrThrMetAlaLysAspLysProThrLeuAspIleGluLeuLe-
uLysThrGluValThrAsnProAla> 1110 1120 1130 1140 1150 1160 1170
1180 1190 1200
GTCTTGCGCAAACTGTGCATTGAAGCTAAAATATCAAACACCACCACCGATTCAAGGTGTCCAACACAAGGAGA-
GGCTACACTGGTGGAAGAACAGGACT
ValLeuArgLysLeuCysIleGlyAlaLysIleSerAsnThrThrThrAspSerArgCysProThrGlnGlyGL-
uAlaThrLeuValGluGluGlnAsp> 1210 1220 1230 1240 1250 1260 1270
1280 1290 1300
CGAACTTTGTGTGTCGACGAACGTTTGTGGACAGAGGCTGGGGTAATGGCTGCGGACTATTTGGAAAAGGAAGC-
CTACTGACGTGTGCTAAGTTCAAGTG
SerAsnPheValCysArgArgThrPheValAspArgGlyTrpGlyAsnGlyCysGlyLeuPheGlyLysGlySe-
rLeuLeuThrCysALaLysPheLysCys> 1310 1320 1330 1340 1350 1360 1370
1380 1390 1400
TGTGACAAAACTAGAAGGAAAGATAGTTCAATATGAAAACTTAAAATATTCAGTGATAGTCACTGTCCACACTG-
GGGACCAGCACCAGGTGGGAAACGAG
ValThrLysLeuGluGlyLysIleValGlnTyrGluAsnLeuLysTyrSerValileValThrValHisThrGl-
yAspGlnHisGlnValGlyAsnGlu> 1410 1420 1430 1440 1450 1460 1470
1480 1490 1500
ACTACAGAACATGGAACAATTGCAACCATAACACCTCAAGCTCCTACGTCGGAAATACAGCTGACTGACTACGG-
AGCCCTCACATTGGACTGCTCGCCTA
ThrThrGluHisGlyThrIleAlaThrIleThrProglnAlaProThrSerGluIleGlnLeuThrAspTyrGl-
yAlaLeuThrLeuAspCysSerPro> 1510 1520 1530 1540 1550 1560 1570
1580 1590 1600
GAACAGGGCTGGACTTTAATGAGATGGTTCTATTGACAATGAAAGAAAAATCATGGCTTGTCCACAAACAATGG-
TTTCTAGACTTACCACTGCCTTGGAC
ArgThrGlyLeuAspPheAsnGluMetValLeuLeuThrMetLysGluLysSerTrpLeuValHisLysGlnTr-
pPheLeuAspLeuProLeuProTrpThr> 1610 1620 1630 1640 1650 1660 1670
1680 1690 1700
TTCAGGAGCTTCAACATCTCAAGAGACTTGGAACAGACAAGATTTGCTGGTCACATTCAAGACAGCTCATGCAA-
AGAAACAGGAAGTAGTCGTACTGGGA
SerGlyAlaSerThrSerGlnGluThrTrpAsnArgGlnAspLeuLeuValThrPheLysThrAlaHisAlaLy-
sLysGlnGluValValValLeuGly> 1710 1720 1730 1740 1750 1760 1770
1780 1790 1800
TCACAGGAAGGAGCAATGCACACTGCGTTGACTGGGGCGACAGAAATCCAGACGTCAGGAACGACAACAATCTT-
TGCAGGACACCTGAAATGCAGACTAA
SerGlnGluGLyAlaMetHisThrAlaLeuThrGlyAlaThrGluIleGlnThrSerGlyThrThrThrIlePh-
eAlaGlyHisLeuLysCysArgLeu> 1810 1820 1830 1840 1850 1860 1870
1880 1890 1900
AAATGGATAAACTGACTTTAAAAGGGATGTCATATGTAATGTGCACAGGCTCATTTAAGCTAGAGAAGGAAGTG-
GCTGAGACCCAGCATGGAACTGTTTT
LysMetAspLysLeuThrLeuLysGlyMetSerTyrValmetCysThrGlySerPheLysLeuGluLysGluVa-
lAlaGluThrGlnHisGlyThrValLeu> 1910 1920 1930 1940 1950 1960 1970
1980 1990 2000
AGTGCAGGTTAAATACGAAGGAACAGATGCGCCATGCAAGATCCCTTTTTCGGCCCAAGATGAGAAAGGAGTGA-
CCCAGAATGGGAGATTGATAACAGCC
ValGlnValLysTyrGluGlyThrAspAlaProCysLysIleProPheSerAlaGlnAspGluLysGlyValTh-
rGlnAsnGlyArgLeuIleThrAla> 2010 2020 2030 2040 2050 2060 2070
2080 2090 2100
AACCCCATAGTCACTGACAAAGAAAAACCAGTCAACATTGAGACAGAACCACCTTTTGGTGAGAGCTACATCGT-
GGTAGGGGCAGGTGAAAAAGCTTTGA
AsnProIleValThrAspLysGluLysProValAsnIleGluThrGluProProPheGlyGluSerTyrIleVa-
lValGlyAlaGlyGluLysAlaLeu> 2110 2120 2130 2140 2150 2160 2170
2180 2190 2200
AACTGAGCTGGTTCAAGAAAGGGAGCAGCATAGGGAAAATGTTCGAAGCAACTGCCCGAGGAGCGCGAAGGATG-
GCTATCCTGGGAGACACCGCATGGGA
LysLeuSerTrpPheLysLysGlySerSerIleGlyLysMetPheGluAlaThrAlaArgGlyAlaArgArgMe-
tAlaIleLeuGlyAspThrAlaTrpAsp> 2210 2220 2230 2240 2250 2260 2270
2280 2290 2300
CTTTGGCTCTATAGGAGGAGTGTTCACATCAGTGGGAAAATTGGTACACCAGGTTTTTGGAGCCGCATATGGGG-
TTCTGTTCAGCGGTGTTTCTTGGACC
PheGlySerIleGlyGlyValPheThrSerValGlyLysLeuValHisGlnValPheGlyAlaAlaTyrGlyVa-
lLeuPheSerGlyValSerTrpThr> 2310 2320 2330 2340 2350 2360 2370
2380 2390 2400
ATGAAAATAGGAATAGGGATTCTGCTGACATGGCTAGGATTAAACTCGAGGAACACTTCAATGGCTATGACGTG-
CATAGCTGTTGGAGGAATCACTCTGT
MetLysIleGlyIleGlyIleLeuLeuThrTrpLeuGlyLeuAsnSerArgAsnThrSerMetAlaMerThrCy-
sIleAlaValGlyGlyIleThrLeu> 2410 2420 TTCTGGGCTTCACAGTTCAAGCA
PheLeuGlyPheThrValGlnAla Bases 1 to 404 (PstI): DEN4 Bases 405
(PstI) to 2345 (XhoI): DEN1 Bases 2346 (XhoI) to 2423: DEN4 Bases
102 to 440: C protein ORF Bases 441 to 938: prM protein ORF Bases
939 to 2423: B protein ORF
While the present invention has been described in some detail for
purposes of clarity and understanding, one skilled in the art will
appreciate that various changes in form and detail can be made
without departing from the true scope of the invention. All
figures, tables, appendices, patents, patent applications and
publications, referred to above, are hereby incorporated by
reference.
SEQUENCE LISTINGS
1
53182RNADengue 1 virus 1gcagcagcgg ggcccaacac caggggaagc uguacccugg
ugguaaggac uagagguuag 60aggagacccc ccgcaacaac aa 82284RNADengue 2
virus 2agcaacaaug ggggcccaag gugagaugaa gcuguagucu cacuggaagg
acuagagguu 60agaggagacc cccccaaaac aaaa 84383RNADengue 3 virus
3gcagcagcgg ggcccgagcu cugagggaag cuguaccucc uugcaaagga cuagagguua
60gaggagaccc cccgcaaaua aaa 83483RNADengue 4 virus 4agcaaaaggg
ggcccgaagc caggaggaag cuguacuccu gguggaagga cuagagguua 60gaggagaccc
ccccaacaca aaa 83516RNAArtificial SequenceDengue 1 delta 30
5ggggcccaag acuaga 16616RNAArtificial SequenceDengue 2 delta 30
6ggggcccaag acuaga 16716RNAArtificial SequenceDengue 3 delta 30
7ggggcccaag acuaga 16816RNAArtificial SequenceDengue 4 delta 30
8ggggcccaag acuaga 16951DNAArtificial SequenceTL2 region of p2
plasmid 9tgggggccca aggtgagatg aagctgtagt ctcactggaa ggactagagg t
511021DNAArtificial SequenceTL2 region of p2 delta 30 10tgggggccca
agactagagg t 211151DNAArtificial SequenceTL2 region of p3 plasmid
11cggggcccga gctctgaggg aagctgtacc tccttgcaaa ggactagagg t
511220DNAArtificial SequenceTL2 region of p3 delta 30 12gggggcccaa
gactagaggt 201329DNAArtificial SequenceSpe1 linker in p3
13actagttaga ctaacttaag tcaactagt 291451DNAArtificial
SequencerDEN2/4 junction 1 14cagtttgttt gaatagagag cagatctctg
atgaataacc aacgaaaaaa g 51157PRTArtificial SequencerDEN2/4 junction
1 15Met Asn Asn Gln Arg Lys Lys 1 5 1651DNAArtificial
SequencerDEN2/4 junction 2 16attatcacat ggataggaat gaactcgagg
aacacttcaa tggctatgac g 511717PRTArtificial SequencerDEN2/4
junction 2 17Ile Ile Thr Trp Ile Gly Met Asn Ser Arg Asn Thr Ser
Met Ala Met 1 5 10 15 Thr1851DNAArtificial SequencerDEN2/4 junction
3 18atcttgaacg ggagaaaaag gtctgcaggc atgatcatta tgctgattcc a
511917PRTArtificial SequencerDEN2/4 junction 3 19Ile Leu Asn Gly
Arg Lys Arg Ser Ala Gly Met Ile Ile Met Leu Ile 1 5 10 15
Pro2050DNAArtificial SequencerDEN3/4 junction 1 20cagtttgttt
gaatagagag cagatctctg gaaaaatgaa caaccaacgg 50215PRTArtificial
SequencerDEN3/4 junction 1 21Met Asn Asn Gln Arg 1 5
2251DNAArtificial SequencerDEN3/4 junction 2 22cttttaacct
ggatagggtt gaactcgagg aacacttcaa tggctatgac g 512317PRTArtificial
SequencerDEN3/4 junction 2 23Leu Leu Thr Trp Ile Gly Leu Asn Ser
Arg Asn Thr Ser Met Ala Met 1 5 10 15 Thr2451DNAArtificial
SequencerDEN3/4 junction 3 24atcttgaacg ggagaaaaag gtctgcagtc
tgtctcatga tgatgttacc a 512517PRTArtificial SequencerDEN3/4
junction 3 25Ile Leu Asn Gly Arg Lys Arg Ser Ala Val Cys Leu Met
Met Met Leu 1 5 10 15 Pro2650DNAArtificial SequencerDEN1/4 junction
1 26cagtttgttt gaatagagag cagatctctg gaaaaatgaa caaccaacgg
50275PRTArtificial SequencerDEN1/4 junction 1 27Met Asn Asn Gln Arg
1 5 2851DNAArtificial SequencerDEN1/4 junction 2 28ctgctgacat
ggctaggatt aaactcgagg aacacttcaa tggctatgac g 512917PRTArtificial
SequencerDEN1/4 junction 2 29Leu Leu Thr Trp Leu Gly Leu Asn Ser
Arg Asn Thr Ser Met Ala Met 1 5 10 15 Thr3051DNAArtificial
SequencerDEN1/4 junction 3 30atcttgaacg ggagaaaaag gtctgcagcc
atgctcctca tgctgctgcc c 513117PRTArtificial SequencerDEN1/4
junction 3 31Ile Leu Asn Gly Arg Lys Arg Ser Ala Ala Met Leu Leu
Met Leu Leu 1 5 10 15 Pro3260RNADengue 4 virus 32ccaacaaccu
ugacagcauc cuuagucaug cuuuuagucc auuaugcaau aauaggccca
603320PRTDengue 4 virus 33Pro Thr Thr Leu Thr Ala Ser Leu Val Met
Leu Leu Val His Thr Ala 1 5 10 15 Ile Ile Gly Pro 20 3460RNADengue
1 virus 34ccgcugacgc ugacagcggc gguauuuaug cuaguggcuc auuaugccau
aauuggaccc 603520PRTDengue 1 virus 35Pro Leu Thr Leu Thr Ala Ala
Val Pro Met Leu Val Ala His Thr Ala 1 5 10 15 Ile Ile Gly Pro 20
3660RNADengue 2 virus 36ccuauaaccc ucacagcggc ucuucuuuua uugguagcac
auuaugccau cauaggaccg 603720PRTDengue 2 virus 37Pro Ile Thr Leu Thr
Ala Ala Leu Leu Leu Leu Val Ala His Thr Ala 1 5 10 15 Ile Ile Gly
Pro 20 3860RNADengue 3 virus 38ccacuaacuc ucacagcggc aguucuccug
cuagucacgc auuaugcuau uauaggucca 603920PRTDengue 3 virus 39Pro Leu
Thr Leu Thr Ala Ala Val Leu Leu Leu Val Thr His Thr Ala 1 5 10 15
Ile Ile Gly Pro 20 4013DNAArtificial Sequenceprimer 40ccacgggcgc
cgt 134110DNAArtificial Sequenceprimer 41aaggcctgga
104212DNAArtificial Sequenceprimer 42tatccccggg ac
124311DNAArtificial Sequenceprimer 43agagctctct c
114415DNAArtificial Sequenceprimer 44gaatctccac ccgga
154510DNAArtificial Sequenceprimer 45ctgtcgaatc
104615159DNAArtificial SequenceDengue 2 plasmid p2 46agttgttagt
ctacgtggac cgacaaagac agattctttg agggagctaa gctcaacgta 60gttctaactg
ttttttgatt agagagcaga tctctgatga ataaccaacg gaaaaaggcg
120agaaacacgc ctttcaatat gctgaaacgc gagagaaacc gcgtgtcaac
tgtacaacag 180ttgacaaaga gattctcact tggaatgctg cagggacgag
gaccactaaa attgttcatg 240gccctggtgg cattccttcg tttcctaaca
atcccaccaa cagcagggat attaaaaaga 300tggggaacaa ttaaaaaatc
aaaggctatt aatgttctga gaggcttcag gaaagagatt 360ggaaggatgc
tgaatatctt aaacaggaga cgtagaactg taggcatgat catcatgctg
420actccaacag tgatggcgtt tcatctgacc acacgcaacg gagaaccaca
catgattgtc 480agtagacaag aaaaagggaa aagccttctg ttcaagacaa
aggatggcac gaacatgtgt 540accctcatgg ccatggacct tggtgagttg
tgtgaagaca caatcacgta taaatgtcct 600tttctcaagc agaacgaacc
agaagacata gattgttggt gcaactccac gtccacatgg 660gtaacttatg
ggacatgtac caccacagga gagcacagaa gagaaaaaag atcagtggcg
720cttgttccac acgtgggaat gggattggag acacgaactg aaacatggat
gtcatcagaa 780ggggcctgga aacatgccca gagaattgaa acttggattc
tgagacatcc aggctttacc 840ataatggccg caatcctggc atacaccata
gggacgacgc atttccaaag agtcctgata 900ttcatcctac tgacagccat
cgctccttca atgacaatgc gctgcatagg aatatcaaat 960agggactttg
tggaaggagt gtcaggaggg agttgggttg acatagtttt agaacatgga
1020agttgtgtga cgacgatggc aaaaaacaaa ccaacactgg actttgaact
gataaaaaca 1080gaagccaaac aacctgccac cttaaggaag tactgtatag
aggccaaact gaccaacacg 1140acaacagact cgcgctgccc aacacaaggg
gaacccaccc tgaatgaaga gcaggacaaa 1200aggtttgtct gcaaacattc
catggtagac agaggatggg gaaatggatg tggattgttt 1260ggaaaaggag
gcatcgtgac ctgtgctatg ttcacatgca aaaagaacat ggaaggaaaa
1320attgtgcagc cagaaaacct ggaatacact gtcgtgataa cacctcattc
aggggaagaa 1380catgcagtgg gaaatgacac aggaaaacat ggtaaagaag
tcaagataac accacagagc 1440tccatcacag aggcggaact gacaggctat
ggcactgtta cgatggagtg ctctccaaga 1500acgggcctcg acttcaatga
gatggtgttg ctgcaaatgg aagacaaagc ctggctggtg 1560cacagacaat
ggttcctaga cctaccgttg ccatggctgc ccggagcaga cacacaagga
1620tcaaattgga tacagaaaga aacactggtc accttcaaaa atccccatgc
gaaaaaacag 1680gatgttgttg tcttaggatc ccaagagggg gccatgcata
cagcactcac aggggctacg 1740gaaatccaga tgtcatcagg aaacctgctg
ttcacaggac atctcaagtg caggctgaga 1800atggacaaat tacaacttaa
agggatgtca tactccatgt gcacaggaaa gtttaaaatt 1860gtgaaggaaa
tagcagaaac acaacatgga acaatagtca ttagagtaca atatgaagga
1920gacggctctc catgcaagat cccctttgag ataatggatc tggaaaaaag
acatgttttg 1980ggccgcctga tcacagtcaa cccaattgta acagaaaagg
acagtccagt caacatagaa 2040gcagaacctc cattcggaga cagctacatc
atcataggag tggaaccagg acaattgaag 2100ctggactggt tcaagaaagg
aagttccatc ggccaaatgt ttgagacaac aatgagggga 2160gcgaaaagaa
tggccatttt gggtgacaca gcctgggatt ttggatctct gggaggagtg
2220ttcacatcaa taggaaaggc tctccaccag gtttttggag caatctacgg
ggctgctttc 2280agtggggtct catggactat gaagatcctc ataggagtta
tcatcacatg gataggaatg 2340aactcacgta gcactagtct gagcgtgtca
ctggtgttag tgggaatcgt gacactttac 2400ttgggagtta tggtgcaggc
cgatagtggt tgcgttgtga gctggaagaa caaagaacta 2460aaatgtggca
gtggaatatt cgtcacagat aacgtgcata catggacaga acaatacaag
2520ttccaaccag aatccccttc aaaactggcc tcagccatcc agaaagcgca
tgaagagggc 2580atctgtggaa tccgctcagt aacaagactg gaaaatctta
tgtggaaaca gataacatca 2640gaattgaatc atattctatc agaaaatgaa
gtgaaactga ccatcatgac aggagacatc 2700aaaggaatca tgcaggtagg
aaaacgatct ttgcggcctc aacccactga gttgaggtat 2760tcatggaaaa
catggggtaa agcgaaaatg ctctccacag aactccacaa tcagaccttc
2820ctcattgatg gtcccgaaac agcagaatgc cccaacacaa acagagcttg
gaattcactg 2880gaagttgagg actacggctt tggagtattc actaccaata
tatggctaag attgagagaa 2940aagcaggatg tattttgtga ctcaaaactc
atgtcagcgg ccataaagga caacagagcc 3000gtccatgctg atatgggtta
ttggatagaa agcgcactca atgatacatg gaagatagag 3060aaagcttctt
tcattgaagt caaaagttgc cactggccaa agtcacacac cctatggagt
3120aatggagtgc tagaaagcga gatggtcatt ccaaagaatt tcgctggacc
agtgtcacaa 3180cataataaca gaccaggcta ttacacacaa acagcaggac
cttggcatct aggcaagctt 3240gagatggact ttgatttctg cgaagggact
acagtggtgg taaccgagaa ctgtggaaac 3300agagggccct ctttaagaac
aaccactgcc tcaggaaaac tcataacgga atggtgttgt 3360cgatcttgca
cactaccacc actaagatac agaggtgagg atggatgttg gtacgggatg
3420gaaatcagac cattgaaaga gaaagaagaa aatctggtca gttctctggt
tacagccgga 3480catgggcaga ttgacaattt ctcattagga atcttgggaa
tggcactgtt ccttgaagaa 3540atgctcagga ctcgagtagg aacaaaacat
gcaatattac tcgtcgcagt ttctttcgtg 3600acgctaatca cagggaacat
gtcttttaga gacctgggaa gagtgatggt tatggtgggt 3660gccaccatga
cagatgacat aggcatgggt gtgacttatc tcgctctact agcagctttt
3720agagtcagac caacctttgc agctggactg ctcttgagaa aactgacctc
caaggaatta 3780atgatgacta ccataggaat cgttcttctc tcccagagta
gcataccaga gaccattctt 3840gaactgaccg acgcgttagc tctaggcatg
atggtcctca agatggtgag aaacatggaa 3900aaatatcagc tggcagtgac
catcatggct attttgtgcg tcccaaatgc tgtgatatta 3960cagaacgcat
ggaaagtgag ttgcacaata ttggcagtgg tgtctgtttc ccccctgctc
4020ttaacatcct cacaacagaa agcggactgg ataccattag cgttgacgat
caaaggtctt 4080aatccaacag ccatttttct aacaaccctc tcaagaacca
acaagaaaag gagctggcct 4140ttaaatgagg ccatcatggc ggttgggatg
gtgagtatct tggccagctc tctcttaaag 4200aatgacatcc ccatgacagg
accattagtg gctggagggc tccttactgt gtgctacgtg 4260ctaactgggc
ggtcagccga tctggaatta gagagagcta ccgatgtcaa atgggatgac
4320caggcagaga tatcaggtag cagtccaatc ctgtcaataa caatatcaga
agatggcagc 4380atgtcaataa agaatgaaga ggaagagcaa acactgacta
tactcattag aacaggattg 4440cttgtgatct caggactctt tccggtatca
ataccaatta cagcagcagc atggtatctg 4500tgggaagtaa agaaacaacg
ggctggagtg ctgtgggatg tcccctcacc accacccgtg 4560ggaaaagctg
aattggaaga tggagcctac agaatcaagc aaaaaggaat ccttggatat
4620tcccagatcg gagctggagt ttacaaagaa ggaacatttc acacaatgtg
gcacgtcaca 4680cgtggcgctg tcctaatgca taaggggaag aggattgaac
catcatgggc ggacgtcaag 4740aaagacttaa tatcatatgg aggaggttgg
aagctagaag gagaatggaa agaaggagaa 4800gaagtccagg tcttggcatt
ggagccaggg aaaaatccaa gagccgtcca aacaaagcct 4860ggccttttta
gaaccaacac tggaaccata ggtgccgtat ctctggactt ttcccctggg
4920acgtcaggat ctccaatcgt cgacaaaaaa ggaaaagttg taggtctcta
tggcaatggt 4980gtcgttacaa ggagtggagc atatgtgagt gccatagctc
agactgaaaa aagcattgaa 5040gacaatccag agattgaaga tgacatcttt
cgaaagagaa gattgactat catggatctc 5100cacccaggag caggaaagac
aaagagatac ctcccggcca tagtcagaga ggccataaaa 5160agaggcttga
gaacactaat cctagccccc actagagtcg tggcagctga aatggaggaa
5220gcccttagag gacttccaat aagataccaa actccagcta tcagggctga
gcacaccggg 5280cgggagattg tagacttaat gtgtcatgcc acatttacca
tgaggctgct atcaccaatc 5340agggtgccaa attacaacct gatcatcatg
gacgaagccc attttacaga tccagcaagc 5400atagcagcta ggggatacat
ctcaactcga gtggagatgg gggaggcagc tggaattttt 5460atgacagcca
ctcctccggg tagtagagat ccatttcctc agagcaatgc accaattatg
5520gacgaagaaa gagaaattcc ggaacgttca tggaactctg ggcacgagtg
ggtcacggat 5580tttaaaggaa agactgtctg gtttgttcca agcataaaaa
ccggaaatga catagcagcc 5640tgcctgagaa agaatggaaa gagggtgata
caactcagta ggaagacctt tgattctgaa 5700tatgtcaaga ctagaaccaa
tgactgggat ttcgtggtta caactgacat ctcggaaatg 5760ggcgccaact
ttaaagctga gagggtcata gaccccagac gctgcatgaa accagttata
5820ttgacagacg gcgaagagcg ggtgattctg gcaggaccca tgccagtgac
ccactctagt 5880gcagcacaaa gaagagggag aataggaagg aatccaagga
atgaaaatga tcaatatata 5940tatatggggg aaccactgga aaatgatgaa
gactgtgcgc actggaagga agctaagatg 6000ctcctagata atatcaacac
acctgaagga atcattccca gcttgttcga gccagagcgt 6060gaaaaggtgg
atgccattga cggtgaatat cgcttgagag gagaagcacg gaaaactttt
6120gtggacctaa tgagaagagg agacctacca gtctggttgg cttataaagt
ggcagctgaa 6180ggtatcaact acgcagacag aagatggtgt tttgacggaa
ccagaaacaa tcaaatcttg 6240gaagaaaatg tggaagtgga aatctggaca
aaggaagggg aaaggaaaaa attgaaacct 6300agatggttag atgctaggat
ctactccgac ccactggcgc taaaagagtt caaggaattt 6360gcagccggaa
gaaagtccct aaccctgaac ctaattacag agatgggcag actcccaact
6420tttatgactc agaaggccag agatgcacta gacaacttgg cggtgctgca
cacggctgaa 6480gcgggtggaa aggcatacaa tcatgctctc agtgaattac
cggagaccct ggagacattg 6540cttttgctga cactgttggc cacagtcacg
ggaggaatct tcctattcct gatgagcgga 6600aggggtatgg ggaagatgac
cctgggaatg tgctgcataa tcacggccag catcctctta 6660tggtatgcac
aaatacagcc acattggata gcagcctcaa taatattgga gttctttctc
6720atagtcttgc tcattccaga accagaaaag cagaggacac ctcaggataa
tcaattgact 6780tatgtcatca tagccatcct cacagtggtg gccgcaacca
tggcaaacga aatgggtttt 6840ctggaaaaaa caaagaaaga cctcggactg
ggaaacattg caactcagca acctgagagc 6900aacattctgg acatagatct
acgtcctgca tcagcatgga cgttgtatgc cgtggctaca 6960acatttatca
caccaatgtt gagacatagc attgaaaatt cctcagtaaa tgtgtcccta
7020acagccatag ctaaccaagc cacagtgcta atgggtctcg gaaaaggatg
gccattgtca 7080aagatggaca ttggagttcc cctccttgct attgggtgtt
actcacaagt caaccctata 7140accctcacag cggctcttct tttattggta
gcacattatg ccatcatagg accgggactt 7200caagccaaag caactagaga
agctcagaaa agagcagcag cgggcatcat gaaaaaccca 7260actgtggatg
gaataacagt gatagatcta gatccaatac cctatgatcc aaagtttgaa
7320aagcagttgg gacaagtaat gctcctagtc ctctgcgtga cccaagtgct
gatgatgagg 7380actacgtggg ctttgtgtga agccttaact ctagcaactg
gacccgtgtc cacattgtgg 7440gaaggaaatc cagggagatt ctggaacaca
accattgcag tgtcaatggc aaacatcttt 7500agagggagtt acctggctgg
agctggactt ctcttttcta tcatgaagaa cacaaccagc 7560acgagaagag
gaactggcaa tataggagaa acgttaggag agaaatggaa aagcagactg
7620aacgcattgg ggaaaagtga attccagatc tacaaaaaaa gtggaattca
agaagtggac 7680agaaccttag caaaagaagg cattaaaaga ggagaaacgg
atcatcacgc tgtgtcgcga 7740ggctcagcaa aactgagatg gttcgttgaa
aggaatttgg tcacaccaga agggaaagta 7800gtggaccttg gttgtggcag
agggggctgg tcatactatt gtggaggatt aaagaatgta 7860agagaagtta
aaggcttaac aaaaggagga ccaggacacg aagaacctat ccctatgtca
7920acatatgggt ggaatctagt acgcttacag agcggagttg atgttttttt
tgttccacca 7980gagaagtgtg acacattgtt gtgtgacata ggggaatcat
caccaaatcc cacggtagaa 8040gcgggacgaa cactcagagt cctcaaccta
gtggaaaatt ggctgaacaa taacacccaa 8100ttttgcgtaa aggttcttaa
cccgtacatg ccctcagtca ttgaaagaat ggaaacctta 8160caacggaaat
acggaggagc cttggtgaga aatccactct cacggaattc cacacatgag
8220atgtactggg tgtccaatgc ttccgggaac atagtgtcat cagtgaacat
gatttcaaga 8280atgctgatca acagattcac tatgagacac aagaaggcca
cctatgagcc agatgtcgac 8340ctcggaagcg gaacccgcaa tattggaatt
gaaagtgaga caccgaacct agacataatt 8400gggaaaagaa tagaaaaaat
aaaacaagag catgaaacgt catggcacta tgatcaagac 8460cacccataca
aaacatgggc ttaccatggc agctatgaaa caaaacagac tggatcagca
8520tcatccatgg tgaacggagt agtcagattg ctgacaaaac cctgggacgt
tgttccaatg 8580gtgacacaga tggcaatgac agacacaact ccttttggac
aacagcgcgt cttcaaagag 8640aaggtggata cgagaaccca agaaccaaaa
gaaggcacaa aaaaactaat gaaaatcacg 8700gcagagtggc tctggaaaga
actaggaaag aaaaagacac ctagaatgtg taccagagaa 8760gaattcacaa
aaaaggtgag aagcaatgca gccttggggg ccatattcac cgatgagaac
8820aagtggaaat cggcgcgtga agccgttgaa gatagtaggt tttgggagct
ggttgacaag 8880gaaaggaacc tccatcttga agggaaatgt gaaacatgtg
tatacaacat gatggggaaa 8940agagagaaaa aactaggaga gtttggtaaa
gcaaaaggca gcagagccat atggtacatg 9000tggctcggag cacgcttctt
agagtttgaa gccctaggat ttttgaatga agaccattgg 9060ttctccagag
agaactccct gagtggagtg gaaggagaag ggctgcataa gctaggttac
9120atcttaagag aggtgagcaa gaaagaagga ggagcaatgt atgccgatga
caccgcaggc 9180tgggacacaa gaatcacaat agaggatttg aaaaatgaag
aaatgataac gaaccacatg 9240gcaggagaac acaagaaact tgccgaggcc
atttttaaat tgacgtacca aaacaaggtg 9300gtgcgtgtgc aaagaccaac
accaagaggc acagtaatgg acatcatatc gagaagagac 9360caaaggggta
gtggacaagt tggcacctat ggcctcaaca ctttcaccaa catggaagca
9420caactaatta ggcaaatgga gggggaagga atcttcaaaa gcatccagca
cttgacagcc 9480tcagaagaaa tcgctgtgca agattggcta gtaagagtag
ggcgtgaaag gttgtcaaga 9540atggccatca gtggagatga ttgtgttgtg
aaacctttag atgatagatt tgcaagagct 9600ctaacagctc taaatgacat
gggaaaggtt aggaaggaca tacagcaatg ggagccctca 9660agaggatgga
acgactggac gcaggtgccc ttctgttcac accattttca cgagttaatt
9720atgaaagatg gtcgcacact cgtagttcca tgcagaaacc aagatgaatt
gatcggcaga 9780gcccgaattt cccagggagc tgggtggtct ttacgggaga
cggcctgttt ggggaagtct 9840tacgcccaaa tgtggagctt gatgtacttc
cacagacgtg atctcaggct agcggcaaat 9900gccatctgct cggcagtccc
atcacactgg attccaacaa gccggacaac
ctggtccata 9960cacgccagcc atgaatggat gacgacggaa gacatgttga
cagtttggaa cagagtgtgg 10020atcctagaaa atccatggat ggaagacaaa
actccagtgg aatcatggga ggaaatccca 10080tacctgggaa aaagagaaga
ccaatggtgc ggctcgctga ttgggctgac aagcagagcc 10140acctgggcga
agaatatcca gacagcaata aaccaagtca gatccctcat tggcaatgag
10200gaatacacag attacatgcc atccatgaaa agattcagaa gagaagagga
agaggcagga 10260gttttgtggt agaaaaacat gaaacaaaac agaagtcagg
tcggattaag ccatagtacg 10320ggaaaaacta tgctacctgt gagccccgtc
caaggacgtt aaaagaagtc aggccatttt 10380gatgccatag cttgagcaaa
ctgtgcagcc tgtagctcca cctgagaagg tgtaaaaaat 10440ccgggaggcc
acaaaccatg gaagctgtac gcatggcgta gtggactagc ggttagagga
10500gacccctccc ttacagatcg cagcaacaat gggggcccaa ggtgagatga
agctgtagtc 10560tcactggaag gactagaggt tagaggagac ccccccaaaa
caaaaaacag catattgacg 10620ctgggaaaga ccagagatcc tgctgtctcc
tcagcatcat tccaggcaca ggacgccaga 10680aaatggaatg gtgctgttga
atcaacaggt tctggtaccg gtaggcatcg tggtgtcacg 10740ctcgtcgttt
ggtatggctt cattcagctc cggttcccaa cgatcaaggc gagttacatg
10800atcccccatg ttgtgcaaaa aagcggttag ctccttcggt cctccgatcg
ttgtcagaag 10860taagttggcc gcagtgttat cactcatggt tatggcagca
ctgcataatt ctcttactgt 10920catgccatcc gtaagatgct tttctgtgac
tggtgagtac tcaaccaagt cattctgaga 10980atagtgtatg cggcgaccga
gttgctcttg cccggcgtca acacgggata ataccgcgcc 11040acatagcaga
actttaaaag tgctcatcat tggaaaacgt tcttcggggc gaaaactctc
11100aaggatctta ccgctgttga gatccagttc gatgtaaccc actcgtgcac
ccaactgatc 11160ttcagcatct tttactttca ccagcgtttc tgggtgagca
aaaacaggaa ggcaaaatgc 11220cgcaaaaaag ggaataaggg cgacacggaa
atgttgaata ctcatactct tcctttttca 11280atattattga agcatttatc
agggttattg tctcatgagc ggatacatat ttgaatgtat 11340ttagaaaaat
aaacaaatag gggttccgcg cacatttccc cgaaaagtgc cacctgacgt
11400ctaagaaacc attattatca tgacattaac ctataaaaat aggcgtatca
cgaggccctt 11460tcgtcttcaa gaattctcat gtttgacagc ttatcatcga
taagctttaa tgcggtagtt 11520tatcacagtt aaattgctaa cgcagtcagg
caccgtgtat gaaatctaac aatgcgctca 11580tcgtcatcct cggcaccgtc
accctggatg ctgtaggcat aggcttggtt atgccggtac 11640tgccgggcct
cttgcgggat atcgtccatt ccgacagcat cgccagtcac tatggcgtgc
11700tgctggcgct atatgcgttg atgcaatttc tatgcgcacc cgttctcgga
gcactgtccg 11760accgctttgg ccgccgccca gtcctgctcg cttcgctact
tggagccact atcgactacg 11820cgatcatggc gaccacaccc gtcctgtgga
tcctctacgc cggacgcatc gtggccggca 11880tcaccggcgc cacaggtgcg
gttgctggcg cctatatcgc cgacatcacc gatggggaag 11940atcgggctcg
ccacttcggg ctcatgagcg cttgtttcgg cgtgggtatg gtggcaggcc
12000ccgtggccgg gggactgttg ggcgccatct ccttgcatgc accattcctt
gcggcggcgg 12060tgctcaacgg cctcaaccta ctactgggct gcttcctaat
gcaggagtcg cataagggag 12120agcgtcgacc gatgcccttg agagccttca
acccagtcag ctccttccgg tgggcgcggg 12180gcatgactat cgtcgccgca
cttatgactg tcttctttat catgcaactc gtaggacagg 12240tgccggcagc
gctctgggtc attttcggcg aggaccgctt tcgctggagc gcgacgatga
12300tcggcctgtc gcttgcggta ttcggaatct tgcacgccct cgctcaagcc
ttcgtcactg 12360gtcccgccac caaacgtttc ggcgagaagc aggccattat
cgccggcatg gcggccgacg 12420cgctgggcta cgtcttgctg gcgttcgcga
cgcgaggctg gatggccttc cccattatga 12480ttcttctcgc ttccggcggc
atcgggatgc ccgcgttgca ggccatgctg tccaggcagg 12540tagatgacga
ccatcaggga cagcttcaag gatcgctcgc ggctcttacc agcctaactt
12600cgatcactgg accgctgatc gtcacggcga tttatgccgc ctcggcgagc
acatggaacg 12660ggttggcatg gattgtaggc gccgccctat accttgtctg
cctccccgcg ttgcgtcgcg 12720gtgcatggag ccgggccacc tcgacctgaa
tggaagccgg cggcacctcg ctaacggatt 12780caccactcca agaattggag
ccaatcaatt cttgcggaga actgtgaatg cgcaaaccaa 12840cccttggcag
aacatatcca tcgcgtccgc catctccagc agccgcacgc ggcgcatctc
12900gggcagcgtt gggtcctggc cacgggtgcg catgatcgtg ctcctgtcgt
tgaggacccg 12960gctaggctgg cggggttgcc ttactggtta gcagaatgaa
tcaccgatac gcgagcgaac 13020gtgaagcgac tgctgctgca aaacgtctgc
gacctgagca acaacatgaa tggtcttcgg 13080tttccgtgtt tcgtaaagtc
tggaaacgcg gaagtcagcg ccctgcacca ttatgttccg 13140gatctgcatc
gcaggatgct gctggctacc ctgtggaaca cctacatctg tattaacgaa
13200gcgctggcat tgaccctgag tgatttttct ctggtcccgc cgcatccata
ccgccagttg 13260tttaccctca caacgttcca gtaaccgggc atgttcatca
tcagtaaccc gtatcgtgag 13320catcctctct cgtttcatcg gtatcattac
ccccatgaac agaaatcccc cttacacgga 13380ggcatcagtg accaaacagg
aaaaaaccgc ccttaacatg gcccgcttta tcagaagcca 13440gacattaacg
cttctggaga aactcaacga gctggacgcg gatgaacagg cagacatctg
13500tgaatcgctt cacgaccacg ctgatgagct ttaccgcagc tgcctcgcgc
gtttcggtga 13560tgacggtgaa aacctctgac acatgcagct cccggagacg
gtcacagctt gtctgtaagc 13620ggatgccggg agcagacaag cccgtcaggg
cgcgtcagcg ggtgttggcg ggtgtcgggg 13680cgcagccatg acccagtcac
gtagcgatag cggagtgtat actggcttaa ctatgcggca 13740tcagagcaga
ttgtactgag agtgcaccat atgcggtgtg aaataccgca cagatgcgta
13800aggagaaaat accgcatcag gcgctcttcc gcttcctcgc tcactgactc
gctgcgctcg 13860gtcgttcggc tgcggcgagc ggtatcagct cactcaaagg
cggtaatacg gttatccaca 13920gaatcagggg ataacgcagg aaagaacatg
tgagcaaaag gccagcaaaa ggccaggaac 13980cgtaaaaagg ccgcgttgct
ggcgtttttc cataggctcc gcccccctga cgagcatcac 14040aaaaatcgac
gctcaagtca gaggtggcga aacccgacag gactataaag ataccaggcg
14100tttccccctg gaagctccct cgtgcgctct cctgttccga ccctgccgct
taccggatac 14160ctgtccgcct ttctcccttc gggaagcgtg gcgctttctc
atagctcacg ctgtaggtat 14220ctcagttcgg tgtaggtcgt tcgctccaag
ctgggctgtg tgcacgaacc ccccgttcag 14280cccgaccgct gcgccttatc
cggtaactat cgtcttgagt ccaacccggt aagacacgac 14340ttatcgccac
tggcagcagc cactggtaac aggattagca gagcgaggta tgtaggcggt
14400gctacagagt tcttgaagtg gtggcctaac tacggctaca ctagaaggac
agtatttggt 14460atctgcgctc tgctgaagcc agttaccttc ggaaaaagag
ttggtagctc ttgatccggc 14520aaacaaacca ccgctggtag cggtggtttt
tttgtttgca agcagcagat tacgcgcaga 14580aaaaaaggat ctcaagaaga
tcctttgatc ttttctacgg ggtctgacgc tcagtggaac 14640gaaaactcac
gttaagggat tttggtcatg agattatcaa aaaggatctt cacctagatc
14700cttttaaatt aaaaatgaag ttttaaatca atctaaagta tatatgagta
aacttggtct 14760gacagttacc aatgcttaat cagtgaggca cctatctcag
cgatctgtct atttcgttca 14820tccatagttg cctgactccc cgtcgtgtag
ataactacga tacgggaggg cttaccatct 14880ggccccagtg ctgcaatgat
accgcgagac ccacgctcac cggctccaga tttatcagca 14940ataaaccagc
cagccggaag ggccgagcgc agaagtggtc ctgcaacttt atccgcctcc
15000atccagtcta ttaattgttg ccgggaagct agagtaagta gttcgccagt
taatagtttg 15060cgcaacgttg ttgccattgc tgcaagatct ggctagcgat
gaccctgctg attggttcgc 15120tgaccatttc cgggcgcgcc gatttaggtg
acactatag 15159473391PRTDengue 2 virus (Tonga/74) 47Met Asn Asn Gln
Arg Lys Lys Ala Arg Asn Thr Pro Phe Asn Met Leu 1 5 10 15 Lys Arg
Glu Arg Asn Arg Val Ser Thr Val Gln Gln Leu Thr Lys Arg 20 25 30
Phe Ser Leu Gly Met Leu Gln Gly Arg Gly Pro Leu Lys Leu Phe Met 35
40 45 Ala Leu Val Ala Phe Leu Arg Phe Leu Thr Ile Pro Pro Thr Ala
Gly 50 55 60 Ile Leu Lys Arg Trp Gly Thr Ile Lys Lys Ser Lys Ala
Ile Asn Val65 70 75 80 Leu Arg Gly Phe Arg Lys Glu Ile Gly Arg Met
Leu Asn Ile Leu Asn 85 90 95 Arg Arg Arg Arg Thr Val Gly Met Ile
Ile Met Leu Thr Pro Thr Val 100 105 110 Met Ala Phe His Leu Thr Thr
Arg Asn Gly Glu Pro His Met Ile Val 115 120 125 Ser Arg Gln Glu Lys
Gly Lys Ser Leu Leu Phe Lys Thr Lys Asp Gly 130 135 140 Thr Asn Met
Cys Thr Leu Met Ala Met Asp Leu Gly Glu Leu Cys Glu145 150 155 160
Asp Thr Ile Thr Tyr Lys Cys Pro Phe Leu Lys Gln Asn Glu Pro Glu 165
170 175 Asp Ile Asp Cys Trp Cys Asn Ser Thr Ser Thr Trp Val Thr Tyr
Gly 180 185 190 Thr Cys Thr Thr Thr Gly Glu His Arg Arg Glu Lys Arg
Ser Val Ala 195 200 205 Leu Val Pro His Val Gly Met Gly Leu Glu Thr
Arg Thr Glu Thr Trp 210 215 220 Met Ser Ser Glu Gly Ala Trp Lys His
Ala Gln Arg Ile Glu Thr Trp225 230 235 240 Ile Leu Arg His Pro Gly
Phe Thr Ile Met Ala Ala Ile Leu Ala Tyr 245 250 255 Thr Ile Gly Thr
Thr His Phe Gln Arg Val Leu Ile Phe Ile Leu Leu 260 265 270 Thr Ala
Ile Ala Pro Ser Met Thr Met Arg Cys Ile Gly Ile Ser Asn 275 280 285
Arg Asp Phe Val Glu Gly Val Ser Gly Gly Ser Trp Val Asp Ile Val 290
295 300 Leu Glu His Gly Ser Cys Val Thr Thr Met Ala Lys Asn Lys Pro
Thr305 310 315 320 Leu Asp Phe Glu Leu Ile Lys Thr Glu Ala Lys Gln
Pro Ala Thr Leu 325 330 335 Arg Lys Tyr Cys Ile Glu Ala Lys Leu Thr
Asn Thr Thr Thr Asp Ser 340 345 350 Arg Cys Pro Thr Gln Gly Glu Pro
Thr Leu Asn Glu Glu Gln Asp Lys 355 360 365 Arg Phe Val Cys Lys His
Ser Met Val Asp Arg Gly Trp Gly Asn Gly 370 375 380 Cys Gly Leu Phe
Gly Lys Gly Gly Ile Val Thr Cys Ala Met Phe Thr385 390 395 400 Cys
Lys Lys Asn Met Glu Gly Lys Ile Val Gln Pro Glu Asn Leu Glu 405 410
415 Tyr Thr Val Val Ile Thr Pro His Ser Gly Glu Glu His Ala Val Gly
420 425 430 Asn Asp Thr Gly Lys His Gly Lys Glu Val Lys Ile Thr Pro
Gln Ser 435 440 445 Ser Ile Thr Glu Ala Glu Leu Thr Gly Tyr Gly Thr
Val Thr Met Glu 450 455 460 Cys Ser Pro Arg Thr Gly Leu Asp Phe Asn
Glu Met Val Leu Leu Gln465 470 475 480 Met Glu Asp Lys Ala Trp Leu
Val His Arg Gln Trp Phe Leu Asp Leu 485 490 495 Pro Leu Pro Trp Leu
Pro Gly Ala Asp Thr Gln Gly Ser Asn Trp Ile 500 505 510 Gln Lys Glu
Thr Leu Val Thr Phe Lys Asn Pro His Ala Lys Lys Gln 515 520 525 Asp
Val Val Val Leu Gly Ser Gln Glu Gly Ala Met His Thr Ala Leu 530 535
540 Thr Gly Ala Thr Glu Ile Gln Met Ser Ser Gly Asn Leu Leu Phe
Thr545 550 555 560 Gly His Leu Lys Cys Arg Leu Arg Met Asp Lys Leu
Gln Leu Lys Gly 565 570 575 Met Ser Tyr Ser Met Cys Thr Gly Lys Phe
Lys Ile Val Lys Glu Ile 580 585 590 Ala Glu Thr Gln His Gly Thr Ile
Val Ile Arg Val Gln Tyr Glu Gly 595 600 605 Asp Gly Ser Pro Cys Lys
Ile Pro Phe Glu Ile Met Asp Leu Glu Lys 610 615 620 Arg His Val Leu
Gly Arg Leu Ile Thr Val Asn Pro Ile Val Thr Glu625 630 635 640 Lys
Asp Ser Pro Val Asn Ile Glu Ala Glu Pro Pro Phe Gly Asp Ser 645 650
655 Tyr Ile Ile Ile Gly Val Glu Pro Gly Gln Leu Lys Leu Asp Trp Phe
660 665 670 Lys Lys Gly Ser Ser Ile Gly Gln Met Phe Glu Thr Thr Met
Arg Gly 675 680 685 Ala Lys Arg Met Ala Ile Leu Gly Asp Thr Ala Trp
Asp Phe Gly Ser 690 695 700 Leu Gly Gly Val Phe Thr Ser Ile Gly Lys
Ala Leu His Gln Val Phe705 710 715 720 Gly Ala Ile Tyr Gly Ala Ala
Phe Ser Gly Val Ser Trp Thr Met Lys 725 730 735 Ile Leu Ile Gly Val
Ile Ile Thr Trp Ile Gly Met Asn Ser Arg Ser 740 745 750 Thr Ser Leu
Ser Val Ser Leu Val Leu Val Gly Ile Val Thr Leu Tyr 755 760 765 Leu
Gly Val Met Val Gln Ala Asp Ser Gly Cys Val Val Ser Trp Lys 770 775
780 Asn Lys Glu Leu Lys Cys Gly Ser Gly Ile Phe Val Thr Asp Asn
Val785 790 795 800 His Thr Trp Thr Glu Gln Tyr Lys Phe Gln Pro Glu
Ser Pro Ser Lys 805 810 815 Leu Ala Ser Ala Ile Gln Lys Ala His Glu
Glu Gly Ile Cys Gly Ile 820 825 830 Arg Ser Val Thr Arg Leu Glu Asn
Leu Met Trp Lys Gln Ile Thr Ser 835 840 845 Glu Leu Asn His Ile Leu
Ser Glu Asn Glu Val Lys Leu Thr Ile Met 850 855 860 Thr Gly Asp Ile
Lys Gly Ile Met Gln Val Gly Lys Arg Ser Leu Arg865 870 875 880 Pro
Gln Pro Thr Glu Leu Arg Tyr Ser Trp Lys Thr Trp Gly Lys Ala 885 890
895 Lys Met Leu Ser Thr Glu Leu His Asn Gln Thr Phe Leu Ile Asp Gly
900 905 910 Pro Glu Thr Ala Glu Cys Pro Asn Thr Asn Arg Ala Trp Asn
Ser Leu 915 920 925 Glu Val Glu Asp Tyr Gly Phe Gly Val Phe Thr Thr
Asn Ile Trp Leu 930 935 940 Arg Leu Arg Glu Lys Gln Asp Val Phe Cys
Asp Ser Lys Leu Met Ser945 950 955 960 Ala Ala Ile Lys Asp Asn Arg
Ala Val His Ala Asp Met Gly Tyr Trp 965 970 975 Ile Glu Ser Ala Leu
Asn Asp Thr Trp Lys Ile Glu Lys Ala Ser Phe 980 985 990 Ile Glu Val
Lys Ser Cys His Trp Pro Lys Ser His Thr Leu Trp Ser 995 1000 1005
Asn Gly Val Leu Glu Ser Glu Met Val Ile Pro Lys Asn Phe Ala Gly
1010 1015 1020 Pro Val Ser Gln His Asn Asn Arg Pro Gly Tyr Tyr Thr
Gln Thr Ala1025 1030 1035 1040Gly Pro Trp His Leu Gly Lys Leu Glu
Met Asp Phe Asp Phe Cys Glu 1045 1050 1055 Gly Thr Thr Val Val Val
Thr Glu Asn Cys Gly Asn Arg Gly Pro Ser 1060 1065 1070 Leu Arg Thr
Thr Thr Ala Ser Gly Lys Leu Ile Thr Glu Trp Cys Cys 1075 1080 1085
Arg Ser Cys Thr Leu Pro Pro Leu Arg Tyr Arg Gly Glu Asp Gly Cys
1090 1095 1100 Trp Tyr Gly Met Glu Ile Arg Pro Leu Lys Glu Lys Glu
Glu Asn Leu1105 1110 1115 1120Val Ser Ser Leu Val Thr Ala Gly His
Gly Gln Ile Asp Asn Phe Ser 1125 1130 1135 Leu Gly Ile Leu Gly Met
Ala Leu Phe Leu Glu Glu Met Leu Arg Thr 1140 1145 1150 Arg Val Gly
Thr Lys His Ala Ile Leu Leu Val Ala Val Ser Phe Val 1155 1160 1165
Thr Leu Ile Thr Gly Asn Met Ser Phe Arg Asp Leu Gly Arg Val Met
1170 1175 1180 Val Met Val Gly Ala Thr Met Thr Asp Asp Ile Gly Met
Gly Val Thr1185 1190 1195 1200Tyr Leu Ala Leu Leu Ala Ala Phe Arg
Val Arg Pro Thr Phe Ala Ala 1205 1210 1215 Gly Leu Leu Leu Arg Lys
Leu Thr Ser Lys Glu Leu Met Met Thr Thr 1220 1225 1230 Ile Gly Ile
Val Leu Leu Ser Gln Ser Ser Ile Pro Glu Thr Ile Leu 1235 1240 1245
Glu Leu Thr Asp Ala Leu Ala Leu Gly Met Met Val Leu Lys Met Val
1250 1255 1260 Arg Asn Met Glu Lys Tyr Gln Leu Ala Val Thr Ile Met
Ala Ile Leu1265 1270 1275 1280Cys Val Pro Asn Ala Val Ile Leu Gln
Asn Ala Trp Lys Val Ser Cys 1285 1290 1295 Thr Ile Leu Ala Val Val
Ser Val Ser Pro Leu Leu Leu Thr Ser Ser 1300 1305 1310 Gln Gln Lys
Ala Asp Trp Ile Pro Leu Ala Leu Thr Ile Lys Gly Leu 1315 1320 1325
Asn Pro Thr Ala Ile Phe Leu Thr Thr Leu Ser Arg Thr Asn Lys Lys
1330 1335 1340 Arg Ser Trp Pro Leu Asn Glu Ala Ile Met Ala Val Gly
Met Val Ser1345 1350 1355 1360Ile Leu Ala Ser Ser Leu Leu Lys Asn
Asp Ile Pro Met Thr Gly Pro 1365 1370 1375 Leu Val Ala Gly Gly Leu
Leu Thr Val Cys Tyr Val Leu Thr Gly Arg 1380 1385 1390 Ser Ala Asp
Leu Glu Leu Glu Arg Ala Thr Asp Val Lys Trp Asp Asp 1395 1400 1405
Gln Ala Glu Ile Ser Gly Ser Ser Pro Ile Leu Ser Ile Thr Ile Ser
1410 1415 1420 Glu Asp Gly Ser Met Ser Ile Lys Asn Glu Glu Glu Glu
Gln Thr Leu1425 1430 1435 1440Thr Ile Leu Ile Arg Thr Gly Leu Leu
Val Ile Ser Gly Leu Phe Pro 1445 1450 1455 Val Ser Ile Pro Ile Thr
Ala Ala Ala Trp Tyr Leu Trp Glu Val Lys 1460 1465 1470 Lys Gln Arg
Ala Gly Val Leu Trp Asp Val Pro Ser Pro Pro Pro Val 1475 1480 1485
Gly Lys Ala Glu Leu Glu Asp Gly Ala Tyr Arg Ile Lys Gln Lys Gly
1490 1495 1500 Ile Leu Gly Tyr Ser Gln
Ile Gly Ala Gly Val Tyr Lys Glu Gly Thr1505 1510 1515 1520Phe His
Thr Met Trp His Val Thr Arg Gly Ala Val Leu Met His Lys 1525 1530
1535 Gly Lys Arg Ile Glu Pro Ser Trp Ala Asp Val Lys Lys Asp Leu
Ile 1540 1545 1550 Ser Tyr Gly Gly Gly Trp Lys Leu Glu Gly Glu Trp
Lys Glu Gly Glu 1555 1560 1565 Glu Val Gln Val Leu Ala Leu Glu Pro
Gly Lys Asn Pro Arg Ala Val 1570 1575 1580 Gln Thr Lys Pro Gly Leu
Phe Arg Thr Asn Thr Gly Thr Ile Gly Ala1585 1590 1595 1600Val Ser
Leu Asp Phe Ser Pro Gly Thr Ser Gly Ser Pro Ile Val Asp 1605 1610
1615 Lys Lys Gly Lys Val Val Gly Leu Tyr Gly Asn Gly Val Val Thr
Arg 1620 1625 1630 Ser Gly Ala Tyr Val Ser Ala Ile Ala Gln Thr Glu
Lys Ser Ile Glu 1635 1640 1645 Asp Asn Pro Glu Ile Glu Asp Asp Ile
Phe Arg Lys Arg Arg Leu Thr 1650 1655 1660 Ile Met Asp Leu His Pro
Gly Ala Gly Lys Thr Lys Arg Tyr Leu Pro1665 1670 1675 1680Ala Ile
Val Arg Glu Ala Ile Lys Arg Gly Leu Arg Thr Leu Ile Leu 1685 1690
1695 Ala Pro Thr Arg Val Val Ala Ala Glu Met Glu Glu Ala Leu Arg
Gly 1700 1705 1710 Leu Pro Ile Arg Tyr Gln Thr Pro Ala Ile Arg Ala
Glu His Thr Gly 1715 1720 1725 Arg Glu Ile Val Asp Leu Met Cys His
Ala Thr Phe Thr Met Arg Leu 1730 1735 1740 Leu Ser Pro Ile Arg Val
Pro Asn Tyr Asn Leu Ile Ile Met Asp Glu1745 1750 1755 1760Ala His
Phe Thr Asp Pro Ala Ser Ile Ala Ala Arg Gly Tyr Ile Ser 1765 1770
1775 Thr Arg Val Glu Met Gly Glu Ala Ala Gly Ile Phe Met Thr Ala
Thr 1780 1785 1790 Pro Pro Gly Ser Arg Asp Pro Phe Pro Gln Ser Asn
Ala Pro Ile Met 1795 1800 1805 Asp Glu Glu Arg Glu Ile Pro Glu Arg
Ser Trp Asn Ser Gly His Glu 1810 1815 1820 Trp Val Thr Asp Phe Lys
Gly Lys Thr Val Trp Phe Val Pro Ser Ile1825 1830 1835 1840Lys Thr
Gly Asn Asp Ile Ala Ala Cys Leu Arg Lys Asn Gly Lys Arg 1845 1850
1855 Val Ile Gln Leu Ser Arg Lys Thr Phe Asp Ser Glu Tyr Val Lys
Thr 1860 1865 1870 Arg Thr Asn Asp Trp Asp Phe Val Val Thr Thr Asp
Ile Ser Glu Met 1875 1880 1885 Gly Ala Asn Phe Lys Ala Glu Arg Val
Ile Asp Pro Arg Arg Cys Met 1890 1895 1900 Lys Pro Val Ile Leu Thr
Asp Gly Glu Glu Arg Val Ile Leu Ala Gly1905 1910 1915 1920Pro Met
Pro Val Thr His Ser Ser Ala Ala Gln Arg Arg Gly Arg Ile 1925 1930
1935 Gly Arg Asn Pro Arg Asn Glu Asn Asp Gln Tyr Ile Tyr Met Gly
Glu 1940 1945 1950 Pro Leu Glu Asn Asp Glu Asp Cys Ala His Trp Lys
Glu Ala Lys Met 1955 1960 1965 Leu Leu Asp Asn Ile Asn Thr Pro Glu
Gly Ile Ile Pro Ser Leu Phe 1970 1975 1980 Glu Pro Glu Arg Glu Lys
Val Asp Ala Ile Asp Gly Glu Tyr Arg Leu1985 1990 1995 2000Arg Gly
Glu Ala Arg Lys Thr Phe Val Asp Leu Met Arg Arg Gly Asp 2005 2010
2015 Leu Pro Val Trp Leu Ala Tyr Lys Val Ala Ala Glu Gly Ile Asn
Tyr 2020 2025 2030 Ala Asp Arg Arg Trp Cys Phe Asp Gly Thr Arg Asn
Asn Gln Ile Leu 2035 2040 2045 Glu Glu Asn Val Glu Val Glu Ile Trp
Thr Lys Glu Gly Glu Arg Lys 2050 2055 2060 Lys Leu Lys Pro Arg Trp
Leu Asp Ala Arg Ile Tyr Ser Asp Pro Leu2065 2070 2075 2080Ala Leu
Lys Glu Phe Lys Glu Phe Ala Ala Gly Arg Lys Ser Leu Thr 2085 2090
2095 Leu Asn Leu Ile Thr Glu Met Gly Arg Leu Pro Thr Phe Met Thr
Gln 2100 2105 2110 Lys Ala Arg Asp Ala Leu Asp Asn Leu Ala Val Leu
His Thr Ala Glu 2115 2120 2125 Ala Gly Gly Lys Ala Tyr Asn His Ala
Leu Ser Glu Leu Pro Glu Thr 2130 2135 2140 Leu Glu Thr Leu Leu Leu
Leu Thr Leu Leu Ala Thr Val Thr Gly Gly2145 2150 2155 2160Ile Phe
Leu Phe Leu Met Ser Gly Arg Gly Met Gly Lys Met Thr Leu 2165 2170
2175 Gly Met Cys Cys Ile Ile Thr Ala Ser Ile Leu Leu Trp Tyr Ala
Gln 2180 2185 2190 Ile Gln Pro His Trp Ile Ala Ala Ser Ile Ile Leu
Glu Phe Phe Leu 2195 2200 2205 Ile Val Leu Leu Ile Pro Glu Pro Glu
Lys Gln Arg Thr Pro Gln Asp 2210 2215 2220 Asn Gln Leu Thr Tyr Val
Ile Ile Ala Ile Leu Thr Val Val Ala Ala2225 2230 2235 2240Thr Met
Ala Asn Glu Met Gly Phe Leu Glu Lys Thr Lys Lys Asp Leu 2245 2250
2255 Gly Leu Gly Asn Ile Ala Thr Gln Gln Pro Glu Ser Asn Ile Leu
Asp 2260 2265 2270 Ile Asp Leu Arg Pro Ala Ser Ala Trp Thr Leu Tyr
Ala Val Ala Thr 2275 2280 2285 Thr Phe Ile Thr Pro Met Leu Arg His
Ser Ile Glu Asn Ser Ser Val 2290 2295 2300 Asn Val Ser Leu Thr Ala
Ile Ala Asn Gln Ala Thr Val Leu Met Gly2305 2310 2315 2320Leu Gly
Lys Gly Trp Pro Leu Ser Lys Met Asp Ile Gly Val Pro Leu 2325 2330
2335 Leu Ala Ile Gly Cys Tyr Ser Gln Val Asn Pro Ile Thr Leu Thr
Ala 2340 2345 2350 Ala Leu Leu Leu Leu Val Ala His Tyr Ala Ile Ile
Gly Pro Gly Leu 2355 2360 2365 Gln Ala Lys Ala Thr Arg Glu Ala Gln
Lys Arg Ala Ala Ala Gly Ile 2370 2375 2380 Met Lys Asn Pro Thr Val
Asp Gly Ile Thr Val Ile Asp Leu Asp Pro2385 2390 2395 2400Ile Pro
Tyr Asp Pro Lys Phe Glu Lys Gln Leu Gly Gln Val Met Leu 2405 2410
2415 Leu Val Leu Cys Val Thr Gln Val Leu Met Met Arg Thr Thr Trp
Ala 2420 2425 2430 Leu Cys Glu Ala Leu Thr Leu Ala Thr Gly Pro Val
Ser Thr Leu Trp 2435 2440 2445 Glu Gly Asn Pro Gly Arg Phe Trp Asn
Thr Thr Ile Ala Val Ser Met 2450 2455 2460 Ala Asn Ile Phe Arg Gly
Ser Tyr Leu Ala Gly Ala Gly Leu Leu Phe2465 2470 2475 2480Ser Ile
Met Lys Asn Thr Thr Ser Thr Arg Arg Gly Thr Gly Asn Ile 2485 2490
2495 Gly Glu Thr Leu Gly Glu Lys Trp Lys Ser Arg Leu Asn Ala Leu
Gly 2500 2505 2510 Lys Ser Glu Phe Gln Ile Tyr Lys Lys Ser Gly Ile
Gln Glu Val Asp 2515 2520 2525 Arg Thr Leu Ala Lys Glu Gly Ile Lys
Arg Gly Glu Thr Asp His His 2530 2535 2540 Ala Val Ser Arg Gly Ser
Ala Lys Leu Arg Trp Phe Val Glu Arg Asn2545 2550 2555 2560Leu Val
Thr Pro Glu Gly Lys Val Val Asp Leu Gly Cys Gly Arg Gly 2565 2570
2575 Gly Trp Ser Tyr Tyr Cys Gly Gly Leu Lys Asn Val Arg Glu Val
Lys 2580 2585 2590 Gly Leu Thr Lys Gly Gly Pro Gly His Glu Glu Pro
Ile Pro Met Ser 2595 2600 2605 Thr Tyr Gly Trp Asn Leu Val Arg Leu
Gln Ser Gly Val Asp Val Phe 2610 2615 2620 Phe Val Pro Pro Glu Lys
Cys Asp Thr Leu Leu Cys Asp Ile Gly Glu2625 2630 2635 2640Ser Ser
Pro Asn Pro Thr Val Glu Ala Gly Arg Thr Leu Arg Val Leu 2645 2650
2655 Asn Leu Val Glu Asn Trp Leu Asn Asn Asn Thr Gln Phe Cys Val
Lys 2660 2665 2670 Val Leu Asn Pro Tyr Met Pro Ser Val Ile Glu Arg
Met Glu Thr Leu 2675 2680 2685 Gln Arg Lys Tyr Gly Gly Ala Leu Val
Arg Asn Pro Leu Ser Arg Asn 2690 2695 2700 Ser Thr His Glu Met Tyr
Trp Val Ser Asn Ala Ser Gly Asn Ile Val2705 2710 2715 2720Ser Ser
Val Asn Met Ile Ser Arg Met Leu Ile Asn Arg Phe Thr Met 2725 2730
2735 Arg His Lys Lys Ala Thr Tyr Glu Pro Asp Val Asp Leu Gly Ser
Gly 2740 2745 2750 Thr Arg Asn Ile Gly Ile Glu Ser Glu Thr Pro Asn
Leu Asp Ile Ile 2755 2760 2765 Gly Lys Arg Ile Glu Lys Ile Lys Gln
Glu His Glu Thr Ser Trp His 2770 2775 2780 Tyr Asp Gln Asp His Pro
Tyr Lys Thr Trp Ala Tyr His Gly Ser Tyr2785 2790 2795 2800Glu Thr
Lys Gln Thr Gly Ser Ala Ser Ser Met Val Asn Gly Val Val 2805 2810
2815 Arg Leu Leu Thr Lys Pro Trp Asp Val Val Pro Met Val Thr Gln
Met 2820 2825 2830 Ala Met Thr Asp Thr Thr Pro Phe Gly Gln Gln Arg
Val Phe Lys Glu 2835 2840 2845 Lys Val Asp Thr Arg Thr Gln Glu Pro
Lys Glu Gly Thr Lys Lys Leu 2850 2855 2860 Met Lys Ile Thr Ala Glu
Trp Leu Trp Lys Glu Leu Gly Lys Lys Lys2865 2870 2875 2880Thr Pro
Arg Met Cys Thr Arg Glu Glu Phe Thr Lys Lys Val Arg Ser 2885 2890
2895 Asn Ala Ala Leu Gly Ala Ile Phe Thr Asp Glu Asn Lys Trp Lys
Ser 2900 2905 2910 Ala Arg Glu Ala Val Glu Asp Ser Arg Phe Trp Glu
Leu Val Asp Lys 2915 2920 2925 Glu Arg Asn Leu His Leu Glu Gly Lys
Cys Glu Thr Cys Val Tyr Asn 2930 2935 2940 Met Met Gly Lys Arg Glu
Lys Lys Leu Gly Glu Phe Gly Lys Ala Lys2945 2950 2955 2960Gly Ser
Arg Ala Ile Trp Tyr Met Trp Leu Gly Ala Arg Phe Leu Glu 2965 2970
2975 Phe Glu Ala Leu Gly Phe Leu Asn Glu Asp His Trp Phe Ser Arg
Glu 2980 2985 2990 Asn Ser Leu Ser Gly Val Glu Gly Glu Gly Leu His
Lys Leu Gly Tyr 2995 3000 3005 Ile Leu Arg Glu Val Ser Lys Lys Glu
Gly Gly Ala Met Tyr Ala Asp 3010 3015 3020 Asp Thr Ala Gly Trp Asp
Thr Arg Ile Thr Ile Glu Asp Leu Lys Asn3025 3030 3035 3040Glu Glu
Met Ile Thr Asn His Met Ala Gly Glu His Lys Lys Leu Ala 3045 3050
3055 Glu Ala Ile Phe Lys Leu Thr Tyr Gln Asn Lys Val Val Arg Val
Gln 3060 3065 3070 Arg Pro Thr Pro Arg Gly Thr Val Met Asp Ile Ile
Ser Arg Arg Asp 3075 3080 3085 Gln Arg Gly Ser Gly Gln Val Gly Thr
Tyr Gly Leu Asn Thr Phe Thr 3090 3095 3100 Asn Met Glu Ala Gln Leu
Ile Arg Gln Met Glu Gly Glu Gly Ile Phe3105 3110 3115 3120Lys Ser
Ile Gln His Leu Thr Ala Ser Glu Glu Ile Ala Val Gln Asp 3125 3130
3135 Trp Leu Val Arg Val Gly Arg Glu Arg Leu Ser Arg Met Ala Ile
Ser 3140 3145 3150 Gly Asp Asp Cys Val Val Lys Pro Leu Asp Asp Arg
Phe Ala Arg Ala 3155 3160 3165 Leu Thr Ala Leu Asn Asp Met Gly Lys
Val Arg Lys Asp Ile Gln Gln 3170 3175 3180 Trp Glu Pro Ser Arg Gly
Trp Asn Asp Trp Thr Gln Val Pro Phe Cys3185 3190 3195 3200Ser His
His Phe His Glu Leu Ile Met Lys Asp Gly Arg Thr Leu Val 3205 3210
3215 Val Pro Cys Arg Asn Gln Asp Glu Leu Ile Gly Arg Ala Arg Ile
Ser 3220 3225 3230 Gln Gly Ala Gly Trp Ser Leu Arg Glu Thr Ala Cys
Leu Gly Lys Ser 3235 3240 3245 Tyr Ala Gln Met Trp Ser Leu Met Tyr
Phe His Arg Arg Asp Leu Arg 3250 3255 3260 Leu Ala Ala Asn Ala Ile
Cys Ser Ala Val Pro Ser His Trp Ile Pro3265 3270 3275 3280Thr Ser
Arg Thr Thr Trp Ser Ile His Ala Ser His Glu Trp Met Thr 3285 3290
3295 Thr Glu Asp Met Leu Thr Val Trp Asn Arg Val Trp Ile Leu Glu
Asn 3300 3305 3310 Pro Trp Met Glu Asp Lys Thr Pro Val Glu Ser Trp
Glu Glu Ile Pro 3315 3320 3325 Tyr Leu Gly Lys Arg Glu Asp Gln Trp
Cys Gly Ser Leu Ile Gly Leu 3330 3335 3340 Thr Ser Arg Ala Thr Trp
Ala Lys Asn Ile Gln Thr Ala Ile Asn Gln3345 3350 3355 3360Val Arg
Ser Leu Ile Gly Asn Glu Glu Tyr Thr Asp Tyr Met Pro Ser 3365 3370
3375 Met Lys Arg Phe Arg Arg Glu Glu Glu Glu Ala Gly Val Leu Trp
3380 3385 3390 4815153DNAArtificial SequenceDengue 3 plasmid p3
48agttgttagt ctacgtggac cgacaagaac agtttcgact cggaagcttg cttaacgtag
60tactgacagt tttttattag agagcagatc tctgatgaac aaccaacgga aaaagacggg
120aaaaccgtct atcaatatgc tgaaacgcgt gagaaaccgt gtgtcaactg
gatcacagtt 180ggcgaagaga ttctcaagag gactgctgaa cggccaagga
ccaatgaaat tggttatggc 240gttcatagct ttcctcagat ttctagccat
tccaccgaca gcaggagtct tggctagatg 300gggaaccttt aagaagtcgg
gggctattaa ggtcctgaga ggcttcaaga aggagatctc 360aaacatgctg
agcattatca acagacggaa aaagacatcg ctctgtctca tgatgatgtt
420accagcaaca cttgctttcc acttgacttc acgagatgga gagccgcgca
tgattgtggg 480gaagaatgaa agaggaaaat ccctactttt taagacagcc
tctggaatca acatgtgcac 540actcatagcc atggatttgg gagagatgtg
tgatgacacg gtcacctaca aatgccccct 600cattactgaa gtggagcctg
aagacattga ctgctggtgc aaccttacat cgacatgggt 660gacctacgga
acgtgcaatc aagctggaga gcacagacgc gacaaaagat cggtggcgtt
720agctccccat gtcggcatgg gactggacac acgcacccaa acctggatgt
cggctgaagg 780agcttggaga caggtcgaga aggtagagac atgggccttt
aggcacccag ggttcacaat 840actagcccta tttcttgccc attacatagg
cacttccttg acccagaaag tggttatttt 900catactacta atgctggtca
ccccatccat gacaatgaga tgcgtgggag taggaaacag 960agattttgtg
gaaggcctat caggagctac gtgggttgac gtggtgctcg agcacggtgg
1020gtgtgtgact accatggcta agaacaagcc cacgctggat atagagctcc
agaagaccga 1080ggccacccaa ctggcgaccc taaggaaact atgtattgag
ggaaaaatta ccaacgtaac 1140aaccgactca aggtgcccca cccaagggga
agcgatttta cctgaggagc aggaccagaa 1200ccacgtgtgc aagcacacat
acgtggacag aggctgggga aacggttgtg gtttgtttgg 1260caagggaagc
ctggtaacat gcgcgaaatt tcaatgtttg gaatcaatag agggaaaagt
1320ggtgcagcat gagaacctca aatacaccgt catcatcaca gtgcacacag
gagatcaaca 1380ccaggtggga aatgaaacgc agggagtcac ggctgagata
acaccccagg catcaaccgt 1440tgaagccatc ttacctgaat atggaaccct
tgggctagaa tgctcaccac ggacaggttt 1500agatttcaat gaaatgattt
tgttgacaat gaagaacaaa gcatggatgg tacatagaca 1560atggtttttt
gacctacctt taccatggac atcaggagct acaacagaaa caccaacctg
1620gaataagaaa gagcttcttg tgacattcaa aaacgcacat gcaaaaaagc
aagaagtagt 1680agtccttgga tcgcaagagg gagcaatgca cacagcactg
acaggagcta cagagatcca 1740aacctcagga ggcacaagta tttttgcggg
gcacttaaaa tgtagactca agatggacaa 1800attggaactc aaggggatga
gctatgcaat gtgcttgaat gcctttgtgt tgaagaaaga 1860agtctccgaa
acgcaacatg ggacaatact catcaaggtt gagtacaaag gggaagatgc
1920accttgcaag attcctttct ccacggagga tggacaaggg aaagcccaca
atggcagact 1980gatcacagct aacccagtgg tgaccaagaa ggaggagcct
gtcaatattg aggcagaacc 2040tccttttggg gaaagcaata tagtaattgg
aattggagac aaagccttga aaatcaactg 2100gtacaagaag ggaagctcga
ttgggaagat gttcgaggcc actgccagag gtgcaaggcg 2160catggccatc
ttgggagaca cagcctggga ctttggatca gtaggtggtg ttttaaattc
2220attaggaaaa atggtgcacc aaatatttgg aagtgcttac acagccctat
ttagtggagt 2280ctcctggata atgaaaattg gaataggtgt ccttttaacc
tggatagggt tgaattcaaa 2340aaacactagt atgagcttta gctgcattgt
gataggaatc attacactct atctgggagc 2400cgtggtgcaa gctgacatgg
ggtgtgtcat aaactggaaa ggcaaagaac tcaaatgtgg 2460aagtggaatt
ttcgtcacta atgaggtcca cacctggaca gagcaataca aatttcaagc
2520agactccccc aaaagactgg cgacagccat tgcaggcgct tgggagaatg
gagtgtgcgg 2580aatcaggtcg acaaccagaa tggagaacct cttgtggaag
caaatagcca atgaactgaa 2640ctacatatta tgggaaaaca acatcaaatt
aacggtagtt gtgggtgata taattggggt 2700cttagagcaa gggaaaagaa
cactaacacc acaacccatg gaactaaaat attcatggaa 2760aacatgggga
aaggcgaaga tagtgacagc tgaaacacaa aattcctctt tcataataga
2820tgggccaaac acaccagagt gtccaagtgc ctcaagagca tggaatgtgt
gggaggtgga 2880agattacggg ttcggagtct tcacaactaa catatggctg
aaactccgag agatgtacac 2940ccaactatgt gaccacaggc taatgtcggc
agccgttaag gatgagaggg ccgtacacgc 3000cgacatgggc tattggatag
aaagccaaaa gaatggaagt tggaagctag aaaaggcatc 3060cctcatagag
gtaaaaacct gcacatggcc aaaatcacac actctttgga gcaatggtgt
3120gctagagagt gacatgatca tcccaaagag tctggctggt cccatttcgc
aacacaacta 3180caggcccgga taccacaccc aaacggcagg accctggcac
ttaggaaaat tggagctgga 3240cttcaactat tgtgaaggaa caacagttgt
catcacagaa aattgtggga caagaggccc 3300atcactgaga acaacaacag
tgtcagggaa gttgatacac gaatggtgtt gccgctcgtg 3360tacacttcct
cccctgcgat acatgggaga agacggctgc tggtatggca tggaaattag
3420acccattaat gagaaagaag agaacatggt aaagtcttta gtctcagcag
ggagtggaaa 3480ggtggataac ttcacaatgg gtgtcttgtg tttggcaatc
ctttttgaag aggtgatgag 3540aggaaaattt gggaaaaagc acatgattgc
aggggttctc ttcacgtttg tactccttct 3600ctcagggcaa ataacatgga
gagacatggc gcacacactc ataatgattg ggtccaacgc 3660ctctgacaga
atgggaatgg gcgtcactta cctagcattg attgcaacat ttaaaattca
3720gccatttttg gctttgggat tcttcctgag gaaactgaca tctagagaaa
atttattgtt 3780gggagttggg ttggccatgg caacaacgtt acaactgcca
gaggacattg aacaaatggc 3840gaatggaata gctttagggc tcatggctct
taaattaata acacaatttg aaacatacca 3900actatggacg gcattagtct
ccctaatgtg ttcaaataca attttcacgt tgactgttgc 3960ctggagaaca
gccaccctga ttttggccgg aatttctctt ttgccagtgt gccagtcttc
4020gagcatgagg aaaacagatt ggctcccaat ggctgtggca gctatgggag
ttccacccct 4080accacttttt attttcagtt tgaaagatac gctcaaaagg
agaagctggc cactgaatga 4140gggggtgatg gctgttggac ttgtgagtat
tctagctagt tctctcctta ggaatgacgt 4200gcccatggct ggaccattag
tggctggggg cttgctgata gcgtgctacg tcataactgg 4260cacgtcagca
gacctcactg tagaaaaagc agcagatgtg acatgggagg aagaggctga
4320gcaaacagga gtgtcccaca atttaatgat cacagttgat gacgatggaa
caatgagaat 4380aaaagatgat gagactgaga acatcttaac agtgcttttg
aaaacagcat tactaatagt 4440gtcaggcatt tttccatact ccatacccgc
aacactgttg gtctggcaca cttggcaaaa 4500gcaaacccaa agatccggtg
tcctatggga cgttcccagc cccccagaga cacagaaagc 4560agaactggaa
gaaggggttt ataggatcaa gcagcaagga atttttggga aaacccaagt
4620gggggttgga gtacaaaaag aaggagtttt ccacaccatg tggcacgtca
caagaggagc 4680agtgttgaca cacaatggga aaagactgga accaaactgg
gctagcgtga aaaaagatct 4740gatttcatac ggaggaggat ggaaattgag
tgcacaatgg caaaaaggag aggaggtgca 4800ggttattgcc gtagagcctg
ggaagaaccc aaagaacttt caaaccatgc caggcatttt 4860ccagacaaca
acaggggaga taggagcgat tgcactggac ttcaagcctg gaacttcagg
4920atctcccatc ataaacagag agggaaaggt actgggattg tatggcaatg
gagtggtcac 4980aaagaatggt ggctatgtca gtggaatagc acaaacaaat
gcagaaccag acggaccgac 5040accagagttg gaagaagaga tgttcaaaaa
gcgaaatcta accataatgg atctccatcc 5100cgggtcagga aagacgcgga
aatatcttcc agctattgtt agagaggcaa tcaagagacg 5160cttaaggact
ctaattttgg caccaacaag ggtagttgca gctgagatgg aagaagcatt
5220gaaagggctc ccaataaggt atcaaacaac tgcaacaaaa tctgaacaca
cagggagaga 5280gattgttgat ctaatgtgcc acgcaacgtt cacaatgcgt
ttgctgtcac cagtcagggt 5340tccaaactac aacttgataa taatggatga
ggctcatttc acagacccag ccagtatagc 5400ggctagaggg tacatatcaa
ctcgtgtagg aatgggagag gcagccgcaa ttttcatgac 5460agccacaccc
cctggaacag ctgatgcctt tcctcagagc aacgctccaa ttcaagatga
5520agaaagagac ataccagaac gctcatggaa ttcaggcaat gaatggatta
ccgactttgc 5580cgggaagacg gtgtggtttg tccctagcat caaagctgga
aatgacatag caaactgctt 5640gcggaaaaat ggaaaaaagg tcattcaact
tagtaggaag acttttgaca cagaatatca 5700aaagactaaa ctaaatgatt
gggactttgt ggtgacaaca gacatttcag aaatgggagc 5760caatttcaaa
gcagacagag tgatcgaccc aagaagatgt ctcaagccag tgattttgac
5820agacggaccc gagcgcgtga tcctggcggg accaatgcca gtcaccgtag
cgagcgctgc 5880gcaaaggaga gggagagttg gcaggaaccc acaaaaagaa
aatgaccaat acatattcat 5940gggccagccc ctcaataatg atgaagacca
tgctcactgg acagaagcaa aaatgctgct 6000agacaacatc aacacaccag
aagggatcat accagctctc tttgaaccag aaagggagaa 6060gtcagccgcc
atagacggcg aataccgcct gaagggtgag tccaggaaga ccttcgtgga
6120actcatgagg aggggtgacc tcccagtttg gctagcccat aaagtagcat
cagaagggat 6180caaatataca gatagaaagt ggtgttttga tggagaacgc
aacaatcaaa ttttagagga 6240gaatatggat gtggaaatct ggacaaagga
aggagaaaag aaaaaattga gacctaggtg 6300gcttgatgcc cgcacttatt
cagatccctt agcgctcaag gaattcaagg actttgcggc 6360tggtagaaag
tcaattgccc ttgatcttgt gacagaaata ggaagagtgc cttcacactt
6420agctcacaga acgagaaacg ccctggacaa tctggtgatg ttgcacacgt
cagaacatgg 6480cgggagggcc tacaggcatg cagtggagga actaccagaa
acaatggaaa cactcttact 6540cctgggactc atgatcctgt taacaggtgg
agcaatgctt ttcttgatat caggtaaagg 6600gattggaaag acttcaatag
gactcatttg tgtagctgct tccagcggta tgttatggat 6660ggctgatgtc
ccactccaat ggatcgcgtc tgccatagtc ctggagtttt ttatgatggt
6720gttacttata ccagaaccag aaaagcagag aactccccaa gacaatcaac
tcgcatatgt 6780cgtgataggc atactcacac tggctgcaat agtagcagcc
aatgaaatgg gactgttgga 6840aaccacaaag agagatttag gaatgtccaa
agaaccaggt gttgtttctc caaccagcta 6900tttggatgtg gacttgcacc
cagcatcagc ctggacattg tacgctgtgg ccacaacagt 6960aataacacca
atgttgagac ataccataga gaattccaca gcaaatgtgt ccctggcagc
7020tatagccaac caggcagtgg tcctgatggg tttagacaaa ggatggccga
tatcgaaaat 7080ggacttaggc gtgccactat tggcactggg ttgttattca
caagtgaacc cactaactct 7140cacagcggca gttctcctgc tagtcacgca
ttatgctatt ataggtccag gattgcaggc 7200aaaagccact cgtgaagctc
aaaaaaggac agctgctgga ataatgaaga atccaacggt 7260ggatgggata
atgacaatag acctagatcc tgtaatatac gattcaaaat ttgaaaagca
7320actaggacag gttatgctcc tggttctgtg tgcagttcaa cttttgttaa
tgagaacatc 7380atgggctttt tgtgaagctc taaccctagc cacaggacca
ataacaacac tctgggaagg 7440atcacctggg aagttctgga acaccacgat
agctgtttcc atggcgaaca tctttagagg 7500gagctattta gcaggagctg
ggcttgcttt ttctatcatg aaatcagttg gaacaggaaa 7560gagagggaca
gggtcacagg gtgaaacctt gggagaaaag tggaaaaaga aattgaatca
7620attaccccgg aaagagtttg acctttacaa gaaatccgga atcactgaag
tggatagaac 7680agaagccaaa gaagggttga aaagaggaga aataacacac
catgccgtgt ccagaggcag 7740cgcaaaactt caatggttcg tggagagaaa
catggtcatc cccgaaggaa gagtcataga 7800cttaggctgt ggaagaggag
gctggtcata ttattgtgca ggactgaaaa aagttacaga 7860agtgcgagga
tacacaaaag gcggcccagg acatgaagaa ccagtaccta tgtctacata
7920cggatggaac atagtcaagt taatgagtgg aaaggatgtg ttttatcttc
cacctgaaaa 7980gtgtgatact ctattgtgtg acattggaga atcttcacca
agcccaacag tggaagaaag 8040cagaaccata agagtcttga agatggttga
accatggcta aaaaataacc agttttgcat 8100taaagtattg aacccttaca
tgccaactgt gattgagcac ctagaaagac tacaaaggaa 8160acatggagga
atgcttgtga gaaatccact ctcacgaaac tccacgcacg aaatgtactg
8220gatatctaat ggcacaggca atatcgtttc ttcagtcaac atggtatcca
gattgctact 8280taacagattc acaatgacac ataggagacc caccatagag
aaagatgtgg atttaggagc 8340ggggacccga catgtcaatg cggaaccaga
aacacccaac atggatgtca ttggggaaag 8400aataagaagg atcaaggagg
agcatagttc aacatggcac tatgatgatg aaaatcctta 8460taaaacgtgg
gcttaccatg gatcctatga agttaaggcc acaggctcag cctcctccat
8520gataaatgga gtcgtgaaac tcctcacgaa accatgggat gtggtgccca
tggtgacaca 8580gatggcaatg acggatacaa ccccattcgg ccagcaaagg
gtttttaaag agaaagtgga 8640caccaggaca cccagaccta tgccaggaac
aagaaaggtt atggagatca cagcggaatg 8700gctttggaga accctgggaa
ggaacaaaag acccagatta tgtacgagag aggagttcac 8760aaaaaaggtc
agaaccaacg cagctatggg cgccgttttt acagaggaga accaatggga
8820cagtgctaga gctgctgttg aggatgaaga attctggaaa ctcgtggaca
gagaacgtga 8880actccacaaa ttgggcaagt gtggaagctg cgtttacaac
atgatgggca agagagagaa 8940gaaacttgga gagtttggca aagcaaaagg
cagtagagcc atatggtaca tgtggttggg 9000agccagatac cttgagttcg
aagcactcgg attcttaaat gaagaccatt ggttctcgcg 9060tgaaaactct
tacagtggag tagaaggaga aggactgcac aagctgggat acatcttaag
9120agacatttcc aagatacccg gaggagctat gtatgctgat gacacagctg
gttgggacac 9180aagaataaca gaagatgacc tgcacaatga ggaaaaaatc
acacagcaaa tggaccctga 9240acacaggcag ttagcaaacg ctatattcaa
gctcacatac caaaacaaag tggtcaaagt 9300tcaacgacca actccaaagg
gcacggtaat ggacatcata tctaggaaag accaaagagg 9360cagtggacag
gtgggaactt atggtctgaa tacattcacc aacatggaag cccagttaat
9420cagacaaatg gaaggagaag gtgtgttgtc gaaggcagac ctcgagaacc
ctcatctgct 9480agagaagaaa gttacacaat ggttggaaac aaaaggagtg
gagaggttaa aaagaatggc 9540catcagcggg gatgattgcg tggtgaaacc
aattgatgac aggttcgcca atgccctgct 9600tgccctgaat gacatgggaa
aagttaggaa ggacatacct caatggcagc catcaaaggg 9660atggcatgat
tggcaacagg tccctttctg ctcccaccac tttcatgaat tgatcatgaa
9720agatggaaga aagttggtag ttccctgcag acctcaggat gaattaatcg
ggagagcgag 9780aatctctcaa ggagcaggat ggagccttag agaaactgca
tgcctaggga aagcctacgc 9840ccaaatgtgg actctcatgt actttcacag
aagagatctt agactagcat ccaacgccat 9900atgttcagca gtaccagtcc
attgggtccc cacaagcaga acgacgtggt ctattcatgc 9960tcaccatcag
tggatgacta cagaagacat gcttactgtt tggaacaggg tgtggataga
10020ggataatcca tggatggaag acaaaactcc agtcaaaacc tgggaagatg
ttccatatct 10080agggaagaga gaagaccaat ggtgcggatc actcattggt
ctcacttcca gagcaacctg 10140ggcccagaac atacttacgg caatccaaca
ggtgagaagc cttataggca atgaagagtt 10200tctggactac atgccttcga
tgaagagatt caggaaggag gaggagtcag agggagccat 10260ttggtaaacg
taggaagtga aaaagaggca aactgtcagg ccaccttaag ccacagtacg
10320gaagaagctg tgcagcctgt gagccccgtc caaggacgtt aaaagaagaa
gtcaggccca 10380aaagccacgg tttgagcaaa ccgtgctgcc tgtggctccg
tcgtggggac gtaaaacctg 10440ggaggctgca aactgtggaa gctgtacgca
cggtgtagca gactagcggt tagaggagac 10500ccctcccatg acacaacgca
gcagcggggc ccgagctctg agggaagctg tacctccttg 10560caaaggacta
gaggttagag gagacccccc gcaaataaaa acagcatatt gacgctggga
10620gagaccagag atcctgctgt ctcctcagca tcattccagg cacagaacgc
cagaaaatgg 10680aatggtgctg ttgaatcaac aggttctggt accggtaggc
atcgtggtgt cacgctcgtc 10740gtttggtatg gcttcattca gctccggttc
ccaacgatca aggcgagtta catgatcccc 10800catgttgtgc aaaaaagcgg
ttagctcctt cggtcctccg atcgttgtca gaagtaagtt 10860ggccgcagtg
ttatcactca tggttatggc agcactgcat aattctctta ctgtcatgcc
10920atccgtaaga tgcttttctg tgactggtga gtactcaacc aagtcattct
gagaatagtg 10980tatgcggcga ccgagttgct cttgcccggc gtcaacacgg
gataataccg cgccacatag 11040cagaacttta aaagtgctca tcattggaaa
acgttcttcg gggcgaaaac tctcaaggat 11100cttaccgctg ttgagatcca
gttcgatgta acccactcgt gcacccaact gatcttcagc 11160atcttttact
ttcaccagcg tttctgggtg agcaaaaaca ggaaggcaaa atgccgcaaa
11220aaagggaata agggcgacac ggaaatgttg aatactcata ctcttccttt
ttcaatatta 11280ttgaagcatt tatcagggtt attgtctcat gagcggatac
atatttgaat gtatttagaa 11340aaataaacaa ataggggttc cgcgcacatt
tccccgaaaa gtgccacctg acgtctaaga 11400aaccattatt atcatgacat
taacctataa aaataggcgt atcacgaggc cctttcgtct 11460tcaagaattc
tcatgtttga cagcttatca tcgataagct ttaatgcggt agtttatcac
11520agttaaattg ctaacgcagt caggcaccgt gtatgaaatc taacaatgcg
ctcatcgtca 11580tcctcggcac cgtcaccctg gatgctgtag gcataggctt
ggttatgccg gtactgccgg 11640gcctcttgcg ggatatcgtc cattccgaca
gcatcgccag tcactatggc gtgctgctgg 11700cgctatatgc gttgatgcaa
tttctatgcg cacccgttct cggagcactg tccgaccgct 11760ttggccgccg
cccagtcctg ctcgcttcgc tacttggagc cactatcgac tacgcgatca
11820tggcgaccac acccgtcctg tggatcctct acgccggacg catcgtggcc
ggcatcaccg 11880gcgccacagg tgcggttgct ggcgcctata tcgccgacat
caccgatggg gaagatcggg 11940ctcgccactt cgggctcatg agcgcttgtt
tcggcgtggg tatggtggca ggccccgtgg 12000ccgggggact gttgggcgcc
atctccttgc atgcaccatt ccttgcggcg gcggtgctca 12060acggcctcaa
cctactactg ggctgcttcc taatgcagga gtcgcataag ggagagcgtc
12120gaccgatgcc cttgagagcc ttcaacccag tcagctcctt ccggtgggcg
cggggcatga 12180ctatcgtcgc cgcacttatg actgtcttct ttatcatgca
actcgtagga caggtgccgg 12240cagcgctctg ggtcattttc ggcgaggacc
gctttcgctg gagcgcgacg atgatcggcc 12300tgtcgcttgc ggtattcgga
atcttgcacg ccctcgctca agccttcgtc actggtcccg 12360ccaccaaacg
tttcggcgag aagcaggcca ttatcgccgg catggcggcc gacgcgctgg
12420gctacgtctt gctggcgttc gcgacgcgag gctggatggc cttccccatt
atgattcttc 12480tcgcttccgg cggcatcggg atgcccgcgt tgcaggccat
gctgtccagg caggtagatg 12540acgaccatca gggacagctt caaggatcgc
tcgcggctct taccagccta acttcgatca 12600ctggaccgct gatcgtcacg
gcgatttatg ccgcctcggc gagcacatgg aacgggttgg 12660catggattgt
aggcgccgcc ctataccttg tctgcctccc cgcgttgcgt cgcggtgcat
12720ggagccgggc cacctcgacc tgaatggaag ccggcggcac ctcgctaacg
gattcaccac 12780tccaagaatt ggagccaatc aattcttgcg gagaactgtg
aatgcgcaaa ccaacccttg 12840gcagaacata tccatcgcgt ccgccatctc
cagcagccgc acgcggcgca tctcgggcag 12900cgttgggtcc tggccacggg
tgcgcatgat cgtgctcctg tcgttgagga cccggctagg 12960ctggcggggt
tgccttactg gttagcagaa tgaatcaccg atacgcgagc gaacgtgaag
13020cgactgctgc tgcaaaacgt ctgcgacctg agcaacaaca tgaatggtct
tcggtttccg 13080tgtttcgtaa agtctggaaa cgcggaagtc agcgccctgc
accattatgt tccggatctg 13140catcgcagga tgctgctggc taccctgtgg
aacacctaca tctgtattaa cgaagcgctg 13200gcattgaccc tgagtgattt
ttctctggtc ccgccgcatc cataccgcca gttgtttacc 13260ctcacaacgt
tccagtaacc gggcatgttc atcatcagta acccgtatcg tgagcatcct
13320ctctcgtttc atcggtatca ttacccccat gaacagaaat cccccttaca
cggaggcatc 13380agtgaccaaa caggaaaaaa ccgcccttaa catggcccgc
tttatcagaa gccagacatt 13440aacgcttctg gagaaactca acgagctgga
cgcggatgaa caggcagaca tctgtgaatc 13500gcttcacgac cacgctgatg
agctttaccg cagctgcctc gcgcgtttcg gtgatgacgg 13560tgaaaacctc
tgacacatgc agctcccgga gacggtcaca gcttgtctgt aagcggatgc
13620cgggagcaga caagcccgtc agggcgcgtc agcgggtgtt ggcgggtgtc
ggggcgcagc 13680catgacccag tcacgtagcg atagcggagt gtatactggc
ttaactatgc ggcatcagag 13740cagattgtac tgagagtgca ccatatgcgg
tgtgaaatac cgcacagatg cgtaaggaga 13800aaataccgca tcaggcgctc
ttccgcttcc tcgctcactg actcgctgcg ctcggtcgtt 13860cggctgcggc
gagcggtatc agctcactca aaggcggtaa tacggttatc cacagaatca
13920ggggataacg caggaaagaa catgtgagca aaaggccagc aaaaggccag
gaaccgtaaa 13980aaggccgcgt tgctggcgtt tttccatagg ctccgccccc
ctgacgagca tcacaaaaat 14040cgacgctcaa gtcagaggtg gcgaaacccg
acaggactat aaagatacca ggcgtttccc 14100cctggaagct ccctcgtgcg
ctctcctgtt ccgaccctgc cgcttaccgg atacctgtcc 14160gcctttctcc
cttcgggaag cgtggcgctt tctcatagct cacgctgtag gtatctcagt
14220tcggtgtagg tcgttcgctc caagctgggc tgtgtgcacg aaccccccgt
tcagcccgac 14280cgctgcgcct tatccggtaa ctatcgtctt gagtccaacc
cggtaagaca cgacttatcg 14340ccactggcag cagccactgg taacaggatt
agcagagcga ggtatgtagg cggtgctaca 14400gagttcttga agtggtggcc
taactacggc tacactagaa ggacagtatt tggtatctgc 14460gctctgctga
agccagttac cttcggaaaa agagttggta gctcttgatc cggcaaacaa
14520accaccgctg gtagcggtgg tttttttgtt tgcaagcagc agattacgcg
cagaaaaaaa 14580ggatctcaag aagatccttt gatcttttct acggggtctg
acgctcagtg gaacgaaaac 14640tcacgttaag ggattttggt catgagatta
tcaaaaagga tcttcaccta gatcctttta 14700aattaaaaat gaagttttaa
atcaatctaa agtatatatg agtaaacttg gtctgacagt 14760taccaatgct
taatcagtga ggcacctatc tcagcgatct gtctatttcg ttcatccata
14820gttgcctgac tccccgtcgt gtagataact acgatacggg agggcttacc
atctggcccc 14880agtgctgcaa tgataccgcg agacccacgc tcaccggctc
cagatttatc agcaataaac 14940cagccagccg gaagggccga gcgcagaagt
ggtcctgcaa ctttatccgc ctccatccag 15000tctattaatt gttgccggga
agctagagta agtagttcgc cagttaatag tttgcgcaac 15060gttgttgcca
ttgctgcaag atctggctag cgatgaccct gctgattggt tcgctgacca
15120tttccgggcg cgccgattta ggtgacacta tag 15153493390PRTDengue 3
(Sleman/78) virus 49Met Asn Asn Gln Arg Lys Lys Thr Gly Lys Pro Ser
Ile Asn Met Leu 1 5 10 15 Lys Arg Val Arg Asn Arg Val Ser Thr Gly
Ser Gln Leu Ala Lys Arg 20 25 30 Phe Ser Arg Gly Leu Leu Asn Gly
Gln Gly Pro Met Lys Leu Val Met 35 40 45 Ala Phe Ile Ala Phe Leu
Arg Phe Leu Ala Ile Pro Pro Thr Ala Gly 50 55 60 Val Leu Ala Arg
Trp Gly Thr Phe Lys Lys Ser Gly Ala Ile Lys Val65 70 75 80 Leu Arg
Gly Phe Lys Lys Glu Ile Ser Asn Met Leu Ser Ile Ile Asn 85 90 95
Arg Arg Lys Lys Thr Ser Leu Cys Leu Met Met Met Leu Pro Ala Thr 100
105 110 Leu Ala Phe His Leu Thr Ser Arg Asp Gly Glu Pro Arg Met Ile
Val 115 120 125 Gly Lys Asn Glu Arg Gly Lys Ser Leu Leu Phe Lys Thr
Ala Ser Gly 130 135 140 Ile Asn Met Cys Thr Leu Ile Ala Met Asp Leu
Gly Glu Met Cys Asp145 150 155 160 Asp Thr Val Thr Tyr Lys Cys Pro
Leu Ile Thr Glu Val Glu Pro Glu 165 170 175 Asp Ile Asp Cys Trp Cys
Asn Leu Thr Ser Thr Trp Val Thr Tyr Gly 180 185 190 Thr Cys Asn Gln
Ala Gly Glu His Arg Arg Asp Lys Arg Ser Val Ala 195 200 205 Leu Ala
Pro His Val Gly Met Gly Leu Asp Thr Arg Thr Gln Thr Trp 210 215 220
Met Ser Ala Glu Gly Ala Trp Arg Gln Val Glu Lys Val Glu Thr Trp225
230 235 240 Ala Phe Arg His Pro Gly Phe Thr Ile Leu Ala Leu Phe Leu
Ala His 245 250 255 Tyr Ile Gly Thr Ser Leu Thr Gln Lys Val Val Ile
Phe Ile Leu Leu 260 265 270 Met Leu Val Thr Pro Ser Met Thr Met Arg
Cys Val Gly Val Gly Asn 275 280 285 Arg Asp Phe Val Glu Gly Leu Ser
Gly Ala Thr Trp Val Asp Val Val 290 295 300 Leu Glu His Gly Gly Cys
Val Thr Thr Met Ala Lys Asn Lys Pro Thr305 310 315 320 Leu Asp Ile
Glu Leu Gln Lys Thr Glu Ala Thr Gln Leu Ala Thr Leu 325 330 335 Arg
Lys Leu Cys Ile Glu Gly Lys Ile Thr Asn Val Thr Thr Asp Ser 340 345
350 Arg Cys Pro Thr Gln Gly Glu Ala Ile Leu Pro Glu Glu Gln Asp Gln
355 360 365 Asn His Val Cys Lys His Thr Tyr Val Asp Arg Gly Trp Gly
Asn Gly 370 375 380 Cys Gly Leu Phe Gly Lys Gly Ser Leu Val Thr Cys
Ala Lys Phe Gln385 390 395
400 Cys Leu Glu Ser Ile Glu Gly Lys Val Val Gln His Glu Asn Leu Lys
405 410 415 Tyr Thr Val Ile Ile Thr Val His Thr Gly Asp Gln His Gln
Val Gly 420 425 430 Asn Glu Thr Gln Gly Val Thr Ala Glu Ile Thr Pro
Gln Ala Ser Thr 435 440 445 Val Glu Ala Ile Leu Pro Glu Tyr Gly Thr
Leu Gly Leu Glu Cys Ser 450 455 460 Pro Arg Thr Gly Leu Asp Phe Asn
Glu Met Ile Leu Leu Thr Met Lys465 470 475 480 Asn Lys Ala Trp Met
Val His Arg Gln Trp Phe Phe Asp Leu Pro Leu 485 490 495 Pro Trp Thr
Ser Gly Ala Thr Thr Glu Thr Pro Thr Trp Asn Lys Lys 500 505 510 Glu
Leu Leu Val Thr Phe Lys Asn Ala His Ala Lys Lys Gln Glu Val 515 520
525 Val Val Leu Gly Ser Gln Glu Gly Ala Met His Thr Ala Leu Thr Gly
530 535 540 Ala Thr Glu Ile Gln Thr Ser Gly Gly Thr Ser Ile Phe Ala
Gly His545 550 555 560 Leu Lys Cys Arg Leu Lys Met Asp Lys Leu Glu
Leu Lys Gly Met Ser 565 570 575 Tyr Ala Met Cys Leu Asn Ala Phe Val
Leu Lys Lys Glu Val Ser Glu 580 585 590 Thr Gln His Gly Thr Ile Leu
Ile Lys Val Glu Tyr Lys Gly Glu Asp 595 600 605 Ala Pro Cys Lys Ile
Pro Phe Ser Thr Glu Asp Gly Gln Gly Lys Ala 610 615 620 His Asn Gly
Arg Leu Ile Thr Ala Asn Pro Val Val Thr Lys Lys Glu625 630 635 640
Glu Pro Val Asn Ile Glu Ala Glu Pro Pro Phe Gly Glu Ser Asn Ile 645
650 655 Val Ile Gly Ile Gly Asp Lys Ala Leu Lys Ile Asn Trp Tyr Lys
Lys 660 665 670 Gly Ser Ser Ile Gly Lys Met Phe Glu Ala Thr Ala Arg
Gly Ala Arg 675 680 685 Arg Met Ala Ile Leu Gly Asp Thr Ala Trp Asp
Phe Gly Ser Val Gly 690 695 700 Gly Val Leu Asn Ser Leu Gly Lys Met
Val His Gln Ile Phe Gly Ser705 710 715 720 Ala Tyr Thr Ala Leu Phe
Ser Gly Val Ser Trp Ile Met Lys Ile Gly 725 730 735 Ile Gly Val Leu
Leu Thr Trp Ile Gly Leu Asn Ser Lys Asn Thr Ser 740 745 750 Met Ser
Phe Ser Cys Ile Val Ile Gly Ile Ile Thr Leu Tyr Leu Gly 755 760 765
Ala Val Val Gln Ala Asp Met Gly Cys Val Ile Asn Trp Lys Gly Lys 770
775 780 Glu Leu Lys Cys Gly Ser Gly Ile Phe Val Thr Asn Glu Val His
Thr785 790 795 800 Trp Thr Glu Gln Tyr Lys Phe Gln Ala Asp Ser Pro
Lys Arg Leu Ala 805 810 815 Thr Ala Ile Ala Gly Ala Trp Glu Asn Gly
Val Cys Gly Ile Arg Ser 820 825 830 Thr Thr Arg Met Glu Asn Leu Leu
Trp Lys Gln Ile Ala Asn Glu Leu 835 840 845 Asn Tyr Ile Leu Trp Glu
Asn Asn Ile Lys Leu Thr Val Val Val Gly 850 855 860 Asp Ile Ile Gly
Val Leu Glu Gln Gly Lys Arg Thr Leu Thr Pro Gln865 870 875 880 Pro
Met Glu Leu Lys Tyr Ser Trp Lys Thr Trp Gly Lys Ala Lys Ile 885 890
895 Val Thr Ala Glu Thr Gln Asn Ser Ser Phe Ile Ile Asp Gly Pro Asn
900 905 910 Thr Pro Glu Cys Pro Ser Ala Ser Arg Ala Trp Asn Val Trp
Glu Val 915 920 925 Glu Asp Tyr Gly Phe Gly Val Phe Thr Thr Asn Ile
Trp Leu Lys Leu 930 935 940 Arg Glu Met Tyr Thr Gln Leu Cys Asp His
Arg Leu Met Ser Ala Ala945 950 955 960 Val Lys Asp Glu Arg Ala Val
His Ala Asp Met Gly Tyr Trp Ile Glu 965 970 975 Ser Gln Lys Asn Gly
Ser Trp Lys Leu Glu Lys Ala Ser Leu Ile Glu 980 985 990 Val Lys Thr
Cys Thr Trp Pro Lys Ser His Thr Leu Trp Ser Asn Gly 995 1000 1005
Val Leu Glu Ser Asp Met Ile Ile Pro Lys Ser Leu Ala Gly Pro Ile
1010 1015 1020 Ser Gln His Asn Tyr Arg Pro Gly Tyr His Thr Gln Thr
Ala Gly Pro1025 1030 1035 1040Trp His Leu Gly Lys Leu Glu Leu Asp
Phe Asn Tyr Cys Glu Gly Thr 1045 1050 1055 Thr Val Val Ile Thr Glu
Asn Cys Gly Thr Arg Gly Pro Ser Leu Arg 1060 1065 1070 Thr Thr Thr
Val Ser Gly Lys Leu Ile His Glu Trp Cys Cys Arg Ser 1075 1080 1085
Cys Thr Leu Pro Pro Leu Arg Tyr Met Gly Glu Asp Gly Cys Trp Tyr
1090 1095 1100 Gly Met Glu Ile Arg Pro Ile Asn Glu Lys Glu Glu Asn
Met Val Lys1105 1110 1115 1120Ser Leu Val Ser Ala Gly Ser Gly Lys
Val Asp Asn Phe Thr Met Gly 1125 1130 1135 Val Leu Cys Leu Ala Ile
Leu Phe Glu Glu Val Met Arg Gly Lys Phe 1140 1145 1150 Gly Lys Lys
His Met Ile Ala Gly Val Leu Phe Thr Phe Val Leu Leu 1155 1160 1165
Leu Ser Gly Gln Ile Thr Trp Arg Asp Met Ala His Thr Leu Ile Met
1170 1175 1180 Ile Gly Ser Asn Ala Ser Asp Arg Met Gly Met Gly Val
Thr Tyr Leu1185 1190 1195 1200Ala Leu Ile Ala Thr Phe Lys Ile Gln
Pro Phe Leu Ala Leu Gly Phe 1205 1210 1215 Phe Leu Arg Lys Leu Thr
Ser Arg Glu Asn Leu Leu Leu Gly Val Gly 1220 1225 1230 Leu Ala Met
Ala Thr Thr Leu Gln Leu Pro Glu Asp Ile Glu Gln Met 1235 1240 1245
Ala Asn Gly Ile Ala Leu Gly Leu Met Ala Leu Lys Leu Ile Thr Gln
1250 1255 1260 Phe Glu Thr Tyr Gln Leu Trp Thr Ala Leu Val Ser Leu
Met Cys Ser1265 1270 1275 1280Asn Thr Ile Phe Thr Leu Thr Val Ala
Trp Arg Thr Ala Thr Leu Ile 1285 1290 1295 Leu Ala Gly Ile Ser Leu
Leu Pro Val Cys Gln Ser Ser Ser Met Arg 1300 1305 1310 Lys Thr Asp
Trp Leu Pro Met Ala Val Ala Ala Met Gly Val Pro Pro 1315 1320 1325
Leu Pro Leu Phe Ile Phe Ser Leu Lys Asp Thr Leu Lys Arg Arg Ser
1330 1335 1340 Trp Pro Leu Asn Glu Gly Val Met Ala Val Gly Leu Val
Ser Ile Leu1345 1350 1355 1360Ala Ser Ser Leu Leu Arg Asn Asp Val
Pro Met Ala Gly Pro Leu Val 1365 1370 1375 Ala Gly Gly Leu Leu Ile
Ala Cys Tyr Val Ile Thr Gly Thr Ser Ala 1380 1385 1390 Asp Leu Thr
Val Glu Lys Ala Ala Asp Val Thr Trp Glu Glu Glu Ala 1395 1400 1405
Glu Gln Thr Gly Val Ser His Asn Leu Met Ile Thr Val Asp Asp Asp
1410 1415 1420 Gly Thr Met Arg Ile Lys Asp Asp Glu Thr Glu Asn Ile
Leu Thr Val1425 1430 1435 1440Leu Leu Lys Thr Ala Leu Leu Ile Val
Ser Gly Ile Phe Pro Tyr Ser 1445 1450 1455 Ile Pro Ala Thr Leu Leu
Val Trp His Thr Trp Gln Lys Gln Thr Gln 1460 1465 1470 Arg Ser Gly
Val Leu Trp Asp Val Pro Ser Pro Pro Glu Thr Gln Lys 1475 1480 1485
Ala Glu Leu Glu Glu Gly Val Tyr Arg Ile Lys Gln Gln Gly Ile Phe
1490 1495 1500 Gly Lys Thr Gln Val Gly Val Gly Val Gln Lys Glu Gly
Val Phe His1505 1510 1515 1520Thr Met Trp His Val Thr Arg Gly Ala
Val Leu Thr His Asn Gly Lys 1525 1530 1535 Arg Leu Glu Pro Asn Trp
Ala Ser Val Lys Lys Asp Leu Ile Ser Tyr 1540 1545 1550 Gly Gly Gly
Trp Lys Leu Ser Ala Gln Trp Gln Lys Gly Glu Glu Val 1555 1560 1565
Gln Val Ile Ala Val Glu Pro Gly Lys Asn Pro Lys Asn Phe Gln Thr
1570 1575 1580 Met Pro Gly Ile Phe Gln Thr Thr Thr Gly Glu Ile Gly
Ala Ile Ala1585 1590 1595 1600Leu Asp Phe Lys Pro Gly Thr Ser Gly
Ser Pro Ile Ile Asn Arg Glu 1605 1610 1615 Gly Lys Val Leu Gly Leu
Tyr Gly Asn Gly Val Val Thr Lys Asn Gly 1620 1625 1630 Gly Tyr Val
Ser Gly Ile Ala Gln Thr Asn Ala Glu Pro Asp Gly Pro 1635 1640 1645
Thr Pro Glu Leu Glu Glu Glu Met Phe Lys Lys Arg Asn Leu Thr Ile
1650 1655 1660 Met Asp Leu His Pro Gly Ser Gly Lys Thr Arg Lys Tyr
Leu Pro Ala1665 1670 1675 1680Ile Val Arg Glu Ala Ile Lys Arg Arg
Leu Arg Thr Leu Ile Leu Ala 1685 1690 1695 Pro Thr Arg Val Val Ala
Ala Glu Met Glu Glu Ala Leu Lys Gly Leu 1700 1705 1710 Pro Ile Arg
Tyr Gln Thr Thr Ala Thr Lys Ser Glu His Thr Gly Arg 1715 1720 1725
Glu Ile Val Asp Leu Met Cys His Ala Thr Phe Thr Met Arg Leu Leu
1730 1735 1740 Ser Pro Val Arg Val Pro Asn Tyr Asn Leu Ile Ile Met
Asp Glu Ala1745 1750 1755 1760His Phe Thr Asp Pro Ala Ser Ile Ala
Ala Arg Gly Tyr Ile Ser Thr 1765 1770 1775 Arg Val Gly Met Gly Glu
Ala Ala Ala Ile Phe Met Thr Ala Thr Pro 1780 1785 1790 Pro Gly Thr
Ala Asp Ala Phe Pro Gln Ser Asn Ala Pro Ile Gln Asp 1795 1800 1805
Glu Glu Arg Asp Ile Pro Glu Arg Ser Trp Asn Ser Gly Asn Glu Trp
1810 1815 1820 Ile Thr Asp Phe Ala Gly Lys Thr Val Trp Phe Val Pro
Ser Ile Lys1825 1830 1835 1840Ala Gly Asn Asp Ile Ala Asn Cys Leu
Arg Lys Asn Gly Lys Lys Val 1845 1850 1855 Ile Gln Leu Ser Arg Lys
Thr Phe Asp Thr Glu Tyr Gln Lys Thr Lys 1860 1865 1870 Leu Asn Asp
Trp Asp Phe Val Val Thr Thr Asp Ile Ser Glu Met Gly 1875 1880 1885
Ala Asn Phe Lys Ala Asp Arg Val Ile Asp Pro Arg Arg Cys Leu Lys
1890 1895 1900 Pro Val Ile Leu Thr Asp Gly Pro Glu Arg Val Ile Leu
Ala Gly Pro1905 1910 1915 1920Met Pro Val Thr Val Ala Ser Ala Ala
Gln Arg Arg Gly Arg Val Gly 1925 1930 1935 Arg Asn Pro Gln Lys Glu
Asn Asp Gln Tyr Ile Phe Met Gly Gln Pro 1940 1945 1950 Leu Asn Asn
Asp Glu Asp His Ala His Trp Thr Glu Ala Lys Met Leu 1955 1960 1965
Leu Asp Asn Ile Asn Thr Pro Glu Gly Ile Ile Pro Ala Leu Phe Glu
1970 1975 1980 Pro Glu Arg Glu Lys Ser Ala Ala Ile Asp Gly Glu Tyr
Arg Leu Lys1985 1990 1995 2000Gly Glu Ser Arg Lys Thr Phe Val Glu
Leu Met Arg Arg Gly Asp Leu 2005 2010 2015 Pro Val Trp Leu Ala His
Lys Val Ala Ser Glu Gly Ile Lys Tyr Thr 2020 2025 2030 Asp Arg Lys
Trp Cys Phe Asp Gly Glu Arg Asn Asn Gln Ile Leu Glu 2035 2040 2045
Glu Asn Met Asp Val Glu Ile Trp Thr Lys Glu Gly Glu Lys Lys Lys
2050 2055 2060 Leu Arg Pro Arg Trp Leu Asp Ala Arg Thr Tyr Ser Asp
Pro Leu Ala2065 2070 2075 2080Leu Lys Glu Phe Lys Asp Phe Ala Ala
Gly Arg Lys Ser Ile Ala Leu 2085 2090 2095 Asp Leu Val Thr Glu Ile
Gly Arg Val Pro Ser His Leu Ala His Arg 2100 2105 2110 Thr Arg Asn
Ala Leu Asp Asn Leu Val Met Leu His Thr Ser Glu His 2115 2120 2125
Gly Gly Arg Ala Tyr Arg His Ala Val Glu Glu Leu Pro Glu Thr Met
2130 2135 2140 Glu Thr Leu Leu Leu Leu Gly Leu Met Ile Leu Leu Thr
Gly Gly Ala2145 2150 2155 2160Met Leu Phe Leu Ile Ser Gly Lys Gly
Ile Gly Lys Thr Ser Ile Gly 2165 2170 2175 Leu Ile Cys Val Ala Ala
Ser Ser Gly Met Leu Trp Met Ala Asp Val 2180 2185 2190 Pro Leu Gln
Trp Ile Ala Ser Ala Ile Val Leu Glu Phe Phe Met Met 2195 2200 2205
Val Leu Leu Ile Pro Glu Pro Glu Lys Gln Arg Thr Pro Gln Asp Asn
2210 2215 2220 Gln Leu Ala Tyr Val Val Ile Gly Ile Leu Thr Leu Ala
Ala Ile Val2225 2230 2235 2240Ala Ala Asn Glu Met Gly Leu Leu Glu
Thr Thr Lys Arg Asp Leu Gly 2245 2250 2255 Met Ser Lys Glu Pro Gly
Val Val Ser Pro Thr Ser Tyr Leu Asp Val 2260 2265 2270 Asp Leu His
Pro Ala Ser Ala Trp Thr Leu Tyr Ala Val Ala Thr Thr 2275 2280 2285
Val Ile Thr Pro Met Leu Arg His Thr Ile Glu Asn Ser Thr Ala Asn
2290 2295 2300 Val Ser Leu Ala Ala Ile Ala Asn Gln Ala Val Val Leu
Met Gly Leu2305 2310 2315 2320Asp Lys Gly Trp Pro Ile Ser Lys Met
Asp Leu Gly Val Pro Leu Leu 2325 2330 2335 Ala Leu Gly Cys Tyr Ser
Gln Val Asn Pro Leu Thr Leu Thr Ala Ala 2340 2345 2350 Val Leu Leu
Leu Val Thr His Tyr Ala Ile Ile Gly Pro Gly Leu Gln 2355 2360 2365
Ala Lys Ala Thr Arg Glu Ala Gln Lys Arg Thr Ala Ala Gly Ile Met
2370 2375 2380 Lys Asn Pro Thr Val Asp Gly Ile Met Thr Ile Asp Leu
Asp Pro Val2385 2390 2395 2400Ile Tyr Asp Ser Lys Phe Glu Lys Gln
Leu Gly Gln Val Met Leu Leu 2405 2410 2415 Val Leu Cys Ala Val Gln
Leu Leu Leu Met Arg Thr Ser Trp Ala Phe 2420 2425 2430 Cys Glu Ala
Leu Thr Leu Ala Thr Gly Pro Ile Thr Thr Leu Trp Glu 2435 2440 2445
Gly Ser Pro Gly Lys Phe Trp Asn Thr Thr Ile Ala Val Ser Met Ala
2450 2455 2460 Asn Ile Phe Arg Gly Ser Tyr Leu Ala Gly Ala Gly Leu
Ala Phe Ser2465 2470 2475 2480Ile Met Lys Ser Val Gly Thr Gly Lys
Arg Gly Thr Gly Ser Gln Gly 2485 2490 2495 Glu Thr Leu Gly Glu Lys
Trp Lys Lys Lys Leu Asn Gln Leu Pro Arg 2500 2505 2510 Lys Glu Phe
Asp Leu Tyr Lys Lys Ser Gly Ile Thr Glu Val Asp Arg 2515 2520 2525
Thr Glu Ala Lys Glu Gly Leu Lys Arg Gly Glu Ile Thr His His Ala
2530 2535 2540 Val Ser Arg Gly Ser Ala Lys Leu Gln Trp Phe Val Glu
Arg Asn Met2545 2550 2555 2560Val Ile Pro Glu Gly Arg Val Ile Asp
Leu Gly Cys Gly Arg Gly Gly 2565 2570 2575 Trp Ser Tyr Tyr Cys Ala
Gly Leu Lys Lys Val Thr Glu Val Arg Gly 2580 2585 2590 Tyr Thr Lys
Gly Gly Pro Gly His Glu Glu Pro Val Pro Met Ser Thr 2595 2600 2605
Tyr Gly Trp Asn Ile Val Lys Leu Met Ser Gly Lys Asp Val Phe Tyr
2610 2615 2620 Leu Pro Pro Glu Lys Cys Asp Thr Leu Leu Cys Asp Ile
Gly Glu Ser2625 2630 2635 2640Ser Pro Ser Pro Thr Val Glu Glu Ser
Arg Thr Ile Arg Val Leu Lys 2645 2650 2655 Met Val Glu Pro Trp Leu
Lys Asn Asn Gln Phe Cys Ile Lys Val Leu 2660 2665 2670 Asn Pro Tyr
Met Pro Thr Val Ile Glu His Leu Glu Arg Leu Gln Arg 2675 2680 2685
Lys His Gly Gly Met Leu Val Arg Asn Pro Leu Ser Arg Asn Ser Thr
2690 2695 2700 His Glu Met Tyr Trp Ile Ser Asn Gly Thr Gly Asn Ile
Val Ser Ser2705 2710
2715 2720Val Asn Met Val Ser Arg Leu Leu Leu Asn Arg Phe Thr Met
Thr His 2725 2730 2735 Arg Arg Pro Thr Ile Glu Lys Asp Val Asp Leu
Gly Ala Gly Thr Arg 2740 2745 2750 His Val Asn Ala Glu Pro Glu Thr
Pro Asn Met Asp Val Ile Gly Glu 2755 2760 2765 Arg Ile Arg Arg Ile
Lys Glu Glu His Ser Ser Thr Trp His Tyr Asp 2770 2775 2780 Asp Glu
Asn Pro Tyr Lys Thr Trp Ala Tyr His Gly Ser Tyr Glu Val2785 2790
2795 2800Lys Ala Thr Gly Ser Ala Ser Ser Met Ile Asn Gly Val Val
Lys Leu 2805 2810 2815 Leu Thr Lys Pro Trp Asp Val Val Pro Met Val
Thr Gln Met Ala Met 2820 2825 2830 Thr Asp Thr Thr Pro Phe Gly Gln
Gln Arg Val Phe Lys Glu Lys Val 2835 2840 2845 Asp Thr Arg Thr Pro
Arg Pro Met Pro Gly Thr Arg Lys Val Met Glu 2850 2855 2860 Ile Thr
Ala Glu Trp Leu Trp Arg Thr Leu Gly Arg Asn Lys Arg Pro2865 2870
2875 2880Arg Leu Cys Thr Arg Glu Glu Phe Thr Lys Lys Val Arg Thr
Asn Ala 2885 2890 2895 Ala Met Gly Ala Val Phe Thr Glu Glu Asn Gln
Trp Asp Ser Ala Arg 2900 2905 2910 Ala Ala Val Glu Asp Glu Glu Phe
Trp Lys Leu Val Asp Arg Glu Arg 2915 2920 2925 Glu Leu His Lys Leu
Gly Lys Cys Gly Ser Cys Val Tyr Asn Met Met 2930 2935 2940 Gly Lys
Arg Glu Lys Lys Leu Gly Glu Phe Gly Lys Ala Lys Gly Ser2945 2950
2955 2960Arg Ala Ile Trp Tyr Met Trp Leu Gly Ala Arg Tyr Leu Glu
Phe Glu 2965 2970 2975 Ala Leu Gly Phe Leu Asn Glu Asp His Trp Phe
Ser Arg Glu Asn Ser 2980 2985 2990 Tyr Ser Gly Val Glu Gly Glu Gly
Leu His Lys Leu Gly Tyr Ile Leu 2995 3000 3005 Arg Asp Ile Ser Lys
Ile Pro Gly Gly Ala Met Tyr Ala Asp Asp Thr 3010 3015 3020 Ala Gly
Trp Asp Thr Arg Ile Thr Glu Asp Asp Leu His Asn Glu Glu3025 3030
3035 3040Lys Ile Thr Gln Gln Met Asp Pro Glu His Arg Gln Leu Ala
Asn Ala 3045 3050 3055 Ile Phe Lys Leu Thr Tyr Gln Asn Lys Val Val
Lys Val Gln Arg Pro 3060 3065 3070 Thr Pro Lys Gly Thr Val Met Asp
Ile Ile Ser Arg Lys Asp Gln Arg 3075 3080 3085 Gly Ser Gly Gln Val
Gly Thr Tyr Gly Leu Asn Thr Phe Thr Asn Met 3090 3095 3100 Glu Ala
Gln Leu Ile Arg Gln Met Glu Gly Glu Gly Val Leu Ser Lys3105 3110
3115 3120Ala Asp Leu Glu Asn Pro His Leu Leu Glu Lys Lys Val Thr
Gln Trp 3125 3130 3135 Leu Glu Thr Lys Gly Val Glu Arg Leu Lys Arg
Met Ala Ile Ser Gly 3140 3145 3150 Asp Asp Cys Val Val Lys Pro Ile
Asp Asp Arg Phe Ala Asn Ala Leu 3155 3160 3165 Leu Ala Leu Asn Asp
Met Gly Lys Val Arg Lys Asp Ile Pro Gln Trp 3170 3175 3180 Gln Pro
Ser Lys Gly Trp His Asp Trp Gln Gln Val Pro Phe Cys Ser3185 3190
3195 3200His His Phe His Glu Leu Ile Met Lys Asp Gly Arg Lys Leu
Val Val 3205 3210 3215 Pro Cys Arg Pro Gln Asp Glu Leu Ile Gly Arg
Ala Arg Ile Ser Gln 3220 3225 3230 Gly Ala Gly Trp Ser Leu Arg Glu
Thr Ala Cys Leu Gly Lys Ala Tyr 3235 3240 3245 Ala Gln Met Trp Thr
Leu Met Tyr Phe His Arg Arg Asp Leu Arg Leu 3250 3255 3260 Ala Ser
Asn Ala Ile Cys Ser Ala Val Pro Val His Trp Val Pro Thr3265 3270
3275 3280Ser Arg Thr Thr Trp Ser Ile His Ala His His Gln Trp Met
Thr Thr 3285 3290 3295 Glu Asp Met Leu Thr Val Trp Asn Arg Val Trp
Ile Glu Asp Asn Pro 3300 3305 3310 Trp Met Glu Asp Lys Thr Pro Val
Lys Thr Trp Glu Asp Val Pro Tyr 3315 3320 3325 Leu Gly Lys Arg Glu
Asp Gln Trp Cys Gly Ser Leu Ile Gly Leu Thr 3330 3335 3340 Ser Arg
Ala Thr Trp Ala Gln Asn Ile Leu Thr Ala Ile Gln Gln Val3345 3350
3355 3360Arg Ser Leu Ile Gly Asn Glu Glu Phe Leu Asp Tyr Met Pro
Ser Met 3365 3370 3375 Lys Arg Phe Arg Lys Glu Glu Glu Ser Glu Gly
Ala Ile Trp 3380 3385 3390502426DNAArtificial SequenceDengue 1 CME
chimeric region 50agttgttagt ctgtgtggac cgacaaggac agttccaaat
cggaagcttg cttaacacag 60ttctaacagt ttgtttgaat agagagcaga tctctggaaa
aatgaacaac caacggaaaa 120agacgggtcg accgtctttc aatatgctga
aacgcgcgag aaaccgcgtg tcaactggtt 180cacagttggc gaagagattc
tcaaaaggat tgctttcagg ccaaggaccc atgaaattgg 240tgatggcttt
catagcattt ctaagatttc tagccatacc cccaacagca ggaattttgg
300ctagatggag ctcattcaag aagaatggag cgatcaaagt gttacggggt
ttcaaaaaag 360agatctcaag catgttgaac attatgaaca ggaggaaaaa
atctgtgacc atgctcctca 420tgctgctgcc cacagccctg gcgttccatt
tgaccacacg agggggagag ccacacatga 480tagttagtaa gcaggaaaga
ggaaagtcac tgttgtttaa gacctctgca ggcatcaata 540tgtgcactct
cattgcgatg gatttgggag agttatgcga ggacacaatg acctacaaat
600gcccccggat cactgaggcg gaaccagatg acgttgactg ctggtgcaat
gccacagaca 660catgggtgac ctatgggacg tgttctcaaa ccggcgaaca
ccgacgagac aaacgttccg 720tggcactggc cccacacgtg ggacttggtc
tagaaacaag aaccgaaaca tggatgtcct 780ctgaaggtgc ctggaaacaa
gtacaaaaag tggagacttg ggctttgaga cacccaggat 840tcacggtgac
agcccttttt ttagcacatg ccataggaac atccattact cagaaaggga
900tcattttcat tctgctgatg ctagtaacac catcaatggc catgcgatgt
gtgggaatag 960gcaacagaga cttcgttgaa ggactgtcag gagcaacgtg
ggtggacgtg gtattggagc 1020atggaagctg cgtcaccacc atggcaaaag
ataaaccaac attggacatt gaactcttga 1080agacggaggt cacaaaccct
gccgtcttgc gcaaactgtg cattgaagct aaaatatcaa 1140acaccaccac
cgattcaagg tgtccaacac aaggagaggc tacactggtg gaagaacagg
1200actcgaactt tgtgtgtcga cgaacgtttg tggacagagg ctggggtaat
ggctgcggac 1260tatttggaaa aggaagccta ctgacgtgtg ctaagttcaa
gtgtgtgaca aaactagaag 1320gaaagatagt tcaatatgaa aacttaaaat
attcagtgat agtcactgtc cacactgggg 1380accagcacca ggtgggaaac
gagactacag aacatggaac aattgcaacc ataacacctc 1440aagctcctac
gtcggaaata cagctgactg actacggagc cctcacattg gactgctcgc
1500ctagaacagg gctggacttt aatgagatgg ttctattgac aatgaaagaa
aaatcatggc 1560ttgtccacaa acaatggttt ctagacttac cactgccttg
gacttcagga gcttcaacat 1620ctcaagagac ttggaacaga caagatttgc
tggtcacatt caagacagct catgcaaaga 1680aacaggaagt agtcgtactg
ggatcacagg aaggagcaat gcacactgcg ttgactgggg 1740cgacagaaat
ccagacgtca ggaacgacaa caatctttgc aggacacctg aaatgcagac
1800taaaaatgga taaactgact ttaaaaggga tgtcatatgt aatgtgcaca
ggctcattta 1860agctagagaa ggaagtggct gagacccagc atggaactgt
tttagtgcag gttaaatacg 1920aaggaacaga tgcgccatgc aagatccctt
tttcggccca agatgagaaa ggagtgaccc 1980agaatgggag attgataaca
gccaacccca tagtcactga caaagaaaaa ccagtcaaca 2040ttgagacaga
accacctttt ggtgagagct acatcgtggt aggggcaggt gaaaaagctt
2100tgaaactgag ctggttcaag aaagggagca gcatagggaa aatgttcgaa
gcaactgccc 2160gaggagcgcg aaggatggct atcctgggag acaccgcatg
ggactttggc tctataggag 2220gagtgttcac atcagtggga aaattggtac
accaggtttt tggagccgca tatggggttc 2280tgttcagcgg tgtttcttgg
accatgaaaa taggaatagg gattctgctg acatggctag 2340gattaaactc
gaggaacact tcaatggcta tgacgtgcat agctgttgga ggaatcactc
2400tgtttctggg cttcacagtt caagca 242651775PRTArtificial
SequenceDengue 1 CME chimeric region 51Met Asn Asn Gln Arg Lys Lys
Thr Gly Arg Pro Ser Phe Asn Met Leu 1 5 10 15 Lys Arg Ala Arg Asn
Arg Val Ser Thr Gly Ser Gln Leu Ala Lys Arg 20 25 30 Phe Ser Lys
Gly Leu Leu Ser Gly Gln Gly Pro Met Lys Leu Val Met 35 40 45 Ala
Phe Ile Ala Phe Leu Arg Phe Leu Ala Ile Pro Pro Thr Ala Gly 50 55
60 Ile Leu Ala Arg Trp Ser Ser Phe Lys Lys Asn Gly Ala Ile Lys
Val65 70 75 80 Leu Arg Gly Phe Lys Lys Glu Ile Ser Ser Met Leu Asn
Ile Met Asn 85 90 95 Arg Arg Lys Lys Ser Val Thr Met Leu Leu Met
Leu Leu Pro Thr Ala 100 105 110 Leu Ala Phe His Leu Thr Thr Arg Gly
Gly Glu Pro His Met Ile Val 115 120 125 Ser Lys Gln Glu Arg Gly Lys
Ser Leu Leu Phe Lys Thr Ser Ala Gly 130 135 140 Ile Asn Met Cys Thr
Leu Ile Ala Met Asp Leu Gly Glu Leu Cys Glu145 150 155 160 Asp Thr
Met Thr Tyr Lys Cys Pro Arg Ile Thr Glu Ala Glu Pro Asp 165 170 175
Asp Val Asp Cys Trp Cys Asn Ala Thr Asp Thr Trp Val Thr Tyr Gly 180
185 190 Thr Cys Ser Gln Thr Gly Glu His Arg Arg Asp Lys Arg Ser Val
Ala 195 200 205 Leu Ala Pro His Val Gly Leu Gly Leu Glu Thr Arg Thr
Glu Thr Trp 210 215 220 Met Ser Ser Glu Gly Ala Trp Lys Gln Val Gln
Lys Val Glu Thr Trp225 230 235 240 Ala Leu Arg His Pro Gly Phe Thr
Val Thr Ala Leu Phe Leu Ala His 245 250 255 Ala Ile Gly Thr Ser Ile
Thr Gln Lys Gly Ile Ile Phe Ile Leu Leu 260 265 270 Met Leu Val Thr
Pro Ser Met Ala Met Arg Cys Val Gly Ile Gly Asn 275 280 285 Arg Asp
Phe Val Glu Gly Leu Ser Gly Ala Thr Trp Val Asp Val Val 290 295 300
Leu Glu His Gly Ser Cys Val Thr Thr Met Ala Lys Asp Lys Pro Thr305
310 315 320 Leu Asp Ile Glu Leu Leu Lys Thr Glu Val Thr Asn Pro Ala
Val Leu 325 330 335 Arg Lys Leu Cys Ile Glu Ala Lys Ile Ser Asn Thr
Thr Thr Asp Ser 340 345 350 Arg Cys Pro Thr Gln Gly Glu Ala Thr Leu
Val Glu Glu Gln Asp Ser 355 360 365 Asn Phe Val Cys Arg Arg Thr Phe
Val Asp Arg Gly Trp Gly Asn Gly 370 375 380 Cys Gly Leu Phe Gly Lys
Gly Ser Leu Leu Thr Cys Ala Lys Phe Lys385 390 395 400 Cys Val Thr
Lys Leu Glu Gly Lys Ile Val Gln Tyr Glu Asn Leu Lys 405 410 415 Tyr
Ser Val Ile Val Thr Val His Thr Gly Asp Gln His Gln Val Gly 420 425
430 Asn Glu Thr Thr Glu His Gly Thr Ile Ala Thr Ile Thr Pro Gln Ala
435 440 445 Pro Thr Ser Glu Ile Gln Leu Thr Asp Tyr Gly Ala Leu Thr
Leu Asp 450 455 460 Cys Ser Pro Arg Thr Gly Leu Asp Phe Asn Glu Met
Val Leu Leu Thr465 470 475 480 Met Lys Glu Lys Ser Trp Leu Val His
Lys Gln Trp Phe Leu Asp Leu 485 490 495 Pro Leu Pro Trp Thr Ser Gly
Ala Ser Thr Ser Gln Glu Thr Trp Asn 500 505 510 Arg Gln Asp Leu Leu
Val Thr Phe Lys Thr Ala His Ala Lys Lys Gln 515 520 525 Glu Val Val
Val Leu Gly Ser Gln Glu Gly Ala Met His Thr Ala Leu 530 535 540 Thr
Gly Ala Thr Glu Ile Gln Thr Ser Gly Thr Thr Thr Ile Phe Ala545 550
555 560 Gly His Leu Lys Cys Arg Leu Lys Met Asp Lys Leu Thr Leu Lys
Gly 565 570 575 Met Ser Tyr Val Met Cys Thr Gly Ser Phe Lys Leu Glu
Lys Glu Val 580 585 590 Ala Glu Thr Gln His Gly Thr Val Leu Val Gln
Val Lys Tyr Glu Gly 595 600 605 Thr Asp Ala Pro Cys Lys Ile Pro Phe
Ser Ala Gln Asp Glu Lys Gly 610 615 620 Val Thr Gln Asn Gly Arg Leu
Ile Thr Ala Asn Pro Ile Val Thr Asp625 630 635 640 Lys Glu Lys Pro
Val Asn Ile Glu Thr Glu Pro Pro Phe Gly Glu Ser 645 650 655 Tyr Ile
Val Val Gly Ala Gly Glu Lys Ala Leu Lys Leu Ser Trp Phe 660 665 670
Lys Lys Gly Ser Ser Ile Gly Lys Met Phe Glu Ala Thr Ala Arg Gly 675
680 685 Ala Arg Arg Met Ala Ile Leu Gly Asp Thr Ala Trp Asp Phe Gly
Ser 690 695 700 Ile Gly Gly Val Phe Thr Ser Val Gly Lys Leu Val His
Gln Val Phe705 710 715 720 Gly Ala Ala Tyr Gly Val Leu Phe Ser Gly
Val Ser Trp Thr Met Lys 725 730 735 Ile Gly Ile Gly Ile Leu Leu Thr
Trp Leu Gly Leu Asn Ser Arg Asn 740 745 750 Thr Ser Met Ala Met Thr
Cys Ile Ala Val Gly Gly Ile Thr Leu Phe 755 760 765 Leu Gly Phe Thr
Val Gln Ala 770 775 522423DNAArtificial SequenceDengue 1 ME
chimeric region 52agttgttagt ctgtgtggac cgacaaggac agttccaaat
cggaagcttg cttaacacag 60ttctaacagt ttgtttgaat agagagcaga tctctggaaa
aatgaaccaa cgaaaaaagg 120tggttagacc acctttcaat atgctgaaac
gcgagagaaa ccgcgtatca acccctcaag 180ggttggtgaa gagattctca
accggacttt tttctgggaa aggaccctta cggatggtgc 240tagcattcat
cacgtttttg cgagtccttt ccatcccacc aacagcaggg attctgaaga
300gatggggaca gttgaagaaa aataaggcca tcaagatact gattggattc
aggaaggaga 360taggccgcat gctgaacatc ttgaacggga gaaaaaggtc
tgcagccatg ctcctcatgc 420tgctgcccac agccctggcg ttccatttga
ccacacgagg gggagagcca cacatgatag 480ttagtaagca ggaaagagga
aagtcactgt tgtttaagac ctctgcaggc atcaatatgt 540gcactctcat
tgcgatggat ttgggagagt tatgcgagga cacaatgacc tacaaatgcc
600cccggatcac tgaggcggaa ccagatgacg ttgactgctg gtgcaatgcc
acagacacat 660gggtgaccta tgggacgtgt tctcaaaccg gcgaacaccg
acgagacaaa cgttccgtgg 720cactggcccc acacgtggga cttggtctag
aaacaagaac cgaaacatgg atgtcctctg 780aaggtgcctg gaaacaagta
caaaaagtgg agacttgggc tttgagacac ccaggattca 840cggtgacagc
ccttttttta gcacatgcca taggaacatc cattactcag aaagggatca
900ttttcattct gctgatgcta gtaacaccat caatggccat gcgatgtgtg
ggaataggca 960acagagactt cgttgaagga ctgtcaggag caacgtgggt
ggacgtggta ttggagcatg 1020gaagctgcgt caccaccatg gcaaaagata
aaccaacatt ggacattgaa ctcttgaaga 1080cggaggtcac aaaccctgcc
gtcttgcgca aactgtgcat tgaagctaaa atatcaaaca 1140ccaccaccga
ttcaaggtgt ccaacacaag gagaggctac actggtggaa gaacaggact
1200cgaactttgt gtgtcgacga acgtttgtgg acagaggctg gggtaatggc
tgcggactat 1260ttggaaaagg aagcctactg acgtgtgcta agttcaagtg
tgtgacaaaa ctagaaggaa 1320agatagttca atatgaaaac ttaaaatatt
cagtgatagt cactgtccac actggggacc 1380agcaccaggt gggaaacgag
actacagaac atggaacaat tgcaaccata acacctcaag 1440ctcctacgtc
ggaaatacag ctgactgact acggagccct cacattggac tgctcgccta
1500gaacagggct ggactttaat gagatggttc tattgacaat gaaagaaaaa
tcatggcttg 1560tccacaaaca atggtttcta gacttaccac tgccttggac
ttcaggagct tcaacatctc 1620aagagacttg gaacagacaa gatttgctgg
tcacattcaa gacagctcat gcaaagaaac 1680aggaagtagt cgtactggga
tcacaggaag gagcaatgca cactgcgttg actggggcga 1740cagaaatcca
gacgtcagga acgacaacaa tctttgcagg acacctgaaa tgcagactaa
1800aaatggataa actgacttta aaagggatgt catatgtaat gtgcacaggc
tcatttaagc 1860tagagaagga agtggctgag acccagcatg gaactgtttt
agtgcaggtt aaatacgaag 1920gaacagatgc gccatgcaag atcccttttt
cggcccaaga tgagaaagga gtgacccaga 1980atgggagatt gataacagcc
aaccccatag tcactgacaa agaaaaacca gtcaacattg 2040agacagaacc
accttttggt gagagctaca tcgtggtagg ggcaggtgaa aaagctttga
2100aactgagctg gttcaagaaa gggagcagca tagggaaaat gttcgaagca
actgcccgag 2160gagcgcgaag gatggctatc ctgggagaca ccgcatggga
ctttggctct ataggaggag 2220tgttcacatc agtgggaaaa ttggtacacc
aggtttttgg agccgcatat ggggttctgt 2280tcagcggtgt ttcttggacc
atgaaaatag gaatagggat tctgctgaca tggctaggat 2340taaactcgag
gaacacttca atggctatga cgtgcatagc tgttggagga atcactctgt
2400ttctgggctt cacagttcaa gca 242353774PRTArtificial SequenceDengue
1 ME chimeric region 53Met Asn Gln Arg Lys Lys Val Val Arg Pro Pro
Phe Asn Met Leu Lys 1 5 10 15 Arg Glu Arg Asn Arg Val Ser Thr Pro
Gln Gly Leu Val Lys Arg Phe 20 25 30 Ser Thr Gly Leu Phe Ser Gly
Lys Gly Pro Leu Arg Met Val Leu Ala 35 40 45 Phe Ile Thr Phe Leu
Arg Val Leu Ser Ile Pro Pro Thr Ala Gly Ile 50 55 60 Leu Lys Arg
Trp Gly Gln Leu Lys Lys Asn Lys Ala Ile Lys Ile Leu65 70 75 80
Ile
Gly Phe Arg Lys Glu Ile Gly Arg Met Leu Asn Ile Leu Asn Gly 85 90
95 Arg Lys Arg Ser Ala Ala Met Leu Leu Met Leu Leu Pro Thr Ala Leu
100 105 110 Ala Phe His Leu Thr Thr Arg Gly Gly Glu Pro His Met Ile
Val Ser 115 120 125 Lys Gln Glu Arg Gly Lys Ser Leu Leu Phe Lys Thr
Ser Ala Gly Ile 130 135 140 Asn Met Cys Thr Leu Ile Ala Met Asp Leu
Gly Glu Leu Cys Glu Asp145 150 155 160 Thr Met Thr Tyr Lys Cys Pro
Arg Ile Thr Glu Ala Glu Pro Asp Asp 165 170 175 Val Asp Cys Trp Cys
Asn Ala Thr Asp Thr Trp Val Thr Tyr Gly Thr 180 185 190 Cys Ser Gln
Thr Gly Glu His Arg Arg Asp Lys Arg Ser Val Ala Leu 195 200 205 Ala
Pro His Val Gly Leu Gly Leu Glu Thr Arg Thr Glu Thr Trp Met 210 215
220 Ser Ser Glu Gly Ala Trp Lys Gln Val Gln Lys Val Glu Thr Trp
Ala225 230 235 240 Leu Arg His Pro Gly Phe Thr Val Thr Ala Leu Phe
Leu Ala His Ala 245 250 255 Ile Gly Thr Ser Ile Thr Gln Lys Gly Ile
Ile Phe Ile Leu Leu Met 260 265 270 Leu Val Thr Pro Ser Met Ala Met
Arg Cys Val Gly Ile Gly Asn Arg 275 280 285 Asp Phe Val Glu Gly Leu
Ser Gly Ala Thr Trp Val Asp Val Val Leu 290 295 300 Glu His Gly Ser
Cys Val Thr Thr Met Ala Lys Asp Lys Pro Thr Leu305 310 315 320 Asp
Ile Glu Leu Leu Lys Thr Glu Val Thr Asn Pro Ala Val Leu Arg 325 330
335 Lys Leu Cys Ile Glu Ala Lys Ile Ser Asn Thr Thr Thr Asp Ser Arg
340 345 350 Cys Pro Thr Gln Gly Glu Ala Thr Leu Val Glu Glu Gln Asp
Ser Asn 355 360 365 Phe Val Cys Arg Arg Thr Phe Val Asp Arg Gly Trp
Gly Asn Gly Cys 370 375 380 Gly Leu Phe Gly Lys Gly Ser Leu Leu Thr
Cys Ala Lys Phe Lys Cys385 390 395 400 Val Thr Lys Leu Glu Gly Lys
Ile Val Gln Tyr Glu Asn Leu Lys Tyr 405 410 415 Ser Val Ile Val Thr
Val His Thr Gly Asp Gln His Gln Val Gly Asn 420 425 430 Glu Thr Thr
Glu His Gly Thr Ile Ala Thr Ile Thr Pro Gln Ala Pro 435 440 445 Thr
Ser Glu Ile Gln Leu Thr Asp Tyr Gly Ala Leu Thr Leu Asp Cys 450 455
460 Ser Pro Arg Thr Gly Leu Asp Phe Asn Glu Met Val Leu Leu Thr
Met465 470 475 480 Lys Glu Lys Ser Trp Leu Val His Lys Gln Trp Phe
Leu Asp Leu Pro 485 490 495 Leu Pro Trp Thr Ser Gly Ala Ser Thr Ser
Gln Glu Thr Trp Asn Arg 500 505 510 Gln Asp Leu Leu Val Thr Phe Lys
Thr Ala His Ala Lys Lys Gln Glu 515 520 525 Val Val Val Leu Gly Ser
Gln Glu Gly Ala Met His Thr Ala Leu Thr 530 535 540 Gly Ala Thr Glu
Ile Gln Thr Ser Gly Thr Thr Thr Ile Phe Ala Gly545 550 555 560 His
Leu Lys Cys Arg Leu Lys Met Asp Lys Leu Thr Leu Lys Gly Met 565 570
575 Ser Tyr Val Met Cys Thr Gly Ser Phe Lys Leu Glu Lys Glu Val Ala
580 585 590 Glu Thr Gln His Gly Thr Val Leu Val Gln Val Lys Tyr Glu
Gly Thr 595 600 605 Asp Ala Pro Cys Lys Ile Pro Phe Ser Ala Gln Asp
Glu Lys Gly Val 610 615 620 Thr Gln Asn Gly Arg Leu Ile Thr Ala Asn
Pro Ile Val Thr Asp Lys625 630 635 640 Glu Lys Pro Val Asn Ile Glu
Thr Glu Pro Pro Phe Gly Glu Ser Tyr 645 650 655 Ile Val Val Gly Ala
Gly Glu Lys Ala Leu Lys Leu Ser Trp Phe Lys 660 665 670 Lys Gly Ser
Ser Ile Gly Lys Met Phe Glu Ala Thr Ala Arg Gly Ala 675 680 685 Arg
Arg Met Ala Ile Leu Gly Asp Thr Ala Trp Asp Phe Gly Ser Ile 690 695
700 Gly Gly Val Phe Thr Ser Val Gly Lys Leu Val His Gln Val Phe
Gly705 710 715 720 Ala Ala Tyr Gly Val Leu Phe Ser Gly Val Ser Trp
Thr Met Lys Ile 725 730 735 Gly Ile Gly Ile Leu Leu Thr Trp Leu Gly
Leu Asn Ser Arg Asn Thr 740 745 750 Ser Met Ala Met Thr Cys Ile Ala
Val Gly Gly Ile Thr Leu Phe Leu 755 760 765 Gly Phe Thr Val Gln Ala
770
* * * * *